Approved Drugs

CUMULATIVE
SUPPLEMENT 10
OCTOBER 2015
APPROVED
DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
35th EDITION
Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
2015
Prepared By
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration
APPROVED DRUG PRODUCTS
with
35th EDITION Cumulative

Supplement 10
October 2015
CONTENTS
PAGE
1.0 INTRODUCTION ........................................................................................................................................ iii
1.1 How to use the Cumulative Supplement ........................................................................................... iii
1.2 Cumulative Supplement Content ...................................................................................................... iv
1.3 Applicant Name Changes .................................................................................................................. v
1.4 Levothyroxine Sodium ....................................................................................................................... .v
1.5 Availability of the Edition.................................................................................................................... vi
1.6 Report of Counts for the Prescription Drug Product List .................................................................. vii
1.7 Cumulative Supplement Legend ...................................................................................................... viii
DRUG PRODUCT LISTS
Prescription Drug Product List ...................................................................................................... 1-1
OTC Drug Product List .................................................................................................................. 2-1
Drug Products with Approval under Section 505 of the Act
Administered by the Center for Biologics Evaluation and Research List ................................... 3-1
Orphan Product Designations and Approvals List ........................................................................ 4-1
Drug Products W hich Must Demonstrate in vivo Bioavailability
Only if Product Fails to Achieve Adequate Dissolution ............................................................. 5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists ................................................................................................... A-1
B. Patent and Exclusivity Terms ................................................................................................ B-1
APPROVED DRUG PRODUCTS
with
35th EDITION CUMULATIVE

SUPPLEMENT 10
October 2015
1.0 INTRODUCTION
1.1
HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the
Approved Drug Products with Therapeutic Equivalence Evaluations, 35th
Edition (the List). The List is composed of four parts: approved
prescription drug products with therapeutic equivalence evaluations;
over-the-counter (OTC) drug products that require approved applications
as a condition of marketing; drug products with approval under Section
505 of the Act administered by the Center for Biologics Evaluation and
Research; and products that have never been marketed, are for
exportation, are for military use, have been discontinued from marketing
or that have had their approvals withdrawn for other than safety or
efficacy reasons.
The Cumulative Supplement provides, among other things, information on
newly approved drugs and, if necessary, revised therapeutic equivalence
evaluations and updated patent and exclusivity data. The Addendum
contains appropriate drug patent and exclusivity information required of
the Agency by the "Drug Price Competition and Patent Term Restoration Act
of 1984" for the Prescription, OTC, and Drug Products with Approval under
Section 505 of the Act Administered by the Center for Biologics
Evaluation and Research Lists.
Because all parts of the publication are subject to changes, additions,
or deletions, the List must be used in conjunction with the most current
Cumulative Supplement. Users may wish to mark to the left of the
ingredient(s) in the List to indicate that changes to that entry appear
in the Cumulative Supplement. Drug product information is provided in
each Cumulative Supplement for completeness to assist in locating the
proper place in the List for the revision.
The presence of any therapeutic equivalence code indicates that the drug
product is multisource; the deletion of a therapeutic equivalence code
indicates that the drug product has become single source. (An infrequent
exception exists when a therapeutic equivalence code is revised. In that
case, the deletion of the therapeutic equivalence code is followed
immediately by the addition of the revised one.)
Products that have never been marketed, are for exportation, are for
military use, or have been discontinued from marketing or that have had
their approvals withdrawn for other than safety or efficacy reasons, will
be flagged in this Cumulative Supplement with the "@" symbol to designate
their non-marketed status. All products having a "@" symbol in the 12th
Cumulative Supplement of this Edition List will then be added to the
"Discontinued Drug Product List" appearing in the next Edition. The
current Annual Edition Section 2.1, How To Use The Drug Product Lists,
describes the layout and usage of the List.
iii
New additions to the Prescription Drug Product List and OTC Drug Product
List are indicated by the symbol >A>. The Patent and Exclusivity List
new additions are indicated by the symbol >A> to the left of Patent
Number or Exclusivity Code. The >A> symbol is then dropped in subsequent
Cumulative Supplements for that item.
New deletions to the Prescription Drug Product List and OTC Drug Product
List are indicated by the symbol >D> (DELETE) to the left of the line.
The information line with the >D> symbol is dropped in subsequent
Cumulative Supplements for that item.
The Patent and Exclusivity List is arranged in alphabetical order by
active ingredient name(s) and trade name. The trade name will follow the
active ingredient name separated by a dash symbol. Also shown is the
application number and product number (FDA's internal file number) for
reference purposes. All patents with their expiration dates are
displayed for each application number. Drug substance and drug product
patents are indicated as such with DS or DP in the Patent codes column.
Use patents are indicated with the symbol "U" followed by a number
representing a specific use. Exclusivity information for a specific drug
is indicated by an abbreviation followed by the date upon which the
exclusivity expires. Refer to the Exclusivity Terms, Section B, in the
Patent and Exclusivity Information Addendum for an explanation of all
codes and abbreviations. Refer to Section 1.3 for internet access to the
most current list of Patent and Exclusivity terms.
1.2
CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book
(EOB) product information for new generic drug approvals. Daily generic
updates provide the consumer with the current list of approved generic
products which is important for substitution purposes. Previously, a
first-time-generic product approved early in the month would not be
published in the Cumulative Supplement (CS) for several weeks.
The CS monthly update publish goal is by the end of the following months
second work week (e.g., Novembers supplement will be updated by the end
of the second full work week in December).
Currently, the monthly PDF CS includes:

Generic product ANDA (Abbreviated New Drug Approval) approvals as of

the date of publication.
All product changes received and processed as of the date of

publication.
o Refer to CS Section 1.8 Cumulative Supplement Legend for
types of changes
o Discontinued products will be processed as of the date of
publication. There will be circumstances where a product is
discontinued in one month, however, it will be reported in
a different month's CS. For example, the Orange Book Staff
received a letter November 7 that the product has been
discontinued from manufacturing and marketing. The Orange
Book subsequently publishes the October CS on November 14.
The product will show in the October CS that it is
discontinued even though the date of discontinuance is the
day that the Orange Book Staff receives notification (November 7).
New Drug Application (NDA) approvals appear in the CS month they were
approved.
iv
Patent information, also updated daily in the EOB, is current to

the date of publication.
Exclusivity information is updated monthly and current to the date of

publication.
Every effort is made to ensure the Cumulative Supplement is current and

accurate. Applicant holders are requested to inform the FDA Orange Book
Staff (OBS) of any changes or corrections. The OBS can be contacted by
email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.
mail to:
1.3
FDA/CDER Orange Book Staff
7620 Standish Place
Rockville, MD 20855-2773
APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and
every product involved when an applicant transfers its entire line of
approved drug products to another applicant, or when an applicant changes
its name. Therefore, the cumulation of these transfers and name changes
will be identified in this section only. Where only partial lines of
approved products are transferred between applicants, each approved
product involved will appear as an applicant name change entry in the
Cumulative Supplement.
It is also not practical to identify each and every product involved when
an applicant name is changed to meet internal publication standards
(e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively
to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this
occurs, each product involved (either currently in the Cumulative
Supplement or in the following year's edition) will reflect the new
abbreviated name. Consequently, it will not appear as an applicant name
change entry in the Cumulative Supplement nor will the cumulation of
these name changes appear in this section. The Electronic Orange Book
Query, updated monthly, will contain the most current applicant holder
name.
FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)
1.4
NEW APPLICANT NAME

(NEW ABBREVIATED NAME)
AGILA SPECIALTIES PRIVATE LTD

(AGILA SPECLTS)
MYLAN LABORORATORIES LTD

(MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC

(EXCELLIUM)
LEADING PHARMA LLC

(LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC

(MYLAN PHARMS INC)
MYLAN LABORATORIES LTD

(MYLAN LABS LTD)
ONCO THERAPIES LTD

(ONCO THERAPIES LTD)
MYLAN LABORATORIES LTD

(MYLAN LABS LTD)
REDKITT BENCKISER
PHARMACEUTICALS INC
(RECKITT BENCKISER)
INDIVIOR INC
(INDIVIOR INC)
LEVOTHYROXINE SODIUM
Because there are multiple reference listed drugs of levothyroxine sodium
tablets and some reference listed drugs' sponsors have conducted studies
v
to establish their drugs' therapeutic equivalence to other reference

listed drugs, FDA has determined that its usual practice of assigning two
or three character TE codes may be potentially confusing and inadequate
for these drug products. Accordingly, FDA provides the following
explanation and chart of therapeutic equivalence evaluations for
levothyroxine sodium drug products.
Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342)
tablets have been determined to be therapeutically equivalent to
corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.
Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187),
Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck
KGAA ANDA 76752)tablets have been determined to be therapeutically
equivalent to corresponding strengths of Synthroid (Abbott NDA 021402)
tablets.
Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210),
Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck
KGAA ANDA 76752) tablets have been determined to be therapeutically
equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301)
tablets.
Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to
be therapeutically equivalent to corresponding strengths of Levothroid
(Lloyd NDA 021116) tablets.
The chart outlines TE codes for all 0.025mg products. Other product
strengths may be similar. Therapeutic equivalence has been established
between products that have the same AB+number TE code. More than one TE
code may apply to some products. One common TE code indicates therapeutic
equivalence between products.
Trade Name
Applicant
Potency
Appl No
Product No
UNITHROID
LEVOTHYROXINE
SODIUM
LEVOXYL
SYNTHROID
LEVO-T
STEVENS J
MYLAN
0.025MG AB1
0.025MG AB1
TE Code
21210
76187
001
001
KING PHARMS 0.025MG AB1

ABBOTT
0.025MG AB1
ALARA PHARM 0.025MG AB1
21301
21402
21342
001
001
001
SYNTHROID
LEVOTHYROXINE
SODIUM
LEVO-T
UNITHROID
ABBOTT
MYLAN
0.025MG AB2
0.025MG AB2
21402
76187
001
001
ALARA PHARM 0.025MG AB2

STEVENS J
0.025MG AB2
21342
21210
001
001
LEVOXYL
LEVO-T
UNITHROID
LEVOTHYROXINE
SODIUM
KUNG PHARMS
ALARA PHARM
STEVENS J
MYLAN
0.025MG
0.025MG
0.025MG
0.025MG
AB3
AB3
AB3
AB3
21301
21342
21210
76187
001
001
001
001
LEVOTHROID
LEVOTHYROXINE
SODIUM
LLOYD
MYLAN
0.025MG AB4
0.025MG AB4
21116
76187
001
001
1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ)
http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been
available on the internet and has become the updated-every-month Orange
Book. The Query provides searching of the approved drug list by active
ingredient, proprietary name, applicant holder, applicant number or patent
vi
number. Product search categories are: prescription, over-the-counter,

discontinued drugs. There are links to patent and exclusivity information
that may be applicable to each product.
Commencing with the 25th edition, the Annual Edition and monthly
Cumulative Supplements have been provided in downloadable Portable
Document Format (PDF) at the EOB home page by clicking on Publications.
The PDF annual and cumulative supplements duplicate previous paper
versions. Over time, there will be an archive for the annuals and each
year's December Cumulative Supplement.
The downloaded Annual Edition and Cumulative Supplements are also
available in a paper version (Approved Drug Products with Therapeutic
Equivalence Evaluations, ADP) from the U.S. Government Printing Office:
http://bookstore.gpo.gov; toll free 866-512-1800.
There are historical lists of Orange Book cumulative supplement product
monthly changes at
http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are
ASCII text files of the Orange Book drug product, patent, and exclusivity
data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The
drug product text files are provided in eobzip.zip format. The files are
updated concurrently with the monthly cumulative supplements. The annual
Orange Book Edition Appendices A, B, and C in PDF format are updated
quarterly.
Effective August 18, 2003, patent submissions for publication in the
Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542
which may be downloaded from the FDA Forms List,
http://www.fda.gov/opacom/morechoices/fdaforms/default.html.
The current listing of the Orphan Product Designations and Approvals is
available at http://www.fda.gov/orphan/designat/list.htm.
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT
This report provides summary counts derived from the product information
in the Prescription Drug Product List and the current Cumulative
Supplement. Products included in the counts are domestically marketed
drug products approved for both safety and effectiveness under section
505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved
drug products marketed by distributors; those marketed solely abroad; and
those now regarded as medical devices, biologics or foods.
The baseline column (December of the previous Annual Edition) refers to
the products in the Prescription Drug Product List. For each three-month
period, a column of quarterly data is added which incorporates counts of
product activity from the previous quarter(s) with those in the baseline
count.
DEFINITIONS
Drug Product
For this report, a drug product is the representation in the Prescription
Drug Product List of an active moiety (molecular entity and its salts,
esters and derivatives) either as a single ingredient or as a combination
product provided in a specific dosage form and strength for a given route
of administration with approval for marketing by a firm under a
particular generic or trade name.
vii
New Molecular Entity

A new molecular entity is considered an active moiety that has not
previously been approved (either as the parent compound or as a salt,
ester or derivative of the parent compound) in the United States for use
in a drug product either as a single ingredient or as part of a
combination.
REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER
CATEGORIES COUNTED
DEC 2014
MAR 2015
JUN 2015
SEPT 2015
DRUG PRODUCTS LISTED

SINGLE SOURCE
16150
2572
(15.9%)
16352
2608
(15.9%)
16543
2586
(15.6%)
16824
2613
(15.5%)
MULTISOURCE
13578
(84.1%)
13744
(84.1%)
13957
(84.4%)
14211
(84.5%)
THERAPEUTICALLY
EQUIVALENT
13443
(83.2%)
13610
(83.2%)
13832
(83.6%)
14089
(83.7%)
NOT THERAPEUTICALLY
EQUIVALENT
135
(0.8%)
134
(0.8%)
125
(0.8%)
122
(0.7%)
77
(0.5%)
75
(0.5%)
75
(0.5%)
75
(0.4%)
NEW MOLECULAR ENTITIES
APPROVED
13
22
12
37
NUMBER OF APPLICANTS
927
935
957
975
EXCEPTIONS1
DEC 2015
Amino acid-containing products of varying composition (see Introduction, page xx of the

List).
1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the
Dosage Form; Route and then by trade name.
The individual product record contains the Therapeutic Equivalence Code,
Reference Listed Drug symbol, applicant holder, strength(s), New Drug
Application number, product number, and approval date. The application
number preceded by N is a New Drug Application (NDA or innovator). The
application number preceded by an A is an Abbreviated New Drug
Application (ANDA or generic). The last two columns describe the action.
The Action Month is the CS month the action occurred. The OB Action is
the type of change that has occurred.
New ingredient(s), new dosage form; route(s), new trade names, and new
product additions are preceded by >A> during the action month. The change
month is the current CS month; the change code for new approvals is NEWA.
Following months will display the same information without the >A>.
Changes to currently listed products will list two records. The deleted
product record will be proceeded by >D>. The product record change
addition being made will be preceded by >A>. Following months will
display only the >A> record without the >A>. All changes that occur to
the product through the Annual year will be listed. The change month and
change code will document the change.
The change code and description:
NEWA
CAHN
New drug product approval usually in the supplement

month.
Applicant holder firm name has changed.
viii
CAIN
CDFR
CFTG
CMFD
CMS1
CMS2
CPOT
CRLD
CTEC
CTNA
DISC
Change. There has been a change in the Ingredient(s) name.

All products will be deleted under the old name and all
products will be added under the changed ingredient(s) name.
Change. Dosage Form; Route of Administration.
Change. A first time generic for the innovator product. A
TE Code is added.
Change. The product is moved from the Discontinued Section
due to a change in marketing status.
Change. Miscellaneous addition to list.
Change. Miscellaneous deletion from list.
Change. Potency amount/unit.
Change. Reference Listed Drug.
Change. Therapeutic Equivalence Code.
Change. Trade Name.
Discontinued. The Rx or OTC listed product is not
being marketed and will be moved to the discontinued
section in the next edition.
ix
PRESCRIPTION DRUG PRODUCT LIST

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT
35TH
1 -1

2015
N 204767
001 Oct 28, 2015
Oct NEWA
A 205120
001 Oct 30, 2015
Oct NEWA
A 089987
A 089987
001 Oct 26, 1992

001 Oct 26, 1992
Oct CTEC
Oct CTEC
ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
FIORICET
@ ACTAVIS LABS UT INC
325MG;50MG;40MG
A 088616
001 Nov 09, 1984
Feb CAHN
AB
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE
+
ACTAVIS LABS UT INC
325MG;50MG;40MG;30MG
N 020232
001 Jul 30, 1992
Jan CAHN
AA
AA
ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
SUN PHARM INDS LTD
300MG;30MG
300MG;60MG
A 085868
A 087083
001
001
Apr CAHN
Apr CAHN
A 040846
A 040826
001 Jun 09, 2010

001 Aug 16, 2007
Feb CTEC
Apr CAHN
A 040148
A 040148
004 Jul 07, 2014

005 Jul 07, 2014
Feb NEWA
Feb NEWA
>A>
>A> AA
>D>
>A> AA
1GM/100ML (10MG/ML)
ACETAMINOPHEN; BUTALBITAL
TABLET;ORAL
BUTALBITAL AND ACETAMINOPHEN
TEDOR PHARMA INC
325MG;50MG
BUTAPAP
+
MIKART
325MG;50MG
+
325MG;50MG
EDITION

October
ACETAMINOPHEN
SOLUTION;IV (INFUSION)
ACETAMINOPHEN
FRESENIUS KABI USA
10
AA
AA
ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
+
MIKART
325MG;2.5MG
@ SUN PHARM INDS LTD
325MG;10MG
NORCO
ACTAVIS LABS FL INC
325MG;2.5MG
325MG;5MG
AB
ACETAZOLAMIDE
CAPSULE, EXTENDED RELEASE;ORAL
DIAMOX
+
TEVA BRANDED PHARM
500MG
N 012945
001
Jun CAHN
ACETOHEXAMIDE
TABLET;ORAL
ACETOHEXAMIDE
@ ANI PHARMS INC
@
A 070869
A 070870
001 Feb 09, 1987

001 Feb 09, 1987
Jul CAHN
Jul CAHN
A 203173
A 203624
001 Mar 24, 2015

001 Jun 19, 2015
Mar NEWA
Jun NEWA
A 204674
A 203853
001 Feb 11, 2014

001 Jun 21, 2012
Sep CAHN
Sep CAHN
A 202148
A 203707
A 203707
A 202148
A 204633
A 204633
A 204633
001
001
002
002
001
002
003
Aug
Aug
Aug
Aug
May
May
May
AA
AP
AP
AN
AN
AB
AB
AB
AB
AB
AB
AB
250MG
500MG
ACETYLCYSTEINE
INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE
AKORN INC
6GM/30ML (200MG/ML)
MYLAN INSTITUTIONAL
6GM/30ML (200MG/ML)
SOLUTION;INHALATION, ORAL
ACETYLCYSTEINE
ALVOGEN INC
10%
20%
ACITRETIN
CAPSULE;ORAL
ACITRETIN
MYLAN PHARMS INC
SIGMAPHARM LABS LLC
10MG
17.5MG
22.5MG
25MG
10MG
17.5MG
22.5MG
Sep
Sep
Sep
Sep
May
May
May
10,
10,
10,
10,
22,
22,
22,
2015
2015
2015
2015
2015
2015
2015
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
10
1 -2

October
2015
A 204633
004 May 22, 2015
May NEWA

N 202450
N 202450
001 Jul 23, 2012

001 Jul 23, 2012
Apr CAHN

Aug CPOT

A 074980
A 074980
001 Sep 30, 1998

002 Sep 30, 1998
Apr CAHN

Apr CAHN

A 203790
001 Sep 30, 2015
Sep NEWA

N 022320
001 Dec 08, 2008
Sep CFTG

N 207917
N 207917
001 Jul 15, 2015

001 Jul 15, 2015
Aug CAHN

Jul NEWA

CAPSULE;ORAL
ACITRETIN
AB
25MG
ACLIDINIUM BROMIDE
POWDER, METERED;INHALATION
TUDORZA PRESSAIR
+
ASTRAZENECA PHARMS
0.375MG/INH
+
0.4MG/INH
AB
AB
AB
AB
AP
AA
ACYCLOVIR
TABLET;ORAL
ACYCLOVIR
SUN PHARM INDS LTD
400MG
800MG
ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE
ACTAVIS MID ATLANTIC
0.1%;2.5%
EPIDUO
+
GALDERMA LABS LP
0.1%;2.5%
EPIDUO FORTE
+
GALDERMA LABS
0.3%;2.5%
+
GALDERMA R AND D
0.3%;2.5%
ADENOSINE
INJECTABLE;INJECTION
ADENOSINE
EUROHLTH INTL SARL
@
@ WOCKHARDT
3MG/ML
3MG/ML
3MG/ML
A 076500
A 076501
A 090220
001 Jun 16, 2004

001 Jun 16, 2004
001 Jul 20, 2009
Jun CAHN

Sep CAHN

May DISC

ALBENDAZOLE
TABLET, CHEWABLE;ORAL
ALBENZA
+
AMEDRA PHARMS LLC
200MG
N 207844
001 Jun 11, 2015
Jun NEWA

N 205636
001 Mar 31, 2015
Mar NEWA

A 074454
001 Sep 25, 1995
Apr CAHN

N 020291
001 Oct 24, 1996
May DISC

A 090221
001 Aug 10, 2012
Feb DISC

N 021287
001 Jun 12, 2003
Jun CAHN

N 022545
N 022545
N 022545
N 022545
001
002
003
004
May
May
May
May
ALBUTEROL SULFATE
POWDER, METERED;INHALATION
PROAIR RESPICLICK
+
TEVA BRANDED PHARM
EQ 0.090MG BASE/INH
SYRUP;ORAL
ALBUTEROL SULFATE
G AND W LABS INC
EQ 2MG BASE/5ML
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
COMBIVENT
@ BOEHRINGER INGELHEIM
EQ 0.09MG BASE/INH;0.018MG/INH
AB
ALFUZOSIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE
@ WOCKHARDT LTD
10MG
UROXATRAL
+
CONCORDIA PHARMS INC
10MG
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
TABLET;ORAL
TEKAMLO
@ NOVARTIS
EQ 150MG BASE;EQ
@
EQ 150MG BASE;EQ
@
EQ 300MG BASE;EQ
@
EQ 300MG BASE;EQ
5MG BASE
10MG BASE
5MG BASE
10MG BASE
Aug
Aug
Aug
Aug
26,
26,
26,
26,
2010
2010
2010
2010
DISC

DISC

DISC

DISC

10
October
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
AMTURNIDE
@ NOVARTIS
EQ 150MG BASE;EQ 5MG BASE;12.5MG
N 200045
@
N 200045
@
EQ 300MG BASE;EQ 5MG BASE;25MG
N 200045
@
N 200045
@
EQ 300MG BASE;EQ 10MG BASE;25MG
N 200045
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>D> AA
>A>
>D> AA
>A>
ALMOTRIPTAN MALATE
TABLET;ORAL
ALMOTRIPTAN MALATE
MYLAN PHARMS INC
TEVA PHARMS USA
AXERT
JANSSEN PHARMS
+
EQ
EQ
EQ
EQ
001
002
003
004
005
Dec
Dec
Dec
Dec
Dec
21,
21,
21,
21,
21,
2010
2010
2010
2010
2010
May
May
May
May
May
DISC

DISC

DISC

DISC

DISC

Nov
Nov
Jul
Jul
09,
09,
07,
07,
2015
2015
2015
2015
Oct
Oct
Jun
Jun
NEWA

NEWA

NEWA

NEWA

BASE
BASE
BASE
BASE
A 205171
A 205171
A 078027
A 078027
001
002
001
002
EQ 6.25MG BASE
EQ 12.5MG BASE
N 021001
N 021001
001 May 07, 2001

002 May 07, 2001
Jun CFTG

Jun CFTG

0.5MG BASE
1MG BASE
A 200652
A 200652
001 May 04, 2015

002 May 04, 2015
Apr NEWA

Apr NEWA

0.5MG BASE
1MG BASE
N 021107
N 021107
002 Dec 23, 2003

001 Feb 09, 2000
Apr CFTG

Apr CFTG

A 074085
A 074085
A 074085
A 074085
A 203346
A 203346
A 203346
A 203346
A 200739
A 200739
A 200739
A 200739
001
002
003
004
001
002
003
004
001
002
003
004
Feb
Feb
Feb
Feb
Jul
Jul
Jul
Jul
Apr
Apr
Apr
Apr
16,
16,
16,
26,
31,
31,
31,
31,
15,
15,
15,
15,
1994
1994
1994
1996
2015
2015
2015
2015
2015
2015
2015
2015
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Mar
Mar
Mar
Mar
CAHN

CAHN

CAHN

CAHN

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

A 078489
A 078489
A 078489
A 078489
001
002
003
004
Oct
Oct
Oct
Oct
17,
17,
17,
17,
2008
2008
2008
2008
Sep
Sep
Sep
Sep
CAHN

CAHN

CAHN

CAHN

ALOSETRON HYDROCHLORIDE
TABLET;ORAL
ALOSETRON HYDROCHLORIDE
ROXANE
EQ
EQ
LOTRONEX
PROMETHEUS LABS
EQ
+
EQ
6.25MG
12.5MG
6.25MG
12.5MG
1 -3

2015
ALPRAZOLAM
TABLET;ORAL
ALPRAZOLAM
@ ANI PHARMS INC
@
@
@
AUROBINDO PHARMA LTD
0.25MG
0.5MG
1MG
2MG
0.25MG
0.5MG
1MG
2MG
NATCO PHARMA LTD
0.25MG
0.5MG
1MG
2MG
ALPRAZOLAM
HERITAGE PHARMS INC
0.5MG
1MG
2MG
3MG
AMANTADINE HYDROCHLORIDE
CAPSULE;ORAL
BANNER LIFE SCIENCES
SYRUP;ORAL
@ G AND W LABS INC
+
SILARX
@
+
VINTAGE
@
100MG
A 078720
001 May 29, 2008
Jan CAHN

50MG/5ML
50MG/5ML
50MG/5ML
50MG/5ML
50MG/5ML
A 072655
A 076352
A 076352
A 077992
A 077992
001
001
001
001
001
May
Oct
Oct
Oct
Oct
AMIKACIN SULFATE
AMIKACIN SULFATE
@ IGI LABS INC
@
EQ 50MG BASE/ML
EQ 250MG BASE/ML
A 063167
A 063169
001 Dec 14, 1995

001 Dec 14, 1995
Oct
Sep
Sep
Dec
Dec
30,
10,
10,
12,
12,
1990
2004
2004
2006
2006
CAHN

DISC

DISC

DISC

DISC

Mar CAHN

Mar CAHN

AB
10
1 -4

October
2015
AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

ZYDUS PHARMS USA INC
5MG
A 204180
001 Aug 07, 2015
Jul NEWA

AMINO ACIDS


BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
4% (4GM/100ML)
N 018684
001 Sep 28, 1984
Feb DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE


TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
3.5%;51MG/100ML;131MG/100ML;218MG/ N 020177 001 Oct 23, 1995
Feb DISC

100ML;35MG/100ML

AA
AB
AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

VERSAPHARM INC
TABLET;ORAL

AMINOCAPROIC

VERSAPHARM INC
1.25GM/5ML
A 074759
001 Sep 02, 1998
May CAHN

500MG
A 075602
001 May 24, 2001
May CAHN

A 084910
A 085031
A 085032
A 085030
003
001
001
001
Aug
Aug
Aug
Aug
N 016949
001
Jul CAHN

N 016949
002
Jul CAHN

A 090752
A 090752
A 078224
A 078224
A 078224
A 204900
A 204900
A 204900
A 077974
A 077974
A 077974
001
002
001
002
003
001
002
003
001
002
003
Apr
Apr
Feb
Feb
Feb
Jul
Jul
Jul
Jul
Jul
Jul
15,
15,
27,
27,
27,
23,
23,
23,
09,
09,
09,
2011
2011
2008
2008
2008
2015
2015
2015
2007
2007
2007
Mar
Mar
Sep
Sep
Sep
Jul
Jul
Jul
Apr
Apr
Apr
CAHN

CAHN

CAHN

CAHN

CAHN

NEWA

NEWA

NEWA

CAHN

CAHN

CAHN

A 200797
A 200797
A 200797
A 200797
A 200797
A 201087
A 201087
A 201087
A 201087
A 201087
A 200435
A 200435
A 200435
A 200435
001
002
003
004
005
001
002
003
004
005
001
002
005
003
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Sep
Sep
Sep
Sep
03,
03,
03,
03,
03,
01,
01,
01,
01,
01,
25,
25,
25,
25,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2012
2012
2012
2012
May
May
May
May
May
May
May
May
May
May
May
May
May
May
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

CAIN

CAIN

CAIN

CAIN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

@ ANI PHARMS INC
10MG
@
25MG
@
50MG
@
75MG
AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

@ HERITAGE PHARMS INC
EQ 12.5MG BASE;5MG
LIMBITROL DS

EQ 25MG BASE;10MG
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

CHINA RESOURCES
MYLAN PHARMS INC
SOVEREIGN PHARMS
SUN PHARM INDS LTD
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
5MG BASE
10MG BASE
2.5MG BASE
5MG BASE
10MG BASE
2.5MG BASE
5MG BASE
10MG BASE
2.5MG BASE
5MG BASE
10MG BASE
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

LUPIN LTD
5MG;12.5MG;160MG
5MG;25MG;160MG
10MG;12.5MG;160MG
10MG;25MG;160MG
10MG;25MG;320MG
PAR PHARM
5MG;12.5MG;160MG
5MG;25MG;160MG
10MG;12.5MG;160MG
10MG;25MG;160MG
10MG;25MG;320MG
TEVA PHARMS
5MG;12.5MG;160MG
5MG;25MG;160MG
10MG;12.5MG;160MG
10MG;25MG;160MG
CAHN

CAHN

CAHN

CAHN

2015
A 200435
A 201593
A 201593
A 201593
A 201593
A 201593
A 201593
A 201593
A 201593
A 201593
A 201593
004
001
001
002
002
003
003
004
004
005
005
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL
PRESTALIA
SYMPLMED PHARMS LLC
EQ 2.5MG BASE;3.5MG
EQ 5MG BASE;7MG
+
EQ 10MG BASE;14MG
N 205003
N 205003
N 205003
001 Jan 21, 2015

002 Jan 21, 2015
003 Jan 21, 2015
Jan NEWA
Jan NEWA
Jan NEWA
AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN
ALEMBIC PHARMS LTD
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
LUPIN
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
MATRIX LABS LTD
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
MYLAN PHARMS INC
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
NOVEL LABS INC
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
TEVA PHARMS USA
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
TORRENT PHARMS LTD
EQ 5MG BASE;160MG
EQ 5MG BASE;320MG
EQ 10MG BASE;160MG
EQ 10MG BASE;320MG
A 202713
A 202713
A 202713
A 202713
A 090245
A 090245
A 090245
A 090245
A 090483
A 090483
A 090483
A 090483
A 090483
A 090483
A 090483
A 090483
A 202829
A 202829
A 202829
A 202829
A 091235
A 091235
A 091235
A 091235
A 202377
A 202377
A 202377
A 202377
001
003
002
004
001
003
002
004
001
003
002
004
001
003
002
004
001
003
002
004
001
003
002
004
001
002
003
004
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Apr
Apr
Apr
Apr
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
>A> AP
AP
AMMONIA N-13
AMMONIA N 13
3D IMAGING DRUG
BIOMEDCL RES FDN
A 203779
A 204352
001 Oct 19, 2015

001 May 01, 2015
Oct NEWA
Apr NEWA
AP
CENTRAL RADIOPHARM
IBA MOLECULAR N AM
A 204539
A 204667
001 Jun 23, 2015

001 Apr 22, 2015
Jun NEWA
Apr NEWA
A 204515
A 204510
A 204547
A 204455
001
001
001
001
Jan
Oct
Aug
Apr
A 065016
A 065016
001 Apr 08, 1999

002 Apr 08, 1999
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AP
AP
AB
AB
1 -5
October
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
10
TABLET;ORAL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
10MG;25MG;320MG
TORRENT PHARMS LTD
5MG;12.5MG;160MG
5MG;12.5MG;160MG
5MG;25MG;160MG
5MG;25MG;160MG
10MG;12.5MG;160MG
10MG;12.5MG;160MG
10MG;25MG;160MG
10MG;25MG;160MG
10MG;25MG;320MG
10MG;25MG;320MG
NCM USA BRONX LLC

PETNET
PRECISION NUCLEAR
SPECTRON MRC LLC
AMOXICILLIN
CAPSULE;ORAL
AMOXICILLIN
SUN PHARM INDS LTD
30mCi-300mCi/8ML (3.75-37.5mCi/ML)
48.75mCi-487.5mCi/13ML (3.7537.5mCi/ML)
3.75-260mCi/ML
18.8mCi-188mCi/5ML (3.7537.5mCi/ML)
3.75-260mCi/mL
30mCi-300mCi (3.75-37.5mCi/ML)
3.75-260mCi/ML
30mCi-300mCi/8ML (3.75-37.5mCi/ML)
250MG
500MG
Sep
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Apr
Apr
Apr
Apr
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Feb
Nov
Aug
Apr
25,
03,
04,
03,
04,
03,
04,
03,
04,
03,
04,
03,
03,
03,
03,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
04,
02,
14,
23,
2012
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
May
Sep
May
Sep
May
Sep
May
Sep
May
Sep
May
CAIN
CMS1
NEWA
CMS1
NEWA
CMS1
NEWA
CMS1
NEWA
CMS1
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
CAHN
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
Apr CAHN
Apr CAHN
AB
AB
AB
FOR SUSPENSION;ORAL

AMOXICILLIN

@
TABLET;ORAL

AMOXICILLIN

SUN PHARM INDS LTD

AMOXICILLIN

SUN PHARM INDS LTD
@
AB
@
AB
AB
AB
AB
AB
AB
1 -6

October
2015
200MG/5ML
400MG/5ML
A 065113
A 065113
001 Nov 29, 2002

002 Nov 29, 2002
Apr CAHN

Apr CAHN

500MG
875MG
A 065059
A 065059
001 Nov 24, 2000

002 Nov 24, 2000
Apr CAHN

Apr CAHN

125MG
200MG
250MG
400MG
A 065021
A 065060
A 065021
A 065060
001
001
002
002
Apr
Apr
Apr
Apr
A 065132
A 065132
A 065207
001 Mar 19, 2003

002 Mar 19, 2003
002 Jan 30, 2007
Apr CAHN

Apr CAHN

Apr CAHN

A 065109
A 065102
001 Nov 04, 2002

001 Sep 17, 2002
Apr CAHN

Apr CAHN

A 065161
A 065161
001 Dec 03, 2003

002 Dec 03, 2003
Apr CAHN

Apr CAHN

N 208147
001 Oct 19, 2015
Oct NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SUN PHARM INDS LTD
200MG/5ML;EQ 28.5MG BASE/5ML
400MG/5ML;EQ 57MG BASE/5ML
600MG/5ML;EQ 42.9MG BASE/5ML
TABLET;ORAL


500MG;EQ 125MG BASE
875MG;EQ 125MG BASE


SUN PHARM INDS LTD
200MG;EQ 28.5MG BASE
400MG;EQ 57MG BASE
10
Dec
Nov
Dec
Nov
23,
29,
23,
29,
1999
2000
1999
2000
CAHN

CAHN

CAHN

CAHN

>A>
>A>
>A>
AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

DYANAVEL XR

+
TRIS PHARMA INC
EQ 2.5MG BASE/ML
>A>
>A>
>A>
>A>
>A>
>A>
>A>
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

COREPHARMA
1.875MG;1.875MG;1.875MG;1.875MG
A 040444 005 Nov 03, 2014
May NEWA

3.125MG;3.125MG;3.125MG;3.125MG
A 040444 006 Nov 03, 2014
May NEWA

3.75MG;3.75MG;3.75MG;3.75MG
A 040444 007 Nov 03, 2014
May NEWA

MYLAN PHARMS INC
1.25MG;1.25MG;1.25MG;1.25MG
A 206721 001 Nov 10, 2015
Oct NEWA

1.875MG;1.875MG;1.875MG;1.875MG
A 206721 002 Nov 10, 2015
Oct NEWA

2.5MG;2.5MG;2.5MG;2.5MG
A 206721 003 Nov 10, 2015
Oct NEWA

3.125MG;3.125MG;3.125MG;3.125MG
A 206721 004 Nov 10, 2015
Oct NEWA

3.75MG;3.75MG;3.75MG;3.75MG
A 206721 005 Nov 10, 2015
Oct NEWA

5MG;5MG;5MG;5MG
A 206721 006 Nov 10, 2015
Oct NEWA

7.5MG;7.5MG;7.5MG;7.5MG
A 206721 007 Nov 10, 2015
Oct NEWA

AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

ARBOR PHARMS LLC
+
AP
AP
AP
AP
AP
>A> AP
AMPICILLIN SODIUM


AMPICILLIN SODIUM

HOSPIRA INC
SAGENT PHARMS
5MG
10MG
A 200166
A 200166
001 Aug 09, 2012

002 Aug 09, 2012
Mar CTNA

Mar CTNA

EQ
EQ
EQ
EQ
EQ
EQ
A 202864
A 202864
A 202864
A 202864
A 202865
A 090581
001
002
003
004
001
001
Aug
Aug
Aug
Aug
Aug
Oct
A 061741
001
250MG BASE/VIAL
500MG BASE/VIAL
1GM BASE/VIAL
2GM BASE/VIAL
10GM BASE/VIAL
10GM BASE/VIAL
AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

@ G AND W LABS INC
EQ 3.5GM BASE/BOT;1GM/BOT
Sep
Sep
Sep
Sep
Sep
Oct
04,
04,
04,
04,
04,
20,
2015
2015
2015
2015
2015
2015
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

Apr CAHN

ANASTROZOLE
TABLET;ORAL
ANASTROZOLE
@ KREMERS URBAN PHARMS
AP
AP
AP
AA
AA
AA
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
ARGATROBAN
ARGATROBAN
FRESENIUS KABI USA
+
PFIZER
INJECTABLE;IV (INFUSION)
ARGATROBAN
FRESENIUS KABI USA
ARIPIPRAZOLE
SOLUTION;ORAL
ARIPIPRAZOLE
AMNEAL PHARMS
APOTEX INC
SILARX PHARMS INC
TABLET;ORAL
ABILIFY
OTSUKA
+
+
ARIPIPRAZOLE
ALEMBIC PHARMS LTD
1 -7

October
2015
1MG
A 091331
001 Jan 05, 2011
Mar CAHN
250MG/2.5ML (100MG/ML)
250MG/2.5ML (100MG/ML)
N 201811
N 020883
001 Mar 23, 2015

001 Jun 30, 2000
Apr CDFR
Aug CTNA
250MG/2.5ML (100MG/ML)
N 201811
001 Mar 23, 2015
Mar NEWA
1MG/ML
1MG/ML
1MG/ML
A 203906
A 204094
A 204171
001 Aug 14, 2015

001 Sep 30, 2015
001 Aug 14, 2015
Aug NEWA
Sep NEWA
Aug NEWA
2MG
5MG
10MG
15MG
20MG
30MG
N 021436
N 021436
N 021436
N 021436
N 021436
N 021436
006
005
001
002
003
004
Nov
Nov
Nov
Nov
Nov
Nov
15,
15,
15,
15,
15,
15,
2002
2002
2002
2002
2002
2002
Apr
Apr
Apr
Apr
Apr
Apr
CFTG
CFTG
CFTG
CFTG
CFTG
CFTG
A 202101
A 202101
A 202101
A 202101
A 202101
A 202101
A 078583
A 078583
A 078583
A 078583
A 078583
A 078583
A 203908
A 203908
A 203908
A 203908
A 203908
A 203908
A 205064
A 205064
A 205064
A 205064
A 205064
A 205064
A 078607
A 078607
A 078608
A 078708
A 078708
A 078708
A 201519
A 201519
A 201519
A 201519
A 201519
A 201519
001
002
003
004
005
006
001
002
003
004
005
006
001
002
003
004
005
006
001
002
003
004
005
006
001
002
001
001
002
003
001
003
002
004
005
006
Apr
Apr
Apr
Apr
Apr
Apr
Jul
Jul
Jul
Jul
Jul
Jul
Oct
Oct
Oct
Oct
Oct
Oct
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
28,
28,
28,
28,
28,
28,
24,
24,
24,
24,
24,
24,
08,
08,
08,
08,
08,
08,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
28,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
Apr
Apr
Apr
Apr
Apr
Apr
Jul
Jul
Jul
Jul
Jul
Jul
Sep
Sep
Sep
Sep
Sep
Sep
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
N 021729
N 021729
002 Jun 07, 2006

003 Jun 07, 2006
Apr CFTG
Apr CFTG
A 202102
A 202102
001 Apr 28, 2015

002 Apr 28, 2015
Apr NEWA
Apr NEWA
2MG
5MG
10MG
15MG
20MG
30MG
APOTEX INC
2MG
5MG
10MG
15MG
20MG
30MG
2MG
5MG
10MG
15MG
20MG
30MG
HETERO LABS LTD V
2MG
5MG
10MG
15MG
20MG
30MG
TEVA PHARMS USA
2MG
5MG
10MG
15MG
20MG
30MG
TORRENT PHARMS LTD
2MG
10MG
5MG
15MG
20MG
30MG
TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY
+
OTSUKA
10MG
15MG
ARIPIPRAZOLE
ALEMBIC PHARMS LTD
10MG
15MG
10
>A>

>A>

>A>

>A>

>A>

>A>

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

ALKERMES INC
441MG/1.6ML (275.63MG/ML)
662MG/2.4ML (275.83MG/ML)
+
882MG/3.2ML (275.63MG/ML)
10
October
2015
N 207533
N 207533
N 207533
001 Oct 05, 2015

002 Oct 05, 2015
003 Oct 05, 2015
1 -8

Oct NEWA

Oct NEWA

Oct NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E


M.V.I.-12 LYOPHILIZED

@ IGI LABS INC
100MG/VIAL;0.06MG/VIAL;0.005MG/VIA N 018933 002 Aug 08, 1985
Jun CAHN

L;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;4
0MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/V
IAL;1MG/VIAL;10MG/VIAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM
SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

@ NOVEL LABS INC
4.7GM;100GM;1.015GM;5.9GM;2.691GM; A 090145 001 Jan 25, 2012
Aug CTNA

7.5GM

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC
+
EQ 5MG BASE
EQ 10MG BASE
N 022117
N 022117
001 Aug 13, 2009

002 Aug 13, 2009
Jun CAHN

Jun CAHN

N 200671
001 Sep 04, 2015
Sep NEWA

N 017534
005 Apr 16, 1986
Jan CAHN

N 017534
003 Apr 16, 1986
Jan CAHN

A 203335
001 Oct 30, 2015
Oct NEWA

N 019429
003 Oct 26, 1990
Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+
SUN PHARM INDS
356.4MG;30MG;16MG
N 011483
004 Sep 06, 1983
Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ
385MG;30MG;25MG
+
770MG;60MG;50MG
A 074654
A 074654
001 Dec 31, 1996

002 Dec 31, 1996
Mar CTEC

Mar CTEC

A 090084
001 Mar 22, 2011
Mar CAHN

ASPIRIN


DURLAZA

+
NEW HAVEN PHARMS
162.5MG
ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA

+
ACTAVIS LABS UT INC
325MG;50MG;40MG
TABLET;ORAL

FIORINAL

325MG;50MG;40MG
ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

>A> AB

COASTAL PHARMS
FIORINAL W/CODEINE

AB

+
ACTAVIS LABS UT INC
ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA

ACTAVIS LABS FL INC
325MG;4.8355MG
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AP
ATENOLOL
TABLET;ORAL
ATENOLOL
ALVOGEN IPCO SARL
@ DAVA PHARMS INC

TENORMIN
ALVOGEN IPCO SARL
+
2015
N 206353
001 Jan 29, 2015
Jan NEWA
25MG
50MG
100MG
25MG
A 073646
A 072303
A 072304
A 074099
001
001
001
001
Jul
Jul
Jul
Jun
25MG
50MG
100MG
N 018240
N 018240
N 018240
004 Apr 09, 1990

001
002
Feb CAHN
Feb CAHN
Feb CAHN
A 072301
A 072302
001 May 31, 1990

001 May 31, 1990
Jul CAHN
Jul CAHN
N 018760
001 Jun 08, 1984
Feb CAHN
N 018760
002 Jun 08, 1984
Feb CAHN
ATENOLOL; CHLORTHALIDONE
TABLET;ORAL
ATENOLOL AND CHLORTHALIDONE
ALVOGEN IPCO SARL
50MG;25MG
100MG;25MG
TENORETIC 100
+
ALVOGEN IPCO SARL
100MG;25MG
TENORETIC 50
ALVOGEN IPCO SARL
50MG;25MG
ATORVASTATIN CALCIUM
TABLET;ORAL
ATORVASTATIN CALCIUM
KREMERS URBAN PHARMS
1 -9

October
ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ
+
BRISTOL MYERS SQUIBB EQ 300MG BASE;150MG
10
Jul
Jul
Jul
Apr
31,
15,
15,
28,
1992
1988
1988
1992
CAHN
CAHN
CAHN
DISC
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
10MG
20MG
40MG
80MG
10MG
20MG
40MG
80MG
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
A 091624
A 091624
A 091624
A 091624
A 076477
A 076477
A 076477
A 076477
001
002
003
004
001
002
003
004
Apr
Apr
Apr
Apr
Nov
Nov
Nov
Nov
05,
05,
05,
05,
30,
30,
30,
30,
2013
2013
2013
2013
2011
2011
2011
2011
Mar
Mar
Mar
Mar
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL
LIPTRUZET
@ MERCK SHARP DOHME
EQ
@
EQ
@
EQ
@
EQ
10MG
20MG
40MG
80MG
BASE;10MG
BASE;10MG
BASE;10MG
BASE;10MG
N 200153
N 200153
N 200153
N 200153
001
002
003
004
May
May
May
May
03,
03,
03,
03,
2013
2013
2013
2013
May
May
May
May
DISC
DISC
DISC
DISC
A 091211
002 Apr 06, 2015
Mar NEWA
A 206011
001 Apr 08, 2015
Mar NEWA
A 206010
001 Apr 08, 2015
Mar NEWA
N 206289
001 Jul 18, 2014
May CRLD
N 017744
002
Feb CAHN
N 017744
001
Feb CAHN
SUN PHARM INDS LTD
ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
GLENMARK GENERICS
62.5MG;25MG
ATRACURIUM BESYLATE
ATRACURIUM BESYLATE
10MG/ML
ATRACURIUM BESYLATE PRESERVATIVE FREE
AUROBINDO PHARMA LTD 10MG/ML
ATROPINE SULFATE
SOLUTION/DROPS;OPHTHALMIC
ATROPINE SULFATE
+
AKORN
1%
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
TABLET;ORAL
MOTOFEN
+
SEBELA IRELAND LTD
0.025MG;1MG
MOTOFEN HALF-STRENGTH
@ SEBELA IRELAND LTD
0.025MG;0.5MG
October
2015
1 -10

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
@ ANI PHARMS INC
0.025MG;2.5MG
A 086727
001
Jul CAHN
AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)
AVYCAZ
+
CEREXA INC
EQ 0.5GM BASE;2GM/VIAL
N 206494
001 Feb 25, 2015
Feb NEWA
AZELAIC ACID
AEROSOL, FOAM;TOPICAL
FINACEA
+
BAYER HLTHCARE
N 207071
001 Jul 29, 2015
Jul NEWA
A 090176
001 Jul 28, 2015
Jul NEWA
EQ 100MG BASE/5ML
EQ 200MG BASE/5ML
A 065488
A 065488
001 May 15, 2015

002 May 15, 2015
May NEWA
May NEWA
EQ 500MG BASE/VIAL
A 203294
001 Jun 19, 2015
Jun NEWA
EQ 250MG BASE
EQ 500MG BASE
EQ 600MG BASE
A 065398
A 065399
A 065400
001 May 15, 2015

001 May 15, 2015
001 May 15, 2015
May NEWA
May NEWA
May NEWA
750MG
N 020610
001 Jul 18, 2000
Jul CAHN
1.1GM
A 206336
001 Sep 08, 2015
Aug NEWA
1.1GM
1.1GM
N 022205
N 022205
001 Feb 03, 2012

001 Feb 03, 2012
Aug CFTG
Jul CAHN
AB
AB
AB
AB
AB
AB
AB
AB
BENAZEPRIL HYDROCHLORIDE
TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE
AMNEAL PHARMS LLC
5MG
10MG
20MG
40MG
SUN PHARM INDS LTD
5MG
10MG
20MG
40MG
A 076820
A 076820
A 076820
A 076820
A 076344
A 076344
A 076344
A 076344
001
002
003
004
001
002
003
004
Feb
Feb
Feb
Feb
Feb
Feb
Feb
Feb
03,
03,
03,
03,
11,
11,
11,
11,
2006
2006
2006
2006
2004
2004
2004
2004
Jan
Jan
Jan
Jan
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
AB
AB
AB
AB
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
SUN PHARM INDS LTD
5MG;6.25MG
10MG;12.5MG
20MG;12.5MG
20MG;25MG
A 077483
A 077483
A 077483
A 077483
001
002
003
004
Sep
Sep
Sep
Sep
08,
08,
08,
08,
2005
2005
2005
2005
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
AB
AB
AB
AP
AB
AB
AB
AB
AB
AB
15%
AZELASTINE HYDROCHLORIDE
SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE
BRECKENRIDGE PHARMS
EQ 0.125MG BASE/SPRAY
AZITHROMYCIN
FOR SUSPENSION;ORAL
AZITHROMYCIN
LUPIN LTD
AZITHROMYCIN
TABLET;ORAL
AZITHROMYCIN
LUPIN LTD
BALSALAZIDE DISODIUM
CAPSULE;ORAL
COLAZAL
+
VALEANT PHARMS INTL
TABLET;ORAL
BALSALAZIDE DISODIUM
PAR PHARM INC
GIAZO
+
VALEANT PHARMS INTL
+
10
2015
A 091310
A 091310
A 081297
A 081297
A 202765
A 091133
A 091133
A 091133
A 091133
001
002
001
002
001
001
002
001
002
N 050819
001 Oct 23, 2008
Jun CFTG
A 205128
A 202440
001 Jun 19, 2015

001 Sep 21, 2015
Jun NEWA
Sep NEWA
N 050819
002 Nov 24, 2014
Jan CRLD
A 065385
001 Sep 18, 2015
Sep NEWA
A 090968
001 Jul 20, 2010
Jun CRLD
N 012427
002
Jun DISC
A 204713
A 204713
A 204713
001 Apr 14, 2015

002 Apr 14, 2015
003 Apr 14, 2015
Mar NEWA
Mar NEWA
Mar NEWA
BETAMETHASONE DIPROPIONATE
LOTION;TOPICAL
BETAMETHASONE DIPROPIONATE
G AND W LABS INC
EQ 0.05% BASE
@
EQ 0.05% BASE
A 071467
A 071882
001 Aug 10, 1987

001 Jun 06, 1988
Apr CAHN
Apr CAHN
>A>
>A>
>A>
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL
ENSTILAR
+
LEO PHARMA AS
0.064%;0.005%
N 207589
001 Oct 16, 2015
Oct NEWA
>A> AB
BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
GLENMARK PHARMS LTD
EQ 0.05% BASE;1%
A 202894
001 Oct 30, 2015
Oct NEWA
EQ 0.1% BASE
N 018642
001 Mar 24, 1983
Aug CAHN
EQ 0.1% BASE
A 070072
001 Jun 27, 1985
Apr CAHN
EQ 0.1% BASE
EQ 0.1% BASE
A 070069
A 070069
001 Dec 19, 1985

001 Dec 19, 1985
Oct CAHN
Oct CAHN
AA
AA
AA
AA
AA
AA
AA
AA
AA
AB
AB
AB
AB
AA
AA
AA
AA
AB
AB
AB
>A> AB
>D>

CSPC NBP PHARM CO
STRIDES ARCOLAB LTD
STRIDES PHARMA
100MG
200MG
100MG
200MG
200MG
100MG
200MG
100MG
200MG
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
ACANYA
+
DOW PHARM
2.5%;EQ 1.2% BASE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
ACTAVIS LABS UT INC
2.5%;EQ 1.2% BASE
PERRIGO ISRAEL
5%;EQ 1% BASE
ONEXTON
+
DOW PHARM
3.75%;EQ 1.2% BASE
BENZOYL PEROXIDE; ERYTHROMYCIN
GEL;TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE
LYNE
5%;3%
BENZPHETAMINE HYDROCHLORIDE
TABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE
+
KVK TECH
50MG
DIDREX
@ PHARMACIA AND UPJOHN 50MG
BENZTROPINE MESYLATE
TABLET;ORAL
BENZTROPINE MESYLATE
NUVO PHARM INC
BETAMETHASONE VALERATE
CREAM;TOPICAL
BETA-VAL
G AND W LABS INC
LOTION;TOPICAL
BETA-VAL
G AND W LABS INC
OINTMENT;TOPICAL
BETA-VAL
G AND W LABS INC
@ TEVA
0.5MG
1MG
2MG
1 -11

October
BENZONATATE
CAPSULE;ORAL
BENZONATATE
APOTEX INC
10
Jan
Jan
Jan
Oct
Jul
Jul
Jul
Jul
Jul
16,
16,
29,
30,
31,
30,
30,
30,
30,
2015
2015
1993
2007
2015
2015
2015
2015
2015
Jan
Jan
Jan
Jan
Jul
Jul
Jul
Aug
Aug
NEWA
NEWA
CAHN
CAHN
NEWA
NEWA
NEWA
CAHN
CAHN
AA
AA
AA
AA
AA
AA
BETHANECHOL CHLORIDE
TABLET;ORAL
BETHANECHOL CHLORIDE
HERITAGE PHARMA
LANNETT HOLDINGS INC

DUVOID
WELLSPRING PHARM
AA
AA
AA
10
1 -12

October
2015
5MG
10MG
25MG
50MG
5MG
50MG
A 091256
A 091256
A 091256
A 091256
A 040703
A 040677
001
002
003
004
001
001
10MG
25MG
50MG
A 086262
A 086263
A 085882
001
001
003
Jan CMFD
May CMFD
May CMFD
75MG
75MG
A 203174
A 203174
001 Aug 12, 2014

001 Aug 12, 2014
Jun CMFD
Jan CAHN
75MG
N 021055
001 Dec 29, 1999
Jun CTEC
May
May
May
May
Mar
Mar
04,
04,
04,
04,
27,
27,
2010
2010
2010
2010
2008
2008
Mar
Mar
Mar
Mar
Feb
Feb
CAHN
CAHN
CAHN
CAHN
CMFD
CMFD
AB
BEXAROTENE
CAPSULE;ORAL
BEXAROTENE
@
TARGRETIN
+
VALEANT LUXEMBOURG
AB
AB
BICALUTAMIDE
TABLET;ORAL
BICALUTAMIDE
APOTEX INC
STASON PHARMS
50MG
50MG
A 200274
A 091011
001 May 21, 2015

001 Jun 10, 2015
May NEWA
May NEWA
BIMATOPROST
BIMATOPROST
ALCON RES LTD
APOTEX INC
+
LUPIN LTD
+
+
0.03%
0.03%
0.03%
0.03%
0.03%
A 202565
A 090449
A 203991
A 203991
A 203991
001
001
001
001
001
Apr
Jul
Apr
Mar
Feb
BIPERIDEN HYDROCHLORIDE
TABLET;ORAL
AKINETON
@ ABBVIE
2MG
N 012003
001
Aug DISC
N 050786
001 Sep 28, 2006
Jul CAHN
250MG/VIAL
250MG/VIAL
A 090811
A 090816
001 Jul 14, 2015

001 Jul 14, 2015
Jun NEWA
Jun NEWA
EQ 100MG BASE
EQ 500MG BASE
N 203341
N 203341
001 Sep 04, 2012

002 Sep 04, 2012
Jun CRLD
Jun CRLD
0.25MG
0.5MG
1MG
2MG
3MG
4MG
N 205422
N 205422
N 205422
N 205422
N 205422
N 205422
001
002
003
004
005
006
Jul
Jul
Jul
Jul
Jul
Jul
AB
AT
AT
AT
AT
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL
PYLERA
+
FOREST LABS LLC
140MG;125MG;125MG
AP
AP
BIVALIRUDIN
BIVALIRUDIN
HOSPIRA INC
BOSUTINIB MONOHYDRATE
TABLET;ORAL
BOSULIF
+
WYETH PHARMS INC
BREXPIPRAZOLE
TABLET;ORAL
REXULTI
OTSUKA PHARM CO LTD
May
Jul
Feb
Feb
Feb
Jul
Jul
Jul
Jul
Jul
Jul
05,
20,
20,
20,
20,
10,
10,
10,
10,
10,
10,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
NEWA
NEWA
CTEC
CTEC
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
AT2
AT2
AT1
AT2
AT1
BROMFENAC SODIUM
BROMDAY
@ BAUSCH AND LOMB INC
+
BROMFENAC SODIUM
APOTEX INC
+
COASTAL PHARMS
HI-TECH PHARMACAL
PADDOCK LLC
2015
EQ 0.09% ACID
EQ 0.09% ACID
N 021664
N 021664
002 Oct 16, 2010

002 Oct 16, 2010
Sep DISC

May CTEC

EQ
EQ
EQ
EQ
A 202620
A 201211
A 203395
A 201941
001
001
001
001
May
May
May
Jan
N 205613
001 Oct 07, 2014
Apr CAHN

A 078949
001 May 12, 2014
Mar CTEC

N 203634
001 Jan 14, 2013
Aug CAHN

0.25MG/ML
A 079196
001 Apr 30, 2008
Jun CAHN

0.5MG
0.5MG
1MG
1MG
2MG
2MG
N 018225
N 018225
N 018225
N 018225
N 018225
N 018225
002
002
001
001
003
003
Feb
Feb
Feb
Feb
Jun
Jun
28,
28,
28,
28,
14,
14,
1983
1983
1983
1983
1985
1985
Oct
Oct
Oct
Oct
Oct
Oct
CMFD

CMFD

CMFD

CMFD

CMFD

CMFD

75MCG
150MCG
300MCG
450MCG
600MCG
750MCG
900MCG
N 207932
N 207932
N 207932
N 207932
N 207932
N 207932
N 207932
001
002
003
004
005
006
007
Oct
Oct
Oct
Oct
Oct
Oct
Oct
23,
23,
23,
23,
23,
23,
23,
2015
2015
2015
2015
2015
2015
2015
Oct
Oct
Oct
Oct
Oct
Oct
Oct
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

0.3MG BASE/ML
A 206586
001 Jul 28, 2015
Jul NEWA

2MG
8MG
2MG
8MG
2MG
8MG
A 090819
A 090819
A 201066
A 201066
A 090279
A 090279
001
002
001
002
001
002
Feb
Feb
Mar
Mar
Jun
Jun
19,
19,
06,
06,
10,
10,
2015
2015
2015
2015
2015
2015
Feb
Feb
Feb
Feb
May
May
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

N 022410
N 022410
N 022410
N 022410
001
003
002
004
Aug
Aug
Aug
Aug
30,
10,
30,
10,
2010
2012
2010
2012
Sep
Sep
Sep
Sep
CDFR

CDFR

CDFR

CDFR

A 204431
A 204431
001 Oct 16, 2015

002 Oct 16, 2015
Oct NEWA

Oct NEWA

N 204242
005 Jun 04, 2015
Jun NEWA

ACID
ACID
ACID
ACID
BUDESONIDE
AEROSOL, FOAM;RECTAL
UCERIS
+
VALEANT PHARMS INTL
2MG/ACTUATION
BUDESONIDE
APOTEX INC
0.032MG/INH
UCERIS
+
VALEANT PHARMS INTL
9MG
AP
>D>
>A> AB
>D>
>A> AB
>D>
>A> AB
>A>
>A>
>A>
>A>
>A>
>A>
>A>
>A>
>A>
>A>
BUMETANIDE
BUMETANIDE
EUROHLTH INTL SARL
TABLET;ORAL
BUMEX
@ VALIDUS PHARMS INC
@
@
BUPRENORPHINE HYDROCHLORIDE
FILM;BUCCAL
BELBUCA
ENDO PHARMS INC
AP
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
PAR STERILE PRODUCTS
EQ
TABLET;SUBLINGUAL
ACTAVIS ELIZABETH
EQ
EQ
MYLAN PHARMS INC
EQ
EQ
SANDOZ INC
EQ
EQ
BASE
BASE
BASE
BASE
BASE
BASE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
SUBOXONE
INDIVIOR INC
EQ 2MG BASE;EQ 0.5MG BASE
EQ 4MG BASE;EQ 1MG BASE
+
TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
ETHYPHARM USA CORP
EQ 2MG BASE;EQ 0.5MG BASE
ZUBSOLV
OREXO AB
EQ 2.9MG BASE;EQ 0.71MG BASE
1 -13

October
0.09%
0.09%
0.09%
0.09%
10
Jun
May
Jan
Feb
23,
11,
22,
10,
2014
2011
2014
2015
CTEC

CRLD

CTEC

NEWA

AB1
AB1
AB1
AB2
AB
AB
AB
AB
1 -14

October
2015
BUPROPION HYDROBROMIDE


APLENZIN

VALEANT PHARMS NORTH
174MG
348MG
+
522MG
N 022108
N 022108
N 022108
001 Apr 23, 2008

002 Apr 23, 2008
003 Apr 23, 2008
Feb CAHN

Feb CAHN

Feb CAHN

BUPROPION HYDROCHLORIDE


BUPROPION HYDROCHLORIDE

PRINSTON INC
100MG
150MG
200MG
SANDOZ INC
150MG
@ WOCKHARDT LTD
100MG
@
150MG
@
200MG
A 202304
A 202304
A 202304
A 077475
A 201331
A 201331
A 201331
001
002
003
001
001
002
003
May
May
May
Mar
Aug
Aug
Aug
26,
26,
26,
12,
30,
30,
30,
2015
2015
2015
2008
2012
2012
2012
May
May
May
Mar
May
May
May
NEWA

NEWA

NEWA

CAHN

DISC

DISC

DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

EMCURE PHARMS USA
5MG
10MG
15MG
30MG
A 204582
A 204582
A 204582
A 204582
001
002
003
004
Sep
Sep
Sep
Sep
18,
18,
18,
18,
2015
2015
2015
2015
Sep
Sep
Sep
Sep
NEWA

NEWA

NEWA

NEWA

30MG/5ML
A 085380
001
Jul DISC

50MG
N 000793
003
May DISC

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM

@ MEDA PHARMS
TABLET;ORAL

BUTISOL SODIUM

@ MEDA PHARMS
10
BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

@ ELAN PHARMA INTL LTD
GYNAZOLE-1

+
PERRIGO ISRAEL
2%
N 019881
001 Feb 07, 1997
May CTNA

2%
A 200923
001 May 18, 2012
Jun CTNA

AP
CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 205013
001 Sep 22, 2015
Sep NEWA

AB
CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

GLENMARK PHARMS LTD
0.005%
A 205772
001 Jun 09, 2015
May NEWA

200 IU/ML
A 073690
001 Apr 14, 1995
Mar CAHN

100 IU/ML
200 IU/ML
N 017808
N 017808
001 Jul 03, 1986

002 Mar 29, 1991
Aug CAHN

Aug CAHN

AB
CALCITONIN SALMON


CALCITONIN-SALMON

@ IGI LABS INC
MIACALCIN

@ MYLAN IRELAND LTD
+

MIACALCIN

+
MYLAN IRELAND LTD
200 IU/SPRAY
N 020313
002 Aug 17, 1995
Aug CAHN

0.25MCG
0.5MCG
0.25MCG
0.5MCG
A 091174
A 091174
A 091356
A 091356
001
002
001
002
Jan
Jan
Jan
Jan
AB
AB
AB
AB
CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

STRIDES PHARMA
May
May
Dec
Dec
24,
24,
12,
12,
2013
2013
2014
2014
CAHN

CAHN

CAHN

CAHN


CALCIJEX

@ ABBVIE
@
CALCITRIOL

@ AKORN
@ FRESENIUS KABI USA
@
@ FRESENIUS MEDCL
@
@ LUITPOLD
@
@ SAGENT PHARMS
AB

AB

>A> AB

AB

AB

AB

>A>

>D>

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

HERITAGE PHARMS INC
LUPIN LTD
NOSTRUM LABS INC
TABLET;ORAL

CALCIUM ACETATE

HERITAGE PHARMS INC
>D>

>A>

>D>

>D>

0.001MG/ML
0.002MG/ML
N 018874
N 018874
001 Sep 25, 1986

002 Sep 25, 1986
Jun DISC

Jun DISC

0.002MG/ML
0.001MG/ML
0.002MG/ML
0.001MG/ML
0.002MG/ML
0.001MG/ML
0.002MG/ML
0.001MG/ML
A 078066
A 075836
A 075836
A 075766
A 075766
A 075746
A 075746
A 077102
002
001
002
001
002
001
002
001
Jan
Dec
Dec
Feb
Feb
Sep
Sep
Feb
29,
31,
31,
20,
20,
26,
26,
08,
2008
2002
2002
2003
2003
2003
2003
2006
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
DISC

DISC

DISC

DISC

DISC

DISC

DISC

DISC

EQ
EQ
EQ
EQ
CALCIUM
CALCIUM
CALCIUM
CALCIUM
A 202315
A 202127
A 203179
A 202315
001
001
001
001
Jun
Jul
Oct
Jun
29,
09,
26,
29,
2015
2015
2015
2015
Sep
Jun
Oct
Jun
CAHN

NEWA

NEWA

NEWA

EQ 169MG CALCIUM
EQ 169MG CALCIUM
A 202885
A 202885
001 Jan 22, 2015

001 Jan 22, 2015
GAMBRO RENAL PRODS
Sep CAHN

Jan NEWA

N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703
L;3.05GM/1000ML;0.157GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

010 Oct 10, 2008
Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703
L;3.05GM/1000ML;0.157GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

010 Oct 10, 2008
Jan CPOT

N 021703
012 Oct 10, 2008
Oct CAHN

N 021703
012 Oct 10, 2008
Oct CAHN

N 021703
012 Oct 10, 2008
Jan CPOT

N 021703
011 Oct 10, 2008
Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703
L;3.05GM/1000ML;0.314GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

011 Oct 10, 2008
Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703
L;3.05GM/1000ML;0.314GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

011 Oct 10, 2008
Jan CPOT

013 Oct 10, 2008
Oct CAHN

013 Oct 10, 2008
Oct CAHN

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
3.68GM/1000ML;20GM/1000ML;5.4GM/10
00ML;3.05GM/1000ML;0.157GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)
@ GAMBRO RENAL PRODS

3.68GM/1000ML;20GM/1000ML;5.4GM/10
00ML;3.05GM/1000ML;0.157GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)
@
3.68GM/1000ML;20GM/1000ML;5.4GM/10
00ML;3.05GM/1000ML;0.157GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+
BAXTER HLTHCARE
N/A/1000ML;20GM/1000ML;5.4GM/1000M
L;3.05GM/1000ML;0.314GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

+
>A>

2015
CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
SODIUM CHLORIDE


PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+
BAXTER HLTHCARE
N/A/1000ML;20GM/1000ML;5.4GM/1000M N 021703 010 Oct 10, 2008
Oct CAHN

L;3.05GM/1000ML;0.157GM/1000ML;2.2
1GM/1000ML;7.07GM/1000ML (5000ML)

>A>

1 -15

October
169MG
169MG
169MG
169MG
10
GAMBRO RENAL PRODS

BAXTER HLTHCARE
3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703
00ML;3.05GM/1000ML;0.314GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)
+
GAMBRO RENAL PRODS
3.68GM/1000ML;20GM/1000ML;5.4GM/10 N 021703
00ML;3.05GM/1000ML;0.314GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)

+
>A>
>D>
>A>
>D>
GAMBRO RENAL PRODS
GAMBRO RENAL PRODS
>A>
>D>
>A>
>D>
>A>
>D>
Oct CAHN

3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
006 Oct 25, 2006

00ML;3.05GM/1000ML;N/A/1000ML;3.09
GM/1000ML;6.46GM/1000ML (5000ML)

Jan CPOT

Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
002 Oct 25, 2006

L;2.03GM/1000ML;0.157GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
002 Oct 25, 2006

L;2.03GM/1000ML;0.157GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Jan CPOT

N 021703
003 Oct 25, 2006

Oct CAHN

N 021703
003 Oct 25, 2006

Oct CAHN

N 021703
003 Oct 25, 2006

Jan CPOT

N 021703
005 Oct 25, 2006

Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
005 Oct 25, 2006

L;3.05GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
005 Oct 25, 2006

L;3.05GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Jan CPOT

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER
BAXTER HLTHCARE
N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
015 Oct 10, 2008

L;2.44GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

GAMBRO RENAL PRODS
Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
015 Oct 10, 2008

L;2.44GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Oct CAHN

N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
015 Oct 10, 2008

L;2.44GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

Jan CPOT

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER
BAXTER HLTHCARE
3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
004 Oct 25, 2006

00ML;3.05GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
+
GAMBRO RENAL PRODS
3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
004 Oct 25, 2006

00ML;3.05GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)

+
Jan CPOT

Oct CAHN

BAXTER HLTHCARE
5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.157GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
+
GAMBRO RENAL PRODS
5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.157GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
+
5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.157GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
N/A/1000ML;20GM/1000ML;5.4GM/1000M
L;3.05GM/1000ML;0.314GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

+
1 -16

3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
006 Oct 25, 2006

00ML;3.05GM/1000ML;N/A/1000ML;3.09
GM/1000ML;6.46GM/1000ML (5000ML)

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER
BAXTER HLTHCARE
N/A/1000ML;20GM/1000ML;5.4GM/1000M
N 021703
002 Oct 25, 2006

L;2.03GM/1000ML;0.157GM/1000ML;3.0
9GM/1000ML;6.46GM/1000ML (5000ML)

>D>
-
October
2015



+
3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
013 Oct 10, 2008

00ML;3.05GM/1000ML;0.314GM/1000ML;
2.21GM/1000ML;7.07GM/1000ML
(5000ML)
+
BAXTER HLTHCARE
3.68GM/1000ML;20GM/1000ML;5.4GM/10
N 021703
006 Oct 25, 2006

00ML;3.05GM/1000ML;N/A/1000ML;3.09
GM/1000ML;6.46GM/1000ML (5000ML)

>A>
10
Oct CAHN

Oct CAHN

>A>

>D>

>A>

>A>

>D>

>A>

>D>

1 -17

October
2015
N 021703
004 Oct 25, 2006
Jan CPOT

N 021703
008 Oct 25, 2006
Oct CAHN

N 021703
008 Oct 25, 2006
Oct CAHN

N 021703
008 Oct 25, 2006
Jan CPOT

N 021703
007 Oct 25, 2006
Oct CAHN

N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703
;3.05GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

007 Oct 25, 2006
Oct CAHN

N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703
;3.05GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

007 Oct 25, 2006
Jan CPOT

014 Oct 10, 2008
Oct CAHN

N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703
;2.44GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

014 Oct 10, 2008
Oct CAHN

N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703
;2.44GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

014 Oct 10, 2008
Jan CPOT

001 Oct 25, 2006
Oct CAHN

5.15GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;2.03GM/1000ML;N/A/1000ML;3.09G
M/1000ML;6.46GM/1000ML (5000ML)

001 Oct 25, 2006
Oct CAHN

5.15GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;2.03GM/1000ML;N/A/1000ML;3.09G
M/1000ML;6.46GM/1000ML (5000ML)

001 Oct 25, 2006
Jan CPOT

009 Oct 25, 2006
Oct CAHN

009 Oct 25, 2006
Oct CAHN

009 Oct 25, 2006
Jan CPOT

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

BAXTER HLTHCARE
N/A/1000ML;N/A/1000ML;5.4GM/1000ML N 021703
;2.44GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

GAMBRO RENAL PRODS
>D>



+
3.68GM/1000ML;20GM/1000ML;5.4GM/10
00ML;3.05GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
@ BAXTER HLTHCARE
5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)

5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
@
5.15GM/1000ML;20GM/1000ML;5.4GM/10
00ML;2.03GM/1000ML;0.314GM/1000ML;
3.09GM/1000ML;6.46GM/1000ML
(5000ML)
PRISMASOL BK 0/0 IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
N/A/1000ML;N/A/1000ML;5.4GM/1000ML
;3.05GM/1000ML;N/A/1000ML;3.09GM/1
000ML;6.46GM/1000ML (5000ML)

>D>

>A>

10
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE
5.15GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;2.03GM/1000ML;N/A/1000ML;3.09G
M/1000ML;6.46GM/1000ML (5000ML)

GAMBRO RENAL PRODS
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
3.68GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;3.05GM/1000ML;0.314GM/1000ML;3
.09GM/1000ML;6.46GM/1000ML
(5000ML)

3.68GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;3.05GM/1000ML;0.314GM/1000ML;3
.09GM/1000ML;6.46GM/1000ML
(5000ML)
@
3.68GM/1000ML;N/A/1000ML;5.4GM/100 N 021703
0ML;3.05GM/1000ML;0.314GM/1000ML;3
.09GM/1000ML;6.46GM/1000ML
(5000ML)

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
SODIUM CHLORIDE; SODIUM PHOSPHATE


PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+
GAMBRO LUNDIA
N/A/1000ML;N/A/1000ML;N/A/1000ML;3 N 207026 002 Jan 13, 2015
Jan NEWA

.05GM/1000ML;0.314GM/1000ML;2.21GM
/1000ML;6.95GM/1000ML;0.187GM/1000
ML (5000ML)

10
October

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+
GAMBRO LUNDIA
3.68GM/1000ML;N/A/1000ML;N/A/1000M N 207026
L;3.05GM/1000ML;0.314GM/1000ML
;3.09GM/1000ML;6.34GM/1000ML;0.187
GM/1000ML (5000ML)

1 -18

2015
001 Jan 13, 2015
Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@ ALCON PHARMS LTD
0.154MG/ML;0.92MG/ML;0.2MG/ML;0.18 N 022193 001 Jul 24, 2008
Jun DISC

4MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M
L;0.42MG/ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE;
SODIUM LACTATE


PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
37MG/100ML;5GM/100ML;30MG/100ML;11 N 017390 001
Mar DISC

9MG/100ML;161MG/100ML;94MG/100ML;1
38MG/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM
LACTATE


PLASMA-LYTE R IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
36.8MG/100ML;30.5MG/100ML;74.6MG/1 N 017438 001
Mar DISC

00ML;640MG/100ML;496MG/100ML;89.6M
G/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
PHOSPHATE


PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
+
BAXTER HLTHCARE
N/A/1000ML;3.05GM/1000ML;0.314GM/1 N 207026 002
000ML;2.21GM/1000ML;6.95GM/1000ML;
0.187GM/1000ML (5000ML)
+
GAMBRO LUNDIA
N/A/1000ML;3.05GM/1000ML;0.314GM/1 N 207026 002
000ML;2.21GM/1000ML;6.95GM/1000ML;
0.187GM/1000ML (5000ML)
+
N/A/1000ML;3.05GM/1000ML;0.314GM/1 N 207026 002
000ML;2.21GM/1000ML;6.95GM/1000ML;
0.187GM/1000ML (5000ML)
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
+
BAXTER HLTHCARE
3.68GM/1000ML;3.05GM/1000ML;0.314G N 207026 001
M/1000ML
;3.09GM/1000ML;6.34GM/1000ML;0.187
+
GAMBRO LUNDIA
3.68GM/1000ML;3.05GM/1000ML;0.314G N 207026 001
M/1000ML
;3.09GM/1000ML;6.34GM/1000ML;0.187
+
3.68GM/1000ML;3.05GM/1000ML;0.314G N 207026 001
M/1000ML
;3.09GM/1000ML;6.34GM/1000ML;0.187

>A>
>D>
>A>
>D>
Jan 13, 2015
Oct CAHN

Jan 13, 2015
Oct CAHN

Jan 13, 2015
Feb CAIN

Jan 13, 2015
Oct CAHN

Jan 13, 2015
Oct CAHN

Jan 13, 2015
Feb CAIN

001 Aug 29, 1989
Sep DISC

A 204100
A 204100
A 204100
001 Feb 27, 2015

002 Feb 27, 2015
003 Feb 27, 2015
Feb NEWA

Feb NEWA

Feb NEWA

A 202593
A 202593
001 Apr 23, 2015

002 Apr 23, 2015
Apr NEWA

Apr NEWA

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
20MG/100ML;30MG/100ML;600MG/100ML; N 019933
310MG/100ML

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB
MACLEODS PHARMS LTD
16MG;12.5MG
AB
32MG;12.5MG
AB
32MG;25MG
AB
AB
CAPECITABINE

TABLET;ORAL

CAPECITABINE

ACCORD HLTHCARE
150MG
500MG
SODIUM CHLORIDE; SODIUM
10
1 -19

October
2015
A 074433
A 074462
A 074483
A 074590
A 074433
A 074462
A 074483
A 074590
A 074433
A 074462
A 074483
A 074590
A 074433
A 074462
A 074483
A 074590
A 074434
001
001
001
004
002
002
002
002
003
003
003
001
004
004
004
003
004
Feb
Feb
Feb
Aug
Feb
Feb
Feb
Aug
Feb
Feb
Feb
Aug
Feb
Feb
Feb
Aug
Feb
13,
13,
13,
30,
13,
13,
13,
30,
13,
13,
13,
30,
13,
13,
13,
30,
13,
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
1996
Jul
Apr
Jul
Apr
Jul
Apr
Jul
Apr
Jul
Apr
Jul
Apr
Jul
Apr
Jul
Apr
May
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CRLD
Dec
Dec
Dec
Dec
29,
29,
29,
29,
1997
1997
1997
1997
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
AB
CAPTOPRIL
TABLET;ORAL
CAPTOPRIL
@ G AND W LABS INC
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
+
MYLAN
AB
AB
AB
AB
CAPTOPRIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE
G AND W LABS INC
25MG;15MG
25MG;25MG
50MG;15MG
50MG;25MG
A 074827
A 074827
A 074827
A 074827
001
002
004
003
AB
AB
AB
CARBAMAZEPINE
CARBAMAZEPINE
MYLAN PHARMS INC
100MG
200MG
300MG
A 076697
A 076697
A 076697
001 May 20, 2011

002 May 20, 2011
003 May 20, 2011
May CAHN
May CAHN
May CAHN
N 203312
N 203312
N 203312
N 203312
001
002
003
004
Jan
Jan
Jan
Jan
N 203952
001 Jan 09, 2015
Jan NEWA
N 204370
N 204370
N 204370
N 204370
001
002
003
004
Sep
Sep
Sep
Sep
17,
17,
17,
17,
2015
2015
2015
2015
Sep
Sep
Sep
Sep
NEWA
NEWA
NEWA
NEWA
250MG
350MG
250MG
350MG
A 205126
A 205126
A 205513
A 205513
001
002
001
002
Jul
Jul
Nov
Nov
08,
08,
12,
12,
2015
2015
2015
2015
Jun
Jun
Oct
Oct
NEWA
NEWA
NEWA
NEWA
250MG
N 011792
004 Sep 13, 2007
Jun CTEC
3.125MG
6.25MG
12.5MG
A 077887
A 077887
A 077887
001 Sep 07, 2007

002 Sep 07, 2007
003 Sep 07, 2007
Jun DISC
Jun DISC
Jun DISC
12.5MG
12.5MG
12.5MG
12.5MG
25MG
25MG
25MG
25MG
50MG
50MG
50MG
50MG
100MG
100MG
100MG
100MG
100MG
CARBIDOPA; LEVODOPA
RYTARY
IMPAX LABS INC
23.75MG;95MG
36.25MG;145MG
48.75MG;195MG
+
61.25MG;245MG
SUSPENSION;ENTERAL
DUOPA
+
ABBVIE INC
4.63MG/ML;20MG/ML
CARIPRAZINE HYDROCHLORIDE
CAPSULE;ORAL
VRAYLAR
FOREST RES INST INC
AB
AA
>A> AB
>A> AA
AB
CARISOPRODOL
TABLET;ORAL
CARISOPRODOL
INDICUS PHARMA
SHASUN PHARMS LTD
SOMA
MEDA PHARMS
CARVEDILOL
TABLET;ORAL
CARVEDILOL
@ HIKMA
@
@
EQ
EQ
EQ
EQ
1.5MG BASE
3MG BASE
4.5MG BASE
6MG BASE
Jan
Jan
Jan
Jan
07,
07,
07,
07,
2015
2015
2015
2015
NEWA
NEWA
NEWA
NEWA
AB
AB
AB
AB
AB
AB
AP
AP
AP
AP
AB
AB
AB
AB
TABLET;ORAL
CARVEDILOL
@
SUN PHARM INDS LTD
2015
A 077887
A 076989
A 076989
A 076989
A 076989
004
001
002
003
004
A 065115
A 065115
A 065115
001 Mar 26, 2003

002 Mar 26, 2003
003 Mar 26, 2003
Apr CAHN
Apr CAHN
Apr CAHN
A 063214
A 063207
A 063209
A 063209
001
001
001
002
Jan
Jan
Jan
Jan
N 207131
001 Aug 07, 2015
Sep CAHN
N 207131
001 Aug 07, 2015
Aug NEWA
100MG/5ML
200MG/5ML
A 204835
A 204835
001 Apr 14, 2015

002 Apr 14, 2015
Apr NEWA
Apr NEWA
100MG/5ML
200MG/5ML
A 065129
A 065355
001 Feb 23, 2004

001 Apr 10, 2007
Apr CFTG
Apr CFTG
A 063293
N 050588
A 063293
N 050588
N 050588
001
001
002
002
003
May
Mar
May
Mar
Mar
N 050694
N 050694
002 Jul 30, 1993

001 Jul 30, 1993
Mar CAHN
Mar CAHN
EQ 50MG BASE/5ML
EQ 100MG BASE/5ML
A 065082
A 065082
001 May 31, 2002

002 May 31, 2002
Apr CAHN
Apr CAHN
EQ 100MG BASE
EQ 200MG BASE
A 065083
A 065083
001 Aug 20, 2003

002 Aug 20, 2003
Apr CAHN
Apr CAHN
500MG/VIAL
500MG/VIAL
1GM/VIAL
1GM/VIAL
2GM/VIAL
2GM/VIAL
6GM/VIAL
6GM/VIAL
500MG/VIAL
N 050578
N 050578
N 050578
N 050578
N 050578
N 050578
N 050578
N 050578
N 050578
001
001
002
002
003
003
004
004
001
Oct
Jun
Oct
Jun
Oct
Jun
Oct
Jun
Oct
CEFADROXIL/CEFADROXIL HEMIHYDRATE
FOR SUSPENSION;ORAL
CEFADROXIL
SUN PHARM INDS LTD
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
EQ 500MG BASE/5ML
CEFAZOLIN SODIUM
CEFAZOLIN SODIUM
FACTA FARMA
EQ
EQ
EQ
EQ
500MG BASE/VIAL
1GM BASE/VIAL
10GM BASE/VIAL
20GM BASE/VIAL
+
CEFAZOLIN IN PLASTIC CONTAINER
BAXTER HLTHCARE
EQ 2GM BASE/100ML (EQ 20MG
BASE/ML)
CELERITY PHARMS
EQ 2GM BASE/100ML (EQ 20MG
BASE/ML)
CEFIXIME
FOR SUSPENSION;ORAL
CEFIXIME
SUPRAX
LUPIN PHARMS
CEFOTETAN DISODIUM
CEFOTAN
@ IGI LABS INC
EQ 1GM BASE/VIAL
@
EQ 1GM BASE/VIAL
@
EQ 2GM BASE/VIAL
@
EQ 2GM BASE/VIAL
@
EQ 10GM BASE/VIAL
CEFOTAN IN PLASTIC CONTAINER
@ IGI LABS INC
EQ 20MG BASE/ML
@
EQ 40MG BASE/ML
AB
AB
AB
AB
>D> AP
AP
>D> AP
AP
>D> AP
AP
>D> AP
AP
>A> AP
CEFPODOXIME PROXETIL
FOR SUSPENSION;ORAL
SUN PHARM INDS LTD
TABLET;ORAL
SUN PHARM INDS LTD
CEFTAZIDIME
FORTAZ
+
+
+
+
+
+
+
+
+
IGI LABS INC
1 -20
October
25MG
3.125MG
6.25MG
12.5MG
25MG
10
Sep
Sep
Sep
Sep
Sep
Dec
Dec
Dec
Apr
Apr
Dec
Apr
Dec
Apr
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Jul
07,
05,
05,
05,
05,
27,
27,
27,
30,
29,
27,
29,
27,
25,
19,
19,
19,
19,
19,
19,
19,
19,
19,
2007
2007
2007
2007
2007
1991
1991
1991
1999
1993
1985
1993
1985
1988
1985
1985
1985
1985
1985
1985
1985
1985
1985
Jun
Apr
Apr
Apr
Apr
DISC
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
>A> AP
>A> AP
>A> AP
2015
N 050578
N 050578
N 050578
002 Jul 19, 1985

003 Jul 19, 1985
004 Jul 19, 1985
Oct CAHN
Oct CAHN
Oct CAHN
N 050634
N 050634
N 050634
N 050634
N 050634
N 050634
N 050634
N 050634
N 050634
001
001
002
002
003
003
001
002
003
Oct
Jun
Oct
Jun
Oct
Jun
Oct
Oct
Oct
N 206829
001 Dec 19, 2014
Aug CAHN
A 065269
001 Feb 28, 2007
Jan CAHN
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 250MG BASE/VIAL
A 065268
A 065268
A 065245
001 Feb 28, 2007

002 Feb 28, 2007
001 Feb 15, 2006
Jan CAHN
Jan CAHN
Jul DISC
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
A 065323
A 065323
001 Feb 05, 2008

002 Feb 05, 2008
Apr CAHN
Apr CAHN
EQ
EQ
EQ
EQ
EQ
A 065190
A 065190
A 065118
A 065118
A 065118
001
002
001
002
003
Jul
Jul
Apr
Apr
Apr
EQ 1.5GM BASE/VIAL
EQ 7.5GM BASE/VIAL
A 064125
A 064124
002 May 30, 1997

001 May 30, 1997
Jan CAHN
Jan CAHN
EQ 1.5GM BASE/VIAL
EQ 7.5GM BASE/VIAL
ZINACEF IN PLASTIC CONTAINER
@ CONCORDIA PHARMS INC
EQ 15MG BASE/ML
+
EQ 30MG BASE/ML
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM
FACTA FARMA
EQ 750MG BASE/VIAL
ZINACEF
+
CONCORDIA PHARMS INC EQ 750MG BASE/VIAL
N 050558
N 050558
003 Oct 19, 1983

004 Oct 23, 1986
Jun CAHN
Jun CAHN
N 050643
N 050643
001 Apr 28, 1989

002 Apr 28, 1989
Jun CAHN
Jun CAHN
A 064125
001 May 30, 1997
Jan CAHN
N 050558
002 Oct 19, 1983
Jun CAHN
A 204519
A 204519
A 204519
A 204519
001
002
003
004
Aug
Aug
Aug
Aug
1GM/VIAL
2GM/VIAL
6GM/VIAL
CEFTAZIDIME SODIUM
FORTAZ IN PLASTIC CONTAINER
@ CONCORDIA PHARMS INC EQ
@
EQ
+
EQ
+
EQ
+
EQ
+
EQ
@ IGI LABS INC
EQ
+
EQ
+
EQ
>D>
>D>
>D>
>A>
>A>
>A>
10MG
10MG
20MG
20MG
40MG
40MG
10MG
20MG
40MG
BASE/ML
BASE/ML
BASE/ML
BASE/ML
BASE/ML
BASE/ML
BASE/ML
BASE/ML
BASE/ML
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

ZERBAXA
+
CUBIST PHARMS LLC
EQ 1GM BASE/VIAL;EQ 0.5GM
BASE/VIAL
AP
AB
AB
AB
AB
AB
AB
AB
AP
AP
AP
AP
AB
AB
AB
AB
AB
AB
CEFTRIAXONE SODIUM
CEFTRIAXONE
FACTA FARMA
INJECTABLE;INTRAMUSCULAR,
CEFTRIAXONE
@ FACTA FARMA
@
CEFUROXIME AXETIL
FOR SUSPENSION;ORAL
CEFUROXIME AXETIL
SUN PHARM INDS LTD
TABLET;ORAL
CEFUROXIME AXETIL
ANI PHARMS INC
SUN PHARM INDS LTD
CEFUROXIME SODIUM
CEFUROXIME SODIUM
FACTA FARMA
+
+
EQ 10GM BASE/VIAL
INTRAVENOUS
250MG
500MG
125MG
250MG
500MG
ZINACEF
CELECOXIB
CAPSULE;ORAL
CELECOXIB
ALEMBIC PHARMS LTD
50MG
100MG
200MG
400MG
BASE
BASE
BASE
BASE
BASE
1 -21
October
FORTAZ
+
+
+
10
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Oct
Oct
Apr
Apr
Apr
Aug
Aug
Aug
Aug
28,
28,
28,
28,
28,
28,
28,
28,
28,
18,
18,
25,
25,
25,
21,
21,
21,
21,
1989
1989
1989
1989
1989
1989
1989
1989
1989
2004
2004
2003
2003
2003
2015
2015
2015
2015
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
NEWA
NEWA
NEWA
NEWA
2015
50MG
100MG
200MG
50MG
100MG
200MG
400MG
100MG
200MG
400MG
100MG
200MG
400MG
50MG
100MG
200MG
400MG
A 204197
A 204197
A 204197
A 207446
A 207446
A 207446
A 207446
A 202240
A 202240
A 202240
A 078857
A 078857
A 078857
A 200562
A 200562
A 200562
A 200562
001
002
003
001
002
003
004
002
003
004
002
003
004
001
002
003
004
EQ 250MG BASE
EQ 500MG BASE
A 065007
A 065007
001 Sep 16, 1999

002 Sep 16, 1999
Apr CAHN

Apr CAHN

EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
A 065081
A 065081
001 Jul 27, 2001

002 Jul 27, 2001
Apr CAHN

Apr CAHN

AA
CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

ZYRTEC

+
J AND J CONSUMER INC
5MG/5ML
N 020346
001 Sep 27, 1996
Aug CAHN

AP
CHLOROTHIAZIDE SODIUM


CHLOROTHIAZIDE SODIUM

SAGENT PHARMS
EQ 500MG BASE/VIAL
A 202462
001 May 29, 2015
May NEWA

N 206323
001 Jun 22, 2015
Jun NEWA

A 206438
001 Jan 27, 2015
Jan NEWA

N 204307
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
CIPLA LTD
LUPIN LTD
MYLAN PHARMS INC
WATSON LABS INC
CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

SUN PHARM INDS LTD
FOR SUSPENSION;ORAL

CEPHALEXIN

@
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE


CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

SPRIASO LLC
8MG;54.3MG
1 -22

October
CAPSULE;ORAL

CELECOXIB

APOTEX INC
10
Jun
Jun
Jun
Sep
Sep
Sep
Sep
Jun
Jun
Jun
Feb
Feb
Feb
Feb
Feb
Feb
Feb
02,
02,
02,
23,
23,
23,
23,
09,
09,
09,
11,
11,
11,
11,
11,
11,
11,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
May
May
May
Sep
Sep
Sep
Sep
May
May
May
Jan
Jan
Jan
Jan
Jan
Jan
Jan
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

AA
CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

TRIS PHARMA INC
4MG/5ML;5MG/5ML
VITUZ

+
CYPRESS PHARM
4MG/5ML;5MG/5ML
001 Feb 20, 2013
Jan CFTG

AA
CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

COASTAL PHARMS
4MG/5ML;5MG/5ML;60MG/5ML
A 205657 001 Aug 03, 2015
Jul NEWA

AA
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

+
TRIS PHARMA INC
EQ 2.8MG BASE/5ML;EQ 14.7MG
BASE/5ML
+
VERNALIS R AND D LTD
EQ 2.8MG BASE/5ML;EQ 14.7MG
BASE/5ML

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@ CYCLE PHARMS LTD
30MG/ML
@
100MG/ML
N 207768
001 Apr 30, 2015
Apr NEWA

N 207768
001 Apr 30, 2015
Jun CAHN

A 088157
A 088158
001 Apr 27, 1983

001 Apr 27, 1983
Jun CAHN

Jun CAHN

October
2015
1 -23
A 083329
001
Feb CAHN
A 085331
A 085331
A 085331
A 085331
A 085331
A 080439
A 080439
A 080439
A 080439
A 080439
001
002
003
004
005
001
002
003
004
005
Jun
Jun
Jun
Jun
Jun
May
May
May
May
May
50MG
50MG
50MG
A 088651
A 089286
A 086831
001 May 30, 1985

001 Jul 21, 1986
001
Apr CAHN
Mar CMFD
Jun CTEC
15MG
N 019574
001 Dec 20, 1988
Jun DISC
CHOLESTYRAMINE
POWDER;ORAL
CHOLESTYRAMINE
@ ANI PHARMS INC
@
EQ 4GM RESIN/PACKET
EQ 4GM RESIN/SCOOPFUL
A 074554
A 074554
001 Oct 02, 1996

002 Oct 02, 1996
Aug CAHN
Aug CAHN
CHOLIC ACID
CAPSULE;ORAL
CHOLBAM
ASKLEPION PHARMS LLC
+
RTRX
+
50MG
250MG
50MG
250MG
N 205750
N 205750
N 205750
N 205750
001
002
001
002
Mar
Mar
Apr
Apr
CHOLINE C-11
CHOLINE C-11
+
MCPRF
+
UNIV TX MD ANDERSON
4-33.1mCi/ML
4-33.1mCi/ML
4-33.1mCi/ML
N 203155
N 203155
A 205690
001 Sep 12, 2012

001 Sep 12, 2012
001 Oct 29, 2015
Oct CFTG
Oct CFTG
Oct NEWA
AB
AB
CHOLINE FENOFIBRATE
CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID
ACTAVIS ELIZABETH
EQ 45MG FENOFIBRIC ACID
EQ 135MG FENOFIBRIC ACID
A 200920
A 200920
001 Oct 07, 2015

002 Oct 07, 2015
Sep NEWA
Sep NEWA
AT
CICLOPIROX
SOLUTION;TOPICAL
CICLOPIROX
APOTEX INC
8%
A 078172
001 Sep 18, 2007
Sep CMFD
AP
CIDOFOVIR
CIDOFOVIR
+
MYLAN INSTITUTIONAL
EQ 75MG BASE/ML
A 201276
001 Jun 27, 2012
May CRLD
A 074176
001 Jun 01, 1994
Apr CAHN
+
EUROHLTH INTL SARL
25MG/ML
TABLET;ORAL
@ CYCLE PHARMS LTD
10MG
@
25MG
@
50MG
@
100MG
@
200MG
@ SANDOZ
10MG
@
25MG
@
50MG
@
100MG
@
200MG
AB
AB
>D>
>A> AP
>A> AP
CHLORTHALIDONE
TABLET;ORAL
CHLORTHALIDONE
@ G AND W LABS INC
MUTUAL PHARM
+
MYLAN
THALITONE
@ CITRON PHARMA LLC
CIMETIDINE HYDROCHLORIDE
SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE
@ G AND W LABS INC
EQ 300MG BASE/5ML
10
Mar
Mar
Mar
Mar
17,
17,
17,
17,
2015
2015
2015
2015
CAHN
CAHN
CAHN
CAHN
CAHN
DISC
DISC
DISC
DISC
DISC
NEWA
NEWA
CAHN
CAHN
AP
AP
AP
AP
>D> AT
>A> AT
AB
AB
AB
2015
A 078062
A 078062
001 Apr 29, 2008

002 Apr 29, 2008
Apr CAHN
Apr CAHN
A 078024
A 078024
001 Mar 18, 2008

002 Mar 18, 2008
Apr CAHN
Apr CAHN
0.3% BASE
0.3% BASE
A 077689
A 077689
001 Dec 13, 2006

001 Dec 13, 2006
Oct CAHN
Oct CAHN
250MG BASE
500MG BASE
750MG BASE
A 075747
A 075747
A 075747
001 Jun 09, 2004

002 Jun 09, 2004
003 Jun 09, 2004
Apr CAHN
Apr CAHN
Apr CAHN
A 203183
001 Feb 26, 2015
Feb NEWA
A 203182
A 203182
001 Feb 26, 2015

002 Feb 26, 2015
Feb NEWA
Feb NEWA
A 206774
001 Aug 18, 2015
Aug NEWA
A 077048
A 077048
A 077048
001 Nov 16, 2004

002 Nov 16, 2004
003 Nov 16, 2004
Apr CAHN
Apr CAHN
Apr CAHN
A 065382
A 065382
001 Aug 30, 2007

002 Aug 30, 2007
Apr CAHN
Apr CAHN
A 203584
A 203584
A 065174
A 065174
001
002
001
002
Sep
Sep
Apr
Apr
A 202532
A 065154
001 Sep 15, 2015

001 May 18, 2005
Aug NEWA
Jan CRLD
A 062691
001 Dec 19, 1986
May DISC
N 050590
001 Apr 01, 1985
May DISC
N 050590
002 Apr 01, 1985
May DISC
N 050590
003 Aug 18, 1987
May DISC
N 050658
001 Dec 15, 1989
May DISC

CIPROFLOXACIN
CIPROFLOXACIN
CLARIS PHARMASERVICE
200MG/20ML (10MG/ML)
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
CLARIS PHARMASERVICE 200MG/100ML
400MG/200ML
CIPROFLOXACIN HYDROCHLORIDE
NEXUS PHARMS
EQ
RISING PHARMS INC
EQ
TABLET;ORAL
SUN PHARM INDS LTD
EQ
EQ
EQ
AP
AP
AP
CISPLATIN
CISPLATIN
ACCORD HLTHCARE
AB
AB
AB
CITALOPRAM HYDROBROMIDE
TABLET;ORAL
CITALOPRAM HYDROBROMIDE
G AND W LABS INC
EQ 10MG BASE
EQ 20MG BASE
EQ 40MG BASE
AB
AB
AB
AB
AB
AB
AB
AB
CLARITHROMYCIN
FOR SUSPENSION;ORAL
CLARITHROMYCIN
SUN PHARM INDS LTD
1 -24
October
CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE
FRESENIUS KABI USA
EQ 2MG BASE/ML
CISATRACURIUM BESYLATE PRESERVATIVE FREE
FRESENIUS KABI USA
EQ 2MG BASE/ML
EQ 10MG BASE/ML
AP
10
1MG/ML
125MG/5ML
250MG/5ML
TABLET;ORAL
CLARITHROMYCIN
HEC PHARM USA INC
250MG
500MG
SUN PHARM INDS LTD
250MG
500MG
CLARITHROMYCIN
LUPIN LTD
500MG
+
TEVA
500MG
CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM
TIMENTIN
@ GLAXOSMITHKLINE
EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL
@
BASE/VIAL
@
BASE/VIAL
@
EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL
TIMENTIN IN PLASTIC CONTAINER
@ GLAXOSMITHKLINE
EQ 100MG BASE/100ML;EQ 3GM
BASE/100ML

Sep
Sep
Sep
Sep
28,
28,
24,
24,
2015
2015
2004
2004
NEWA
NEWA
CAHN
CAHN
CLEMASTINE FUMARATE
TABLET;ORAL
CLEMASTINE FUMARATE
@ ANI PHARMS INC
AB
AB
AB
AB
AP
AP
AP
AT
AB
AB
1.34MG
CLINDAMYCIN HYDROCHLORIDE
CAPSULE;ORAL
CLINDAMYCIN HYDROCHLORIDE
G AND W LABS INC
EQ
EQ
SUN PHARM INDS LTD
EQ
EQ
CLINDAMYCIN PHOSPHATE
ALVOGEN INC
@ IGI LABS INC

SOLUTION;TOPICAL
@ BOCA PHARMA LLC
VINTAGE PHARMS
EQ
EQ
EQ
EQ
1 -25

October
2015
A 073282
001 Jan 31, 1992
Jul CAHN
BASE
BASE
BASE
BASE
A 063029
A 063029
A 065061
A 065061
001
002
001
002
Sep
Aug
Feb
Feb
20,
05,
02,
02,
1989
2005
2001
2001
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
150MG
150MG
150MG
150MG
BASE/ML
BASE/ML
BASE/ML
BASE/ML
A 062800
A 062801
A 062943
A 062928
001
001
001
001
Jul
Jul
Sep
Feb
24,
24,
29,
13,
1987
1987
1988
1989
Sep
Sep
Sep
Mar
CAHN
CAHN
CAHN
CAHN
A 062944
A 203343
001 Jan 11, 1989

001 May 29, 2015
Jan CAHN
May NEWA
A 202564
001 Jun 12, 2015
Jun NEWA
N 050802
001 Nov 07, 2006
Jun CTEC
A 075430
001 May 26, 1999
May CRLD
A 074220
001 May 16, 1997
Jun CRLD
A 075368
001 Feb 15, 2000
May CRLD
A 074089
001 Feb 16, 1994
Feb CAHN
A 074331
001 Dec 15, 1995
Mar CMFD
N 018361
001 Mar 22, 1982
Jun DISC
A 090873
A 090873
A 090873
001 May 06, 2014

002 May 06, 2014
003 May 06, 2014
Mar CAHN
Mar CAHN
Mar CAHN
A 071783
A 071784
A 071785
001 Apr 05, 1988

001 Apr 05, 1988
001 Apr 05, 1988
May DISC
May DISC
May DISC
A 202792
A 203320
001 May 15, 2015

001 May 15, 2015
May NEWA
May NEWA
EQ 1% BASE
EQ 1% BASE
CLOBETASOL PROPIONATE
CREAM;TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)
AB2
+
FOUGERA PHARMS
0.05%
CORMAX
AB1
+
HI TECH PHARMA
0.05%
GEL;TOPICAL
AB
+
FOUGERA PHARMS
0.05%
OINTMENT;TOPICAL
AB
G AND W LABS INC
0.05%
SOLUTION;TOPICAL
AT
G AND W LABS INC
0.05%
AB
AB
AB
150MG
300MG
150MG
300MG
CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND TRETINOIN
ACTAVIS MID ATLANTIC 1.2%;0.025%
ZIANA
+
MEDICIS
1.2%;0.025%
CLOMIPHENE CITRATE
TABLET;ORAL
SEROPHENE
@ EMD SERONO
10
50MG
CLONIDINE
FILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE
ACTAVIS LABS UT INC
0.1MG/24HR
0.2MG/24HR
0.3MG/24HR
CLONIDINE HYDROCHLORIDE
TABLET;ORAL
@ DAVA PHARMS INC
0.1MG
@
0.2MG
@
0.3MG
AB2
ACTAVIS ELIZABETH
0.1MG
AB1
0.1MG
AB2
AB1
AB2
AB2
AB1
AB1
AB1
AB1
AB1
AB1
AB1
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
October
2015
A 202792
A 202792
A 203320
A 203320
A 202983
A 202983
A 202983
A 202983
002
002
002
002
001
001
002
002
1 -26



@
0.2MG
0.2MG
@
0.2MG
0.2MG
@ ANCHEN PHARMS
0.1MG
0.1MG
@
0.2MG
0.2MG

ANCHEN PHARMS
0.1MG
@
0.2MG
0.2MG
KAPVAY

+
0.1MG
0.1MG
+
0.1MG
@
0.2MG
+
0.2MG
0.2MG
A 202984
A 202984
A 202984
001 Sep 30, 2013

002 Sep 30, 2013
002 Sep 30, 2013
May CTEC

Aug DISC

May CTEC

N 022331
N 022331
N 022331
N 022331
N 022331
N 022331
003
003
003
004
004
004
Aug
Jun
May
Aug
Jun
May
CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

SUN PHARM INDS LTD
3.75MG
7.5MG
15MG
A 076911
A 076911
A 076911
001 Sep 29, 2004

002 Sep 29, 2004
003 Sep 29, 2004
Apr CAHN

Apr CAHN

Apr CAHN

A 203807
A 203807
001 Sep 17, 2015

002 Sep 17, 2015
Sep NEWA

Sep NEWA

N 019758
N 019758
001 Sep 26, 1989

002 Sep 26, 1989
Aug CAHN

Aug CAHN

A 201824
A 201824
002 Sep 15, 2015

003 Sep 15, 2015
Aug NEWA

Aug NEWA

N 021590
N 021590
001 Feb 10, 2004

002 Feb 10, 2004
Aug CFTG

Aug CFTG

N 205395
001 Jan 29, 2015
Jan NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
AMNEAL PHARMS
10MG/5ML;5MG/5ML;6.25MG/5ML
A 200963 001 Aug 26, 2015
Aug NEWA

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ ROXANE
30MG/5ML
N 202245
001 Jun 30, 2011
Jan DISC

COLCHICINE

CAPSULE;ORAL

MITIGARE

HIKMA INTL PHARMS
0.6MG
N 204820
001 Sep 26, 2014
Jan CAHN

A 083734
001
Aug CAHN

CLOZAPINE

TABLET;ORAL

CLOZAPINE

ACTAVIS LABS FL INC
25MG
100MG
CLOZARIL

HERITAGE LIFE
25MG
+
100MG

CLOZAPINE

MYLAN PHARMS INC
25MG
100MG
FAZACLO ODT

JAZZ PHARMS III
25MG
+
100MG
COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+
JANSSEN PRODS
150MG;EQ 800MG BASE
AA
10
COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

@ ANI PHARMS INC
0.5MG;500MG
May
May
May
May
Apr
Apr
Apr
Apr
Sep
Sep
Sep
Sep
Sep
Sep
15,
15,
15,
15,
02,
02,
02,
02,
28,
28,
28,
28,
28,
28,
2015
2015
2015
2015
2014
2014
2014
2014
2010
2010
2010
2010
2010
2010
Aug
May
Aug
May
Aug
May
Aug
May
DISC

NEWA

DISC

NEWA

DISC

CTEC

DISC

CTEC

CRLD

CRLD

CTEC

DISC

CRLD

CTEC

10
October
2015
1 -27

COLISTIMETHATE SODIUM
COLISTIMETHATE SODIUM
XELLIA PHARMS APS
EQ 150MG BASE/VIAL
A 205356
001 May 29, 2015
May NEWA

CORTICOTROPIN
H.P. ACTHAR GEL
@ MALLINCKRODT ARD
+
40 UNITS/ML
80 UNITS/ML
N 008372
N 008372
006
008
Aug CAHN

Aug CAHN

CYANOCOBALAMIN
CYANOCOBALAMIN
@ EUROHLTH INTL SARL
1MG/ML
A 080515
002
Feb CAHN

AB
AB
AB
AB
CYCLOBENZAPRINE HYDROCHLORIDE
TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE
ORIT LABS LLC
5MG
SUN PHARM INDS LTD
5MG
7.5MG
10MG
A 078218
A 078722
A 078722
A 078722
002
001
002
003
AA
CYPROHEPTADINE HYDROCHLORIDE
TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE
MIRROR PHARMS LLC
4MG
A 205087
001 Sep 23, 2015
Sep NEWA

DABRAFENIB MESYLATE
CAPSULE;ORAL
TAFINLAR
NOVARTIS PHARMS CORP
+
EQ 50MG BASE
EQ 75MG BASE
N 202806
N 202806
001 May 29, 2013

002 May 29, 2013
Mar CAHN

Mar CAHN

DACLATASVIR DIHYDROCHLORIDE
TABLET;ORAL
DAKLINZA
BRISTOL-MYERS SQUIBB
+
EQ 30MG BASE
EQ 60MG BASE
N 206843
N 206843
001 Jul 24, 2015

002 Jul 24, 2015
Jul NEWA

Jul NEWA

7,500 IU/0.75ML
7,500 IU/0.75ML
N 020287
N 020287
008 Apr 04, 2002

008 Apr 04, 2002
Jun CAHN

Apr CAHN

2,500IU/0.2ML (12,500IU/ML)
5,000IU/0.2ML (25,000IU/ML)
7,500IU/0.3ML (25,000IU/ML)
10,000IU/0.4ML (25,000IU/ML)
10,000IU/ML (10,000IU/ML)
12,500IU/0.5ML (25,000IU/ML)
15,000IU/0.6ML (25,000IU/ML)
18,000IU/0.72ML (25,000IU/ML)
95,000IU/3.8ML (25,000IU/ML)
95,000IU/9.5ML (10,000IU/ML)
2,500IU/0.2ML (12,500IU/ML)
5,000IU/0.2ML (25,000IU/ML)
7,500IU/0.3ML (25,000IU/ML)
10,000IU/0.4ML (25,000IU/ML)
10,000IU/ML (10,000IU/ML)
12,500IU/0.5ML (25,000IU/ML)
15,000IU/0.6ML (25,000IU/ML)
18,000IU/0.72ML (25,000IU/ML)
95,000IU/3.8ML (25,000IU/ML)
95,000IU/9.5ML (10,000IU/ML)
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
N 020287
001
003
005
002
004
009
010
011
006
007
001
003
005
002
004
009
010
011
006
007
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
AP
DALTEPARIN SODIUM
FRAGMIN
@ PFIZER INC
@ PHARMACIA AND UPJOHN
INJECTABLE;SUBCUTANEOUS
FRAGMIN
PFIZER INC
+
@
PHARMACIA AND UPJOHN
+
@
Jun
May
May
May
Dec
Mar
Apr
May
Jan
May
May
May
Apr
Apr
Dec
Mar
Apr
May
Jan
May
May
May
Apr
Apr
19,
12,
12,
12,
22,
18,
04,
01,
30,
01,
01,
01,
04,
04,
22,
18,
04,
01,
30,
01,
01,
01,
04,
04,
2015
2008
2008
2008
1994
1996
2002
2007
1998
2007
2007
2007
2002
2002
1994
1996
2002
2007
1998
2007
2007
2007
2002
2002
Jun
Apr
Apr
Apr
NEWA

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

AB
AB
AB
AB
AB
AB
AB
2015
A 076686
A 076686
A 076686
001 Oct 24, 2005

002 Oct 24, 2005
003 Oct 24, 2005
May CAHN
May CAHN
May CAHN
7.5MG BASE
15MG BASE
A 091190
A 091190
001 Mar 13, 2015

002 Mar 13, 2015
Mar NEWA
Mar NEWA
7.5MG BASE
15MG BASE
N 021513
N 021513
001 Dec 22, 2004

002 Dec 22, 2004
Mar CFTG
Mar CFTG
100MG
140MG
N 021986
N 021986
004 May 30, 2008

006 Oct 28, 2010
Sep CRLD
Sep CRLD
50MG/VIAL
N 021790
001 May 02, 2006
Jan CAHN
90MG
180MG
360MG
N 206910
N 206910
N 206910
001 Mar 30, 2015

002 Mar 30, 2015
003 Mar 30, 2015
Mar NEWA
Mar NEWA
Mar NEWA
100MG/ML
N 208030
001 Sep 09, 2015
Sep NEWA
DEMECLOCYCLINE HYDROCHLORIDE
TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE
EPIC PHARMA LLC
150MG
300MG
A 065447
A 065447
001 Aug 18, 2015

002 Aug 18, 2015
Aug NEWA
Aug NEWA
DEOXYCHOLIC ACID
SOLUTION;SUBCUTANEOUS
KYBELLA
+
KYTHERA BIOPHARMS
N 206333
001 Apr 29, 2015
Apr NEWA
DESIPRAMINE HYDROCHLORIDE
TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE
ANI PHARMS INC
25MG
50MG
75MG
150MG
A 071803
A 071803
A 071803
A 071803
002
003
004
005
Sep
Sep
Sep
Sep
DESIRUDIN RECOMBINANT
IPRIVASK
+
15MG/VIAL
N 021271
001 Apr 04, 2003
May CAHN
0.5MG/ML
N 021300
001 Sep 01, 2004
Jun CFTG
0.5MG/ML
A 202592
001 Jun 30, 2015
Jun NEWA
DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE
ANCHEN PHARMS
EQ
EQ
ENABLEX
WARNER CHILCOTT LLC
EQ
+
EQ
DASATINIB
TABLET;ORAL
SPRYCEL
+
BRISTOL MYERS SQUIBB
AP
DECITABINE
DACOGEN
+
OTSUKA PHARM CO LTD
DEFERASIROX
TABLET;ORAL
JADENU
+
DEFERIPRONE
SOLUTION;ORAL
FERRIPROX
+
APOPHARMA INC
AB
AB
AA
AA
25MG
50MG
100MG
DESLORATADINE
SOLUTION;ORAL
CLARINEX
+
MERCK SHARP DOHME
DESLORATADINE
TARO PHARM INDS
20MG/2ML (10MG/ML)
1 -28

October
DANTROLENE SODIUM
CAPSULE;ORAL
DANTROLENE SODIUM
ELITE LABS INC
10
Dec
Dec
Dec
May
08,
08,
08,
29,
1987
1987
1987
1997
CMS1
CMS1
CMS1
CMS1
AB
AB
AB
AB
DESMOPRESSIN ACETATE
TABLET;ORAL
DDAVP
FERRING PHARMS INC
+
DESMOPRESSIN ACETATE
GLENMARK PHARMS LTD
10
2015
0.1MG
0.2MG
N 019955
N 019955
001 Sep 06, 1995

002 Sep 06, 1995
Jan CAHN
Jan CAHN
0.1MG
0.2MG
A 201831
A 201831
001 May 28, 2015

002 May 28, 2015
May NEWA
May NEWA
A 202226
001 Aug 12, 2015
Jul NEWA
N 021090
001 Dec 20, 2000
Aug CAHN
A 202789
001 Aug 12, 2015
Jul NEWA
A 075863
001 Apr 05, 2002
Apr CTEC
A 076681
001 Apr 30, 2015
Apr NEWA
0.05%
A 074027
001 Sep 28, 1992
May CMFD
0.25%
0.25%
A 205082
A 203234
001 Sep 04, 2015

001 Jun 12, 2015
Aug NEWA
Jun NEWA
0.25%
A 077770
001 Apr 20, 2015
Apr NEWA
50MG BASE
100MG BASE
50MG BASE
100MG BASE
50MG BASE
100MG BASE
50MG BASE
100MG BASE
A 204003
A 204003
A 204172
A 204172
A 204095
A 204095
A 204028
A 204028
001
002
001
002
001
002
001
002
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
50MG BASE
100MG BASE
N 021992
N 021992
001 Feb 29, 2008

002 Feb 29, 2008
Jun CFTG
Jun CFTG
A 203129
A 084282
A 087702
001 Sep 30, 2015

001
001 Sep 07, 1982
Sep NEWA
Mar CAHN
Feb CAHN
N 050065
002
Mar CAHN
N 050023
002
Mar CAHN
AB
DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28
BEKYREE
LUPIN LTD
0.15MG,N/A;0.02MG,0.01MG
CYCLESSA
+
ASPEN GLOBAL INC
0.1MG,0.125MG,0.15MG;0.025MG,0.025
MG,0.025MG
ISIBLOOM
SANDOZ INC
0.15MG;0.03MG
KARIVA
+
BARR
0.15MG,N/A;0.02MG,0.01MG
KIMIDESS
VINTAGE PHARMS
0.15MG,N/A;0.02MG,0.01MG
AB
DESONIDE
CREAM;TOPICAL
DESONIDE
TEVA PHARMS
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AP
AT
AT
DESOXIMETASONE
CREAM;TOPICAL
DESOXIMETASONE
ACTAVIS MID ATLANTIC
VERSAPHARM INC
OINTMENT;TOPICAL
DESOXIMETASONE
PERRIGO NEW YORK
1 -29

October
DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE SUCCINATE
ALEMBIC PHARMS LTD
EQ
EQ
LUPIN LTD
EQ
EQ
MYLAN PHARMS INC
EQ
EQ
SANDOZ INC
EQ
EQ
PRISTIQ
+
WYETH PHARMS INC
EQ
+
EQ
DEXAMETHASONE SODIUM PHOSPHATE

DEXAMETHASONE SODIUM PHOSPHATE
BD RX
EQ 4MG PHOSPHATE/ML
EQ 4MG PHOSPHATE/ML
+
EQ 10MG PHOSPHATE/ML
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC
MAXITROL
+
ALCON LABS INC
0.1%;EQ 3.5MG BASE/GM;10,000
UNITS/GM
SUSPENSION/DROPS;OPHTHALMIC
MAXITROL
+
ALCON LABS INC
0.1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
29,
29,
29,
29,
29,
29,
29,
29,
2015
2015
2015
2015
2015
2015
2015
2015
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
AP
AP
>A>
>A>
>A>
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
10
DEXMEDETOMIDINE HYDROCHLORIDE



FRESENIUS KABI USA
EQ 200MCG BASE/2ML (EQ 100MCG
BASE/ML)
SUN PHARM INDS INC

BASE/ML)
PRECEDEX

HOSPIRA
BASE/ML)

+
HQ SPCLT PHARMA
EQ 1MG BASE/10ML (EQ 100MCG
BASE/ML)

BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE



MYLAN PHARMS INC
5MG
10MG
15MG
40MG
WATSON LABS INC
5MG
10MG
TABLET;ORAL


SUN PHARM INDS LTD
2.5MG
5MG
10MG
1 -30

October
2015
A 201072
001 Sep 18, 2015
Sep NEWA

A 202126
001 Aug 20, 2015
Aug NEWA

N 021038
004 Nov 14, 2014
Jan NEWA

N 206628
002 Oct 21, 2015
Oct NEWA

N 206628
001 Oct 21, 2015
Oct NEWA

A 204266
A 204266
A 204266
A 204266
A 079108
A 079108
001
002
003
007
001
002
Aug
Aug
Aug
Aug
Jul
Jul
A 201231
A 201231
A 201231
001 Sep 24, 2015

002 Sep 24, 2015
003 Sep 24, 2015
Aug
Aug
Aug
Aug
Aug
Aug
25,
25,
25,
25,
05,
05,
2015
2015
2015
2015
2015
2015
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

Sep NEWA

Sep NEWA

Sep NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE


PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
5GM/100ML;30MG/100ML;37MG/100ML;36 N 017451 001
Mar DISC

8MG/100ML;526MG/100ML;502MG/100ML

AP
AA
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM


MD-76R

+
LIEBEL-FLARSHEIM
66%;10%
SOLUTION;ORAL, RECTAL

MD-GASTROVIEW

LIEBEL-FLARSHEIM
66%;10%
DICHLORPHENAMIDE

TABLET;ORAL

KEVEYIS

TARO
AT
AT
>D> AB
>A> AB
AA
50MG
DICLOFENAC SODIUM

GEL;TOPICAL

VOLTAREN

+
GLAXOSMITHKLINE CONS
1%
SOLUTION;TOPICAL

DICLOFENAC SODIUM

IGI LABS INC
1.5%
LUPIN LTD
1.5%

DICLOFENAC SODIUM

VALEANT INTL
100MG
VPNA
100MG
DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

+
ACTAVIS LABS UT INC
25MG
N 019292
001 Sep 29, 1989
Feb CAHN

A 087388
001
Jan CAHN

N 011366
002 Aug 07, 2015
Aug NEWA

N 022122
001 Oct 17, 2007
Aug CAHN

A 202769
A 204132
001 Jul 08, 2015

001 Aug 20, 2015
Jun NEWA

Aug NEWA

A 075492
A 075492
001 Feb 11, 2000

001 Feb 11, 2000
Oct CAHN

Oct CAHN

N 011722
002
Mar CAHN

AB

TENUATE DOSPAN
+
ACTAVIS LABS UT INC
75MG
October
2015
1 -31
N 012546
001
Mar CAHN
AB
DIFLORASONE DIACETATE
OINTMENT;TOPICAL
DIFLORASONE DIACETATE
VERSAPHARM INC
0.05%
A 206572
001 Jul 24, 2015
Jul NEWA
AB
DIFLUNISAL
TABLET;ORAL
DIFLUNISAL
HERITAGE PHARMA
500MG
A 202845
001 Mar 08, 2012
Mar CAHN
0.25MG/ML
A 083391
001
Feb CAHN
0.125MG
0.25MG
0.125MG
0.25MG
A 040282
A 040282
A 076363
A 076363
001
002
001
002
Dec
Dec
Jan
Jan
23,
23,
31,
31,
1999
1999
2003
2003
Jan
Jan
Feb
Feb
CTEC
CTEC
CMFD
CMFD
0.0625MG
0.125MG
0.1875MG
0.25MG
0.375MG
0.5MG
N 020405
N 020405
N 020405
N 020405
N 020405
N 020405
001
002
003
004
005
006
Sep
Sep
Sep
Sep
Sep
Sep
30,
30,
30,
30,
30,
30,
1997
1997
1997
1997
1997
1997
Apr
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
A 076151
A 076151
A 076151
A 076151
A 076151
A 076151
A 076151
A 076151
001
001
002
002
003
003
004
004
May
May
May
May
May
May
May
May
20,
20,
20,
20,
20,
20,
20,
20,
2004
2004
2004
2004
2004
2004
2004
2004
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
DISC
DISC
DISC
DISC
DISC
DISC
DISC
DISC
A 075124
001 Mar 18, 1998
Feb CRLD
N 020401
N 020401
N 020401
N 020401
N 020401
N 020401
001
002
003
004
005
006
Feb
Feb
Feb
Feb
Feb
Feb
A 078538
001 Dec 17, 2008
Jun CAHN
AP
AB
AB
AB
AB
DIGOXIN
DIGOXIN
EUROHLTH INTL SARL
TABLET;ORAL
DIGOXIN
MYLAN PHARMS INC
SUN PHARM INDS INC
LANOXIN
AB
AB
+
@
@
>D>
>D>
>A>
>D>
>A>
>D>
>A>
>D>
>A>
10
AP
DILTIAZEM HYDROCHLORIDE
DILT-CD
APOTEX
120MG
@
120MG
180MG
@
180MG
240MG
@
240MG
300MG
@
300MG
+
MYLAN
240MG
TIAZAC
VALEANT PHARMS NORTH 120MG
180MG
240MG
300MG
360MG
+
420MG
EUROHLTH INTL SARL
5MG/ML
AP
DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE
+
EUROHLTH INTL SARL
50MG/ML
A 080817
002
Jun CAHN
AP
DIPYRIDAMOLE
DIPYRIDAMOLE
EUROHLTH INTL SARL
A 074521
001 Oct 18, 1996
Jun CAHN
AB3
AB3
AB3
AB3
AB2
AB4
AB4
AB4
AB4
AB4
AB4
5MG/ML
Sep
Sep
Sep
Sep
Sep
Oct
11,
11,
11,
11,
11,
16,
1995
1995
1995
1995
1995
1998
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
AB
AB
AB
AB
AP
AP
AB
AB
>A> AB
>A> AB
AB
AB
AB
AP
AB
2015
A 203916
A 203916
001 Mar 04, 2015

002 Mar 04, 2015
Feb NEWA
Feb NEWA
DIVALPROEX SODIUM
DIVALPROEX SODIUM
AMNEAL PHARMS
EQ 250MG VALPROIC ACID
@ G AND W LABS INC
A 203730
A 203730
A 078700
001 May 29, 2015

002 May 29, 2015
001 Aug 03, 2009
May NEWA
May NEWA
Jul CAHN
DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE
@ IGI LABS INC
EQ 12.5MG BASE/ML
A 074098
001 Feb 21, 1995
Mar CAHN
A 203877
A 203877
001 Sep 16, 2015

002 Sep 16, 2015
Aug NEWA
Aug NEWA
DONEPEZIL HYDROCHLORIDE
TABLET;ORAL
DONEPEZIL HYDROCHLORIDE
HETERO LABS LTD V
5MG
10MG
LUPIN LTD
23MG
MYLAN PHARMS INC
23MG
SUN PHARM INDS LTD
5MG
10MG
23MG
A 203034
A 203034
A 202782
A 202656
A 076786
A 076786
A 204293
001
002
001
001
001
002
001
Jan
Jan
Oct
Oct
Apr
Apr
May
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

NAMZARIC
FOREST LABS LLC
10MG;14MG
+
10MG;28MG
N 206439
N 206439
001 Dec 23, 2014

002 Dec 23, 2014
Mar CAHN
Mar CAHN
DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE
@ IGI LABS INC
@
@
@
@
@
@
@
40MG/ML
40MG/ML
80MG/ML
80MG/ML
80MG/ML
160MG/ML
160MG/ML
160MG/ML
A 070087
N 018656
A 070089
A 070090
A 070091
A 070092
A 070093
A 070094
001
001
001
001
001
001
001
001
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
DOXAPRAM HYDROCHLORIDE
DOPRAM
+
EUROHLTH INTL SARL
20MG/ML
N 014879
001
Jun CAHN
EQ 100MG BASE
EQ 150MG BASE
A 070791
A 071669
005 May 13, 1986

001 Nov 09, 1987
Jan CRLD
Jan CRLD
5%
N 020126
001 Apr 01, 1994
Mar CAHN
DOCETAXEL
DOCETAXEL
TEVA PHARMS USA
DOXEPIN HYDROCHLORIDE
CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE
+
MYLAN PHARMS INC
+
PAR PHARM
CREAM;TOPICAL
ZONALON
+
DELCOR ASSET CORP
250MG
500MG
20MG/ML (20MG/ML)
80MG/4ML (20MG/ML)
1 -32

October
DISULFIRAM
TABLET;ORAL
DISULFIRAM
MYLAN PHARMS INC
10
Jan
Jan
Oct
Oct
Nov
Nov
Jun
Oct
Jun
Oct
Oct
Oct
Oct
Oct
Oct
30,
30,
30,
22,
26,
26,
05,
23,
28,
23,
23,
23,
23,
23,
23,
2015
2015
2015
2015
2010
2010
2015
1985
1983
1985
1985
1985
1985
1985
1985
NEWA
NEWA
NEWA
NEWA
CAHN
CAHN
NEWA
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
AP
>D>
>D>
>D>
>D>
>D>
>D>
>D>
>A> AP
>A>
>A>
>A>
>A>
>A>
>A>
>A> AP
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A>
>A>
>A>
>A>
>A>
AB
AB
AB
AB
AB
AB
AB
AB
2015
A 203929
001 May 07, 2015
Apr NEWA
N 050629
N 050629
001 Dec 23, 1987

002 May 03, 1988
Oct CTNA
Oct CTNA
N 050467
N 050467
N 050467
N 050467
001
003 May 20, 1985
002
004 Jul 22, 1987
Oct
Oct
Oct
Oct
CTNA
CTNA
CTNA
CTNA
N 050629
N 050629
N 050467
N 050467
N 050467
N 050467
N 050629
N 050629
N 050629
001
001
001
003
002
004
003
002
002
Dec 23, 1987

Dec 23, 1987
Jul
Mar
May
May
22,
28,
03,
03,
1987
2011
1988
1988
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
CMFD
CTNA
CTNA
CTNA
CTNA
CTNA
NEWA
CMFD
CTNA
50MG BASE
75MG BASE
100MG BASE
50MG BASE
75MG BASE
100MG BASE
A 204446
A 204446
A 204446
A 065053
A 065053
A 065053
001
002
003
001
003
002
May
May
May
Nov
Sep
Nov
28,
28,
28,
22,
10,
22,
2015
2015
2015
2000
2003
2000
May
May
May
Apr
Apr
Apr
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
A 065356
A 065356
A 065356
001 May 31, 2006

002 May 31, 2006
003 May 31, 2006
Apr CAHN
Apr CAHN
Apr CAHN
DOXYCYCLINE HYCLATE
DOXYCYCLINE
@
EQ 100MG BASE/VIAL
EQ 200MG BASE/VIAL
A 062450
A 062450
001 Oct 27, 1983

002 Oct 27, 1983
Jun CAHN
Jun CAHN
DROPERIDOL
DROPERIDOL
@ IGI LABS INC
@
@
2.5MG/ML
2.5MG/ML
2.5MG/ML
A 072019
A 072020
A 072021
001 Oct 19, 1988

001 Oct 19, 1988
001 Oct 19, 1988
Mar CAHN
Mar CAHN
Mar CAHN
DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL
GLENMARK PHARMS LTD
3MG;0.02MG
JAI PHARMA LTD
3MG;0.02MG
A 204296
A 202594
001 Aug 17, 2015

001 Oct 22, 2015
Aug NEWA
Oct NEWA
DULOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS;ORAL
ALKEM LABS LTD
EQ 20MG
EQ 30MG
EQ 60MG
ANCHEN PHARMS
EQ 20MG
EQ 30MG
EQ 60MG
INVENTIA HLTHCARE
EQ 20MG
EQ 30MG
A 203197
A 203197
A 203197
A 090780
A 090780
A 090780
A 202336
A 202336
001
002
003
001
002
003
001
002
Aug
Aug
Aug
Oct
Oct
Oct
Oct
Oct
4MCG/2ML (2MCG/ML)
DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN PFS
@ PHARMACIA AND UPJOHN 2MG/ML
@
200MG/100ML
ADRIAMYCIN RDF
@ PHARMACIA AND UPJOHN
10MG/VIAL
@
20MG/VIAL
@
50MG/VIAL
@
150MG/VIAL
DOXORUBICIN HYDROCHLORIDE
+
PHARMACIA AND UPJOHN 2MG/ML
@
2MG/ML
@
10MG/VIAL
@
20MG/VIAL
@
50MG/VIAL
@
150MG/VIAL
150MG/75ML
+
200MG/100ML
@
200MG/100ML
DOXYCYCLINE
CAPSULE;ORAL
DOXYCYCLINE
NOVEL LABS INC
SUN PHARM INDS LTD
TABLET;ORAL
DOXYCYCLINE
SUN PHARM INDS LTD
EQ
EQ
EQ
EQ
EQ
EQ
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
1 -33
October
DOXERCALCIFEROL
DOXERCALCIFEROL
AKORN INC
10
May 20, 1985
Aug
Aug
Aug
Oct
Oct
Oct
Oct
Oct
26,
26,
26,
28,
28,
28,
28,
28,
2015
2015
2015
2015
2015
2015
2015
2015
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
>A> AB
AB
AB
ECONAZOLE NITRATE
CREAM;TOPICAL
ECONAZOLE NITRATE
FOUGERA PHARMS
+
PERRIGO NEW YORK
EDOXABAN TOSYLATE
TABLET;ORAL
SAVAYSA
DAIICHI SANKYO
+
EDROPHONIUM CHLORIDE
ENLON
+
MYLAN INSTITUTIONAL
ELTROMBOPAG OLAMINE
FOR SUSPENSION;ORAL
PROMACTA
+
TABLET;ORAL
PROMACTA
2015
A 202336
003 Oct 28, 2015
Oct NEWA
1%
1%
A 076075
A 076479
001 Nov 26, 2002

001 Jun 23, 2004
Mar CRLD
Mar CRLD
EQ 15MG BASE
EQ 30MG BASE
EQ 60MG BASE
N 206316
N 206316
N 206316
001 Jan 08, 2015

002 Jan 08, 2015
003 Jan 08, 2015
Jan NEWA
Jan NEWA
Jan NEWA
10MG/ML
A 088873
001 Aug 06, 1985
Mar CRLD
EQ 25MG ACID/PACKET
N 207027
001 Aug 24, 2015
Aug NEWA
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
N 022291
N 022291
N 022291
N 022291
N 022291
N 022291
N 022291
N 022291
004
001
002
002
003
003
005
005
Oct
Nov
Nov
Nov
Sep
Sep
Nov
Nov
20,
20,
20,
20,
08,
08,
16,
16,
2011
2008
2008
2008
2009
2009
2012
2012
Mar
Mar
May
Mar
May
Mar
May
Mar
CAHN
CAHN
CRLD
CAHN
CRLD
CAHN
CRLD
CAHN
+
+
+
May
May
May
May
27,
27,
27,
27,
2015
2015
2015
2015
Jul
Jul
May
May
CAHN
CAHN
NEWA
NEWA
12.5MG ACID
25MG ACID
50MG ACID
50MG ACID
75MG ACID
75MG ACID
100MG ACID
100MG ACID
ELUXADOLINE
TABLET;ORAL
VIBERZI
FOREST TOSARA LTD
+
FURIEX PHARMS
+
75MG
100MG
75MG
100MG
N 206940
N 206940
N 206940
N 206940
001
002
001
002
EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL
GLYXAMBI
BOEHRINGER INGELHEIM
+
10MG;5MG
25MG;5MG
N 206073
N 206073
001 Jan 30, 2015

002 Jan 30, 2015
Jan NEWA
Jan NEWA
N 206111
N 206111
N 206111
N 206111
001
002
003
004
Aug
Aug
Aug
Aug
26,
26,
26,
26,
2015
2015
2015
2015
Aug
Aug
Aug
Aug
NEWA
NEWA
NEWA
NEWA
2.5MG
5MG
10MG
20MG
2.5MG
5MG
10MG
20MG
A 075496
A 075496
A 075459
A 075459
A 075556
A 075556
A 075556
A 075556
001
002
001
002
001
002
003
004
Aug
Aug
Aug
Aug
Aug
Aug
Aug
Aug
22,
22,
22,
22,
22,
22,
22,
22,
2000
2000
2000
2000
2000
2000
2000
2000
Mar
Mar
Mar
Mar
Apr
Apr
Apr
Apr
CMFD
CMFD
CMFD
CMFD
CAHN
CAHN
CAHN
CAHN
2.5MG
N 018998
005 Jul 26, 1988
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL
SYNJARDY
BOEHRINGER INGELHEIM 5MG;500MG
5MG;1GM
12.5MG;500MG
+
12.5MG;1GM
AB
AB
AB
AB
AB
1 -34
October

EQ 60MG BASE
10
ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE
SANDOZ INC

@
@
@
VASOTEC
Apr CAHN
10
1 -35

October
2015
N 018998
N 018998
N 018998
001 Dec 24, 1985

002 Dec 24, 1985
003 Dec 24, 1985
Apr CAHN

Apr CAHN

Apr CAHN

AB
AB
ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

G AND W LABS INC
5MG;12.5MG
10MG;25MG
A 075727
A 075727
001 Sep 18, 2001

002 Sep 18, 2001
Apr CAHN

Apr CAHN

AB
ENTACAPONE

TABLET;ORAL

ENTACAPONE

200MG
A 203437
001 Jun 19, 2015
Jun NEWA

0.5MG
1MG
0.5MG
1MG
0.5MG
1MG
A 206652
A 206652
A 206217
A 206217
A 205740
A 205740
001
002
001
002
001
002
Oct
Oct
Aug
Aug
Aug
Aug
TABLET;ORAL

VASOTEC

AB
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
>D>
>D>
>D>
>A>
>A>
>A>
AP
AP
AP
AP
AA
5MG
10MG
20MG
ENTECAVIR

TABLET;ORAL

ENTECAVIR

AMNEAL PHARMS
HETERO LABS LTD V
Nov
Nov
Aug
Aug
Aug
Aug
12,
12,
26,
26,
21,
21,
2015
2015
2015
2015
2015
2015
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+
EQ 1MG BASE/ML (EQ 1MG BASE/ML)
N 204200
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+
EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N 204640
001 Dec 07, 2012
Jul CAIN

001 Dec 18, 2013
Jul CAIN

EPINEPHRINE HYDROCHLORIDE

EPINEPHRINE

BELCHER PHARMS LLC
EQ 1MG BASE/ML
SOLUTION;IV (INFUSION), INTRAOCULAR
EPINEPHRINE

BELCHER PHARMS LLC
N 205029
001 Jul 29, 2014
Oct CDFR

N 205029
001 Jul 29, 2014
Oct CDFR

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE


LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

0.01MG/ML;1%
@
0.01MG/ML;2%
A 080406
A 080406
001
002
Sep CAHN

Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEVETEN HCT

@ ABBVIE
600MG;12.5MG
@
600MG;25MG
N 021268
N 021268
001 Nov 01, 2001

002 Nov 01, 2001
Jun DISC

Jun DISC

2MG/ML
75MG/100ML
A 090854
A 091555
001 Jun 12, 2015

001 Jun 05, 2015
Jun NEWA

May NEWA

2MG/ML
75MG/100ML
N 020718
N 020718
001 May 18, 1998

002 May 18, 1998
Jun CTEC

May CFTG

50,000 IU
A 080704
001
Jan CAHN

EPTIFIBATIDE


EPTIFIBATIDE

TEVA PHARMS USA
+
+
INTEGRILIN

SCHERING
ERGOCALCIFEROL

CAPSULE;ORAL

VITAMIN D

2015
2MG
A 088337
001 Jun 08, 1984
Aug CAHN
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
25MG BASE
100MG BASE
150MG BASE
100MG BASE
100MG BASE
100MG BASE
150MG BASE
150MG BASE
150MG BASE
A 091002
A 091002
A 091002
A 091059
A 091059
A 091059
A 091059
A 091059
A 091059
001
002
003
002
002
002
003
003
003
Jun
Jun
Jun
Aug
Aug
Aug
Aug
Aug
Aug
11,
11,
11,
28,
28,
28,
28,
28,
28,
2014
2014
2014
2015
2015
2015
2015
2015
2015
Sep
Sep
Sep
Oct
Oct
Aug
Oct
Oct
Aug
DISC
DISC
DISC
DISC
DISC
NEWA
DISC
DISC
NEWA
>D> AB
>A>
AB
>D> AB
>A>
AB
EQ
EQ
EQ
EQ
EQ
25MG BASE
100MG BASE
100MG BASE
150MG BASE
150MG BASE
N 021743
N 021743
N 021743
N 021743
N 021743
001
002
002
003
003
Nov
Nov
Nov
Nov
Nov
18,
18,
18,
18,
18,
2004
2004
2004
2004
2004
Sep
Oct
Oct
Oct
Oct
CTEC
CTEC
CTEC
CTEC
CTEC
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
A 062169
A 062169
001 Oct 17, 1990

002 Oct 17, 1990
Apr CAHN
Apr CAHN
ERYTHROMYCIN ETHYLSUCCINATE
GRANULE;ORAL
ERYTHROMYCIN ETHYLSUCCINATE
@ ANI PHARMS INC
EQ 200MG BASE/5ML
A 062055
001
Jul CAHN
EQ 5MG BASE/5ML
A 203967
001 May 26, 2015
May NEWA
EQ
EQ
EQ
EQ
EQ
EQ
A 077550
A 077550
A 077550
A 078032
A 078032
A 078032
001
002
003
001
002
003
Apr
Apr
Apr
Aug
Aug
Aug
A 205520
A 201126
001 Jul 23, 2015

001 Feb 20, 2015
Jul NEWA
Feb NEWA
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
A 078279
A 078279
A 202784
A 202784
A 078003
A 078003
A 078936
A 078936
A 078936
A 078936
A 203636
A 203636
001
002
001
002
001
002
001
002
001
002
001
002
Sep
Sep
Sep
Sep
Jan
Jan
Jul
Jul
Sep
Sep
Oct
Oct
BASE
N 021153
001 Feb 20, 2001
ERLOTINIB HYDROCHLORIDE
TABLET;ORAL
ERLOTINIB HYDROCHLORIDE
@ MYLAN PHARMS INC
@
@
TEVA PHARMS USA
@
@
TARCEVA
OSI PHARMS
>D> AB
>A>
>D> AB
>A>
+
+
ERYTHROMYCIN ESTOLATE
SUSPENSION;ORAL
ERYTHROMYCIN ESTOLATE
@ G AND W LABS INC
@
AA
AB
AB
AB
AB
AB
AB
AP
AP
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AB
ESCITALOPRAM OXALATE
SOLUTION;ORAL
ANTRIM PHARMS LLC
TABLET;ORAL
MYLAN PHARMS INC
PRINSTON INC
ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE
LUITPOLD
5MG BASE
10MG BASE
20MG BASE
5MG BASE
10MG BASE
20MG BASE
10MG/ML
10MG/ML
ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM
DR REDDYS LABS LTD
EQ 20MG
EQ 40MG
HETERO LABS LTD III
EQ 20MG
EQ 40MG
IVAX SUB TEVA PHARMS EQ 20MG
EQ 40MG
MYLAN LABS LTD
EQ 20MG
EQ 40MG
MYLAN PHARMS INC
EQ 20MG
EQ 40MG
TORRENT PHARMS LTD
EQ 20MG
EQ 40MG
NEXIUM
ASTRAZENECA PHARMS
EQ 20MG
1 -36

October
ERGOTAMINE TARTRATE
TABLET;SUBLINGUAL
ERGOSTAT
@ WATSON LABS INC
10
May
May
May
Aug
Aug
Aug
Sep
Sep
Sep
Sep
Jan
Jan
Aug
Aug
Aug
Aug
Oct
Oct
14,
14,
14,
28,
28,
28,
25,
25,
21,
21,
26,
26,
02,
03,
02,
03,
19,
19,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
CAHN
CAHN
NEWA
NEWA
Jan CFTG
AB
AP
ESOMEPRAZOLE SODIUM


ESOMEPRAZOLE SODIUM

ACCORD HLTHCARE
2015
N 021153
002 Feb 20, 2001
Jan CFTG

A 205379
001 Sep 25, 2015
Sep NEWA

N 202342
N 202342
001 Aug 06, 2013

002 Aug 06, 2013
Aug CPOT

Aug CPOT

N 020655
N 020655
N 020655
N 020655
004
001
002
003
Mar
Mar
Mar
Mar
N 203752
005 Sep 23, 2014
Jan NEWA

A 040275
A 040275
A 040275
A 040275
A 040275
A 040275
001
002
003
001
002
003
Oct
Oct
Oct
Oct
Oct
Oct
A 205256
001 May 29, 2015
May DISC

1MG
2MG
3MG
A 202929
A 202929
A 202929
001 Jan 30, 2015

002 Jan 30, 2015
003 Jan 30, 2015
Jan NEWA

Jan NEWA

Jan NEWA

EQ 50MG BASE/VIAL
N 016093
001
Jul CFTG

EQ 50MG BASE/VIAL
A 205473
001 Jul 29, 2015
Jul NEWA

A 075095
A 075095
001 Nov 30, 1999

002 Nov 30, 1999
Jan CMFD

Jan CMFD

A 203163
001 Feb 23, 2015
Feb NEWA
A 202791
A 203164
A 079218
001 Apr 09, 2015

001 Jun 12, 2015
001 Jun 06, 2011
Mar NEWA
Jun NEWA
Mar CTEC
A 073594
001 Dec 13, 1993
Aug CRLD
N 018782
001 Jul 21, 1982
Aug DISC
A 201088
001 May 21, 2015
May NEWA
EQ 40MG BASE/VIAL
ESOMEPRAZOLE STRONTIUM


ESOMEPRAZOLE STRONTIUM

HANMI PHARM CO LTD
24.65MG
+
49.3MG
BX
BX
BX
BX
>A>
>A>
>A>
>D>
>D>
>D>
AB
AB
AB
ESTRADIOL


ALORA

ACTAVIS LABS UT INC
0.025MG/24HR
0.05MG/24HR
0.075MG/24HR
0.1MG/24HR
MINIVELLE

NOVEN
0.025MG/24HR
TABLET;ORAL

ESTRADIOL

@ EPIC PHARMA INC
0.5MG
@
1MG
@
2MG
0.5MG
@
1MG
@
2MG
TABLET;VAGINAL

ESTRADIOL

@ AMNEAL PHARMS
10MCG
ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

MACLEODS PHARMS LTD
AP
ETHACRYNATE SODIUM


EDECRIN

+
ATON
ETHACRYNATE SODIUM

AB
AB
ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

VERSAPHARM INC
100MG
400MG
AP
ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA
AB
GLENMARK GENERICS
0.03MG,0.01MG;0.15MG,N/A
LEVONORGESTREL AND ETHINYL ESTRADIOL
AB
GLENMARK GENERICS
0.02MG;0.09MG
AB
GLENMARK PHARMS LTD
0.03MG;0.15MG
AB
+
WATSON LABS
0.02MG;0.09MG
TABLET;ORAL-28
LEVORA 0.15/30-28
AB
+
WATSON LABS
0.03MG;0.15MG
NORDETTE-28
@ TEVA BRANDED PHARM
0.03MG;0.15MG
VIENVA
AB1
SANDOZ INC
0.02MG;0.1MG
1 -37

October

NEXIUM

+
EQ 40MG BASE
10
Apr
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
05,
20,
20,
20,
29,
29,
29,
29,
29,
29,
2002
1996
1996
1996
1998
1998
1998
1998
1998
1998
CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

AB
10
ETHINYL ESTRADIOL; NORELGESTROMIN


XULANE

+
MYLAN TECHNOLOGIES
0.035MG/24HR;0.15MG/24HR
ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

0.035MG;0.5MG
NORINYL 1+35 21-DAY

AB
ACTAVIS LABS UT INC
0.035MG;1MG
TRI-NORINYL 21-DAY

0.035MG,0.035MG,0.035MG;0.5MG,1MG,
0.5MG

TABLET;ORAL-28

BREVICON 28-DAY

AB
ACTAVIS LABS UT INC
0.035MG;0.5MG
NORETHINDRONE AND ETHINYL ESTRADIOL

AB
FAMY CARE LTD
0.035MG;0.4MG
AB
+
JAI PHARMA LTD
0.035MG;0.4MG
>A> AB
0.035MG;0.5MG
>A> AB
0.035MG;1MG
+
0.05MG;1MG
NORINYL 1+35 28-DAY

AB
ACTAVIS LABS UT INC
0.035MG;1MG
OVCON-35

@ WARNER CHILCOTT LLC
0.035MG;0.4MG
TRI-NORINYL 28-DAY

AB
+
ACTAVIS LABS UT INC
0.035MG,0.035MG,0.035MG;0.5MG,1MG,
0.5MG

>A>
>A> AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
A 200910
001 Apr 16, 2014

Feb CRLD

N 017566
001

Mar CAHN

N 017565
001

Feb CAHN

N 018977
001 Apr 13, 1984

Feb CAHN

N 017743
001

Mar CAHN

A 200897

A 200897

A 200488

A 200489

A 203006

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

WATSON LABS
0.03MG;0.3MG
001
001
001
001
001
May
May
Oct
Oct
Aug
11,
11,
21,
21,
05,
2015

2015

2015

2015

2013

Apr
Jul
Oct
Oct
Jul
NEWA

CRLD

NEWA

NEWA

CTEC

N 017565
002

Feb CAHN

N 017716
001

Jul DISC

N 018977
002 Apr 13, 1984

Feb CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

BLISOVI 24 FE

LUPIN LTD
0.02MG;1MG
A 091398

FEMHRT

WARNER CHILCOTT LLC
0.0025MG;0.5MG
N 021065

LARIN 24 FE

NOVAST LABS LTD
0.02MG;1MG
A 202994

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

+
BARR LABS INC
0.005MG;1MG
A 076221

GLENMARK GENERICS
0.0025MG;0.5MG
A 203038

0.005MG;1MG
A 203038

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+
AMNEAL PHARMS
0.02MG;1MG
A 078267

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

HAUPT PHARMA
0.035MG,0.035MG,0.035MG;0.18MG,0.2
15MG,0.25MG
0.035MG;0.25MG
JAI PHARMA LTD
0.025MG,0.025MG,0.025MG;0.18MG,0.2
15MG,0.25MG
OC PHARMA
0.035MG;0.035MG;0.035MG;0.18MG;0.2
15MG;0.25MG
0.035MG;0.25MG
TRI-LO-ESTARYLLA

SANDOZ INC
0.025MG,0.025MG,0.025MG;0.18MG,0.2
15MG,0.25MG

1 -38

October
2015

001 Oct 28, 2015

Oct NEWA

001 Jan 14, 2005

Mar CTEC

001 Feb 18, 2015

Feb NEWA

001 Nov 06, 2009

001 Apr 02, 2015

002 Apr 02, 2015

Mar CTEC

Mar NEWA

Mar NEWA

001 Sep 01, 2009

Jan CRLD

A 203870
001 Nov 12, 2015

Oct NEWA

A 203865
001 Oct 27, 2015

A 202132
001 Sep 09, 2015

Oct NEWA

Aug NEWA

A 200383
001 Apr 07, 2015

Mar NEWA

A 200384
001 Apr 07, 2015

Mar NEWA

A 091232
001 Jun 29, 2015

Jun NEWA

A 075288
002 Jul 28, 1999

Feb CMFD

AB
AB
AP
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
October
2015
1 -39

250MG
250MG
A 040430
A 200892
001 Oct 28, 2002

001 Sep 25, 2012
Jan CAHN
Sep CAHN
ETODOLAC
TABLET;ORAL
ETODOLAC
@ LEHIGH VALLEY
400MG
A 074927
001 Oct 30, 1997
Sep CAHN
ETONOGESTREL
IMPLANT;IMPLANTATION
IMPLANON
@ ORGANON USA INC
68MG/IMPLANT
N 021529
001 Jul 17, 2006
Jun DISC
10MG
10MG
A 078560
A 078560
001 Jun 26, 2015

001 Jun 26, 2015
Jun DISC
Jun NEWA
10MG
10MG
N 021445
N 021445
001 Oct 25, 2002

001 Oct 25, 2002
Jun CTEC
Jun CFTG
A 075488
A 075799
001 Apr 16, 2001

001 Apr 30, 2002
Jun CAHN
Sep CAHN
A 075486
001 Apr 16, 2001
Jun CAHN
20MG
40MG
N 019462
N 019462
001 Oct 15, 1986

002 Oct 15, 1986
Feb CAHN
Feb CAHN
400MG
600MG
A 202284
A 202284
001 Nov 04, 2015

002 Nov 04, 2015
Oct NEWA
Oct NEWA
FELODIPINE
FELODIPINE
ORCHID HLTHCARE
2.5MG
5MG
10MG
SUN PHARM INDS LTD
2.5MG
5MG
10MG
A 203032
A 203032
A 203032
A 091200
A 091200
A 091200
001
002
003
001
002
003
May
May
May
Apr
Apr
Apr
43MG
130MG
A 201748
A 201748
001 Oct 31, 2014

002 Oct 31, 2014
Apr CAHN
Apr CAHN
54MG
160MG
54MG
107MG
160MG
48MG
145MG
A 204019
A 204019
A 076635
A 076635
A 076635
A 090715
A 090715
001
002
001
002
003
001
002
Aug
Aug
Apr
Apr
Apr
Aug
Aug
AB
AP
ETHOSUXIMIDE
CAPSULE;ORAL
ETHOSUXIMIDE
HERITAGE PHARMS INC
EZETIMIBE
TABLET;ORAL
EZETIMIBE
@ GLENMARK PHARMS LTD
AB
10
+
+
ZETIA
MSD INTL GMBH
FAMOTIDINE
FAMOTIDINE
+
EUROHLTH INTL SARL
@
FAMOTIDINE PRESERVATIVE
+
EUROHLTH INTL SARL
TABLET;ORAL
PEPCID
+
FELBAMATE
TABLET;ORAL
FELBAMATE
COREPHARMA
FENOFIBRATE
CAPSULE;ORAL
FENOFIBRATE
SUN PHARM INDS LTD
TABLET;ORAL
FENOFIBRATE
LUPIN LTD
SUN PHARM INDS LTD
10MG/ML
10MG/ML
FREE
10MG/ML
May
May
May
Dec
Dec
Dec
Aug
Aug
Oct
Oct
Oct
Apr
Apr
21,
21,
21,
13,
13,
13,
17,
17,
31,
31,
31,
05,
05,
2015
2015
2015
2013
2013
2013
2015
2015
2005
2005
2005
2012
2012
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
NEWA
NEWA
CAHN
CAHN
CAHN
CAHN
CAHN
2015
N 022418
N 022418
001 Aug 14, 2009

002 Aug 14, 2009
Jun CAHN
Jun CAHN
A 076709
004 Aug 20, 2007
Mar CAHN
A 077154
005 Jun 11, 2015
Jun NEWA
A 076709
001 Aug 20, 2007
Mar CAHN
A 076709
002 Aug 20, 2007
Mar CAHN
A 076709
003 Aug 20, 2007
Mar CAHN
N 022266
N 022266
N 022266
N 022266
N 022266
001
002
003
004
005
Mar
Mar
Mar
Mar
Mar
N 019101
001 Jul 11, 1984
Feb CAHN
FENTANYL HYDROCHLORIDE
SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS
@ THE MEDICINES CO
10.8MCG
+
EQ 40MCG BASE/ACTIVATION
N 021338
N 021338
001 May 22, 2006

001 May 22, 2006
Apr CAHN
Jun CMFD
FERRIC CITRATE
TABLET;ORAL
AURYXIA
+
KERYX BIOPHARMS
N 205874
001 Sep 05, 2014
Jan CTNA
FERRIC PYROPHOSPHATE CITRATE

TRIFERIC
+
ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML)
272MG IRON/50ML (5.44MG IRON/ML)
N 206317
N 206317
001 Jan 23, 2015

002 Sep 04, 2015
Jan NEWA
Oct NEWA
FIDAXOMICIN
TABLET;ORAL
DIFICID
+
CUBIST PHARMS LLC
200MG
N 201699
001 May 27, 2011
Aug CAHN
50MG
100MG
150MG
50MG
100MG
150MG
50MG
100MG
150MG
A 075882
A 075882
A 075882
A 202821
A 202821
A 202821
A 076421
A 076421
A 076421
001
002
003
001
002
003
001
002
003
Apr
Apr
Apr
Jun
Jun
Jun
Apr
Apr
Apr
35MG
105MG
AB
FENTANYL
FENTANYL-100
ACTAVIS LABS UT INC
100MCG/HR
FENTANYL-12
MALLINCKRODT INC
12.5MCG/HR
FENTANYL-25
ACTAVIS LABS UT INC
25MCG/HR
FENTANYL-50
ACTAVIS LABS UT INC
50MCG/HR
FENTANYL-75
ACTAVIS LABS UT INC
75MCG/HR
AP
FENTANYL CITRATE
FILM;BUCCAL
ONSOLIS
@ BIODELIVERY SCI INTL EQ 0.2MG BASE
@
EQ 0.4MG BASE
@
EQ 0.6MG BASE
@
EQ 0.8MG BASE
@
EQ 1.2MG BASE
FENTANYL CITRATE PRESERVATIVE FREE
+
EUROHLTH INTL SARL
EQ 0.05MG BASE/ML
AB
AB
AB
AB
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE
ANI PHARMS INC
SUN PHARM INDS LTD
EQ 210MG IRON
1 -40

October
FENOFIBRIC ACID
TABLET;ORAL
FIBRICOR
TRIBUTE PHARMS INTL
+
10
Jul
Jul
Jul
Jul
Jul
Oct
Oct
Oct
Jul
Jul
Jul
Mar
Mar
Mar
16,
16,
16,
16,
16,
28,
28,
28,
08,
08,
08,
28,
28,
28,
2009
2009
2009
2009
2009
2002
2002
2002
2015
2015
2015
2003
2003
2003
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
FLIBANSERIN

TABLET;ORAL

ADDYI

+
SPROUT PHARMS
AB
AB
AP
AP
AP
AP
AP
AP
AB
AB
AB
AB
>A> AP
AP
>A> AP
AP
AP
>D>
>A> AP
AP
AP
AP
FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

SUN PHARM INDS LTD
10
100MG

N 022526
001 Aug 18, 2015
Aug NEWA

50MG/5ML
200MG/5ML
A 076332
001 Jul 29, 2004
A 076332
002 Jul 29, 2004
Apr CAHN

Apr CAHN

A 077988
001 May 26, 2010
A 077988
002 May 26, 2010
Apr CAHN

Apr CAHN

A 077947
001 May 26, 2010
A 077947
002 May 26, 2010
Apr CAHN

Apr CAHN

A 077909

A 077909

A 077909

A 077909

003
003
001
002
Apr
Apr
May
May
20,
20,
26,
26,
2015
2015
2010
2010
Apr
Apr
Apr
Apr
NEWA

CAHN

CAHN

CAHN

A 078423

A 078423

A 078423

A 078423

001
002
003
004
Mar
Mar
Mar
Mar
07,
07,
07,
07,
2011
2011
2011
2011
May
May
May
May
CMFD

CMFD

CMFD

CMFD

20-300mCi/ML
20-300mCi/ML
4-40mCi/ML
20-300mCi/ML
20-300mCi/ML
20-500mCi/ML
10-100mCi/ML
4-500mCi/ML
4-40mCi/ML
4-40mCi/ML
20-300mCi/ML

A 203778

A 203591

A 204759

A 203904

A 204472

A 204546

A 203771

A 203911

A 203811

A 203811

A 204531

001
001
001
001
001
001
001
001
001
001
001
Oct
Aug
Oct
Apr
Sep
Apr
Aug
Apr
Jun
Jun
Jul
30,
31,
27,
23,
11,
07,
31,
22,
27,
27,
17,
2015
2015
2015
2015
2015
2015
2015
2015
2013
2013
2015
Oct
Aug
Oct
Apr
Aug
Mar
Aug
Apr
Oct
Oct
Jul
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

CTEC

CTEC

NEWA

0.5MG/5ML (0.1MG/ML)
1MG/10ML (0.1MG/ML)
0.5MG/5ML (0.1MG/ML)
1MG/10ML (0.1MG/ML)

A 076755

A 076755

A 076787

A 076787

002
001
002
001
Oct
Oct
Oct
Oct
12,
12,
12,
12,
2004
2004
2004
2004
Apr
Apr
Jun
Jun
CAHN

CAHN

CAHN

CAHN

0.01%

A 091514
001 Jun 25, 2015
Jun NEWA

0.01%

A 206422
001 Sep 02, 2015
Aug NEWA


FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

100MG/50ML (2MG/ML)
100MG/50ML (2MG/ML)
TABLET;ORAL

FLUCONAZOLE

HARRIS PHARM
50MG

100MG

150MG

200MG

FLUDEOXYGLUCOSE F-18


FLUDEOXYGLUCOSE F18

3D IMAGING DRUG
IBA MOLECULAR N AM
KETTERING MEDCTR
METHODIST HOSP RES
MIPS CRF
PRECISION NUCLEAR
QUEEN HAMAMATSU PET
SPECTRON MRC LLC
+
UCLA BIOMEDICAL
+
UNIV MICHIGAN
FLUMAZENIL


FLUMAZENIL

@ CLARIS PHARMASERVICE
@
EUROHLTH INTL SARL
1 -41

-
October
2015
AT
FLUOCINOLONE ACETONIDE

OIL;TOPICAL


VERSAPHARM INC
SOLUTION;TOPICAL


GAVIS PHARMS LLC
AB
FLUOCINONIDE

GEL;TOPICAL

FLUOCINONIDE

G AND W LABS INC
0.05%

A 072537
001 Feb 07, 1989
Apr CAHN

FLUOROURACIL

CREAM;TOPICAL

CARAC

+
+
0.5%

0.5%

N 020985
001 Oct 27, 2000
N 020985
001 Oct 27, 2000
Apr CFTG

Feb CAHN

AT
AB
AB
2015
0.5%
A 203122
001 Apr 20, 2015
Apr NEWA
4%
N 022259
001 Sep 18, 2015
Sep NEWA
A 076287
A 076287
A 078045
A 078045
A 077469
A 077469
A 204597
A 204597
A 204597
A 076990
001
002
002
002
001
002
001
002
003
001
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Apr
0.05%
0.05%
N 012806
N 012806
001
001
Jun CRLD
May CMFD
0.004MG/SQ CM
N 016455
001
Mar CAHN
50MG
50MG
100MG
100MG
N 018766
N 018766
N 018766
N 018766
002
002
003
003
100MG
100MG
A 074358
A 074358
002 Jun 20, 1994

002 Jun 20, 1994
Oct CRLD
Oct CRLD
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION
BREO ELLIPTA
GLAXO GRP LTD
0.2MG/INH;EQ 0.025MG BASE/INH
N 204275
002 Apr 30, 2015
Apr NEWA
FLUTICASONE PROPIONATE
CREAM;TOPICAL
FLUTICASONE PROPIONATE
PERRIGO NEW YORK
+
A 076793
A 076793
001 May 14, 2004

001 May 14, 2004
Oct CRLD
Oct CRLD
A 202458
001 Sep 11, 2015
Aug NEWA
N 021192
001 Oct 06, 2000
Aug CFTG
A 075897
A 075898
A 075897
A 075898
A 075897
A 075898
001
001
002
002
003
003
Jul
Jul
Jul
Jul
Jul
Jul
FLUOXETINE HYDROCHLORIDE
CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE
@ ANI PHARMS INC
EQ 10MG BASE
@
EQ 20MG BASE
+
MYLAN
EQ 20MG BASE
EQ 20MG BASE
@ SANDOZ
EQ 10MG BASE
@
EQ 20MG BASE
AB1
SCIEGEN PHARMS INC
EQ 10MG BASE
AB1
EQ 20MG BASE
AB
EQ 40MG BASE
AB
SUN PHARM INDS LTD
EQ 40MG BASE
FLURANDRENOLIDE
OINTMENT;TOPICAL
CORDRAN
+
AQUA PHARMS
TAPE;TOPICAL
CORDRAN
+
ACTAVIS LABS UT INC
>D>
>D> AB
>A>
>D> AB
>A>
>D> AB
>A> AB
>D> AB
>A> AB
AB
AB
AB
FLURBIPROFEN
TABLET;ORAL
ANSAID
@
+
@
FLURBIPROFEN
MYLAN
+
0.05%
0.05%
FLUVASTATIN SODIUM
FLUVASTATIN SODIUM
MYLAN PHARMS INC
80MG
LESCOL XL
+
NOVARTIS
80MG
FLUVOXAMINE MALEATE
TABLET;ORAL
FLUVOXAMINE MALEATE
ANI PHARMS INC
@
AB
@
AB
@
25MG
25MG
50MG
50MG
100MG
100MG
1 -42
October
CREAM;TOPICAL
FLUOROURACIL
SPEAR PHARMS INC
TOLAK
+
HILL DERMACEUTICALS
10
May
May
Nov
Nov
Nov
Nov
Mar
Mar
Mar
Dec
Oct
Oct
Oct
Oct
Jan
Mar
Jan
Mar
Jan
Mar
20,
20,
17,
17,
17,
17,
16,
16,
16,
13,
31,
31,
31,
31,
25,
12,
25,
12,
25,
12,
2008
2008
2008
2008
2008
2008
2015
2015
2015
2004
1988
1988
1988
1988
2001
2001
2001
2001
2001
2001
Oct
Oct
Oct
Oct
DISC
DISC
CRLD
CTEC
DISC
DISC
NEWA
NEWA
NEWA
CAHN
DISC
DISC
DISC
DISC
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
10
1 -43

October
2015
A 091145
A 204418
001 Jul 12, 2013

001 Jul 28, 2015
Aug CAHN
Jul NEWA
AA
AA
FOLIC ACID
TABLET;ORAL
FOLIC ACID
AIPING PHARM INC
NUVO PHARM INC
AB
AB
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
SUN PHARM INDS LTD
10MG;12.5MG
20MG;12.5MG
A 076739
A 076739
001 Dec 17, 2004

002 Dec 17, 2004
Apr CAHN
Apr CAHN
FUROSEMIDE
FUROSEMIDE
@ IGI LABS INC
@
10MG/ML
10MG/ML
A 070095
A 070096
001 Sep 09, 1985

001 Sep 09, 1985
Mar CAHN
Mar CAHN
100MG
300MG
400MG
A 076606
A 076606
A 076606
001 Oct 07, 2005

002 Oct 07, 2005
003 Oct 07, 2005
Apr CAHN
Apr CAHN
Apr CAHN
600MG
800MG
A 078782
A 078782
001 Jul 21, 2011

002 Jul 21, 2011
Jun DISC
Jun DISC
N 020937
N 020937
N 020937
N 020937
N 020975
001
002
003
004
001
Dec
Dec
Dec
Dec
Dec
08,
08,
08,
08,
08,
1999
1999
1999
1999
1999
Feb
Feb
Feb
Feb
Feb
CAHN
CAHN
CAHN
CAHN
CAHN
N 020976
N 020976
N 020976
N 020976
002
003
004
001
Dec
Dec
Dec
Dec
08,
08,
08,
08,
1999
1999
1999
1999
Feb
Feb
Feb
Feb
CAHN
CAHN
CAHN
CAHN
AB
AB
AB
GABAPENTIN
CAPSULE;ORAL
GABAPENTIN
SUN PHARM INDS LTD
TABLET;ORAL
GABAPENTIN
@ HIKMA PHARMS
@
1MG
1MG
GADOVERSETAMIDE
OPTIMARK
+
LIEBEL-FLARSHEIM
1654.5MG/5ML (330.9MG/ML)
+
3309MG/10ML (330.9MG/ML)
+
4963.5MG/15ML (330.9MG/ML)
+
6618MG/20ML (330.9MG/ML)
+
16.545GM/50ML (330.9MG/ML)
OPTIMARK IN PLASTIC CONTAINER
+
LIEBEL-FLARSHEIM
3309MG/10ML (330.9MG/ML)
+
4963.5MG/15ML (330.9MG/ML)
+
6618MG/20ML (330.9MG/ML)
+
9927MG/30ML (330.9MG/ML)
AB
AB
AB
AP
AP
GEFITINIB
TABLET;ORAL
IRESSA
+
ASTRAZENECA PHARMS
250MG
N 206995
001 Jul 13, 2015
Jul NEWA
GEMFIBROZIL
TABLET;ORAL
GEMFIBROZIL
600MG
A 202726
001 Sep 16, 2015
Aug NEWA
EQ 320MG BASE
N 021158
001 Apr 04, 2003
Jun CFTG
EQ 320MG BASE
A 090466
001 Jun 15, 2015
Jun NEWA
20MG/ML
N 020622
002 Feb 12, 2002
Mar CFTG
20MG/ML
A 090218
001 Apr 16, 2015
Mar NEWA
GEMIFLOXACIN MESYLATE
TABLET;ORAL
FACTIVE
+
LG LIFE SCIENCES
GEMIFLOXACIN MESYLATE
ORCHID HLTHCARE
GLATIRAMER ACETATE
COPAXONE
+
TEVA PHARMS USA
GLATOPA
SANDOZ INC
2015
A 078952
A 078952
A 078952
001 Aug 01, 2013

002 Aug 01, 2013
003 Aug 01, 2013
Apr DISC
Apr DISC
Apr DISC
A 074387
A 074497
A 074387
A 074497
A 074497
A 074497
001
001
002
002
001
002
Aug
Oct
Aug
Oct
Oct
Oct
A 202298
A 202298
A 202298
001 May 19, 2015

002 May 19, 2015
003 May 19, 2015
May NEWA
May NEWA
May NEWA
N 201849
001 May 08, 2015
May NEWA
1.25MG
2.5MG
5MG
N 017532
N 017532
N 017532
001 May 01, 1984

002 May 01, 1984
003 May 01, 1984
Sep CFTG
Sep CFTG
Sep CFTG
1.25MG
2.5MG
5MG
1.25MG
1.25MG
2.5MG
2.5MG
5MG
5MG
1.25MG
2.5MG
5MG
1.25MG
2.5MG
5MG
A 077537
A 077537
A 077537
A 076257
A 206079
A 076257
A 206079
A 076257
A 206079
A 090937
A 090937
A 090937
A 074388
A 074388
A 074388
001
002
003
001
001
002
002
003
003
001
002
003
001
002
003
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL
GLUCOVANCE
BRISTOL MYERS SQUIBB 1.25MG;250MG
@
1.25MG;250MG
N 021178
N 021178
001 Jul 31, 2000

001 Jul 31, 2000
Oct DISC
Oct DISC
GLYCEROL PHENYLBUTYRATE
LIQUID;ORAL
RAVICTI
+
HORIZON THERAPS INC
1.1GM/ML
N 203284
001 Feb 01, 2013
May CAHN
0.2MG/ML
N 017558
001
Jun CAHN
15.6MCG/INH
N 207923
001 Oct 29, 2015
Oct NEWA
1MG
A 040844
001 Aug 18, 2009
Apr CAHN
1MG
2MG
4MG
GLIPIZIDE
TABLET;ORAL
GLIPIZIDE
@ ANI PHARMS INC
>A> AB
>A> AB
>D> AB
>D> AB
AB
AB
AB
5MG
5MG
@
10MG
10MG
IVAX SUB TEVA PHARMS
5MG
10MG
GLIPIZIDE
MYLAN PHARMS INC
2.5MG
5MG
10MG
GLUCAGON HYDROCHLORIDE
POWDER;INTRAMUSCULAR, INTRAVENOUS
GLUCAGON
+
FRESENIUS KABI USA
EQ 1MG BASE/VIAL
GLYBURIDE
TABLET;ORAL
DIABETA
AB2
SANOFI AVENTIS US
AB2
AB2
+
GLYBURIDE
AB1
AUROBINDO PHARMA
AB1
AB1
AB1
COREPHARMA
AB2
AB1
AB2
AB1
AB2
AB1
HERITAGE PHARMS INC
AB1
AB1
AB1
TEVA
AB1
AB1
+
>D> AB
>A>
AP
>A>
>A>
>A>
AA
GLYCOPYRROLATE
ROBINUL
+
EUROHLTH INTL SARL
POWDER;INHALATION
SEEBRI
+
TABLET;ORAL
GLYCOPYRROLATE
SUN PHARM INDS LTD
1 -44
October
GLIMEPIRIDE
TABLET;ORAL
GLIMEPIRIDE
@ HIKMA PHARMS
@
@
10
Mar
Aug
Mar
Aug
Aug
Aug
Oct
Oct
Oct
Jun
Sep
Jun
Sep
Jun
Sep
Feb
Feb
Feb
Aug
Aug
Aug
04,
31,
04,
31,
31,
31,
18,
18,
18,
27,
30,
27,
30,
27,
30,
28,
28,
28,
29,
29,
29,
1996
1995
1996
1995
1995
1995
2007
2007
2007
2002
2015
2002
2015
2002
2015
2011
2011
2011
1995
1995
1995
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CTEC
CTEC
CTEC
CTEC
NEWA
CTEC
NEWA
CTEC
NEWA
CTEC
CTEC
CTEC
CTEC
CTEC
CTEC
10
1 -45

October
2015

TABLET;ORAL

GLYCOPYRROLATE

AA
>A>
>A>
>A>
>A>
2MG
GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

+
15.6MCG/INH;27.5MCG/INH
AP
AP
AP
AP
GRANISETRON HYDROCHLORIDE


GRANISETRON HYDROCHLORIDE

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

@
EUROHLTH INTL SARL
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
Apr CAHN

N 207930
001 Oct 29, 2015

Oct NEWA

A 078863
001 Jun 30, 2008

Jan CAHN

A 078880

A 078198

A 078198

A 077177

Jan
Apr
Apr
Jun
001
001
002
001
Jun
Jun
Jun
Dec
30,
30,
30,
31,
2008

2008

2008

2007

CAHN

CAHN

CAHN

CAHN

A 078863
002 Jun 30, 2008

Jan CAHN

N 022424
001 May 14, 2015

N 022424
001 May 14, 2015

May NEWA

Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+
MIKART INC
200MG/5ML;2.5MG/5ML;30MG/5ML
N 022279
001 May 14, 2015

May NEWA

GUANFACINE HYDROCHLORIDE


GUANFACINE HYDROCHLORIDE

IMPAX LABS INC
EQ 1MG
EQ 2MG
EQ 3MG
EQ 4MG
MYLAN PHARMS INC
EQ 1MG
EQ 2MG
EQ 3MG
EQ 4MG
SANDOZ INC
EQ 1MG
EQ 2MG
EQ 3MG
EQ 4MG
TEVA PHARMS USA
EQ 1MG
EQ 2MG
EQ 3MG
EQ 4MG
TWI PHARMS INC
EQ 1MG
EQ 2MG
EQ 3MG
EQ 4MG
GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

MIKART INC
200MG/5ML;2.5MG/5ML
MISSION PHARMACAL CO
200MG/5ML;2.5MG/5ML
>A>
>A>
>A>
>A>
A 040844
002 Aug 18, 2009

BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
A 202238

A 202238

A 202238

A 202238

A 202578

A 202578

A 202578

A 202578

A 202568

A 202568

A 202568

A 202568

A 201382

A 201382

A 201382

A 201382

A 201408

A 201408

A 201408

A 201408

001
002
003
004
001
002
003
004
001
002
003
004
001
002
003
004
001
002
003
004
Oct
Oct
Oct
Oct
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
20,
20,
20,
20,
02,
02,
02,
02,
03,
03,
03,
03,
02,
02,
02,
02,
02,
02,
02,
02,
2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

2015

Oct
Oct
Oct
Oct
May
May
May
May
May
May
May
May
May
May
May
May
May
May
May
May
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

001
001
001
001
001
001
Feb
Feb
Feb
May
May
Feb
17,
17,
17,
12,
12,
17,
1987

1987

1987

1987

1987

1987

May
Jun
Jun
Jun
May
Jun
CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

@ CYCLE PHARMS LTD
@
@
@
@
@ ROXANE
0.5MG
1MG
5MG
10MG
20MG
2MG
A 071128

A 071129

A 071131

A 071132

A 071133

A 071130

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD
EQ 2MG BASE/ML
A 072045
001 Apr 12, 1988

May CAHN

HALOPERIDOL
@
AP
AP
AP
AP
AP
AP
AB
AB
AB
AB
AB
AB
AB
HEPARIN SODIUM
HEPARIN SODIUM
+
@
@
@
+
@
@
@
+
@
@
HYDROCHLOROTHIAZIDE
CAPSULE;ORAL
HYDROCHLOROTHIAZIDE
@ SUN PHARM INDS INC
MICROZIDE
+
ACTAVIS LABS UT INC
2015
EQ 5MG BASE/ML
EQ 5MG BASE/ML
A 076791
A 076828
001 Aug 25, 2004

001 Aug 25, 2004
Apr CAHN
May CAHN
1,000 UNITS/ML
1,000 UNITS/ML
2,500 UNITS/ML
5,000 UNITS/ML
5,000 UNITS/0.5ML
5,000 UNITS/ML
5,000 UNITS/0.5ML
7,500 UNITS/ML
10,000 UNITS/ML
10,000 UNITS/ML
15,000 UNITS/ML
20,000 UNITS/ML
N 017007
N 017037
N 017007
N 017007
N 017007
N 017037
N 017037
N 017007
N 017007
N 017037
N 017007
N 017007
001
001
007
002
010
002
013 Apr 07, 1986
003
004
003
005
006
Aug
Jun
Aug
Aug
Aug
Jun
Jun
Aug
Aug
Jun
Aug
Aug
A 040730
A 040136
A 203110
001 Apr 21, 2009

001 Jun 30, 1997
001 Jun 29, 2015
Feb CRLD
Feb CRLD
Jun NEWA
A 040858
A 040858
A 040858
A 040858
001
002
003
004
Sep
Sep
Sep
Sep
12.5MG
A 090651
001 Apr 07, 2014
Aug DISC
12.5MG
N 020504
001 Dec 27, 1996
Feb CAHN
A 076007
A 076007
A 076007
001 Jul 01, 2002

002 Jul 01, 2002
003 Jul 01, 2002
Apr CAHN
Apr CAHN
Apr CAHN
N 019888
N 019888
N 019888
003 Nov 18, 1993

001 Sep 20, 1990
002 Jul 20, 1989
Feb CAHN
Feb CAHN
Feb CAHN
N 021956
N 021956
N 021956
001 Aug 28, 2006

002 Aug 28, 2006
003 Aug 28, 2006
Jun CAHN
Jun CAHN
Jun CAHN
N 018031
N 018031
001
001
Oct DISC
Oct DISC
A 070704
A 072042
A 070705
A 072043
A 070947
A 070947
001
001
001
001
002
002
HYDROCHLOROTHIAZIDE; LISINOPRIL
TABLET;ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE
SUN PHARM INDS LTD
12.5MG;10MG
12.5MG;20MG
25MG;20MG
ZESTORETIC
ALVOGEN IPCO SARL
12.5MG;10MG
+
12.5MG;20MG
+
25MG;20MG
HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE
DUTOPROL
CONCORDIA PHARMS INC 12.5MG;EQ 25MG TARTRATE
12.5MG;EQ 50MG TARTRATE
+
12.5MG;EQ 100MG TARTRATE
>D>
>D> AB
>A>
AB
AB
>D> AB
>A> AB
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL
INDERIDE-40/25
+
WYETH PHARMS INC
25MG;40MG
@
25MG;40MG
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ ANI PHARMS INC
25MG;40MG
25MG;40MG
@
25MG;80MG
25MG;80MG
MYLAN
25MG;40MG
+
25MG;40MG
1 -46
October
HYDRALAZINE HYDROCHLORIDE
+
AKORN
20MG/ML
LUITPOLD
20MG/ML
X-GEN PHARMS INC
20MG/ML
TABLET;ORAL
10MG
@
25MG
@
50MG
@
100MG
10
Feb
Feb
Feb
Feb
Oct
Mar
Oct
Mar
Mar
Mar
26,
26,
26,
26,
01,
14,
01,
14,
04,
04,
2010
2010
2010
2010
1986
1988
1986
1988
1987
1987
Jul
Aug
Jul
Aug
Oct
Oct
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CRLD
CRLD
2015
HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
SUN PHARM INDS LTD
12.5MG;EQ 10MG BASE
12.5MG;EQ 20MG BASE
25MG;EQ 20MG BASE
A 078211
A 078211
A 078211
001 Mar 04, 2009

002 Mar 04, 2009
003 Mar 04, 2009
Apr CAHN
Apr CAHN
Apr CAHN
>A> AB
>A> AB
>A> AB
HYDROCHLOROTHIAZIDE; TELMISARTAN
TABLET;ORAL
TELMISARTAN AND HYDROCHLOROTHIAZIDE
MACLEODS PHARMS LTD
12.5MG;40MG
12.5MG;80MG
25MG;80MG
A 204169
A 204169
A 204169
001 Nov 02, 2015

002 Nov 02, 2015
003 Nov 02, 2015
Oct NEWA
Oct NEWA
Oct NEWA
A 074970
001 Jan 06, 1998
Aug CAHN
AB
HYDROCHLOROTHIAZIDE; TRIAMTERENE
CAPSULE;ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
@ ANI PHARMS INC
25MG;37.5MG
TABLET;ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
ANI PHARMS INC
50MG;75MG
A 073467
001 Jan 31, 1996
Aug CAHN
HYDROCODONE BITARTRATE
ZOHYDRO ER
+
FERRIMILL LTD
10MG
15MG
20MG
30MG
40MG
50MG
+
PERNIX IRELAND PAIN
10MG
15MG
20MG
30MG
40MG
50MG
HYSINGLA
+
PURDUE PHARMA LP
20MG
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
N 202880
001
002
003
004
005
006
001
002
003
004
005
006
Apr
Apr
Apr
Apr
Apr
Apr
Jun
Jun
Jun
Jun
Jun
Jun
N 206627
001 Nov 20, 2014
Mar CRLD
A 040879
001 Aug 20, 2010
Mar CAHN
A 085982
001
Apr DISC
A 083365
A 083365
A 083365
002 Feb 23, 2015

003 Feb 23, 2015
001
Feb NEWA
Feb NEWA
Feb CMFD
HYDROCORTISONE ACETATE
POWDER;FOR RX COMPOUNDING
HYDROCORTISONE ACETATE
@ X GEN PHARMS
100%
A 085981
001
Apr DISC
HYDROCORTISONE VALERATE
CREAM;TOPICAL
HYDROCORTISONE VALERATE
@ G AND W LABS INC
0.2%
A 074489
001 Aug 12, 1998
Apr CAHN
N 060613
001
Jun CMS2

AT
AB
AB
AB
AT
HYDROCORTISONE
CREAM;TOPICAL
HYDROCORTISONE
RISING PHARMS INC
2.5%
POWDER;FOR RX COMPOUNDING
HYDRO-RX
@ X GEN PHARMS
100%
TABLET;ORAL
HYDROCORTISONE
HIKMA INTL PHARMS
5MG
10MG
20MG
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC
CORTISPORIN

+
CITRON PHARMA LLC
1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

1 -47

October
AB
AB
AB
10
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
25,
25,
25,
25,
25,
25,
25,
25,
25,
25,
25,
25,
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
>D>
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AP
AP
AB
AB
AB
HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP
+
PURDUE PHARM PRODS
250MG/VIAL
@
250MG/VIAL
HYDROMORPHONE HYDROCHLORIDE
PADDOCK LLC
8MG
12MG
16MG
10
1 -48

October
2015
N 019034
N 019034
002 Aug 04, 1994

002 Aug 04, 1994
Oct DISC
Oct DISC
A 204278
A 204278
A 204278
001 Apr 06, 2015

002 Apr 06, 2015
003 Apr 06, 2015
Mar NEWA
Mar NEWA
Mar NEWA
HYDROXOCOBALAMIN
CYANOKIT
@ SERB SAS
+
2.5GM/VIAL (5GM/KIT)
5GM/VIAL (5GM/KIT)
N 022041
N 022041
002 Dec 15, 2006

001 Apr 08, 2011
Apr CAHN
Apr CAHN
HYDROXYCHLOROQUINE SULFATE
TABLET;ORAL
PLAQUENIL
+
200MG
N 009768
001
Jun CAHN
HYDROXYPROGESTERONE CAPROATE
HYDROXYPROGESTERONE CAPROATE
125MG/ML
@
250MG/ML
+
MCGUFF
250MG/ML
N 017439
N 017439
A 200271
001
002
001 Aug 24, 2015
Mar CAHN
Mar CAHN
Aug NEWA
HYDROXYZINE HYDROCHLORIDE
TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE
ELITE LABS INC
10MG
25MG
50MG
HERITAGE PHARMA
10MG
25MG
50MG
MIKAH PHARMA
10MG
25MG
50MG
@ MUTUAL PHARM
10MG
@
25MG
@
50MG
@ WATSON LABS
10MG
@
25MG
@
50MG
A 040600
A 040602
A 040604
A 204279
A 204279
A 204279
A 040600
A 040602
A 040604
A 089381
A 089382
A 089383
A 088348
A 088349
A 088350
001
001
001
001
002
003
001
001
001
001
001
001
001
001
001
Jun
Jun
Jun
Mar
Mar
Mar
Mar
Mar
Mar
Jul
Jul
Jul
Jul
Jul
Jul
EQ 25MG HYDROCHLORIDE
EQ 50MG HYDROCHLORIDE
A 201507
A 201507
001 Jun 03, 2013

002 Jun 03, 2013
Mar CAHN
Mar CAHN
EQ 3MG BASE/3ML
EQ 3MG BASE/3ML
A 204222
A 205332
001 Oct 16, 2015

001 Aug 19, 2015
Oct NEWA
Aug NEWA
400MG
600MG
800MG
300MG
400MG
600MG
800MG
A 091625
A 091625
A 091625
A 071230
A 071231
A 071232
A 072004
001
002
003
001
001
001
001
Aug
Aug
Aug
Jul
Jul
Jul
Jul
HYDROXYZINE PAMOATE
CAPSULE;ORAL
HYDROXYZINE PAMOATE
HERITAGE PHARMA
IBANDRONATE SODIUM
IBANDRONATE SODIUM
APOTEX INC
IBUPROFEN
TABLET;ORAL
IBUPROFEN
GRANULES INDIA LTD
@ VINTAGE PHARMS
@
@
@
Dec
Dec
Dec
Aug
Aug
Aug
Dec
Dec
Dec
May
May
May
Sep
Sep
Sep
Sep
Sep
Sep
Oct
Oct
Oct
Nov
28,
28,
28,
20,
20,
20,
28,
28,
28,
19,
19,
19,
15,
15,
15,
15,
15,
15,
22,
22,
22,
18,
2004
2004
2004
2014
2014
2014
2004
2004
2004
1986
1986
1986
1983
1983
1983
2015
2015
2015
1986
1986
1986
1987
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CMFD
CMFD
CMFD
DISC
DISC
DISC
DISC
DISC
DISC
NEWA
NEWA
NEWA
DISC
DISC
DISC
DISC
2015
1MG
2MG
4MG
6MG
8MG
10MG
12MG
N 022192
N 022192
N 022192
N 022192
N 022192
N 022192
N 022192
001
002
003
004
005
006
007
AB
5%
A 200481
001 Apr 18, 2011
Apr CAHN
AB
1.25MG
1.25MG
2.5MG
2.5MG
A 074299
A 074498
A 074299
A 074498
002
002
001
001
Jul
Jul
Jul
Jul
INDOMETHACIN
INDOMETHACIN
JUBILANT GENERICS
75MG
A 202706
001 Oct 05, 2015
Sep NEWA
INGENOL MEBUTATE
GEL;TOPICAL
PICATO
+
LEO PHARMA AS
0.015%
N 202833
001 Jan 23, 2012
May CRLD
INSULIN DEGLUDEC
TRESIBA
NOVO NORDISK INC
+
300 UNITS/3ML (100 UNITS/ML)

600 UNITS/3ML (200 UNITS/ML)
N 203314
N 203314
001 Sep 25, 2015

002 Sep 25, 2015
Sep NEWA
Sep NEWA
INSULIN GLARGINE RECOMBINANT

TOUJEO SOLOSTAR
+
SANOFI US SERVICES
300 UNITS/ML (300 UNITS/ML)
N 206538
001 Feb 25, 2015
Feb NEWA
INSULIN LISPRO RECOMBINANT

HUMALOG KWIKPEN
+
ELI LILLY AND CO
200 UNITS/ML
N 205747
001 May 26, 2015
May NEWA
INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA
SANOFI AVENTIS
12 UNITS/INH
N 022472
003 Apr 17, 2015
Apr NEWA
IOHEXOL
FOR SOLUTION;ORAL
ORALTAG
INTERPHARMA PRAHA AS
9.7GM/BOT
N 205383
001 Mar 26, 2015
Mar NEWA
51%
A 074679
001 Apr 02, 1997
Jan DISC
61%
A 074679
002 Apr 02, 1997
Jan DISC
76%
A 074679
003 Apr 02, 1997
Jan DISC
41%
N 018735
006 Jul 07, 1987
Feb CTEC
IMIQUIMOD
CREAM;TOPICAL
IMIQUIMOD
G AND W LABS INC
INDAPAMIDE
TABLET;ORAL
INDAPAMIDE
ANI PHARMS INC
@
AB
@
AB
IOPAMIDOL
IOPAMIDOL-250
IOPAMIDOL-300
IOPAMIDOL-370
ISOVUE-200
+
BRACCO
1 -49

October
ILOPERIDONE
TABLET;ORAL
FANAPT
+
VANDA PHARMS INC
10
May
May
May
May
May
May
May
Apr
Feb
Jul
Oct
06,
06,
06,
06,
06,
06,
06,
29,
12,
27,
31,
2009
2009
2009
2009
2009
2009
2009
1996
1998
1995
1996
Jan
Jan
Jan
Jan
Jan
Jan
Jan
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
AP
AP
ISOVUE-250
+
BRACCO
+
ISOVUE-300
+
BRACCO
ISOVUE-370
+
BRACCO
SCANLUX-300
MYLAN INSTITUTIONAL
SCANLUX-370
MYLAN INSTITUTIONAL
IOTHALAMATE MEGLUMINE
CONRAY
+
LIEBEL-FLARSHEIM
CONRAY 30
+
LIEBEL-FLARSHEIM
CONRAY 43
+
LIEBEL-FLARSHEIM
SOLUTION;INTRAVESICAL
CYSTO-CONRAY II
LIEBEL-FLARSHEIM
IOVERSOL
OPTIRAY 160
@ LIEBEL-FLARSHEIM
OPTIRAY 240
+
LIEBEL-FLARSHEIM
@
OPTIRAY 300
+
LIEBEL-FLARSHEIM
+
OPTIRAY 320
+
LIEBEL-FLARSHEIM
@
+
@
OPTIRAY 350
+
LIEBEL-FLARSHEIM
+
>D>
>A>
AB
AB
AB
IRBESARTAN
TABLET;ORAL
IRBESARTAN
JUBILANT GENERICS
2015
51%
51%
N 018735
N 020327
007 Jul 06, 1992

002 Oct 12, 1994
Feb CTEC
Feb CTEC
61%
N 020327
003 Oct 12, 1994
Feb CTEC
76%
N 020327
004 Oct 12, 1994
Feb CTEC
61%
A 090394
001 Jun 18, 2010
Aug CAHN
76%
A 090394
002 Jun 18, 2010
Aug CAHN
60%
N 013295
001
Feb CAHN
30%
N 016983
001
Feb CAHN
43%
N 013295
002
Feb CAHN
17.2%
N 017057
002
Feb CAHN
34%
N 019710
003 Dec 30, 1988
Feb CAHN
51%
51%
N 019710
N 020923
002 Dec 30, 1988

001 May 28, 1998
Feb CAHN
Feb CAHN
64%
64%
N 019710
N 020923
004 Jan 22, 1992

004 May 13, 1999
Feb CAHN
Feb CAHN
68%
68%
68%
68%
N 019710
N 020923
N 020923
N 020923
001
002
002
002
Feb
Oct
Oct
Feb
74%
74%
N 019710
N 020923
005 Jan 22, 1992

003 May 28, 1998
Feb CAHN
Feb CAHN
N 018905
002 Jul 26, 1985
May DISC
A 203534
A 203534
A 203534
001 Feb 23, 2015

002 Feb 23, 2015
003 Feb 23, 2015
Feb NEWA
Feb NEWA
Feb NEWA
N 207793
001 Oct 22, 2015
Oct NEWA
N 017441
001
Mar CAHN
75MG
150MG
300MG
IRINOTECAN HYDROCHLORIDE
INJECTABLE, LIPOSOMAL;IV (INFUSION)
ONIVYDE
+
MERRIMACK PHARMS
EQ 43MG BASE/10ML (EQ 4.3MG
BASE/ML)
>A>
>A>
BP
IRON DEXTRAN
INFED
+
ACTAVIS LABS UT INC
EQ 50MG IRON/ML
1 -50

October
IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

HEXABRIX
@ GUERBET
39.3%;19.6%
10
Dec
May
May
May
30,
29,
29,
29,
1988
1998
1998
1998
CAHN
CMFD
CMFD
CAHN
2015
186MG
N 207500
001 Mar 06, 2015
Mar NEWA
372MG
N 207501
001 Mar 06, 2015
Mar NEWA
AB
5MG
40MG
N 012093
N 012093
007 Jul 29, 1988

001 Jul 29, 1988
Feb CAHN
Feb CAHN
25MG
35MG
N 021951
N 021951
005 Aug 15, 2014

006 Aug 15, 2014
Feb NEWA
Feb NEWA
30MG
A 076485
004 Aug 25, 2015
Aug NEWA
10MG
20MG
30MG
40MG
A 076041
A 076041
A 076503
A 076041
001
002
001
003
Apr
Apr
Apr
Apr
30MG
A 202099
004 Feb 23, 2015
Feb NEWA
2.5MG
5MG
A 077169
A 077169
001 Apr 24, 2006

002 Apr 24, 2006
Mar CAHN
Mar CAHN
10MG/ML
A 205573
001 Oct 30, 2015
Oct NEWA
10MG/ML
10MG/ML
N 020657
N 020657
001 Feb 21, 1997

001 Feb 21, 1997
Oct CFTG
Oct CFTG
IVABRADINE HYDROCHLORIDE
TABLET;ORAL
CORLANOR
AMGEN INC
+
EQ 5MG BASE
EQ 7.5MG BASE
N 206143
N 206143
001 Apr 15, 2015

002 Apr 15, 2015
Apr NEWA
Apr NEWA
IVACAFTOR
GRANULE;ORAL
KALYDECO
VERTEX PHARMS INC
+
50MG/PACKET
75MG/PACKET
N 207925
N 207925
001 Mar 17, 2015

002 Mar 17, 2015
Mar NEWA
Mar NEWA
IVACAFTOR; LUMACAFTOR
TABLET;ORAL
ORKAMBI
+
VERTEX PHARMS INC
125MG;200MG
N 206038
001 Jul 02, 2015
Jul NEWA
IXABEPILONE
IXEMPRA KIT
+
R-PHARM US LLC
+
15MG/VIAL
45MG/VIAL
N 022065
N 022065
001 Oct 16, 2007

002 Oct 16, 2007
Jun CAHN
Jun CAHN
ISOSORBIDE DINITRATE
TABLET;ORAL
ISORDIL
+
ISOTRETINOIN
CAPSULE;ORAL
ABSORICA
RANBAXY
AB
AB
AB
AB
AB
AB
AB
AB
>A>
>A> AA
>D>
>A> AA
MYORISAN
DOUGLAS PHARMS
SOTRET
SUN PHARM INDS LTD
ZENATANE
DR REDDYS LABS LTD
ISRADIPINE
CAPSULE;ORAL
ISRADIPINE
ELITE LABS INC
ITRACONAZOLE
SOLUTION;ORAL
ITRACONAZOLE
AMNEAL PHARMS
SPORANOX
+
JANSSEN PHARMS
+
1 -51

October
ISAVUCONAZONIUM SULFATE
CAPSULE;ORAL
CRESEMBA
+
ASTELLAS
CRESEMBA
+
ASTELLAS
10
Dec
Dec
Jun
Dec
24,
24,
20,
24,
2002
2002
2003
2002
CAHN
CAHN
CAHN
CAHN
October
2015
1 -52

EQ 75MG BASE/2ML
EQ 500MG BASE/2ML
EQ 1GM BASE/3ML
A 062324
A 062324
A 062324
001
002
003
Jun CAHN
Jun CAHN
Jun CAHN
15MG/ML
30MG/ML
15MG/ML
30MG/ML
15MG/ML
30MG/ML
A 203242
A 203242
A 075631
A 075631
A 075772
A 075772
001
002
002
001
001
002
15.75MG/SPRAY
N 022382
001 May 14, 2010
Jan CAHN
N 205388
001 May 30, 2014
Feb CPOT
A 076051
001 Jul 05, 2002
Apr CAHN
A 075215
A 075215
A 075215
001 Jul 29, 1999

002 Jul 29, 1999
003 Jul 29, 1999
Jan CMFD
Jan CMFD
Jan CMFD
A 203762
001 Mar 27, 2015
Mar NEWA
LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL
DUTREBIS
@ MERCK SHARP DOHME
150MG;EQ 300MG BASE
+
150MG;EQ 300MG BASE
N 206510
N 206510
001 Feb 06, 2015

001 Feb 06, 2015
Aug DISC
Feb NEWA
AB
AB
AB
LAMIVUDINE; ZIDOVUDINE
TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE
HETERO LABS LTD III
150MG;300MG
STRIDES ARCOLAB LTD
150MG;300MG
STRIDES PHARMA
150MG;300MG
A 079124
A 079128
A 079128
001 Sep 17, 2015

001 May 13, 2015
001 May 13, 2015
Aug NEWA
Apr NEWA
Aug CAHN
A 078134
A 078134
A 078134
A 078134
001
002
003
004
Apr
Apr
Apr
Apr
19,
19,
19,
19,
2011
2011
2011
2011
May
May
May
May
DISC
DISC
DISC
DISC
AB
AB
AB
AB
LAMOTRIGINE
TABLET;ORAL
LAMOTRIGINE
@ HIKMA PHARMS
25MG
@
100MG
@
150MG
@
200MG
LAMOTRIGINE
PAR PHARM
25MG
50MG
100MG
200MG
A 204158
A 204158
A 204158
A 204158
001
002
003
004
Oct
Oct
Oct
Oct
27,
27,
27,
27,
2015
2015
2015
2015
Oct
Oct
Oct
Oct
NEWA
NEWA
NEWA
NEWA
KANAMYCIN SULFATE
KANAMYCIN
@
@
AP
AP
KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE
BD RX
@
@
SPRIX
+
EGALET US INC
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION
OMIDRIA
+
OMEROS
EQ 4.24MG BASE/ML;EQ 12.4MG
BASE/ML
>A>
>A>
>A>
>A>
AB
AB
AB
LABETALOL HYDROCHLORIDE
@ CLARIS PHARMASERVICE 5MG/ML
TABLET;ORAL
MUTUAL PHARM
100MG
200MG
300MG
AA
LACTULOSE
SOLUTION;ORAL, RECTAL
LACTULOSE
BIO-PHARM INC
10GM/15ML
10
Oct
Oct
Jun
Jun
Jul
Jul
07,
07,
29,
29,
21,
21,
2015
2015
2001
2001
2004
2004
Sep
Sep
Apr
Apr
Jun
Jun
NEWA
NEWA
CAHN
CAHN
CAHN
CAHN
AP
AA
AB
AB
AB
AB
AB
AB
AP
AP
AP
AP
AP
AP
AP
AP
AP
AT
AB
AB
October
2015
1 -53

LAPATINIB DITOSYLATE
TABLET;ORAL
TYKERB
+
EQ 250MG BASE
N 022059
001 Mar 13, 2007
Mar CAHN
LENVATINIB MESYLATE
CAPSULE;ORAL
LENVIMA
EISAI INC
+
EQ 4MG BASE
EQ 10MG BASE
N 206947
N 206947
001 Feb 13, 2015

002 Feb 13, 2015
Feb NEWA
Feb NEWA
A 090876
001 Aug 13, 2015
Jul NEWA
100MG/ML
A 201157
001 Jun 04, 2015
May NEWA
N 207958
N 207958
N 207958
N 207958
001
002
003
004
Jul
Jul
Jul
Jul
31,
31,
31,
31,
2015
2015
2015
2015
Jul
Jul
Jul
Jul
NEWA
NEWA
NEWA
NEWA
A 202958
A 202167
A 202167
A 201464
A 201464
A 203468
A 203468
001
001
002
001
002
001
002
Feb
Sep
Sep
May
May
May
May
25,
04,
04,
25,
25,
21,
21,
2015
2015
2015
2012
2012
2015
2015
Feb
Aug
Aug
Aug
Aug
May
May
NEWA
NEWA
NEWA
CAHN
CAHN
NEWA
NEWA
A 075881
001 Mar 29, 2001
Apr DISC
A 203027
A 201653
001 Feb 13, 2015

001 Jun 26, 2015
Feb NEWA
Jun NEWA
A 091436
A 078577
A 078577
001 Jun 05, 2013

001 Aug 12, 2015
002 Aug 12, 2015
Apr CAHN
Jul NEWA
Jul NEWA
A 091397
A 091397
A 091397
A 078579
A 078579
A 078579
001
002
003
001
002
003
Apr
Apr
Apr
Aug
Aug
Aug
A 077700
001 Dec 20, 2010
Jul CRLD
N 021199
001 Aug 18, 2000
Jul DISC
A 203613
A 203613
001 Jun 19, 2015

002 Jun 19, 2015
Jun NEWA
Jun NEWA
LEVETIRACETAM
LEVETIRACETAM
FRESENIUS KABI USA
SOLUTION;ORAL
LEVETIRACETAM
PHARM ASSOC
TABLET;ORAL
SPRITAM
APRECIA PHARMS CO
250MG
500MG
750MG
1GM
LEVETIRACETAM
APOTEX INC
1GM
DEXCEL PHARMA
500MG
750MG
PHARMADAX INC
500MG
750MG
PRINSTON INC
500MG
750MG
LEVOCARNITINE
LEVOCARNITINE
@ TEVA PHARMS USA
AB
AB
10
200MG/ML
LEVOCETIRIZINE DIHYDROCHLORIDE
TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE
APOTEX INC
5MG
SUN PHARM INDS LTD
5MG
LEVOFLOXACIN
LEVOFLOXACIN
HOSPIRA INC
EQ 500MG/20ML (EQ 25MG/ML)

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
CLARIS PHARMASERVICE EQ 250MG/50ML (EQ 5MG/ML)
HOSPIRA INC
LEVOFLOXACIN
+
NEXUS PHARMS
0.5%
QUIXIN
@ SANTEN
0.5%
TABLET;ORAL
LEVOFLOXACIN
JUBILANT GENERICS
250MG
500MG
Aug
Aug
Aug
Sep
Sep
Sep
08,
08,
08,
03,
03,
03,
2013
2013
2013
2015
2015
2015
CAHN
CAHN
CAHN
NEWA
NEWA
NEWA
>A> AP
2015
BASE/17.5ML (EQ 10MG
A 203576
001 Oct 20, 2015
Oct NEWA
BASE/25ML (EQ 10MG
A 203576
002 Oct 20, 2015
Oct NEWA
BASE/25ML (EQ 10MG
A 203563
002 Mar 09, 2015
Feb NEWA
A 203563
001 Mar 09, 2015
Oct CTEC
A 203563
001 Mar 09, 2015
Oct CTEC
A 203563
001 Mar 09, 2015
Feb NEWA
BASE/25ML (EQ 10MG
A 203563
002 Mar 09, 2015
Oct CTEC
BASE/25ML (EQ 10MG
A 203563
002 Mar 09, 2015
Oct CTEC
BASE/25ML (EQ 10MG
A 203563
002 Mar 09, 2015
Mar CRLD
LEVONORGESTREL
INTRAUTERINE DEVICE;INTRAUTERINE
LILETTA
MEDICINES360
52MG
N 206229
001 Feb 26, 2015
Feb NEWA
LEVORPHANOL TARTRATE
TABLET;ORAL
LEVORPHANOL TARTRATE
+
SENTYNL THERAPS INC
2MG
A 074278
001 Mar 31, 2000
Apr CAHN
5%
5%
A 206297
A 080210
001 Aug 07, 2015

001
Jul NEWA
Sep CAHN
5%
5%
A 200675
A 202346
001 Aug 23, 2012

001 Aug 07, 2015
Mar CAHN
Jul NEWA
A 080407
A 080407
A 091564
001
002
001 Aug 14, 2015
Mar CAHN
Mar CAHN
Aug NEWA
A 084625
A 084625
001
002
Feb CAHN
Feb CAHN
2%
A 080429
001
Jan CAHN
2%
A 081318
001 Apr 29, 1993
Apr CAHN
LIDOCAINE; PRILOCAINE
CREAM;TOPICAL
EMLA
+
ACTAVIS LABS UT INC
2.5%;2.5%
N 019941
001 Dec 30, 1992
Feb CAHN
LINACLOTIDE
CAPSULE;ORAL
LINZESS
FOREST LABS LLC
+
145MCG
290MCG
N 202811
N 202811
001 Aug 30, 2012

002 Aug 30, 2012
Mar CAHN
Mar CAHN
>A> AP
SANDOZ
>D>
SANDOZ INC
>A> AP
>D>
>A> AP
+
+
AT
AB
AB
AP
AB
LIDOCAINE
OINTMENT;TOPICAL
LIDOCAINE
AMNEAL PHARMS
@ BELMORA LLC
PATCH;TOPICAL
LIDOCAINE
ACTAVIS LABS UT INC
MYLAN TECHNOLOGIES
LIDOCAINE HYDROCHLORIDE
@
LUITPOLD
@
JELLY;TOPICAL
ANESTACON
@ BANNER LIFE SCIENCES
@ G AND W LABS INC
EQ 175MG
BASE/ML)
EQ 250MG
BASE/ML)
EQ 250MG
BASE/ML)
EQ 175MG
BASE/ML)
EQ 175MG
BASE/ML)
EQ 175MG
BASE/ML)
EQ 250MG
BASE/ML)
EQ 250MG
BASE/ML)
EQ 250MG
BASE/ML)
1%
2%
1%
PRESERVATIVE FREE
1%
2%
1 -54
October
LEVOLEUCOVORIN CALCIUM
LEVOLEUCOVORIN CALCIUM
MYLAN TEORANTA
10
October
2015
1 -55

EQ 300MG BASE/ML
N 050317
001
May CFTG

EQ 300MG BASE/ML
A 201746
001 Jun 04, 2015
May NEWA

100MG/5ML
A 200068
001 Jun 03, 2015
May NEWA

100MG/5ML
N 021132
001 Apr 18, 2000
May CFTG

(2MG/ML)
(2MG/ML)
(2MG/ML)
(2MG/ML)
PLASTIC CONTAINER
(2MG/ML)
A 205442
A 200904
A 200904
A 200222
001
001
002
001
Jun
Jul
Jul
May
N 206473
001 Jun 18, 2015
Jun NEWA

(2MG/ML)
(2MG/ML)
(2MG/ML)
(2MG/ML)
N 021131
N 021131
N 021131
N 021131
001
001
002
003
Jul
May
May
May
A 078061
001 May 18, 2015
May NEWA

N 021130
002 Apr 18, 2000
May CFTG

2.5MG
5MG
10MG
20MG
30MG
40MG
A 075944
A 075944
A 075944
A 075944
A 075944
A 075944
001
002
003
004
006
005
Jul
Jul
Jul
Jul
Feb
Jul
01,
01,
01,
01,
11,
01,
2002
2002
2002
2002
2003
2002
Apr
Apr
Apr
Apr
Apr
Apr
CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

2.5MG
5MG
10MG
20MG
30MG
40MG
N 019777
N 019777
N 019777
N 019777
N 019777
N 019777
005
001
002
003
006
004
Apr
May
May
May
Jan
May
29,
19,
19,
19,
20,
19,
1993
1988
1988
1988
1999
1988
Feb
Feb
Feb
Feb
Feb
Feb
CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

LITHIUM CARBONATE
LITHIUM CARBONATE
ALEMBIC PHARMS LTD
300MG
@ HIKMA INTL PHARMS
450MG
UNIQUE PHARM LABS
300MG
A 204445
A 076490
A 204779
001 Jun 10, 2015

001 Jun 17, 2003
001 Jul 27, 2015
May NEWA

Feb DISC

Jul NEWA

EQ 30MG BASE
EQ 40MG BASE
EQ 60MG BASE
N 203858
N 203858
N 203858
004 Apr 23, 2015

005 Apr 23, 2015
006 Apr 23, 2015
Apr NEWA

Apr NEWA

Apr NEWA

5MG
N 017588
004 Dec 19, 2014
Jan NEWA

AP
AP
AB
AB
AP
AP
AP
AP
AP
AP
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
LINCOMYCIN HYDROCHLORIDE
LINCOCIN
+
LINCOMYCIN
X-GEN PHARMS INC
LINEZOLID
FOR SUSPENSION;ORAL
LINEZOLID
ROXANE
ZYVOX
+
LINEZOLID
HOSPIRA INC
SANDOZ INC
600MG/300ML
200MG/100ML
600MG/300ML
TEVA PHARMS
600MG/300ML
LINEZOLID IN SODIUM CHLORIDE 0.9% IN
+
HOSPIRA INC
600MG/300ML
ZYVOX
200MG/100ML
200MG/100ML
400MG/200ML
+
600MG/300ML
TABLET;ORAL
LINEZOLID
TEVA PHARMS USA
600MG
ZYVOX
+
600MG
LISINOPRIL
TABLET;ORAL
LISINOPRIL
SUN PHARM INDS LTD
ZESTRIL
ALVOGEN IPCO SARL
LOMITAPIDE MESYLATE
CAPSULE;ORAL
JUXTAPID
AEGERION
LOMUSTINE
CAPSULE;ORAL
GLEOSTINE
CORDEN PHARMA
10
Jul
Jul
Jul
Jun
Apr
Apr
Apr
Apr
07,
16,
16,
27,
18,
18,
18,
18,
2015
2015
2015
2012
2000
2000
2000
2000
NEWA

NEWA

NEWA

CDFR

CTEC

CDFR

NEWA

NEWA

AB
AP
AP
>A>
>A>
>A>
>D>
>D>
>D>
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
>A> AB
AB
AB
AB
October
2015
1 -56

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
IMODIUM
@ J AND J CONSUMER INC
+
2MG
2MG
N 017690
N 017694
001
001
Jul CAHN
Jul CAHN
LOPINAVIR; RITONAVIR
CAPSULE;ORAL
KALETRA
@ ABBVIE
133.3MG;33.3MG
N 021226
001 Sep 15, 2000
Jun DISC
2MG/ML
4MG/ML
N 018140
N 018140
001
002
Jun CAHN
Jun CAHN
0.5MG
1MG
2MG
0.5MG
1MG
2MG
0.5MG
1MG
2MG
A 077396
A 077396
A 077396
A 077396
A 077396
A 077396
A 076045
A 076045
A 076045
001
002
003
001
002
003
001
002
003
Dec
Dec
Dec
Dec
Dec
Dec
Aug
Aug
Aug
13,
13,
13,
13,
13,
13,
29,
29,
29,
2006
2006
2006
2006
2006
2006
2001
2001
2001
Oct
Oct
Oct
Oct
Oct
Oct
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
25MG
50MG
100MG
25MG
50MG
100MG
25MG
50MG
100MG
A 203835
A 203835
A 203835
A 203030
A 203030
A 203030
A 091129
A 091129
A 091129
001
002
003
001
002
003
001
002
003
Aug
Aug
Aug
Oct
Oct
Oct
Oct
Oct
Oct
12,
12,
12,
14,
14,
14,
06,
06,
06,
2015
2015
2015
2015
2015
2015
2010
2010
2010
Jul
Jul
Jul
Oct
Oct
Oct
Feb
Feb
Feb
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
CMFD
CMFD
CMFD
N 021316
N 021316
N 021316
N 021316
001
002
003
004
Jun
Jun
Jun
Jun
26,
26,
26,
26,
2002
2002
2002
2002
May
May
May
May
CAHN
CAHN
CAHN
CAHN
EQ 25MG BASE/ML
N 017658
001
Mar CAHN
EQ 50MG BASE/ML
N 018039
001
Mar CAHN
EQ
EQ
EQ
EQ
5MG BASE
10MG BASE
25MG BASE
50MG BASE
A 076868
A 076868
A 076868
A 076868
001
002
003
004
EQ
EQ
EQ
EQ
5MG BASE
10MG BASE
25MG BASE
50MG BASE
N 017525
N 017525
N 017525
N 017525
001
002
003
004
LORAZEPAM
ATIVAN
+
EUROHLTH INTL SARL
+
TABLET;ORAL
LORAZEPAM
ANI PHARMS INC
IVAX SUB TEVA PHARMS
SUN PHARM INDS LTD
LOSARTAN POTASSIUM
TABLET;ORAL
LOSARTAN POTASSIUM
HETERO LABS LTD V
UNICHEM LABS LTD
WATSON LABS
LOVASTATIN
ALTOPREV
@ COVIS PHARMA SARL
10MG
20MG
40MG
+
60MG
LOXAPINE HYDROCHLORIDE
CONCENTRATE;ORAL
LOXITANE C
LOXITANE IM
AB
AB
AB
AB
10
LOXAPINE SUCCINATE
CAPSULE;ORAL
LOXAPINE SUCCINATE
ELITE LABS INC
LOXITANE
@
@
@
Aug
Aug
Aug
Aug
04,
04,
04,
04,
2005
2005
2005
2005
May
May
May
May
CAHN
CAHN
CAHN
CAHN
Mar
Mar
Mar
Mar
CAHN
CAHN
CAHN
CAHN
October
2015

1 -57

EQ 10MG BASE
EQ 25MG BASE
EQ 50MG BASE
N 017525
N 017525
N 017525
006

007

008

Mar CAHN

Mar CAHN

Mar CAHN

8.5ML
N 021746
001 Mar 06, 2012

May DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE


PLASMA-LYTE 56 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE
32MG/100ML;128MG/100ML;234MG/100ML N 019047
001 Jun 15, 1984

Mar DISC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

EXELA PHARMA SCS LLC
5GM/10ML (500MG/ML)
+
FRESENIUS KABI USA
5GM/10ML (500MG/ML)
+
HOSPIRA
5GM/10ML (500MG/ML)
HOSPIRA INC
10GM/20ML (500MG/ML)
A 206039
N 019316
A 075151
A 202411
001
001
001
001
Apr
Apr
Apr
Apr
MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+
FRESENIUS KABI USA
1GM/2ML (500MG/ML)
N 019316
002 Sep 08, 1986

TABLET;ORAL

LOXITANE

@
@
LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

@ DISCOVERY LABS
AP
AP
AP
10
Dec
Sep
Apr
May
18,
08,
25,
14,
2014

1986

2000

2015

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM
BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

SUCLEAR

@ BRAINTREE LABS
1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/ N 203595 001 Jan 18, 2013

A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.
74GM,2.86GM,5.6GM

>A>
>A>
>A>
>A>
AA
AA
AA
CDFR

CPOT

CDFR

NEWA

Apr NEWA

Aug DISC

MANNITOL


MANNITOL 25%

@ IGI LABS INC
@
12.5GM/50ML
12.5GM/50ML
A 089239
A 089240
001 May 06, 1987

001 May 06, 1987

Mar CAHN

Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@ ANI PHARMS INC
@
@ VINTAGE PHARMS
@
12.5MG
25MG
12.5MG
25MG
A 084975
A 084657
A 040179
A 040179
001

001

001 Jan 30, 1997

002 Jan 30, 1997

Aug
Aug
Jun
Jun
MELOXICAM

CAPSULE;ORAL

VIVLODEX

IROKO PHARMS LLC
+
5MG
10MG
N 207233
N 207233
001 Oct 22, 2015

002 Oct 22, 2015

Oct NEWA

Oct NEWA

N 022525
N 022525
N 022525
N 022525
001
002
003
004
Mar
Mar
Mar
Mar
A 202790
A 204033
001 Oct 13, 2015

001 Oct 13, 2015

Sep NEWA

Sep NEWA

N 021627
N 021627
001 Apr 18, 2005

001 Apr 18, 2005

Sep CFTG

Mar CAHN

MEMANTINE HYDROCHLORIDE


NAMENDA XR

FOREST LABS LLC
7MG
14MG
21MG
+
28MG
SOLUTION;ORAL


MACLEODS PHARMS LTD
2MG/ML
SILARX PHARMS INC
2MG/ML
NAMENDA

+
FOREST LABS LLC
2MG/ML
+
2MG/ML
Jun
Jun
Jun
Jun
21,
21,
21,
21,
2010

2010

2010

2010

CAHN

CAHN

DISC

DISC

CAHN

CAHN

CAHN

CAHN

>D>
>D> AB
AB
>D> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AP
AP
AP
2015
A 090058
A 090058
A 090058
A 090058
001
001
002
002
May
May
May
May
05,
05,
05,
05,
2010
2010
2010
2010
Oct
Mar
Oct
Mar
CTNA
CMFD
CTNA
CMFD
A 200891
A 200891
A 090041
A 090041
A 203175
A 203175
A 090048
A 090048
A 091585
A 091585
A 090051
A 090051
A 202840
A 202840
A 079225
A 079225
A 079225
A 079225
A 079225
A 079225
A 090058
A 090058
A 090052
A 090052
A 200155
A 200155
A 200022
A 200022
A 090043
A 090043
A 090073
A 090073
001
002
001
002
001
002
001
002
001
002
001
002
001
002
001
001
001
002
002
002
001
002
001
002
001
002
001
002
001
002
001
002
Oct
Oct
Apr
Apr
Oct
Oct
Apr
Apr
Oct
Oct
Apr
Apr
Oct
Oct
Jan
Jan
Jan
Jan
Jan
Jan
May
May
Oct
Oct
Oct
Oct
Oct
Oct
Jul
Jul
Sep
Sep
13,
13,
10,
10,
13,
13,
14,
14,
13,
13,
10,
10,
13,
13,
30,
30,
30,
30,
30,
30,
05,
05,
25,
25,
13,
13,
13,
13,
31,
31,
04,
04,
2015
2015
2015
2015
2015
2015
2010
2010
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2010
2010
2011
2011
2015
2015
2015
2015
2015
2015
2015
2015
Sep
Sep
Mar
Mar
Sep
Sep
Jun
Jun
Sep
Sep
Mar
Mar
Sep
Sep
Jun
Mar
Jan
Jun
Mar
Jan
Oct
Oct
May
May
Sep
Sep
Sep
Sep
Jul
Jul
Aug
Aug
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
CMFD
CMFD
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
CMFD
DISC
NEWA
CMFD
DISC
NEWA
CTNA
CTNA
CMFD
CMFD
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
N 021487
N 021487
001 Oct 16, 2003

002 Oct 16, 2003
Mar CAHN
Mar CAHN
MENOTROPINS (FSH;LH)
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX
@ FERRING
75 IU/VIAL;75 IU/VIAL
N 021047
001 Aug 27, 1999
May DISC
MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE
EUROHLTH INTL SARL
25MG/ML
50MG/ML
75MG/ML
100MG/ML
@ IGI LABS INC
25MG/ML
@
50MG/ML
@
50MG/ML
@
50MG/ML
@
75MG/ML
@
100MG/ML
@
100MG/ML
@
100MG/ML
A 080445
A 080445
A 080445
A 080445
A 089781
A 089782
A 089783
A 089784
A 089785
A 089786
A 089787
A 089788
001
002
003
004
001
001
001
001
001
001
001
001
Feb
Feb
Feb
Feb
May
Mar
Mar
Mar
Mar
Mar
Mar
Mar
MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

MEPERGAN
25MG/ML;25MG/ML
N 011730
001
5MG
5MG
10MG
10MG
ALEMBIC PHARMS LTD
5MG
10MG
AMNEAL PHARMS
5MG
10MG
AUROBINDO PHARMA LTD 5MG
10MG
DR REDDYS LABS LTD
5MG
10MG
JUBILANT GENERICS
5MG
10MG
LUPIN LTD
5MG
10MG
MACLEODS PHARMS LTD
5MG
10MG
MYLAN PHARMS INC
5MG
@
5MG
5MG
10MG
@
10MG
10MG
SUN PHARMA GLOBAL
5MG
10MG
TEVA PHARMS
5MG
10MG
TORRENT PHARMS LTD
5MG
10MG
UNICHEM LABS LTD
5MG
10MG
UPSHER SMITH
5MG
10MG
WOCKHARDT LTD
5MG
10MG
NAMENDA
FOREST LABS LLC
5MG
+
10MG
1 -58
October
TABLET;ORAL
MEMANTINE
SUN PHARMA GLOBAL
10
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
31,
31,
31,
31,
31,
31,
31,
31,
1989
1989
1989
1989
1989
1989
1989
1989
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
Jun CAHN
10
AB
>D>
>D>
>A>
2015
N 202106
N 202106
001 Apr 30, 2015

002 Apr 30, 2015
Apr NEWA

Apr NEWA

N 022301
001 Oct 31, 2008
Jul CAHN

A 076841
001 Sep 30, 2004
Aug CAHN

N 021252
N 021252
001 Jan 05, 2001

002 Nov 05, 2004
Aug CAHN

Aug CAHN

N 019651
N 019651
001 Jan 31, 1992

001 Jan 31, 1992
Oct DISC

Oct DISC

0.1MG;2MG
N 013625
004
Mar CAHN

0.05MG;1MG
N 013625
002
Mar CAHN

0.05MG;1MG
N 016659
001
Mar CAHN

0.4%
0.6%
0.4%
0.6%
A 071786
A 070804
A 075586
A 075586
001
001
001
002
10MG/5ML
10MG/5ML
A 072761
A 073034
001 Feb 27, 1992

001 Aug 30, 1991
Apr CAHN

Apr CAHN

400MG
640MG
A 040486
N 022503
001 Feb 27, 2015

001 Jun 01, 2015
Feb NEWA

Jun NEWA

500MG/5ML
N 021591
001 Sep 11, 2003
Apr CAHN

A 204802
A 204802
001 Nov 05, 2015

002 Nov 05, 2015
Oct NEWA

Oct NEWA

N 022386
N 022386
001 Jun 23, 2008

002 Jun 23, 2008
Jun CFTG

Jun CFTG

A 200624
A 200624
001 Jul 15, 2015

002 Jul 15, 2015
Jun NEWA

Jun NEWA

MESALAMINE
APRISO
+
VALEANT PHARMS INTL
375MG
ENEMA;RECTAL
MESALAMINE
G AND W LABS INC
4GM/60ML
SUPPOSITORY;RECTAL
CANASA
@ FOREST LABS LLC
500MG
+
1GM
TABLET, DELAYED RELEASE;ORAL
ASACOL
+
WARNER CHILCOTT LLC
400MG
@
400MG
MESTRANOL; NORETHINDRONE
TABLET;ORAL-20
NORINYL
TABLET;ORAL-21
NORINYL 1+50 21-DAY
TABLET;ORAL-28
NORINYL 1+50 28-DAY
+
ACTAVIS LABS UT INC
METAPROTERENOL SULFATE
SOLUTION;INHALATION
@ MYLAN SPECLT
@
@ WOCKHARDT
@
SYRUP;ORAL
@ G AND W LABS INC
@
METAXALONE
TABLET;ORAL
METAXALONE
COREPHARMA
METFORMIN HYDROCHLORIDE
SOLUTION;ORAL
RIOMET
+
SUN PHARM INDS LTD
>A> AB
>A> AB
AB
AB
AB
AB
1 -59

October
MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
B BRAUN MEDICAL INC
500MG/VIAL
1GM/VIAL
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
MACLEODS PHARMS LTD
500MG;EQ 15MG BASE
850MG;EQ 15MG BASE
METFORMIN HYDROCHLORIDE; REPAGLINIDE
TABLET;ORAL
PRANDIMET
NOVO NORDISK INC
500MG;1MG
+
500MG;2MG
REPAGLINIDE AND METFORMIN HYDROCHLORIDE
LUPIN LTD
500MG;1MG
500MG;2MG
Aug
Aug
May
May
05,
17,
30,
30,
1988
1987
2002
2002
Apr
Apr
Apr
Apr
DISC

DISC

DISC

DISC

2015
N 021410
N 021410
N 021410
N 021410
002
003
004
005
Oct
Oct
Aug
Aug
10,
10,
25,
25,
2002
2002
2003
2003
May
May
May
May
DISC
DISC
DISC
DISC
A 077337
A 077337
A 077337
A 077337
001
002
004
003
May
May
May
May
07,
07,
07,
07,
2014
2014
2014
2014
May
May
May
May
CTEC
CTEC
CRLD
CTEC
AA
AA
AA
AA
A 203502
A 203502
A 090065
A 090065
001
002
001
002
Aug
Aug
Aug
Aug
31,
31,
18,
18,
2015
2015
2015
2015
Aug
Aug
Aug
Aug
NEWA
NEWA
NEWA
NEWA
AB
AB
5MG
10MG
A 040734
A 040734
001 Dec 14, 2007

002 Dec 14, 2007
Mar CAHN
Mar CAHN
1GM/10ML (100MG/ML)
N 011790
001
Jun CAHN
METHADONE HYDROCHLORIDE
TABLET;ORAL
METHADONE HYDROCHLORIDE
AUROLIFE PHARMA LLC
5MG
10MG
COREPHARMA
5MG
10MG
METHIMAZOLE
TABLET;ORAL
METHIMAZOLE
HERITAGE PHARMA
1 -60
October
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL
AVANDAMET
@ SB PHARMCO
500MG;EQ 2MG BASE
@
500MG;EQ 4MG BASE
@
1GM;EQ 2MG BASE
@
1GM;EQ 4MG BASE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
TEVA
500MG;EQ 2MG BASE
500MG;EQ 4MG BASE
+
1GM;EQ 4MG BASE
1GM;EQ 2MG BASE
10
AP
METHOCARBAMOL
SOLUTION;IM-IV
ROBAXIN
+
EUROHLTH INTL SARL
AP
METHOTREXATE SODIUM
METHOTREXATE PRESERVATIVE FREE
FRESENIUS KABI USA
EQ 25MG BASE/ML
A 040265
001 Feb 26, 1999
May CMFD
AB
METHOXSALEN
CAPSULE;ORAL
METHOXSALEN
ACTAVIS INC
A 202603
001 Jun 09, 2015
May NEWA
N 205831
N 205831
N 205831
N 205831
N 205831
N 205831
N 205831
001
002
003
004
005
006
007
Apr
Apr
Apr
Apr
Apr
Apr
Apr
17,
17,
17,
17,
17,
17,
17,
2015
2015
2015
2015
2015
2015
2015
Apr
Apr
Apr
Apr
Apr
Apr
Apr
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
A 203583
A 203583
A 203583
A 203583
A 203583
A 203583
001
002
003
004
005
006
Sep
Sep
Sep
Sep
Sep
Sep
29,
29,
29,
29,
29,
29,
2015
2015
2015
2015
2015
2015
Sep
Sep
Sep
Sep
Sep
Sep
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
N 021284
N 021284
003 Jun 05, 2002

005 Oct 27, 2014
Feb CRLD
Feb CRLD
A 204602
A 204602
001 Aug 14, 2015

002 Aug 14, 2015
Aug NEWA
Aug NEWA
A 207416
A 207416
A 207416
001 Sep 22, 2015

002 Sep 22, 2015
003 Sep 22, 2015
Sep NEWA
Sep NEWA
Sep NEWA
AB2
AB2
AB2
AB2
AB2
AB2
AB1
AA
AA
AB
AB
AB
10MG
METHYLPHENIDATE HYDROCHLORIDE
APTENSIO XR
RHODES PHARMS
10MG
15MG
20MG
30MG
40MG
50MG
+
60MG
MALLINCKRODT INC
10MG
20MG
30MG
40MG
50MG
60MG
RITALIN LA
NOVARTIS
40MG
+
60MG
SOLUTION;ORAL
NOVEL LABS INC
5MG/5ML
10MG/5ML
TABLET;ORAL
ASCENT PHARMS INC
5MG
10MG
20MG
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AP
AB
AB
AB
AB
>A>
>A>
>A>
>D>
>D>
>D>
2015
N 021475
N 021475
N 021475
001 Apr 15, 2003

002 Apr 15, 2003
003 Apr 15, 2003
Feb CFTG
Feb CFTG
Feb CFTG
A 204115
A 204115
A 204115
001 Feb 25, 2015

002 Feb 25, 2015
003 Feb 25, 2015
Feb NEWA
Feb NEWA
Feb NEWA
A 075629
001 May 09, 2000
May CTEC
A 207488
A 207488
001 Jun 09, 2015

002 Jun 09, 2015
May NEWA
May NEWA
10MG
A 204851
001 Sep 21, 2015
Sep NEWA
10MG
A 083976
001
Sep CTEC
1MG/ML
A 078950
001 Apr 29, 2013
Apr CAHN
37.5MG
75MG
A 076704
A 076704
004 Mar 18, 2015

005 Mar 18, 2015
Mar NEWA
Mar NEWA
1%
N 020743
001 Sep 26, 1997
Feb CAHN
1.3%
N 205223
001 Mar 24, 2014
Feb CAHN
1.3%
N 205223
001 Mar 24, 2014
Feb CTNA
500MG/100ML
CONTAINER
500MG/100ML
N 018907
001 Mar 30, 1984
Aug CAHN
A 078084
001 Mar 31, 2008
Apr CAHN
250MG
500MG
250MG
500MG
A 205245
A 205245
A 203974
A 203974
001
002
001
002
Sep
Sep
May
May
23,
23,
29,
29,
2015
2015
2015
2015
Sep
Sep
May
May
NEWA
NEWA
NEWA
NEWA
MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE
@ IDT AUSTRALIA LTD
@
@
@ SANDOZ
@
@
150MG
200MG
250MG
150MG
200MG
250MG
A 074450
A 074450
A 074450
A 074450
A 074450
A 074450
001
002
003
001
002
003
May
May
May
May
May
May
16,
16,
16,
16,
16,
16,
1996
1996
1996
1996
1996
1996
Oct
Oct
Oct
Oct
Oct
Oct
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
MICONAZOLE
TABLET;BUCCAL
ORAVIG
+
DARA BIOSCIENCES
50MG
N 022404
001 Apr 16, 2010
2.5MG
5MG
+
10MG
NOVEL LABS INC
2.5MG
5MG
10MG
METHYLIN ER
MALLINCKRODT INC
10MG
ABHAI
10MG
20MG
METHYLTESTOSTERONE
CAPSULE;ORAL
METHYLTESTOSTERONE
IMPAX LABS INC
TESTRED
+
VALEANT PHARM INTL
METOPROLOL TARTRATE
METOPROLOL TARTRATE
TABLET;ORAL
METOPROLOL TARTRATE
MYLAN
METRONIDAZOLE
CREAM;TOPICAL
NORITATE
+
GEL;VAGINAL
METRONIDAZOLE
+
ACTAVIS LABS UT INC
NUVESSA
+
ACTAVIS LABS UT INC
METRONIDAZOLE
METRONIDAZOLE IN PLASTIC
TABLET;ORAL
METRONIDAZOLE
APPCO PHARMA LLC
1 -61

October
METHYLIN
MALLINCKRODT
10
Apr CAHN
AP
AP
AA
AB
AA
AB
AA
AB
AA
AB
AA
AB
AA
AB
AA
AP
AP
AP
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
MIGLITOL
TABLET;ORAL
GLYSET
+
+
MIGLITOL
ORIENT PHARMA CO LTD
MILRINONE LACTATE
MILRINONE LACTATE
BEDFORD
EUROHLTH INTL SARL
@
+
HIKMA FARMACEUTICA
2015
A 075637
A 075637
A 075243
A 075243
A 075263
A 078141
A 078511
A 078141
A 078511
001
002
001
002
001
001
001
002
002
A 076058
001 Mar 15, 2002
Apr CAHN
25MG
25MG
50MG
50MG
100MG
100MG
N 020682
N 020682
N 020682
N 020682
N 020682
N 020682
001
001
002
002
003
003
Dec
Dec
Dec
Dec
Dec
Dec
18,
18,
18,
18,
18,
18,
1996
1996
1996
1996
1996
1996
Mar
Feb
Mar
Feb
Mar
Feb
CTEC
CFTG
CTEC
CFTG
CTEC
CFTG
25MG
25MG
50MG
50MG
100MG
100MG
A 203965
A 203965
A 203965
A 203965
A 203965
A 203965
001
001
002
002
003
003
Feb
Feb
Feb
Feb
Feb
Feb
24,
24,
24,
24,
24,
24,
2015
2015
2015
2015
2015
2015
Mar
Feb
Mar
Feb
Mar
Feb
CTEC
NEWA
CTEC
NEWA
CTEC
NEWA
A 075660
A 075530
A 075852
A 077966
001
001
001
001
May
May
May
Dec
28,
28,
28,
03,
2002
2002
2002
2010
Jan
Jun
Sep
Jan
CRLD
CAHN
CAHN
CRLD
A 065062
A 065062
A 065062
A 065062
A 065062
A 065062
001
002
003
001
002
003
Nov
Nov
Nov
Nov
Nov
Nov
30,
30,
30,
30,
30,
30,
2000
2000
2000
2000
2000
2000
Apr
Apr
Apr
Jun
Jun
Jun
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
N 201922
N 201922
N 201922
N 201922
N 201922
001
002
003
004
005
Jul
Jul
Jul
Jul
Jul
11,
11,
11,
11,
11,
2012
2012
2012
2012
2012
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
A 065156
A 065156
A 065156
A 065156
A 065156
A 065156
001
002
003
001
002
003
Jan
Jan
Jan
Jan
Jan
Jan
06,
06,
06,
06,
06,
06,
2004
2004
2004
2004
2004
2004
Apr
Apr
Apr
Jun
Jun
Jun
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
A 090422
A 091118
A 091118
A 091118
003
001
004
005
Aug
Sep
Sep
Sep
13,
25,
25,
25,
2009
2014
2014
2014
Sep
Apr
Apr
Apr
CRLD
CAHN
CAHN
CAHN
EQ
EQ
EQ
EQ
1MG
1MG
1MG
1MG
BASE/ML
BASE/ML
BASE/ML
BASE/ML
MINOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
SUN PHARM INDS LTD
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
TORRENT PHARMA INC
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
XIMINO
EQ 45MG BASE
@
EQ 67.5MG BASE
@
EQ 90MG BASE
@
EQ 112.5MG BASE
@
EQ 135MG BASE
TABLET;ORAL
SUN PHARM INDS LTD
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
TORRENT PHARMA INC
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
+
SANDOZ
EQ 135MG BASE
SUN PHARM INDS LTD
EQ 45MG BASE
EQ 80MG BASE
EQ 90MG BASE
1 -62

October
MIDAZOLAM HYDROCHLORIDE
@ CLARIS PHARMASERVICE EQ 1MG BASE/ML
@
EQ 5MG BASE/ML
EUROHLTH INTL SARL
EQ 1MG BASE/ML
EQ 5MG BASE/ML
@ IGI LABS INC
EQ 5MG BASE/ML
@ WOCKHARDT
EQ 1MG BASE/ML
@
EQ 1MG BASE/ML
@
EQ 5MG BASE/ML
@
EQ 5MG BASE/ML
SYRUP;ORAL
SUN PHARM INDS LTD
EQ 2MG BASE/ML
10
Oct
Oct
Jun
Jun
Jun
May
Nov
May
Nov
31,
31,
20,
20,
26,
30,
10,
30,
10,
2000
2000
2000
2000
2000
2008
2008
2008
2008
Apr
Apr
Jun
Jun
Apr
Mar
Mar
Mar
Mar
CAHN
CAHN
CAHN
CAHN
CAHN
DISC
DISC
DISC
DISC
AB
AB
AB
AB
MIVACURIUM CHLORIDE


MIVACRON

ABBVIE
+
2015
A 091118
A 091118
006 Sep 25, 2014

008 Sep 25, 2014
Apr CAHN

Apr CAHN

N 050808
N 050808
N 050808
008 Aug 27, 2010

007 Aug 27, 2010
005 Jul 23, 2009
Sep CRLD

Sep CRLD

Sep CRLD


N 020098
EQ 20MG BASE/10ML (EQ 2MG BASE/ML) N 020098
004 Jan 22, 1992

005 Jan 22, 1992
Jan NEWA

Jan NEWA

A 090453
A 090453
A 090453
001 Mar 20, 2015

002 Mar 20, 2015
003 Mar 20, 2015
Mar NEWA

Mar NEWA

Mar NEWA

EQ 4MG BASE/PACKET
A 203438
001 Jul 31, 2015
Jul NEWA

EQ
EQ
EQ
EQ
10MG
10MG
10MG
10MG
A 203432
A 204604
A 201522
A 204290
001
001
001
001
Jul
Sep
Aug
Oct
31,
04,
03,
08,
2015
2015
2012
2015
Jul
Aug
Mar
Sep
NEWA

NEWA

CAHN

NEWA

EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
4MG
5MG
4MG
5MG
4MG
5MG
4MG
5MG
4MG
5MG
4MG
5MG
A 203328
A 203328
A 205695
A 205695
A 204093
A 204093
A 203795
A 203795
A 200405
A 200405
A 203582
A 203582
001
002
001
002
001
002
001
002
001
002
001
002
Jul
Jul
Nov
Nov
May
May
Feb
Feb
Aug
Aug
Mar
Mar
31,
31,
05,
05,
22,
22,
27,
27,
03,
03,
12,
12,
2015
2015
2015
2015
2015
2015
2015
2015
2012
2012
2015
2015
Jul
Jul
Oct
Oct
May
May
Feb
Feb
Mar
Mar
Feb
Feb
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

CAHN

CAHN

NEWA

NEWA

N 021260
N 021260
N 021260
N 021260
N 021260
N 021260
001
005
002
006
003
004
Mar
Dec
Mar
Dec
Mar
Mar
20,
18,
20,
18,
20,
20,
2002
2008
2002
2008
2002
2002
Sep
Sep
Sep
Sep
Sep
Sep
DISC

DISC

DISC

DISC

DISC

DISC

N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
N 020616
008
001
004
009
009
002
005
010
010
006
003
011
012
007
Apr
Jul
Mar
Jul
Jul
Jul
Mar
Jul
Jul
Oct
Jul
Jul
Jul
Feb
20,
03,
09,
09,
09,
03,
09,
09,
09,
27,
03,
09,
09,
27,
2007
1996
2001
2012
2012
1996
2001
2012
2012
2006
1996
2012
2012
2007
Mar
Mar
Mar
May
Mar
Mar
Mar
May
Mar
Mar
Mar
Mar
Mar
Mar
CAHN

CAHN

CAHN

CTEC

CAHN

CAHN

CAHN

CTEC

CAHN

CAHN

CAHN

CAHN

CAHN

CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

COREPHARMA
5MG
10MG
+
25MG
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB1
AB1
AB1
AB1
AB1
AB1
AB1
AB1
AB1
AB1
MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AJANTA PHARMA LTD
TABLET;ORAL

MONTELUKAST SODIUM

AJANTA PHARMA LTD
AMNEAL PHARMS
UNICHEM LABS LTD

MONTELUKAST SODIUM

AJANTA PHARMA LTD
ANBISON LAB CO LTD
HETERO LABS LTD V
JUBILANT GENERICS
MACLEODS PHARMS LTD
MORPHINE SULFATE


AVINZA

@ KING PHARMS LLC
30MG
@
45MG
@
60MG
@
75MG
@
90MG
@
120MG
KADIAN

+
ACTAVIS LABS UT INC
10MG
20MG
30MG
40MG
40MG
50MG
60MG
70MG
70MG
80MG
+
100MG
130MG
150MG
+
200MG
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
1 -63

October


EQ 105MG BASE
EQ 135MG BASE
SOLODYN

MEDICIS
EQ 55MG BASE
EQ 80MG BASE
+
EQ 115MG BASE
10
AB1
AB1
AP
AP
AP
AP
AP
AP
AP
AP
AA
AA
>A> AA
>A>
>A>
>A>
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AT2
AT1
AT2
AT1
AT
AT1
AB
>D> AB
>A>
10

MORPHINE SULFATE

ACTAVIS ELIZABETH
30MG
45MG
60MG
75MG
90MG
+
120MG
TEVA PHARMS USA
40MG
70MG
DURAMORPH PF
+
EUROHLTH INTL SARL
0.5MG/ML
+
1MG/ML
INFUMORPH
+
EUROHLTH INTL SARL
10MG/ML
+
25MG/ML
MORPHINE SULFATE
EUROHLTH INTL SARL
4MG/ML
8MG/ML
10MG/ML
+
HOSPIRA INC
4MG/ML
+
8MG/ML
+
10MG/ML
SOLUTION;ORAL
MORPHINE SULFATE
TRIS PHARMA INC
10MG/5ML
100MG/5ML
VINTAGE PHARMS LLC
20MG/5ML
MORPHABOND
IDT
15MG
30MG
60MG
+
100MG
MORPHINE SULFATE
ACTAVIS ELIZABETH
15MG
30MG
60MG
100MG
200MG
SUN PHARM INDS LTD
15MG
30MG
60MG
100MG
200MG
MOXIFLOXACIN HYDROCHLORIDE
+
FRESENIUS KABI USA
EQ 400MG BASE/250ML (EQ 1.6MG
BASE/ML)
MOXEZA
+
ALCON PHARMS LTD
EQ 0.5% BASE
LUPIN LTD
EQ 0.5% BASE
EQ 0.5% BASE
WATSON LABS INC
EQ 0.5% BASE
EQ 0.5% BASE
VIGAMOX
+
ALCON PHARMS LTD
EQ 0.5% BASE
TABLET;ORAL
MYLAN PHARMS INC
EQ 400MG BASE
MYCOPHENOLATE MOFETIL
CAPSULE;ORAL
MYCOPHENOLATE MOFETIL
DR REDDYS LABS LTD
@
250MG
250MG
1 -64

October
2015
A 079040
A 079040
A 079040
A 079040
A 079040
A 079040
A 202718
A 202718
001
002
003
004
005
006
007
008
N 018565
N 018565
001 Sep 18, 1984

002 Sep 18, 1984
Jun CAHN
Jun CAHN
N 018565
N 018565
003 Jul 19, 1991

004 Jul 19, 1991
Jun CAHN
Jun CAHN
A 205758
A 205758
A 205758
N 202515
N 202515
N 202515
001
002
003
002
003
004
May
May
May
May
May
May
A 203518
A 203518
A 202310
001 May 12, 2015

002 May 12, 2015
001 Oct 30, 2015
May NEWA
May NEWA
Oct NEWA
N 206544
N 206544
N 206544
N 206544
001
002
003
004
Oct
Oct
Oct
Oct
02,
02,
02,
02,
2015
2015
2015
2015
Oct
Oct
Oct
Oct
NEWA
NEWA
NEWA
NEWA
A 203849
A 203849
A 203849
A 203849
A 203849
A 078761
A 078761
A 078761
A 078761
A 078761
001
002
003
004
005
001
002
003
004
005
Apr
Apr
Apr
Apr
Apr
May
May
May
May
May
06,
06,
06,
06,
06,
11,
11,
11,
11,
11,
2015
2015
2015
2015
2015
2012
2012
2012
2012
2012
Mar
Mar
Mar
Mar
Mar
Apr
Apr
Apr
Apr
Apr
NEWA
NEWA
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
CAHN
CAHN
N 205572
001 Apr 03, 2015
Apr NEWA
N 022428
001 Nov 19, 2010
May CFTG
A 202867
A 204079
A 202525
A 202525
001
001
001
001
May
May
May
Feb
N 021598
001 Apr 15, 2003
May CTEC
A 204635
001 Aug 31, 2015
Aug NEWA
A 091315
A 091315
001 Oct 27, 2011

001 Oct 27, 2011
Oct DISC
Oct DISC
Jan
Jan
Jan
Jan
Jan
Jan
Jun
Jun
May
May
May
Nov
Nov
Nov
Sep
May
Mar
Mar
16,
16,
16,
16,
16,
16,
03,
03,
21,
21,
21,
14,
14,
14,
04,
28,
06,
06,
2013
2013
2013
2013
2013
2013
2015
2015
2015
2015
2015
2011
2011
2011
2014
2015
2015
2015
Sep
Sep
Sep
Sep
Sep
Sep
May
May
CTEC
CTEC
CTEC
CTEC
CTEC
CTEC
NEWA
NEWA
NEWA
NEWA
NEWA
CFTG
CFTG
CFTG
CTEC
NEWA
CTEC
NEWA
>D>
>D>
>D>
>D>
>D>
>A>
>A>
>A>
>A>
>A>
2015
20MG
40MG
80MG
120MG
160MG
20MG
40MG
80MG
120MG
160MG
N 018063
N 018063
N 018063
N 018063
N 018063
N 018063
N 018063
N 018063
N 018063
N 018063
005 Oct 28, 1986

001
002
003
004
005 Oct 28, 1986
001
002
003
004
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
40MG
80MG
A 201893
A 201893
001 Sep 16, 2015

002 Sep 16, 2015
Aug NEWA
Aug NEWA
NALBUPHINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE
@ IGI LABS INC
@
@
@
@
@
10MG/ML
10MG/ML
10MG/ML
20MG/ML
20MG/ML
20MG/ML
A 072070
A 072071
A 072072
A 072073
A 072074
A 072075
001
001
001
001
001
001
Mar
Mar
Mar
Mar
Mar
Mar
NALMEFENE HYDROCHLORIDE
REVEX
@
EQ 0.1MG BASE/ML
EQ 1MG BASE/ML
N 020459
N 020459
001 Apr 17, 1995

002 Apr 17, 1995
Jun CAHN
Jun CAHN
0.4MG/ML
A 070299
001 Sep 24, 1986
Mar CAHN
0.02MG/ML
0.02MG/ML
0.02MG/ML
0.02MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
0.4MG/ML
1MG/ML
1MG/ML
1MG/ML
A 072082
A 072083
A 072084
A 072085
A 072086
A 072087
A 072088
A 072089
A 072090
A 072091
A 072092
A 072093
001
001
001
001
001
001
001
001
001
001
001
001
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
Mar
0.02MG/ML
0.4MG/ML
1MG/ML
N 016636
N 016636
N 016636
002
001
003 Jun 14, 1982
Aug CAHN
Aug CAHN
Aug CAHN
AB
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
SUN PHARM INDS LTD
EQ 0.5MG BASE;EQ 50MG BASE
A 075523
001 Mar 17, 2000
Apr CAHN
AB
NAPROXEN
SUSPENSION;ORAL
NAPROSYN
+
PEDIAPHARM INC
N 018965
001 Mar 23, 1987
Apr CAHN
N 020353
N 020353
N 020353
001 Jan 05, 1996

002 Jan 05, 1996
003 Jan 05, 1996
Oct CAHN
Oct CAHN
Oct CAHN
AB
AB
AB
+
@
@
AB
AB
AB
AB
AB
US WORLD MEDS LLC

+
@
@
NADOLOL
ORION CORP ORION
NALOXONE HYDROCHLORIDE
NALOXONE
NALOXONE HYDROCHLORIDE
@ IGI LABS INC
@
@
@
@
@
@
@
@
@
@
@
NARCAN
@ ADAPT
@
@
>D> AB
>D> AB
>D>
25MG/ML
NAPROXEN SODIUM
NAPRELAN
ALMATICA PHARMA INC
EQ 375MG BASE
EQ 500MG BASE
+
EQ 750MG BASE
1 -65

October
NADOLOL
TABLET;ORAL
CORGARD
KING PHARMS
10
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
10,
10,
10,
10,
10,
10,
11,
11,
11,
11,
11,
11,
11,
11,
11,
11,
11,
11,
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
1989
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
>A> AB
>A> AB
>A>
AB
AB
AB
AB
AB
AB
AB
AB
AB
2015
N 020353
N 020353
N 020353
001 Jan 05, 1996

002 Jan 05, 1996
003 Jan 05, 1996
Oct CAHN
Oct CAHN
Oct CAHN
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL
TREXIMET
PERNIX IRELAND LTD
60MG;EQ 10MG BASE
N 021926
002 May 14, 2015
Jun NEWA
NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE
@ ALKEM LABS LTD
EQ
EQ
@
EQ
EQ
@
EQ
EQ
@
EQ
EQ
@ AMERIGEN PHARMS LTD
EQ
EQ
@
EQ
EQ
@
EQ
EQ
@
EQ
EQ
@ INDCHEMIE HEALTH
EQ
EQ
@
EQ
EQ
@
EQ
EQ
@
EQ
EQ
A 203741
A 203741
A 203741
A 203741
A 203741
A 203741
A 203741
A 203741
A 203659
A 203659
A 203659
A 203659
A 203659
A 203659
A 203659
A 203659
A 203828
A 203828
A 203828
A 203828
A 203828
A 203828
A 203828
A 203828
001
001
002
002
003
003
004
004
001
001
002
002
003
003
004
004
001
001
002
002
003
003
004
004
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Jul
24,
24,
24,
24,
24,
24,
24,
24,
16,
16,
16,
16,
16,
16,
16,
16,
29,
29,
29,
29,
29,
29,
29,
29,
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Jun
Apr
Mar
Apr
Mar
Apr
Mar
Apr
Mar
Jul
Jul
Jul
Jul
Jul
Jul
Jul
Jul
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
DISC
NEWA
50MG
100MG
150MG
200MG
250MG
50MG
100MG
150MG
200MG
250MG
A 076072
A 076072
A 076072
A 076072
A 076072
A 076409
A 076409
A 076409
A 076409
A 076409
001
002
003
004
005
001
002
003
004
005
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
Sep
16,
16,
16,
16,
16,
16,
16,
16,
16,
16,
2003
2003
2003
2003
2003
2003
2003
2003
2003
2003
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
250MG/50ML (5MG/ML)
N 021877
001 Oct 28, 2005
Mar CAHN
NEOSTIGMINE METHYLSULFATE
NEOSTIGMINE METHYLSULFATE
FRESENIUS KABI USA
5MG/10ML (0.5MG/ML)
10MG/10ML (1MG/ML)
N 203629
N 203629
001 Jan 08, 2015

002 Jan 08, 2015
Jan NEWA
Jan NEWA
NEVIRAPINE
NEVIRAPINE
ALVOGEN MALTA
100MG
100MG
400MG
ALVOGEN PINE BROOK
400MG
400MG
CIPLA LTD
400MG
A 204621
A 204621
A 204621
A 204621
A 204621
A 206448
002
002
001
001
001
001
Oct
Oct
Oct
Oct
Jun
Oct
NEFAZODONE HYDROCHLORIDE
TABLET;ORAL
NEFAZODONE HYDROCHLORIDE
@ IDT AUSTRALIA LTD
@
@
@
@
SUN PHARM INDS LTD
NELARABINE
ARRANON
+
>A>
>A>
>A>
>D>
AB
AB
AB
AB
AB
>A> AB
2.5MG BASE
2.5MG BASE
5MG BASE
5MG BASE
10MG BASE
10MG BASE
20MG BASE
20MG BASE
2.5MG BASE
2.5MG BASE
5MG BASE
5MG BASE
10MG BASE
10MG BASE
20MG BASE
20MG BASE
2.5MG BASE
2.5MG BASE
5MG BASE
5MG BASE
10MG BASE
10MG BASE
20MG BASE
20MG BASE
1 -66
October

NAPRELAN
ALVOGEN MALTA
EQ 375MG BASE
EQ 500MG BASE
+
EQ 750MG BASE
10
Nov
Nov
Jul
Jul
Jul
Oct
09,
09,
10,
10,
10,
15,
2015
2015
2015
2015
2015
2015
NEWA
CAHN
CAHN
CAHN
NEWA
NEWA
10
October
2015
1 -67

A 206271
001 Nov 09, 2015
Oct NEWA

>D>
>A> AB

NEVIRAPINE
MYLAN PHARMS INC
100MG
VIRAMUNE XR
100MG
100MG
N 201152
N 201152
002 Nov 08, 2012

002 Nov 08, 2012
Oct CFTG

Oct CFTG

AB
AB
NIACIN
NIACIN
AMNEAL PHARMS
500MG
1GM
A 203578
A 203578
001 Jul 24, 2015

002 Jul 24, 2015
Jul NEWA

Jul NEWA

A 202644
A 202644
001 Apr 25, 2013

002 Apr 25, 2013
Mar CAHN

Mar CAHN

A 075289
A 075289
002 Feb 06, 2001

001 Sep 27, 2000
Aug CAHN

Aug CAHN

>A> AB
AB
AB
AB2
AB2
AB
AB
NIFEDIPINE
CAPSULE;ORAL
NIFEDIPINE
HERITAGE PHARMA
10MG
20MG
NIFEDIPINE
30MG
60MG
NILUTAMIDE
TABLET;ORAL
NILANDRON
@ CONCORDIA PHARMS INC
+
50MG
150MG
N 020169
N 020169
001 Sep 19, 1996

002 Apr 30, 1999
Apr CAHN

Apr CAHN

NIMODIPINE
CAPSULE;ORAL
NIMODIPINE
+
SOFGEN PHARMS
30MG
30MG
A 076740
A 201832
001 Jan 17, 2008

001 Jul 24, 2015
Jan CAHN

Jul NEWA

NINTEDANIB ESYLATE
CAPSULE;ORAL
OFEV
+
EQ 100MG BASE
EQ 150MG BASE
N 205832
N 205832
001 Oct 15, 2014

002 Oct 15, 2014
Mar CAIN

Mar CAIN

NITRIC OXIDE
GAS;INHALATION
INOMAX
@ INO
100PPM
N 020845
002 Dec 23, 1999
Jun DISC

N 016620
N 016620
N 016620
N 016620
N 016620
N 016620
N 016620
003
003
001
002
003
001
002
Oct
Jun
Oct
Oct
Oct
Oct
Oct
A 091095
A 091095
A 091095
001 Jun 18, 2015

002 Jun 18, 2015
003 Jun 18, 2015
Jun NEWA

Jun NEWA

Jun NEWA

A 202250
001 Jul 08, 2015
Jun NEWA

AB
AB
AB
NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL
MACRODANTIN
ALVOGEN INC
25MG
25MG
50MG
+
100MG
ALVOGEN MALTA
25MG
50MG
+
100MG
NITROFURANTOIN
ACTAVIS LABS FL INC
25MG
50MG
100MG
AB
NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
WATSON LABS INC
75MG;25MG
>D> AB
AB
>D> AB
>D> AB
>A> AB
>A> AB
>A> AB
CAHN

CTEC

CAHN

CAHN

CAHN

CAHN

CAHN

October
2015
1 -68

NORETHINDRONE
TABLET;ORAL-28
NOR-QD
AB1
+
ACTAVIS LABS UT INC
0.35MG
N 017060
001
Mar CAHN
NORGESTREL
TABLET;ORAL
OVRETTE
@ LABORATOIRE HRA
0.075MG
N 017031
001
Jun CAHN
100,000 UNITS/GM
A 061966
001
Jun CMFD
100,000 UNITS/ML
100,000 UNITS/ML
A 062349
A 062776
001 Jul 14, 1982

001 Dec 17, 1987
Apr CAHN
Apr CAHN
A 062367
001 May 28, 1985
Mar CMFD
A 062733
001 Mar 09, 1987
Mar CMFD
A 076093
003 Sep 02, 2003
Jul CMFD
A 202295
A 202295
A 202295
A 202295
A 202295
A 202295
A 077301
001
002
003
004
005
006
001
Oct
Oct
Oct
Oct
Oct
Oct
Apr
20,
20,
20,
20,
20,
20,
29,
2015
2015
2015
2015
2015
2015
2015
Oct
Oct
Oct
Oct
Oct
Oct
Apr
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
A 203044
A 203044
A 203044
A 203044
A 202937
A 202937
A 202937
A 202937
001
002
003
004
001
002
003
004
Feb
Feb
Feb
Feb
Mar
Mar
Mar
Mar
20,
20,
20,
20,
02,
02,
02,
02,
2015
2015
2015
2015
2015
2015
2015
2015
Feb
Feb
Feb
Feb
Feb
Feb
Feb
Feb
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
N 206162
001 Dec 19, 2014
Jan CTNA
N 206756
001 May 21, 2015
May NEWA
A 090848
001 Jul 13, 2015
Jun NEWA
N 021545
001 Dec 22, 2004
Jun CFTG
AT
AA
NYSTATIN
CREAM;TOPICAL
NYSTATIN
G AND W LABS INC
SUSPENSION;ORAL
NYSTATIN
G AND W LABS INC
@
AT
NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
MYKACET
G AND W LABS INC
100,000 UNITS/GM;0.1%
OINTMENT;TOPICAL
MYKACET
G AND W LABS INC
100,000 UNITS/GM;0.1%
AB
OFLOXACIN
TABLET;ORAL
OFLOXACIN
LARKEN LABS
AT
>A>
>A>
>A>
>A>
>A>
>A>
10
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
400MG
OLANZAPINE
TABLET;ORAL
OLANZAPINE
ALKEM LABS LTD
2.5MG
5MG
7.5MG
10MG
15MG
20MG
IVAX PHARMS INC
20MG
OLANZAPINE
MACLEODS PHARMS LTD
5MG
10MG
15MG
20MG
ORCHID HLTHCARE
5MG
10MG
15MG
20MG
OLAPARIB
CAPSULE;ORAL
LYNPARZA
ASTRAZENECA PHARMS
50MG
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION
STIOLTO RESPIMAT
+
BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH;EQ 0.0025MG
BASE/INH
AT
AT
OLOPATADINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE
BARR LABS INC
EQ 0.2% BASE
PATADAY
+
ALCON PHARMS LTD
EQ 0.2% BASE
AB
AB
AB
AB
2015
N 206276
001 Jan 30, 2015
Jan NEWA

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

+
ABBVIE INC
12.5MG;75MG;50MG
+
12.5MG;75MG;50MG
N 207931
N 207931
001 Jul 24, 2015

001 Jul 25, 2015
Aug CMS1

Jul NEWA

OMEPRAZOLE


OMEPRAZOLE

AUROBINDO PHARMA USA
10MG
20MG
40MG
LUPIN LTD
40MG
A 203270
A 203270
A 203270
A 202384
001
002
003
001
Aug
Aug
Aug
Aug
AB
AB
A 078602
A 078602
001 Feb 24, 2011

002 Feb 24, 2011
Apr CAHN

Apr CAHN

AB
AB
N 020781
N 020781
001 Jan 27, 1999

002 Jan 27, 1999
Mar CAHN

Mar CAHN

A 206846
A 078288
A 077365
001 Jul 13, 2015

001 Feb 22, 2013
001 Dec 26, 2006
Jun NEWA

Apr CAHN

Jun CAHN

A 078287
A 077541
A 078014
001 Feb 22, 2013

001 Dec 26, 2006
001 Mar 21, 2008
Apr CAHN

Jun CAHN

Jan DISC

N 020007
001 Jan 04, 1991
Mar CAHN

N 020007
003 Dec 10, 1993
Mar CAHN
N 020605
001 Jan 24, 1997
Mar CAHN
N 020103
N 020103
N 020103
001 Dec 31, 1992

002 Dec 31, 1992
003 Aug 27, 1999
Mar CAHN
Mar CAHN
Mar CAHN
30MG/ML
30MG/ML
N 013055
N 013055
001
001
Apr CAHN
Mar DISC
30MG/ML
A 040484
001 May 24, 2006
Mar CRLD
OXACILLIN SODIUM
CAPSULE;ORAL
OXACILLIN SODIUM
@ ANI PHARMS INC
@
EQ 250MG BASE
EQ 500MG BASE
A 062222
A 062222
001
002
Aug CAHN
Aug CAHN
OXANDROLONE
TABLET;ORAL
OXANDRIN
GEMINI LABS LLC
+
2.5MG
10MG
N 013718
N 013718
001
002 Nov 05, 2001
Aug CAHN
Aug CAHN
ONDANSETRON


ONDANSETRON

SUN PHARM INDS LTD
4MG
8MG
ZOFRAN ODT

4MG
+
8MG
AB
AB
AB
ONDANSETRON HYDROCHLORIDE


ONDANSETRON HYDROCHLORIDE

ACCORD HLTHCARE
EQ 2MG BASE/ML
EQ 2MG BASE/ML
EUROHLTH INTL SARL
EQ 2MG BASE/ML
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

EQ 2MG BASE/ML
EUROHLTH INTL SARL
EQ 2MG BASE/ML
@ TARO PHARMS IRELAND
EQ 2MG BASE/ML
ZOFRAN

+
EQ 2MG BASE/ML
ZOFRAN PRESERVATIVE FREE

+
NOVARTIS PHARMS CORP EQ 2MG BASE/ML
SOLUTION;ORAL
ZOFRAN
+
NOVARTIS PHARMS CORP EQ 4MG BASE/5ML
TABLET;ORAL
ZOFRAN
NOVARTIS PHARMS CORP EQ 4MG BASE
EQ 8MG BASE
+
EQ 24MG BASE
AP
ORPHENADRINE CITRATE
NORFLEX
@ IGI LABS INC
@ MEDICIS
ORPHENADRINE CITRATE
+
AKORN
AP
AP
AP
AP
AP
AP
AP
AA
AB
AB
1 -69

October
PAZEO

+
ALCON RES LTD
EQ 0.7% BASE
10
Aug
Aug
Aug
Aug
19,
19,
19,
25,
2015
2015
2015
2015
NEWA

NEWA

NEWA

NEWA

AB
AB
OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

SUN PHARM INDS LTD
OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+
ACTAVIS LABS UT INC
AB
AB
AA
AA
AA
2015
A 078734
001 Jun 26, 2009
Apr CAHN

N 021351
002 Feb 26, 2003
Mar CAHN

N 202513
001 Dec 07, 2011
Mar CAHN

10%(100MG/PACKET)
N 022204
001 Jan 27, 2009
Mar CAHN

5MG
5MG
A 202773
A 204752
001 Aug 17, 2015

001 Aug 24, 2015
Aug NEWA

Aug NEWA

5MG/5ML
100MG/5ML
5MG/5ML
A 204979
A 204603
A 206456
001 Jun 01, 2015

001 Apr 29, 2015
001 Jun 16, 2015
May NEWA

Apr NEWA

Jun NEWA

5MG
7.5MG
5MG
7.5MG
5MG
7.5MG
N 202080
N 202080
N 202080
N 202080
N 202080
N 202080
001
002
001
002
001
002
Jun
Jun
Jun
Jun
Jun
Jun
17,
17,
17,
17,
17,
17,
2011
2011
2011
2011
2011
2011
Mar
Mar
May
May
Jul
Jul
CTNA

CTNA

CAHN

CAHN

CAHN

CAHN

A 076636
A 202662
A 202662
A 202662
A 202662
A 077712
A 077712
003
001
002
003
004
004
005
Apr
Sep
Sep
Sep
Sep
Apr
Apr
07,
22,
22,
22,
22,
13,
13,
2015
2015
2015
2015
2015
2015
2015
Mar
Sep
Sep
Sep
Sep
Mar
Mar
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

A 203506
A 203506
A 203506
A 203506
A 203506
A 203506
A 203506
001
002
003
004
005
006
007
Apr
Apr
Apr
Apr
Apr
Apr
Apr
24,
24,
24,
24,
24,
24,
24,
2015
2015
2015
2015
2015
2015
2015
Apr
Apr
Apr
Apr
Apr
Apr
Apr
NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

NEWA

OXYBUTYNIN


OXYTROL

+
ACTAVIS LABS UT INC
3.9MG/24HR
GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+
ACTAVIS LABS UT INC
3%
OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL


AVANTHI INC
NOVEL LABS INC
SOLUTION;ORAL


ANI PHARMS INC
NOVEL LABS INC
WOCKHARDT BIO AG
TABLET;ORAL

OXAYDO

ACURA PHARMS INC
EGALET LTD
EGALET US INC

ACTAVIS ELIZABETH
5MG
EPIC PHARMA LLC
5MG
10MG
15MG
30MG
VINTAGE PHARMS
10MG
20MG
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
OXYMORPHONE HYDROCHLORIDE


OXYMORPHONE HYDROCHLORIDE

SUN PHARM INDS LTD
5MG
7.5MG
10MG
15MG
20MG
30MG
40MG
AP
AP
OXYTOCIN


OXYTOCIN

+
EUROHLTH INTL SARL
+
PALBOCICLIB

CAPSULE;ORAL

IBRANCE

PFIZER INC
+
1 -70

October
300MG/5ML
10
10USP UNITS/ML (10USP UNITS/ML)

N 018243
100USP UNITS/10ML (10USP UNITS/ML) N 018243
001
002 Jan 10, 2007
Feb CAHN

Feb CAHN

75MG
100MG
125MG
001 Feb 03, 2015

002 Feb 03, 2015
003 Feb 03, 2015
Feb NEWA

Feb NEWA

Feb NEWA

N 207103
N 207103
N 207103
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AP
AP
AP
AP
2015
N 021999
N 021999
N 021999
N 021999
006
001
002
003
Aug
Dec
Dec
Dec
26,
19,
19,
19,
2008
2006
2006
2006
Jul
Jul
Jul
Jul
CFTG
CFTG
CFTG
CFTG
A 202645
A 202645
A 202645
A 202645
A 203802
A 203802
A 203802
A 203802
001
002
003
004
001
002
003
004
Aug
Aug
Aug
Aug
Sep
Sep
Sep
Sep
03,
03,
03,
03,
24,
24,
24,
24,
2015
2015
2015
2015
2015
2015
2015
2015
Jul
Jul
Jul
Jul
Sep
Sep
Sep
Sep
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
PALIPERIDONE PALMITATE
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA
JANSSEN PHARMS
273MG/0.875ML (273MG/0.875ML)
410MG/1.315ML (311.79MG/ML)
546MG/1.75ML (312MG/ML)
+
819MG/2.625ML (312MG/ML)
N 207946
N 207946
N 207946
N 207946
001
002
003
004
May
May
May
May
18,
18,
18,
18,
2015
2015
2015
2015
May
May
May
May
NEWA
NEWA
NEWA
NEWA
PALONOSETRON HYDROCHLORIDE
ALOXI
+
HELSINN HLTHCARE
N 021372
002 Feb 29, 2008
Sep CFTG
N 021372
001 Jul 25, 2003
Sep CFTG
A 202521
001 Oct 13, 2015
Sep NEWA
A 090713
002 Oct 13, 2015
Sep NEWA
A 090713
001 Oct 13, 2015
Sep NEWA
1MG/ML
2MG/ML
2MG/ML
2MG/ML
A 072210
A 072211
A 072212
A 072213
001
001
001
001
Mar
Mar
Mar
Mar
10MG
15MG
20MG
N 205353
N 205353
N 205353
001 Feb 23, 2015

002 Feb 23, 2015
003 Feb 23, 2015
Feb NEWA
Feb NEWA
Feb NEWA
N 205353
N 205353
N 205353
N 205353
N 205353
N 205353
001
001
002
002
003
003
Mar
Mar
Mar
Mar
Mar
Mar
A 090296
001 Jul 14, 2015
Jun NEWA
A 078281
001 Jan 20, 2011
Mar CAHN
PALIPERIDONE


INVEGA
JANSSEN PHARMS
1.5MG
3MG
+
6MG
9MG
PALIPERIDONE
ACTAVIS LABS FL INC
1.5MG
3MG
6MG
9MG
MYLAN PHARMS INC
1.5MG
3MG
6MG
9MG
EQ 0.075MG BASE/1.5ML (EQ 0.05MG

BASE/ML)
+
EQ 0.25MG BASE/5ML (EQ 0.05MG
BASE/ML)
PALONOSETRON HYDROCHLORIDE
SANDOZ INC
BASE/ML)
TEVA PHARMS USA
EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)
BASE/ML)
PANOBINOSTAT
CAPSULE;ORAL
FARYDAK
+
PANOBINOSTAT LACTATE
CAPSULE;ORAL
FARYDAK
+
+
AB
EQ
EQ
EQ
EQ
EQ
EQ
10MG
10MG
15MG
15MG
20MG
20MG
BASE
BASE
BASE
BASE
BASE
BASE
PANTOPRAZOLE SODIUM
PANTOPRAZOLE SODIUM
SANDOZ INC
EQ 40MG BASE/VIAL
PANTOPRAZOLE SODIUM
KREMERS URBAN PHARMS EQ 20MG BASE
1 -71

October
PANCURONIUM BROMIDE
PANCURONIUM BROMIDE
@ IGI LABS INC
@
@
@
AP
10
Mar
Mar
Mar
Mar
Feb
Feb
Feb
Feb
Feb
Feb
31,
31,
31,
31,
23,
23,
23,
23,
23,
23,
1988
1988
1988
1988
2015
2015
2015
2015
2015
2015
CAHN
CAHN
CAHN
CAHN
CAIN
CPOT
CAIN
CPOT
CAIN
CPOT
2015
A 078281
A 200794
A 200794
002 Jan 20, 2011

001 May 02, 2012
002 May 02, 2012
Mar CAHN
Apr CAHN
Apr CAHN
1MCG
2MCG
4MCG
A 202539
A 202539
A 202539
001 Mar 27, 2014

002 Mar 27, 2014
003 Mar 27, 2014
Jan CAHN
Jan CAHN
Jan CAHN
EQ 8.4GM BASE/PACKET
N 205739
N 205739
N 205739
001 Oct 21, 2015

002 Oct 21, 2015
003 Oct 21, 2015
Oct NEWA
Oct NEWA
Oct NEWA
EQ 200MG BASE
EQ 400MG BASE
EQ 400MG BASE
N 022465
N 022465
N 022465
001 Oct 19, 2009

002 Oct 19, 2009
002 Oct 19, 2009
Mar CAHN
Aug DISC
Mar CAHN
A 075028
001 Jul 20, 1998
Feb CAHN
A 088021
001 Sep 21, 1982
Jan DISC
N 018074
001
Jan CTEC
AB
PHENOXYBENZAMINE HYDROCHLORIDE
CAPSULE;ORAL
DIBENZYLINE
+
CONCORDIA PHARMS INC 10MG
N 008708
001
Jun CAHN
AA
PHENTERMINE HYDROCHLORIDE
CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE
MIKAH PHARMA LLC
37.5MG
A 040228
001 Jun 19, 1997
Jun CMFD
PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
+
AKORN INC
2.5%
2.5%
+
10%
10%
+
PARAGON BIOTECK
2.5%
N 207926
N 207926
N 207926
N 207926
N 203510
001
001
002
002
001
Sep
Jan
Sep
Jan
Sep
AA
PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETH VC PLAIN
+
G AND W LABS INC
5MG/5ML;6.25MG/5ML
A 088761
001 Nov 08, 1984
Jul CAHN
A 040759
A 040732
001 Dec 18, 2007

001 Jan 30, 2008
Jun DISC
Jun DISC
AB
PHENYTOIN SODIUM
CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM
@ WOCKHARDT
30MG EXTENDED
@ WOCKHARDT USA
100MG EXTENDED
PHENYTOIN SODIUM
AUROBINDO PHARMA LTD 100MG EXTENDED
A 204309
001 Jun 10, 2015
May NEWA
AB
AB
AB
AB
AB
AB
>A>
>A>
>A>
>A>
>A>
>A>
PARICALCITOL
CAPSULE;ORAL
PARICALCITOL
PATIROMER SORBITEX CALCIUM

POWDER;ORAL
VELTASSA
RELYPSA INC
+
PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
VOTRIENT
+
@
AB
PENTOXIFYLLINE
PENTOXIFYLLINE
VALEANT PHARMS
400MG
PHENDIMETRAZINE TARTRATE
BONTRIL
@ VALEANT
105MG
PHENDIMETRAZINE TARTRATE
+
SANDOZ
105MG
1 -72

October

PANTOPRAZOLE SODIUM
EQ 40MG BASE
SUN PHARM INDS LTD
EQ 20MG BASE
EQ 40MG BASE
10
Jan
Jan
Jan
Jan
Mar
15,
15,
15,
15,
21,
2015
2015
2015
2015
2013
CRLD
NEWA
CRLD
NEWA
CRLD
October
2015
1 -73

50MG/ML
A 084307
001
Feb CAHN
1MG/0.5ML
10MG/ML
N 012223
N 012223
002
001
Apr CAHN
Apr CAHN
N 018796
001 Oct 01, 1984
Aug DISC
A 076746
001 Nov 16, 2004
Mar CAHN
1MG
2MG
N 017473
N 017473
003 Aug 27, 1997

001 Jul 31, 1984
Sep CFTG
Sep CFTG
1MG
2MG
A 204521
A 204521
001 Sep 28, 2015

002 Sep 28, 2015
Sep NEWA
Sep NEWA
5MG
5MG
5MG
10MG
10MG
10MG
A 073661
A 073687
A 074123
A 073661
A 073687
A 074123
001
001
001
002
002
002
Apr
Apr
Apr
Apr
Apr
Apr
PIRBUTEROL ACETATE
AEROSOL, METERED;INHALATION
MAXAIR
@ MEDICIS
EQ 0.2MG BASE/INH
N 020014
001 Nov 30, 1992
Jan DISC
PIRFENIDONE
CAPSULE;ORAL
ESBRIET
+
GENENTECH INC
267MG
N 022535
001 Oct 15, 2014
Feb CAHN
10MG
20MG
A 074116
A 074118
001 Jun 15, 1993

001 Jun 15, 1993
May CAHN
May CAHN
0.5%
N 020529
001 Mar 13, 1997
Feb CAHN
0.5%
N 019795
001 Dec 13, 1990
Jan CAHN
0.5%
A 090184
001 Jul 21, 2010
May CAHN
A 064211
001 Apr 13, 1998
Jan CAHN
AP
PHENYTOIN SODIUM
+
EUROHLTH INTL SARL
PHYTONADIONE
AQUAMEPHYTON
@ IGI LABS INC
@
AB
AB
AB
AB
AB
PILOCARPINE HYDROCHLORIDE
GEL;OPHTHALMIC
PILOPINE HS
@ ALCON
4%
TABLET;ORAL
PILOCARPINE HYDROCHLORIDE
ELAN PHARMA INTL LTD 5MG
PIMOZIDE
TABLET;ORAL
ORAP
TEVA
+
PIMOZIDE
PAR PHARM
PINDOLOL
TABLET;ORAL
PINDOLOL
@ G AND W LABS INC
@
@
@
@
@
AB
AB
10
PIROXICAM
CAPSULE;ORAL
PIROXICAM
MYLAN PHARMS INC
AT
PODOFILOX
GEL;TOPICAL
CONDYLOX
+
ACTAVIS LABS UT INC
SOLUTION;TOPICAL
CONDYLOX
+
ACTAVIS LABS UT INC
PODOFILOX
BAUSCH AND LOMB INC
AT
POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
ALCON RES LTD
10,000 UNITS/ML;EQ 1MG BASE/ML
AT
Oct
Feb
Apr
Oct
Feb
Apr
31,
26,
17,
31,
26,
17,
1993
1993
1997
1993
1993
1997
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
PONATINIB HYDROCHLORIDE
TABLET;ORAL
ICLUSIG
ARIAD
AB
AB
AB1
AB2
AB2
>A> AB2
>A> AB2
EQ 30MG BASE
POTASSIUM CHLORIDE
KLOR-CON
UPSHER SMITH
8MEQ
10MEQ
FOR SOLUTION;ORAL
POTASSIUM CHLORIDE
PHARMA RES SOFTWARE
20MEQ
POTASSIUM CHLORIDE
ADARE PHARMS INC
20MEQ
MYLAN PHARMS INC
8MEQ
10MEQ
PADDOCK LLC
8MEQ
10MEQ
10
1 -74

October
2015
N 203469
003 Apr 23, 2015
Apr NEWA

A 203106
A 203106
001 Jul 10, 2015

002 Jul 10, 2015
Jun NEWA

Jun NEWA

N 208019
001 Aug 19, 2015
Aug NEWA

A 076368
A 204662
A 204662
A 205993
A 205993
001
001
002
001
002
Jul
Feb
Feb
Oct
Oct
A 090781
006 Sep 11, 2015
Aug NEWA

A 203354
A 203354
A 203354
A 203354
A 203354
001
002
003
004
005
Jul
Jul
Jul
Jul
Jul
Aug
Aug
Aug
Nov
Nov
18,
21,
21,
05,
05,
2004
2014
2014
2015
2015
CAHN

CPOT

CPOT

NEWA

NEWA

AB
AB
AB
AB
AB
PRAMIPEXOLE DIHYDROCHLORIDE
TABLET;ORAL
GLENMARK GENERICS
0.75MG
DR REDDYS LABS LTD
0.375MG
0.75MG
1.5MG
3MG
4.5MG
AB
PREDNICARBATE
OINTMENT;TOPICAL
DERMATOP
+
0.1%
N 019568
001 Sep 23, 1991
Apr CAHN

PREDNISONE
TABLET;ORAL
PREDNISONE
@ HIKMA PHARMS
1MG
A 040890
001 Nov 01, 2010
Aug DISC

25MG
50MG
75MG
100MG
150MG
200MG
225MG
300MG
N 021446
N 021446
N 021446
N 021446
N 021446
N 021446
N 021446
N 021446
001
002
003
004
005
006
007
008
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
A 089219
A 089221
001 Jul 01, 1986

001 Jul 01, 1986
Jun CAHN

Jun CAHN

A 089369
A 089370
A 089371
001 Aug 14, 1987

001 Jan 09, 1987
001 Aug 14, 1987
Jun CAHN

Jun CAHN

Jun CAHN

AB
PREGABALIN
CAPSULE;ORAL
LYRICA
PF PRISM CV
PROCAINAMIDE HYDROCHLORIDE
CAPSULE;ORAL
@ IDT AUSTRALIA LTD
250MG
@
500MG
@ IDT AUSTRALIA LTD
250MG
@
500MG
@
750MG
Aug
Aug
Aug
Aug
Aug
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
07,
07,
07,
07,
07,
30,
30,
30,
30,
30,
30,
30,
30,
2015
2015
2015
2015
2015
2004
2004
2004
2004
2004
2004
2004
2004
NEWA

NEWA

NEWA

NEWA

NEWA

CTEC

CTEC

CTEC

CTEC

CTEC

CTEC

CTEC

CTEC

AP
AB
AB
AO
PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

GEL;VAGINAL

CRINONE

ACTAVIS LABS UT INC
+

PROGESTERONE

+
ACTAVIS LABS UT INC
2015
A 089903
001 Aug 29, 1989
Feb CAHN

100MG
200MG
A 200900
A 200900
001 Aug 16, 2013

002 Aug 16, 2013
Jan CAHN

Jan CAHN

4%
8%
N 020701
N 020701
001 Jul 31, 1997

002 Jul 31, 1997
Feb CAHN

Feb CAHN

50MG/ML
N 017362
002
Mar CAHN

A 083312
A 083312
001
002
Jun CAHN

Jun CAHN

N 010926
N 010926
002
001
Apr CAHN

Apr CAHN

A 040673
A 040673
A 040673
001 Mar 05, 2008

002 Mar 05, 2008
003 Mar 05, 2008
Mar CAHN

Mar CAHN

Mar CAHN

A 202688
A 202688
A 202688
001 Aug 24, 2015

002 Aug 24, 2015
003 Aug 24, 2015
Aug NEWA

Aug NEWA

Aug NEWA

A 040512
A 040512
A 205650
002 Jul 20, 2005

001 Oct 08, 2003
001 Jun 22, 2015
Aug CAHN

Aug CAHN

Jun NEWA

AB
AB
AB
PROMETHAZINE HYDROCHLORIDE



+
EUROHLTH INTL SARL
25MG/ML
+
50MG/ML
SUPPOSITORY;RECTAL

PHENERGAN

@ DELCOR ASSET CORP
12.5MG
@
25MG
TABLET;ORAL


HERITAGE PHARMA
12.5MG
25MG
50MG
AB
AB
AB
PROPAFENONE HYDROCHLORIDE


PROPAFENONE HYDROCHLORIDE

WATSON LABS INC
225MG
325MG
425MG
AP
AP
AB
AB
AB
AB
AB
AB
AB
1 -75

October
PROCHLORPERAZINE EDISYLATE


PROCHLORPERAZINE EDISYLATE

+
EUROHLTH INTL SARL
EQ 5MG BASE/ML
10
PYRIDOSTIGMINE BROMIDE

TABLET;ORAL


@ ANI PHARMS INC
30MG
@
60MG
60MG

MESTINON
+
VALEANT PHARMS LLC
180MG
ALVOGEN INC
180MG
IMPAX LABS INC
180MG
N 011665
001
Jun CFTG
A 204737
A 203184
001 Jun 26, 2015

001 Sep 15, 2015
Jun NEWA
Aug NEWA
PYRIMETHAMINE
TABLET;ORAL
DARAPRIM
+
TURING PHARMS AG
25MG
N 008578
001
Aug CAHN
QUAZEPAM
TABLET;ORAL
DORAL
@ SCIECURE PHARMA INC
15MG
N 018708
001 Dec 27, 1985
Jun DISC
EQ
EQ
EQ
EQ
N 020639
N 020639
N 020639
N 020639
001
007
002
004
May
May
May
May
QUETIAPINE FUMARATE
TABLET;ORAL
SEROQUEL
+
ASTRAZENECA PHARMS
25MG BASE
50MG BASE
100MG BASE
150MG BASE
Sep
Oct
Sep
Dec
26,
04,
26,
20,
1997
2005
1997
1998
CAHN
CAHN
CAHN
CAHN
10
1 -76

October
2015
N 020639
N 020639
N 020639
003 Sep 26, 1997

005 Jul 26, 2000
006 Oct 04, 2005
May CAHN
May CAHN
May CAHN
A 076607
A 076607
A 076607
A 076607
001
002
003
004
Apr
Apr
Apr
Apr
A 088431
001 Jan 06, 1984
Jun CAHN
A 083640
A 085632
001
001
Jun CAHN
Jun CAHN
A 040045
001 Jun 30, 1994
Apr CAHN
A 203729
A 203112
A 204372
001 Jul 15, 2015

001 Apr 24, 2015
001 Jul 22, 2015
Jun NEWA
Apr NEWA
Jul NEWA
TABLET;ORAL
SEROQUEL
AB
AB
AB
AB
AB
AB
AB
EQ 200MG BASE
EQ 300MG BASE
EQ 400MG BASE
QUINAPRIL HYDROCHLORIDE
TABLET;ORAL
QUINAPRIL HYDROCHLORIDE
SUN PHARM INDS LTD
EQ
EQ
EQ
EQ
5MG BASE
10MG BASE
20MG BASE
40MG BASE
QUINIDINE GLUCONATE
QUINIDINE GLUCONATE
@ CYCLE PHARMS LTD
324MG
QUINIDINE SULFATE
TABLET;ORAL
QUINIDINE SULFATE
@ CYCLE PHARMS LTD
200MG
@
300MG
QUINIDINE SULFATE
+
G AND W LABS INC
300MG
Dec
Dec
Dec
Dec
15,
15,
15,
15,
2004
2004
2004
2004
CAHN
CAHN
CAHN
CAHN
AB
AB
AB
QUININE SULFATE
CAPSULE;ORAL
QUININE SULFATE
AMNEAL PHARMS
LUPIN LTD
RICONPHARMA LLC
AB
RABEPRAZOLE SODIUM
RABEPRAZOLE SODIUM
AMNEAL PHARMS
20MG
A 204179
001 Jul 31, 2015
Jul NEWA
AB
AB
RALOXIFENE HYDROCHLORIDE
TABLET;ORAL
RALOXIFENE HYDROCHLORIDE
WATSON LABS INC
60MG
A 204310
A 200825
001 Aug 28, 2015

001 Jan 21, 2015
Aug NEWA
Jan NEWA
AB
RAMELTEON
TABLET;ORAL
RAMELTEON
ACTAVIS LABS FL INC
A 091610
001 Aug 19, 2015
Aug NEWA
N 019090
001 Oct 19, 1984
Jun CAHN
A 075439
A 075439
001 Apr 19, 2000

002 Apr 19, 2000
Apr CAHN
Apr CAHN
A 091517
A 091517
A 091517
001 Apr 24, 2015

002 Apr 24, 2015
003 Apr 24, 2015
Apr NEWA
Apr NEWA
Apr NEWA
AP
AB
AB
AB
324MG
324MG
324MG
8MG
RANITIDINE HYDROCHLORIDE
ZANTAC
+
EQ 25MG BASE/ML
TABLET;ORAL
EQ 150MG BASE
@
EQ 300MG BASE
REPAGLINIDE
TABLET;ORAL
REPAGLINIDE
STANDARD CHEM PHARM
0.5MG
1MG
2MG
RIBAVIRIN

CAPSULE;ORAL

REBETOL

@ MERCK SHARP DOHME
200MG
10
1 -77

October
2015
N 020903
001 Jun 03, 1998
Jun DISC

N 022560
001 Oct 08, 2010
May CFTG

A 203217
001 May 18, 2015
May NEWA

Apr
Apr
Apr
Apr
Apr
AB
RISEDRONATE SODIUM


ATELVIA

+
WARNER CHILCOTT LLC
35MG
RISEDRONATE SODIUM

TEVA PHARMS USA
35MG
AB
AB
AB
AB
AB
RISPERIDONE


RISPERIDONE

SUN PHARM INDS LTD
0.5MG
1MG
2MG
3MG
4MG
A 077542
A 077542
A 077542
A 078474
A 078474
001
002
003
001
002
RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSEN PHARMS
N 022406
001 Jul 01, 2011
Apr CRLD

N 022083
N 022083
N 022083
001 Jul 06, 2007

002 Jul 06, 2007
005 Aug 31, 2012
Aug CFTG
Aug CFTG
Aug CFTG
A 204403
A 204403
A 204403
A 204403
A 204403
A 204403
001
002
003
001
002
003
Sep
Sep
Aug
Sep
Sep
Aug
03,
03,
31,
03,
03,
31,
2015
2015
2015
2015
2015
2015
Aug
Aug
Aug
Aug
Aug
Aug
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
A 090879
A 090879
A 090879
A 090879
001
002
003
004
Jun
Jun
Jun
Jun
10,
10,
10,
10,
2015
2015
2015
2015
May
May
May
May
NEWA
NEWA
NEWA
NEWA
A 203334
A 203334
001 Oct 16, 2015

002 Oct 16, 2015
Oct NEWA
Oct NEWA
50MG/5ML (10MG/ML)
A 091458
A 091458
001 Jul 28, 2010

002 Jul 28, 2010
Aug CAHN
Aug CAHN
ROFLUMILAST
TABLET;ORAL
DALIRESP
+
ASTRAZENECA PHARMS
500MCG
N 022522
001 Feb 28, 2011
Mar CAHN
ROLAPITANT HYDROCHLORIDE
TABLET;ORAL
VARUBI
+
TESARO INC
EQ 90MG BASE
N 206500
001 Sep 01, 2015
Sep NEWA
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AP
AP
10MG
RIVASTIGMINE


EXELON
NOVARTIS
4.6MG/24HR
+
9.5MG/24HR
13.3MG/24HR
RIVASTIGMINE
ALVOGEN INC
4.6MG/24HR
9.5MG/24HR
13.3MG/24HR
ALVOGEN PINE BROOK
4.6MG/24HR
9.5MG/24HR
13.3MG/24HR
RIVASTIGMINE TARTRATE
CAPSULE;ORAL
RIVASTIGMINE TARTRATE
ORCHID HLTHCARE
EQ
EQ
EQ
EQ
1.5MG BASE
3MG BASE
4.5MG BASE
6MG BASE
RIZATRIPTAN BENZOATE
RIZATRIPTAN BENZOATE
JUBILANT GENERICS
EQ 5MG BASE
EQ 10MG BASE
ROCURONIUM BROMIDE
ROCURONIUM BROMIDE
SAGENT PHARMS
Aug
Aug
Aug
Aug
Aug
06,
06,
06,
06,
06,
2010
2010
2010
2010
2010
CAHN

CAHN

CAHN

CAHN

CAHN

AB
AB
AB
AB
AB
AB
AB
SACUBITRIL; VALSARTAN
TABLET;ORAL
ENTRESTO
+
SAPROPTERIN DIHYDROCHLORIDE
POWDER;ORAL
KUVAN
BIOMARIN PHARM
>A>
AB
AB
AB
2015
A 077460
A 077460
A 077460
A 077460
A 077460
A 077460
A 077460
001
002
003
004
005
006
007
24MG;26MG
49MG;51MG
97MG;103MG
N 207620
N 207620
N 207620
001 Jul 07, 2015

002 Jul 07, 2015
003 Jul 07, 2015
Jul NEWA
Jul NEWA
Jul NEWA
500MG/PACKET
N 205065
002 Oct 27, 2015
Oct NEWA
A 078830
A 078830
001 Jan 30, 2015

001 Jan 30, 2015
Mar CAHN
Jan NEWA
N 017874
001
Jan CFTG
A 074537
A 074744
A 074756
001 Aug 02, 1996

001 Jan 27, 1997
001 Nov 25, 1998
Apr CAHN
Apr CAHN
Apr CAHN
A 077864
A 077864
A 077864
A 077977
A 077977
A 077977
A 077977
A 077977
001
002
003
001
002
003
004
005
May
May
May
Apr
Apr
Apr
Apr
Apr
100%
A 203793
001 Nov 03, 2015
Oct NEWA
EQ 10MG BASE/12.5ML (EQ 0.8MG

BASE/ML)
N 022473
001 Nov 18, 2009
Mar CFTG
EQ 10MG BASE/12.5ML (EQ 0.8MG

BASE/ML)
A 203988
001 Apr 01, 2015
Mar NEWA
4MG
8MG
N 022206
N 022206
001 Oct 08, 2008

002 Oct 08, 2008
Mar CAHN
Mar CAHN
0.25MG BASE
0.5MG BASE
1MG BASE
2MG BASE
3MG BASE
4MG BASE
5MG BASE
SCOPOLAMINE
SCOPOLAMINE
PERRIGO PHARMS CO
1MG/72HR
PERRIGO R AND D
1MG/72HR
TRANSDERM SCOP
+
NOVARTIS
1MG/72HR
SELEGILINE HYDROCHLORIDE
TABLET;ORAL
SELEGILINE HYDROCHLORIDE
@ G AND W LABS INC
5MG
@
5MG
@
5MG
AB
AB
AB
SERTRALINE HYDROCHLORIDE
TABLET;ORAL
SERTRALINE HYDROCHLORIDE
@ HIKMA PHARMS
@
@
SUN PHARM INDS LTD
>A> AN
SEVOFLURANE
LIQUID;INHALATION
SEVOFLURANE
SHANGHAI HENGRUI
AP
SILDENAFIL CITRATE
REVATIO
+
PFIZER
AP
SILDENAFIL CITRATE
SILODOSIN
CAPSULE;ORAL
RAPAFLO
+
ACTAVIS LABS UT INC
EQ
EQ
EQ
EQ
EQ
EQ
EQ
EQ
25MG BASE
50MG BASE
100MG BASE
25MG BASE
50MG BASE
100MG BASE
150MG BASE
200MG BASE
1 -78

October
ROPINIROLE HYDROCHLORIDE
TABLET;ORAL
ROPINIROLE HYDROCHLORIDE
G AND W LABS INC
EQ
EQ
EQ
EQ
EQ
EQ
EQ
10
May
May
May
May
May
May
May
Aug
Aug
Aug
Feb
Feb
Feb
Feb
Feb
05,
05,
05,
05,
05,
05,
19,
10,
10,
10,
06,
06,
06,
06,
06,
2008
2008
2008
2008
2008
2008
2008
2009
2009
2009
2007
2007
2007
2007
2007
Apr
Apr
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
DISC
DISC
DISC
CAHN
CAHN
CAHN
CAHN
CAHN
>A>
>A>
>A>
>A>
>A>
>D>
>D>
>D>
>D>
>D>
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AP
AB
>A> AP
AP
AP
AP
AP
AP
AP
>A> AP
AP
AA
AA
2015
A 078034
A 078034
A 078034
A 078034
A 078034
A 078034
A 078034
A 078034
A 078034
A 078034
A 076285
A 076285
A 076285
A 076285
A 076285
001
002
003
004
005
001
002
003
004
005
001
002
003
004
005
A 201850
001 Jan 20, 2012
Feb CAHN
A 201833
001 Sep 24, 2013
Feb CAHN
N 021569
N 021569
N 021569
N 021569
001
002
001
002
Feb
Feb
Feb
Feb
SODIUM FERRIC GLUCONATE COMPLEX

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
EUROHLTH INTL SARL
62.5MG/5ML
A 078215
001 Mar 31, 2011
Jun CAHN
SODIUM FLUORIDE F-18

SODIUM FLUORIDE F-18
3D IMAGING DRUG
CARDINAL HEALTH 414
HOT SHOTS NM LLC
IBA MOLECULAR N AM
MIPS CRF
PRECISION NUCLEAR
SPECTRON MRC LLC
TRIAD ISOTOPES INC
UNIV UTAH CYCLOTRON
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
10-200mCi/ML
A 203777
A 203780
A 204530
A 203592
A 204517
A 204542
A 203912
A 203968
A 204497
001
001
001
001
001
001
001
001
001
Oct
Jul
Jul
Aug
Jul
Feb
Apr
Oct
Apr
SODIUM IODIDE I-123

CAPSULE;ORAL
SODIUM IODIDE I 123
+
CARDINAL HEALTH 418
+
@
100uCi
200uCi
400uCi
N 018671
N 018671
N 018671
001 May 27, 1982

002 May 27, 1982
003 May 27, 1982
Apr CAHN
Apr CAHN
Apr CAHN
N 016692
001
Sep DISC
N 020004
001 Apr 21, 1992
Sep CTEC
A 040905
002 Apr 03, 2015
Mar NEWA
N 011287
001
Apr CAHN
BLU CARIBE
SUN PHARM INDS LTD
5MG
10MG
20MG
40MG
80MG
5MG
10MG
20MG
40MG
80MG
5MG
10MG
20MG
40MG
80MG
SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%
EUROHLTH INTL SARL
9MG/ML
SODIUM CHLORIDE 0.9%
EUROHLTH INTL SARL
9MG/ML
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+
LIEBEL-FLARSHEIM
45MG/50ML (9MG/ML)
112.5MG/125ML (9MG/ML)
+
405MG/50ML (9MG/ML)
1012.5MG/125ML (9MG/ML)
SODIUM LACTATE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
@ BAXTER HLTHCARE
1.87GM/100ML
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
B BRAUN
1.87GM/100ML
AA
SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL
KALEXATE
KVK TECH
15GM/BOT
KAYEXALATE
+
CONCORDIA PHARMS INC 453.6GM/BOT
1 -79

October
SIMVASTATIN
TABLET;ORAL
SIMVASTATIN
BIOCON LIMITED
10
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Jun
Jul
Jul
Jul
Jul
Oct
Jul
Jul
Aug
Jul
Feb
Apr
Oct
Apr
20,
20,
20,
20,
20,
20,
20,
20,
20,
20,
20,
20,
20,
20,
23,
27,
27,
27,
27,
19,
30,
29,
18,
21,
27,
22,
23,
20,
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2015
2015
2015
2015
2015
2015
2015
2015
2015
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Oct
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CPOT
CPOT
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
2015
20MG/2ML (10MG/ML)
A 040541
001 Nov 12, 2004
Jul CRLD
30MG/3ML
N 021148
011 Jan 23, 2015
Jan NEWA
30MG/3ML
30MG/3ML
30MG/3ML
N 021148
N 021148
N 021148
007 Mar 10, 2009

007 Mar 10, 2009
007 Mar 10, 2009
Jul DISC
Mar CMFD
Jan DISC
5MG/VIAL
10MG/VIAL
10MG/VIAL
N 020168
N 020168
N 020168
001 Nov 17, 1993

002 Nov 17, 1993
002 Nov 17, 1993
Jun DISC
Jun DISC
Mar CTEC
10MG/2ML (5MG/ML)
N 020522
001 Dec 29, 1995
Jun DISC
5MG/2ML (2.5MG/ML)
10MG/2ML (5MG/ML)
20MG/2ML (10MG/ML)
N 020522
N 020522
N 020522
003 Jan 03, 2008

005 Jan 03, 2008
004 Jan 03, 2008
Jun CTNA
Jun NEWA
Jun CTNA
20MG/2ML (10MG/ML)
N 020522
006 Jan 03, 2008
Jun NEWA
5MG/VIAL
10MG/VIAL
10MG/VIAL
N 019774
N 019774
N 019774
002 Jan 04, 2002

003 Mar 07, 2012
003 Mar 07, 2012
Mar CTNA
Apr CRLD
Mar NEWA
EQ 200MG BASE
N 205266
001 Jul 24, 2015
Jul NEWA
N 022306
001 Jul 02, 2009
Apr CAHN
80MG
120MG
160MG
240MG
320MG
N 019865
N 019865
N 019865
N 019865
N 019865
001
005
002
003
004
Mar
Mar
Mar
Mar
Mar
STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION
EUROHLTH INTL SARL
100%
A 206369
001 Sep 02, 2015
Aug NEWA
SUCCINYLCHOLINE CHLORIDE
QUELICIN PRESERVATIVE FREE
@ HOSPIRA
100MG/ML
N 008845
004
Jun DISC
AB
SUCRALFATE
TABLET;ORAL
SUCRALFATE
MYLAN PHARMS INC
1GM
A 074415
001 Jun 08, 1998
May CAHN
AP
SUFENTANIL CITRATE
SUFENTANIL CITRATE
EUROHLTH INTL SARL
EQ 0.05MG BASE/ML
A 074413
001 Dec 15, 1995
Jun CAHN
SOMATROPIN RECOMBINANT
NORDITROPIN FLEXPRO
NOVO NORDISK INC
NORDITROPIN NORDIFLEX
@ NOVO NORDISK INC
@
NUTROPIN
@ GENENTECH
@
BX
BX
BX
BX
+
NUTROPIN AQ
@ GENENTECH
NUTROPIN AQ NUSPIN
+
GENENTECH
+
+
NUTROPIN AQ PEN
+
GENENTECH
ZOMACTON
+
FERRING
+
SONIDEGIB PHOSPHATE
CAPSULE;ORAL
ODOMZO
+
SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE
+
ALTATHERA PHARMS LLC
TABLET;ORAL
BETAPACE
AB1
COVIS PHARMA SARL
AB1
AB1
+
AB1
@
AP
1 -80

October
SODIUM TETRADECYL SULFATE

SOTRADECOL
+
MYLAN INSTITUTIONAL
10
Oct
Apr
Oct
Oct
Oct
30,
20,
30,
30,
30,
1992
1994
1992
1992
1992
CAHN
CAHN
CAHN
CAHN
CAHN
AB
>D>
>D> AT
>A>
>D> AT
>A>
AT
>A>
>D>
AB
AB
AB
2015
10%
N 019931
001 Dec 23, 1996
Mar CAHN
10%
10%
A 080021
A 080021
001
001
Oct DISC
Oct DISC
10%
10%
A 080029
A 080029
001
001
Oct CRLD
Oct CRLD
10%
A 040215
001 May 25, 1999
Mar CMFD
SULFAMETHOXAZOLE; TRIMETHOPRIM
SUSPENSION;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ ANI PHARMS INC
200MG/5ML;40MG/5ML
A 070028
001 Jun 02, 1987
Jul CAHN
SULFANILAMIDE
CREAM;VAGINAL
SULFANILAMIDE
@ G AND W LABS INC
15%
A 088718
001 Sep 19, 1985
Apr CAHN
SULFISOXAZOLE
TABLET;ORAL
SULFISOXAZOLE
@ ANI PHARMS INC
@ IVAX SUB TEVA PHARMS
500MG
500MG
A 080142
A 080142
001
001
Oct CAHN
Oct CAHN
SULINDAC
TABLET;ORAL
SULINDAC
@ ANI PHARMS INC
@
150MG
200MG
A 072972
A 072973
001 Feb 28, 1992

001 Feb 28, 1992
Aug CAHN
Aug CAHN
EQ
EQ
EQ
EQ
EQ
EQ
A 076976
A 076976
A 076976
A 076554
A 076554
A 076572
001
002
003
001
002
001
Sep
Sep
Sep
Apr
Apr
Apr
N 206406
N 206406
N 206406
001 Jul 10, 2015

002 Jul 10, 2015
003 Jul 10, 2015
Jul NEWA
Jul NEWA
Jul NEWA
N 203794
001 Oct 15, 2012
May CAHN
N 022304
N 022304
N 022304
001 Nov 20, 2008

002 Nov 20, 2008
003 Nov 20, 2008
May CAHN
May CAHN
May CAHN
N 200533
N 200533
N 200533
N 200533
N 200533
001
002
003
004
005
May
May
May
May
May
SUMATRIPTAN SUCCINATE
TABLET;ORAL
SUMATRIPTAN SUCCINATE
@ SANDOZ
@
@
SUN PHARM INDS LTD
25MG BASE
50MG BASE
100MG BASE
25MG BASE
50MG BASE
100MG BASE
TACROLIMUS
ENVARSUS XR
VELOXIS PHARMS INC
EQ 0.75MG BASE
EQ 1MG BASE
+
EQ 4MG BASE
TAPENTADOL HYDROCHLORIDE
SOLUTION;ORAL
NUCYNTA
+
DEPOMED INC
TABLET;ORAL
NUCYNTA
DEPOMED INC
EQ 20MG BASE/ML
EQ 50MG BASE
EQ 75MG BASE
+
EQ 100MG BASE
NUCYNTA ER
DEPOMED INC
EQ 50MG BASE
EQ 100MG BASE
EQ 150MG BASE
EQ 200MG BASE
+
EQ 250MG BASE
1 -81

October
SULFACETAMIDE SODIUM
LOTION;TOPICAL
KLARON
+
OINTMENT;OPHTHALMIC
CETAMIDE
+
ALCON
@
PERRIGO CO TENNESSEE
+
AKORN
10
Aug
Aug
Aug
Aug
Aug
Feb
Aug
Aug
Aug
Aug
Aug
10,
10,
10,
10,
10,
09,
25,
25,
25,
25,
25,
2009
2009
2009
2009
2009
2009
2011
2011
2011
2011
2011
DISC
DISC
DISC
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
CAHN
TEDIZOLID PHOSPHATE
SIVEXTRO
+
CUBIST PHARMS LLC
TABLET;ORAL
SIVEXTRO
+
CUBIST PHARMS LLC
TELAPREVIR
TABLET;ORAL
INCIVEK
@ VERTEX PHARMS
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
TELMISARTAN
TABLET;ORAL
TELMISARTAN
AMNEAL PHARMS
INVENTIA HLTHCARE
TEMAZEPAM
CAPSULE;ORAL
TEMAZEPAM
VINTAGE PHARMS
TEMOZOLOMIDE
CAPSULE;ORAL
TEMOZOLOMIDE
AMNEAL PHARMS
TERBINAFINE
GEL;TOPICAL
LAMISIL
@ GLAXOSMITHKLINE CONS
2015
200MG/VIAL
N 205436
001 Jun 20, 2014
Sep CAHN
200MG
N 205435
001 Jun 20, 2014
Sep CAHN
375MG
N 201917
001 May 23, 2011
Jan DISC
20MG
40MG
80MG
20MG
40MG
80MG
20MG
40MG
80MG
A 204415
A 204415
A 204415
A 206511
A 206511
A 206511
A 205150
A 205150
A 205150
001
002
003
001
002
003
001
002
003
Sep
Sep
Sep
Sep
Sep
Sep
Oct
Oct
Oct
08,
08,
08,
03,
03,
03,
30,
30,
30,
2015
2015
2015
2015
2015
2015
2015
2015
2015
Aug
Aug
Aug
Aug
Aug
Aug
Oct
Oct
Oct
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
7.5MG
15MG
22.5MG
30MG
A 201781
A 201781
A 201781
A 201781
001
002
003
004
Jun
Jun
Jun
Jun
04,
04,
04,
04,
2015
2015
2015
2015
May
May
May
May
NEWA
NEWA
NEWA
NEWA
5MG
20MG
100MG
140MG
180MG
250MG
A 203691
A 203691
A 203691
A 203691
A 203691
A 203691
001
002
003
004
005
006
May
May
May
May
May
May
08,
08,
08,
08,
08,
08,
2015
2015
2015
2015
2015
2015
Apr
Apr
Apr
Apr
Apr
Apr
NEWA
NEWA
NEWA
NEWA
NEWA
NEWA
A 091612
001 Mar 18, 2015
Mar NEWA
N 021356
001 Oct 26, 2001
Mar CFTG
N 020846
001 Apr 29, 1998
Aug CAHN
N 020749
001 Oct 17, 1997
Aug CAHN
A 078229
001 Jul 02, 2007
Feb DISC
A 077553
001 Mar 09, 2007
Sep CMFD
1%
TERBINAFINE HYDROCHLORIDE
SOLUTION;TOPICAL
LAMISIL
@ GLAXOSMITHKLINE CONS
1%
TABLET;ORAL
TERBINAFINE HYDROCHLORIDE
@ WOCKHARDT
EQ 250MG BASE
AB
TERCONAZOLE
SUPPOSITORY;VAGINAL
TERCONAZOLE
TARO
80MG
1 -82

October
TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE
TEVA PHARMS USA
300MG
VIREAD
+
GILEAD SCIENCES INC
300MG
10
TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

AB1
ABBVIE
AB1
+
TESTIM

AB2
+
AUXILIUM PHARMS
TESTOSTERONE

@
AB1
AB1
BX
ANI PHARMS INC
BX
AB1
PAR PHARM
AB1
AB1
PERRIGO ISRAEL
AB1
VOGELXO

AB2
UPSHER SMITH
GEL, METERED;TRANSDERMAL

ANDROGEL

AB
+
ABBVIE
FORTESTA

AB
+
ENDO PHARMS
TESTOSTERONE

AB
ACTAVIS LABS UT INC
AB
AB
PERRIGO ISRAEL
AB
AB
TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

SUN PHARMA GLOBAL
XENAZINE

AB
AB
AB
AB
AB
+
+
October
1 -83

2015
25MG/2.5GM PACKET
50MG/5GM PACKET
N 021015
001 Feb 28, 2000
N 021015
002 Feb 28, 2000
Jan CTEC

Jan CTEC

50MG/5GM PACKET
N 021454
001 Oct 31, 2002
Jan CTEC

1% (2.5GM/PACKET)
1% (5GM/PACKET)
25MG/2.5GM PACKET
50MG/5GM PACKET
25MG/2.5GM PACKET
50MG/5GM PACKET
25MG/2.5GM PACKET
50MG/5GM PACKET
25MG/2.5GM PACKET
50MG/5GM PACKET
A 076737

A 076737

A 076737

A 076737

N 202763

N 202763

A 076744

A 076744

N 203098

N 203098

Mar
Mar
Jul
Jul
May
May
Aug
Aug
Jan
Jan
50MG/5GM PACKET
N 204399
002 Jun 04, 2014
Jan CTEC

1.62% (20.25MG/1.25GM ACTUATION)
N 022309
001 Apr 29, 2011
Jul CFTG

10MG/0.5GM ACTUATION
N 021463
001 Dec 29, 2010
Jul CFTG

10MG/0.5GM ACTUATION
12.5MG/1.25GM ACTUATION
1.62% (20.25MG/1.25GM ACTUATION)

A 204571
001 Aug 05, 2015
A 076737
003 Mar 09, 2015
A 204268
001 Aug 04, 2015
Jul NEWA

Aug NEWA

Jul NEWA

12.5MG

25MG

A 206129
001 Aug 17, 2015
A 206129
002 Aug 17, 2015
Aug NEWA

Aug NEWA

12.5MG

12.5MG

25MG

25MG

N 021894

N 021894

N 021894

N 021894

Aug
Feb
Aug
Feb
TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

+
HERITAGE PHARMS INC
500MG

TETRACYCLINE HYDROCHLORIDE

@ CHARTWELL CIENCA
250MG

@
500MG

250MG

@
500MG

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

@ MEDICIS
125MG

@
250MG


THEOPHYLLINE

MYLAN PHARMS INC
400MG

+
600MG

THIOTEPA


THIOTEPA

+
EUROHLTH INTL SARL
10
15MG/VIAL

001
002
001
002
001
002
001
002
002
003
001
001
002
002
Jan
Jan
Jan
Jan
Feb
Feb
May
May
Jan
Jan
Aug
Aug
Aug
Aug
27,
27,
27,
27,
14,
14,
23,
23,
31,
31,
15,
15,
15,
15,
2006
2006
2006
2006
2012
2012
2007
2007
2013
2013
2008
2008
2008
2008
CAHN

CAHN

CMFD

CMFD

CAHN

CAHN

CMFD

CMFD

CTEC

CTEC

CFTG

CAHN

CFTG

CAHN

N 050278
001
Apr CRLD

A 062752

A 062752

A 060704

A 060704

Sep
Sep
Apr
Apr
001 Aug 12, 1988

002 Aug 12, 1988
001
002
CAHN

CAHN

DISC

DISC

A 086399
001
A 086399
002
Mar DISC

Mar DISC

A 040595
001 Apr 21, 2006
A 040560
002 Apr 21, 2006
May CAHN

May CAHN

A 075547
001 Apr 02, 2001
May CRLD

2015
60MG
N 022433
002 Sep 03, 2015
Sep NEWA
AP
50MG/VIAL
A 091620
001 May 27, 2015
May NEWA
AP
50MG/VIAL
N 021821
001 Jun 15, 2005
May CFTG
BASE
N 021516
001 Jun 04, 2004
Apr CFTG
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
BASE
A 074466
A 074516
A 074262
A 204936
A 074776
A 077259
A 075163
A 074747
A 078771
001
001
001
001
001
002
001
001
002
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Apr
BASE
N 018086
002
Apr CTEC
A 203808
A 203808
001 Aug 04, 2015

002 Aug 04, 2015
Jul NEWA
Jul NEWA
TIOTROPIUM BROMIDE
SPRAY, METERED;INHALATION
SPIRIVA RESPIMAT
BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH
N 021936
002 Sep 15, 2015
Sep NEWA
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL
LONSURF
TAIHO ONCOLOGY
EQ 6.14MG BASE;15MG
+
EQ 8.19MG BASE;20MG
N 207981
N 207981
001 Sep 22, 2015

002 Sep 22, 2015
Sep NEWA
Sep NEWA
N 205433
001 Dec 02, 2014
Feb CTEC
A 205501
001 Jul 13, 2015
Jun NEWA
N 050541
001
Mar CAHN
A 063119
A 063120
A 063121
A 063122
001
001
001
001
Oct
Oct
Oct
Oct
31,
31,
31,
31,
1994
1994
1994
1994
Mar
Mar
Mar
Mar
CAHN
CAHN
CAHN
CAHN
A 065120
A 065120
A 063116
A 063116
001
001
001
001
Nov
Nov
May
May
29,
29,
18,
18,
2002
2002
1992
1992
Jul
Jul
Jul
Jul
CTEC
CRLD
DISC
CTNA
TIGECYCLINE
TIGECYCLINE
SANDOZ INC
TYGACIL
+
PF PRISM CV
TIMOLOL MALEATE
ISTALOL
AT2
+
BAUSCH AND LOMB
EQ 0.5%
TIMOLOL MALEATE
AT1
AKORN
EQ 0.5%
AT1
EQ 0.5%
AT1
ALCON RES LTD
EQ 0.5%
AT2
APOTEX INC
EQ 0.5%
AT1
BAUSCH AND LOMB
EQ 0.5%
AT1
FDC LTD
EQ 0.5%
AT1
HI TECH PHARMA
EQ 0.5%
AT1
PACIFIC PHARMA
EQ 0.5%
AT1
WOCKHARDT
EQ 0.5%
TIMOPTIC
AT1
+
ATON
EQ 0.5%
AB
AB
AN
AN
AT
AP
AP
TINIDAZOLE
TABLET;ORAL
TINIDAZOLE
EDENBRIDGE PHARMS
250MG
500MG
TOBRAMYCIN
SOLUTION;INHALATION
KITABIS PAK
PULMOFLOW INC
300MG/5ML
TOBRAMYCIN
AMNEAL PHARMS
300MG/5ML
TOBREX
+
ALCON LABS INC
0.3%
TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE
@ IGI LABS INC
EQ 10MG BASE/ML
@
EQ 40MG BASE/ML
@
EQ 40MG BASE/ML
@
EQ 40MG BASE/ML
TOBRAMYCIN SULFATE (PHARMACY BULK)
+
FRESENIUS KABI USA
EQ 40MG BASE/ML
+
EQ 40MG BASE/ML
@ HOSPIRA
EQ 40MG BASE/ML
EQ 40MG BASE/ML
1 -84

October
TICAGRELOR
TABLET;ORAL
BRILINTA
ASTRAZENECA LP
10
Mar
Mar
Apr
Apr
Mar
Apr
Sep
Mar
Sep
25,
25,
28,
17,
25,
30,
10,
25,
28,
1997
1997
1995
2015
1997
2008
2002
1997
2009
CTEC
CTEC
CTEC
NEWA
CTEC
CTEC
CTEC
CTEC
CTEC
TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE
@ G AND W LABS INC
@
@
AB
AB
TOLCAPONE
TABLET;ORAL
TASMAR
+
VALEANT PHARMS LLC
TOLCAPONE
PAR PHARM INC
TOLMETIN SODIUM
TABLET;ORAL
TOLMETIN SODIUM
@ G AND W LABS INC
@
AB
AB
AB
AB
AB
AB
AB
AB
AB
TOPIRAMATE
TABLET;ORAL
TOPIRAMATE
SUN PHARM INDS LTD
@ WOCKHARDT USA
@
@
@
TOPIRAMATE
@ HIKMA PHARMS
@
@
@
AP
AP
TOPOTECAN HYDROCHLORIDE
CAPSULE;ORAL
HYCAMTIN
+
HYCAMTIN
+
TOPOTECAN HYDROCHLORIDE
CHEM WERTH INC
TORSEMIDE
TORSEMIDE
@
@ LUITPOLD
@
2015
100MG
250MG
500MG
N 018894
N 018894
N 018894
001 Nov 02, 1984

002 Nov 02, 1984
003 Nov 02, 1984
Apr CAHN
Apr CAHN
Apr CAHN
100MG
N 020697
001 Jan 29, 1998
Mar CFTG
100MG
A 204584
001 Mar 26, 2015
Mar NEWA
EQ 600MG BASE
EQ 600MG BASE
A 074399
A 074729
001 Mar 28, 1996

001 Feb 27, 1997
May CAHN
Apr CAHN
A 203016
A 203016
001 Aug 11, 2015

002 Aug 11, 2015
Jul NEWA
Jul NEWA
A 077006
A 077006
A 203409
A 203409
001
002
001
002
Feb
Feb
Aug
Aug
23,
23,
31,
31,
2015
2015
2015
2015
Feb
Feb
Aug
Aug
NEWA
NEWA
NEWA
NEWA
25MG
100MG
200MG
25MG
50MG
100MG
200MG
A 076327
A 076327
A 076327
A 090353
A 090353
A 090353
A 090353
001
002
003
001
002
003
004
Mar
Mar
Mar
Sep
Sep
Sep
Sep
27,
27,
27,
01,
01,
01,
01,
2009
2009
2009
2010
2010
2010
2010
Apr
Apr
Apr
Apr
Apr
Apr
Apr
CAHN
CAHN
CAHN
DISC
DISC
DISC
DISC
25MG
50MG
100MG
200MG
A 091185
A 091185
A 091185
A 091185
001
002
003
004
Nov
Nov
Nov
Nov
25,
25,
25,
25,
2013
2013
2013
2013
May
May
May
May
DISC
DISC
DISC
DISC
EQ 0.25MG BASE
EQ 1MG BASE
N 020981
N 020981
001 Oct 11, 2007

002 Oct 11, 2007
Mar CAHN
Mar CAHN
EQ 4MG BASE/VIAL
N 020671
001 May 28, 1996
Mar CAHN
EQ 4MG BASE/VIAL
A 201166
001 Aug 08, 2012
May CAHN
20MG/2ML
50MG/5ML
20MG/2ML
50MG/5ML
A 078007
A 078007
A 090656
A 090656
001
002
001
002
Jan
Jan
Jan
Jan
(10MG/ML)
(10MG/ML)
(10MG/ML)
(10MG/ML)
1 -85

October
TOLTERODINE TARTRATE
TORRENT PHARMS LTD
2MG
4MG
TABLET;ORAL
IVAX SUB TEVA PHARMS 1MG
2MG
MACLEODS PHARMS LTD
1MG
2MG
10
Jun
Jun
Apr
Apr
11,
11,
21,
21,
2008
2008
2010
2010
DISC
DISC
DISC
DISC
>A>
>A>
>A>
>A>
TRABECTEDIN
YONDELIS
+
JANSSEN PRODS
2015
N 207953
001 Oct 23, 2015
Oct NEWA
A 205702
001 Sep 25, 2015
Sep NEWA
A 204421
A 204421
A 204421
001 Oct 20, 2015

002 Oct 20, 2015
003 Oct 20, 2015
Oct NEWA
Oct NEWA
Oct NEWA
N 204114
N 204114
N 204114
001 May 29, 2013

002 May 29, 2013
003 May 29, 2013
Mar CAHN
Mar CAHN
Mar CAHN
100MG/ML
A 091596
001 Mar 02, 2012
Apr CMFD
650MG
A 205133
001 Sep 21, 2015
Sep NEWA
EQ 10MG BASE
N 012342
003 Aug 16, 1985
Jun CAHN
N 204822
001 May 15, 2014
Jul DISC
N 021994
001 Sep 21, 2006
Jun CTEC
A 203431
001 Jul 10, 2015
Jun NEWA
50MG
100MG
150MG
300MG
N 018207
N 018207
N 018207
N 018207
001
002
003 Mar 25, 1985
004 Nov 07, 1988
May
May
May
May
0.02%
0.05%
N 021108
N 019963
001 Aug 31, 2000

001 Dec 29, 1995
Apr CAHN
Apr CAHN
0.1%
N 017340
001
Apr CAHN
0.05%
N 022070
001 Jul 26, 2007
Jul CTEC
0.05%
A 207955
001 Aug 13, 2015
Jul NEWA
TRAMADOL HYDROCHLORIDE
TABLET;ORAL
AB
MACLEODS PHARMS LTD
50MG
>A> AB1
>A> AB1
200MG
>A> AB1
300MG
TRAMETINIB DIMETHYL SULFOXIDE
TABLET;ORAL
MEKINIST
NOVARTIS PHARMS CORP EQ 0.5MG NON-SOLVATED PARENT
EQ 1MG NON-SOLVATED PARENT
+
EQ 2MG NON-SOLVATED PARENT
AB
TRANEXAMIC ACID
TRANEXAMIC ACID
FRESENIUS KABI USA
TABLET;ORAL
TRANEXAMIC ACID
MYLAN
AB
TRANYLCYPROMINE SULFATE
TABLET;ORAL
PARNATE
+
AP
AT
AT
TRAVOPROST
IZBA
@ ALCON LABS INC
0.003%
TRAVATAN Z
+
ALCON PHARMS LTD
0.004%
TRAVOPROST
APOTEX INC
0.004%
TRAZODONE HYDROCHLORIDE
TABLET;ORAL
DESYREL
@ PRAGMA PHARMS LLC
@
@
@
TRETINOIN
CREAM;TOPICAL
RENOVA
+
AB2
+
RETIN-A
AB
+
GEL;TOPICAL
ATRALIN
AB
+
DOW PHARM
TRETINOIN
AB
SPEAR PHARMS INC
1 -86

October
1MG/VIAL
10
CAHN
CAHN
CAHN
CAHN
AT
AT
AT
AT
AT
AT
AT
AT
AT
AT
AT
AT
2015
A 089797
A 089798
001 May 31, 1991

001 May 31, 1991
Apr CMFD
Apr CMFD
A 088042
A 088042
002 Mar 25, 2015

003 Mar 25, 2015
Mar NEWA
Mar NEWA
A 089129
001 Aug 14, 1986
Mar CMFD
N 011600
N 011600
003
001
Mar CMFD
Mar CMFD
A 089795
A 089796
001 Dec 23, 1988

001 Dec 23, 1988
Aug CMFD
Aug CMFD
N 012104
N 012104
001
001
Mar CFTG
Aug CAHN
A 205782
001 Apr 13, 2015
Mar NEWA
50MG
100MG
N 013174
N 013174
001
002
Apr CAHN
Apr CAHN
EQ 50MG BASE
EQ 100MG BASE
N 016792
N 016792
002
003 Sep 15, 1982
Jun CRLD
Jun CRLD
TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL
VAGILIA
@ G AND W LABS INC
3.7%;2.86%;3.42%
A 088821
001 Nov 09, 1987
Jul CAHN
TRIPTORELIN PAMOATE
INJECTABLE;INTRAMUSCULAR
TRELSTAR
+
ACTAVIS LABS UT INC
+
+
N 020715
N 021288
N 022437
001 Jun 15, 2000

001 Jun 29, 2001
001 Mar 10, 2010
Jan CAHN
Jan CAHN
Jan CAHN
N 022103
001 Aug 03, 2007
May DISC
A 091289
A 091289
A 091635
001 Oct 12, 2012

001 Oct 12, 2012
001 Apr 29, 2015
Jun CRLD
May CRLD
Apr NEWA
N 021595
001 May 28, 2004
May DISC
A 091575
A 091575
001 Aug 13, 2010

001 Aug 13, 2010
Jun CRLD
May CRLD
N 021214
N 021214
001 Aug 03, 2000

001 Aug 03, 2000
May CAHN
Jan CAHN
TRIAMTERENE
CAPSULE;ORAL
DYRENIUM
+
AB
AB
AB
AB
AB
AB
AB
TRIMIPRAMINE MALEATE
CAPSULE;ORAL
SURMONTIL
+
ODYSSEY PHARMS
EQ 3.75MG BASE/VIAL
EQ 11.25MG BASE/VIAL
EQ 22.5MG BASE/VIAL
TROSPIUM CHLORIDE
SANCTURA XR
@ ALLERGAN
60MG
TROSPIUM CHLORIDE
ACTAVIS LABS FL INC
60MG
+
60MG
SANDOZ INC
60MG
TABLET;ORAL
SANCTURA
@ ALLERGAN
20MG
TROSPIUM CHLORIDE
GLENMARK GENERICS
20MG
+
20MG
UNOPROSTONE ISOPROPYL
RESCULA
+
R-TECH UENO LTD
0.15%
+
SUCAMPO PHARMA LLC
0.15%
1 -87

October
TRIAMCINOLONE ACETONIDE
CREAM;TOPICAL
G AND W LABS
0.025%
0.1%
TRIDERM
CROWN LABS
0.025%
0.5%
LOTION;TOPICAL
G AND W LABS INC
0.1%
OINTMENT;TOPICAL
KENALOG
DELCOR ASSET CORP
0.025%
0.1%
G AND W LABS
0.025%
0.1%
SPRAY;TOPICAL
KENALOG
+
RANBAXY
0.147MG/GM
+
SUN PHARM INDS LTD
0.147MG/GM
PERRIGO UK FINCO
0.147MG/GM
10
10
October
2015
1 -88

URIDINE TRIACETATE
GRANULE;ORAL
XURIDEN
+
WELLSTAT THERAP
2GM/PACKET
N 208169
001 Sep 04, 2015
Sep NEWA
AB
URSODIOL
CAPSULE;ORAL
ACTIGALL
+
150MG
300MG
N 019594
N 019594
001 Dec 31, 1987

002 Dec 31, 1987
Mar CAHN
Mar CAHN
AB
AB
AB
AB
VALACYCLOVIR HYDROCHLORIDE
TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE
HETERO LABS LTD V
EQ
EQ
SUN PHARM INDS LTD
EQ
EQ
A 203047
A 203047
A 076588
A 076588
001
002
001
002
Mar
Mar
Apr
Apr
A 073484
001 Jun 29, 1993
Jan CAHN
N 022152
N 022152
N 022152
001 Jul 29, 2008

002 Jul 29, 2008
003 Jul 29, 2008
Jan CAHN
Jan CAHN
Jan CAHN
A 204821
A 204821
A 204821
A 204821
001
002
003
004
May
May
May
May
125MG BASE
250MG BASE
A 090439
A 090439
001 Jan 28, 2015

002 Jan 28, 2015
Jan NEWA
Jan NEWA
500MG BASE/VIAL
1GM BASE/VIAL
2GM BASE/VIAL
5GM BASE/VIAL
10GM BASE/VIAL
A 062682
A 062682
A 062682
A 062682
A 062682
001
002
003
004
005
Jun
Jun
Jun
Jun
Jun
500MG BASE/VIAL
1GM BASE/VIAL
A 091377
A 091377
001 Sep 09, 2015

002 Sep 09, 2015
Aug NEWA
Aug NEWA
N 200179
001 Jun 17, 2010
Apr CFTG
A 203689
001 Apr 22, 2015
Apr NEWA
A 090071
A 090071
A 090071
001 Apr 15, 2011

002 Apr 15, 2011
003 Apr 15, 2011
Feb CAHN
Feb CAHN
Feb CAHN
A 202036
A 202036
A 202036
001 May 28, 2015

002 May 28, 2015
003 May 28, 2015
May NEWA
May NEWA
May NEWA
AB
AB
AB
AB
AB
AB
AB
AP
AP
AB
AB
AB
AB
AB
AB
AB
AB
500MG BASE
1GM BASE
500MG BASE
1GM BASE
VALPROIC ACID
CAPSULE;ORAL
VALPROIC ACID
BANNER LIFE SCIENCES 250MG
STAVZOR
@ BANNER LIFE SCIENCES 125MG
@
250MG
@
500MG
VALSARTAN
TABLET;ORAL
VALSARTAN
PRINSTON INC
40MG
80MG
160MG
320MG
VANCOMYCIN HYDROCHLORIDE
CAPSULE;ORAL
LUPIN LTD
EQ
EQ
VANCOLED
EQ
@
EQ
@
EQ
@
EQ
@
EQ
XELLIA PHARMS APS
EQ
EQ
VARDENAFIL HYDROCHLORIDE
STAXYN
+
BAYER HLTHCARE
10MG
VARDENAFIL HYDROCHLORIDE
WATSON LABS INC
10MG
VENLAFAXINE HYDROCHLORIDE
EQ 37.5MG BASE
EQ 75MG BASE
EQ 150MG BASE
TABLET;ORAL
YAOPHARMA CO LTD
EQ 25MG BASE
EQ 37.5MG BASE
EQ 50MG BASE
Apr
Apr
Jan
Jan
Jun
Jun
Jun
Jun
Jul
Mar
May
May
May
08,
08,
31,
31,
09,
09,
09,
09,
22,
30,
11,
11,
11,
2015
2015
2007
2007
2015
2015
2015
2015
1986
1988
1988
1988
1988
NEWA
NEWA
CAHN
CAHN
NEWA
NEWA
NEWA
NEWA
CAHN
CAHN
CAHN
CAHN
CAHN
2015
A 202036
A 202036
004 May 28, 2015

005 May 28, 2015
May NEWA
May NEWA
N 019614
N 019614
N 019614
N 019614
001
003
002
004
Apr
Apr
Apr
Apr
N 020943
N 020943
N 020943
001 Nov 25, 1998

002 Nov 25, 1998
003 Nov 25, 1998
Apr CAHN
Apr CAHN
Apr CAHN
N 018925
001 Mar 30, 1984
Aug CAHN
N 018485
001
Apr CAHN
N 018593
N 018593
N 018593
003 Nov 23, 1987

001 Mar 08, 1982
002 Mar 08, 1982
Apr CAHN
Apr CAHN
Apr CAHN
A 071881
002 Oct 14, 2015
Oct NEWA
15MG/VIAL
N 021119
001 Apr 12, 2000
Mar CAHN
10MG
20MG
40MG
N 022567
N 022567
N 022567
001 Jan 21, 2011

002 Jan 21, 2011
003 Jan 21, 2011
Mar CAHN
Mar CAHN
Mar CAHN
EQ 10MG BASE/ML
A 075992
001 Jun 10, 2003
Sep CAHN
50MG
200MG
A 203503
A 203503
001 Sep 02, 2015

002 Sep 02, 2015
Aug NEWA
Aug NEWA
AB
AB
ZAFIRLUKAST
TABLET;ORAL
ACCOLATE
PAR PHARM INC
+
10MG
20MG
N 020547
N 020547
003 Sep 17, 1999

001 Sep 26, 1996
Feb CAHN
Feb CAHN
AP
AP
AP
AP
ZOLEDRONIC ACID
ZOLEDRONIC ACID
FRESENIUS KABI USA
HOSPIRA INC
MYLAN LABS LTD
USV NORTH AMERICA
EQ
EQ
EQ
EQ
A 091516
A 090621
A 202650
A 202923
001
001
001
001
Apr
Mar
Jul
Mar
AB
AB
AB
AB
AB
AB
AB
AB
>A> AB
VERAPAMIL HYDROCHLORIDE
VERELAN
RECRO GAINESVILLE
120MG
180MG
240MG
+
360MG
VERELAN PM
RECRO GAINESVILLE
100MG
200MG
+
300MG
CALAN
@ EXELA PHARMA SCS LLC 2.5MG/ML
ISOPTIN
@ MT ADAMS
2.5MG/ML
TABLET;ORAL
ISOPTIN
@ MT ADAMS
40MG
@
80MG
@
120MG
VERAPAMIL HYDROCHLORIDE
HERITAGE PHARMS INC
40MG
VERTEPORFIN
VISUDYNE
+
VALEANT LUXEMBOURG
VILAZODONE HYDROCHLORIDE
TABLET;ORAL
VIIBRYD
+
FOREST LABS LLC
AP
AB
AB
VINORELBINE TARTRATE
VINORELBINE TARTRATE
EUROHLTH INTL SARL
VORICONAZOLE
TABLET;ORAL
VORICONAZOLE
GLENMARK PHARMS LTD
4MG
4MG
4MG
4MG
BASE/5ML
BASE/5ML
BASE/5ML
BASE/5ML
1 -89
October
TABLET;ORAL
EQ 75MG BASE
EQ 100MG BASE
10
May
Jan
May
May
Apr
Mar
Mar
Sep
29,
09,
29,
10,
23,
19,
04,
04,
1990
1992
1990
1996
2015
2015
2013
2014
CAHN
CAHN
CAHN
CAHN
NEWA
NEWA
CAHN
CPOT
AB
AB
AB
AB
AB
AB
>A> AB
>A> AB
AB
AB
AB
AB
AB
AB
AB
AB
AB
2015
A 204232
A 204232
A 203772
A 203772
001
002
001
002
Sep
Sep
Sep
Sep
30,
30,
30,
30,
2015
2015
2015
2015
Sep
Sep
Sep
Sep
NEWA
NEWA
NEWA
NEWA
A 202956
A 202956
A 204336
A 204336
001
002
001
002
Sep
Sep
Oct
Oct
17,
17,
22,
22,
2015
2015
2015
2015
Sep
Sep
Oct
Oct
NEWA
NEWA
NEWA
NEWA
5MG/SPRAY
N 022196
001 Dec 19, 2008
Sep CAHN
5MG
10MG
5MG
10MG
A 078129
A 078129
A 078055
A 078055
001
002
001
002
Mar
Mar
Apr
Apr
1.75MG
3.5MG
N 022328
N 022328
001 Nov 23, 2011

002 Nov 23, 2011
May CFTG
May CFTG
1.75MG
3.5MG
A 204299
A 204299
001 Jun 03, 2015

002 Jun 03, 2015
May NEWA
May NEWA
25MG
50MG
100MG
A 077813
A 077813
A 077813
001 Aug 16, 2006

002 Aug 16, 2006
003 Aug 16, 2006
Jan CAHN
Jan CAHN
Jan CAHN
2.5MG
5MG
MACLEODS PHARMS LTD
2.5MG
5MG
ZOLMITRIPTAN
JUBILANT GENERICS
2.5MG
5MG
MACLEODS PHARMS LTD
2.5MG
5MG
ZOLPIDEM TARTRATE
SPRAY, METERED;ORAL
ZOLPIMIST
+
AMHERST PHARMS LLC
TABLET;ORAL
ZOLPIDEM TARTRATE
@ HIKMA
@
SUN PHARM INDS LTD
TABLET;SUBLINGUAL
INTERMEZZO
PURDUE PHARMA
+
ZOLPIDEM TARTRATE
NOVEL LABS INC
ZONISAMIDE
CAPSULE;ORAL
ZONISAMIDE
1 -90
October
ZOLMITRIPTAN
TABLET;ORAL
ZOLMITRIPTAN
ALEMBIC PHARMS LTD
10
Apr
Apr
Apr
Apr
30,
30,
23,
23,
2008
2008
2007
2007
DISC
DISC
CAHN
CAHN
OTC DRUG PRODUCT LIST
35TH
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT
10
EDITION

-
2 -1

October
2015
N 017756
N 017756
002
001
Aug CAHN

Aug CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

120MG
@
650MG

ACETAMINOPHEN

SUN PHARM INDS LTD
650MG
@
650MG
TYLENOL

+
650MG
+
650MG
A 078569
A 090205
001 Dec 14, 2011

001 Nov 18, 2009
Apr CAHN

Apr CAHN

N 019872
N 019872
001 Jun 08, 1994

002 Jan 11, 2001
Aug CAHN

Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+
BAYER HEALTHCARE LLC
3%;7.5%;3%
N 020045
001 Dec 07, 1992
Mar CAHN

BUDESONIDE


RHINOCORT ALLERGY

+
ASTRAZENECA PHARMS
0.032MG/SPRAY
N 020746
003 Mar 23, 2015
Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+
1%
N 021307
001 Dec 07, 2001
Mar CAHN

N 020958
001 Oct 16, 2000
Aug CAHN

N 022429
N 022429
001 Jul 23, 2009

004 Jul 23, 2009
Jan CAHN

Jan CAHN

N 022429
N 022429
003 Jul 23, 2009

002 Jul 23, 2009
Jan CAHN

Jan CAHN

N 022155
002 Nov 16, 2007
Aug CAHN

N 022155
001 Nov 16, 2007
Aug CAHN

A 090760
A 090760
A 077498
A 077498
001
003
001
002
Jul
Jul
Apr
Apr
A 077498
A 077498
003 Dec 27, 2007

004 Dec 27, 2007
Apr CAHN

Apr CAHN

A 090760
A 090760
002 Aug 05, 2015

004 Aug 05, 2015
Jul NEWA

Jul NEWA

N 019835
N 019835
003 Nov 16, 2007

004 Nov 16, 2007
Aug CAHN

Aug CAHN

N 019835
N 019835
005 Nov 16, 2007

006 Nov 16, 2007
Aug CAHN

Aug CAHN

A 091116
A 091116
A 078692
001 Feb 19, 2015

002 Feb 19, 2015
001 Feb 14, 2008
Feb NEWA

Feb NEWA

Feb CTNA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE


PEPCID COMPLETE

+
800MG;10MG;165MG
CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

5MG
+
10MG
CETIRIZINE HYDROCHLORIDE HIVES RELIEF

5MG
+
10MG
SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+
5MG/5ML
CHILDREN'S ZYRTEC HIVES RELIEF

+
5MG/5ML
TABLET;ORAL


5MG
10MG
SUN PHARM INDS LTD
5MG
10MG
CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD
5MG
10MG
CETIRIZINE HYDROCHLORIDE HIVES RELIEF

5MG
10MG
ZYRTEC ALLERGY

5MG
+
10MG
ZYRTEC HIVES RELIEF

5MG
+
10MG

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS
5MG
10MG
SANDOZ
5MG
Aug
Aug
Dec
Dec
05,
05,
27,
27,
2015
2015
2007
2007
NEWA

NEWA

CAHN

CAHN

2015
A 078692
002 Feb 14, 2008
Feb CTNA
A 091116
A 091116
003 Feb 19, 2015

004 Feb 19, 2015
Feb NEWA
Feb NEWA
N 021621
N 021621
003 Nov 16, 2007

004 Nov 16, 2007
Aug CAHN
Aug CAHN
N 021621
N 021621
005 Nov 16, 2007

006 Nov 16, 2007
Aug CAHN
Aug CAHN
A 205490
001 Sep 02, 2015
Aug NEWA
N 022578
001 Sep 03, 2010
Aug CAHN
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

ZYRTEC-D 12 HOUR
+
J AND J CONSUMER INC 5MG;120MG
N 021150
002 Nov 09, 2007
Aug CAHN
CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON
@ BAYER HEALTHCARE LLC 8MG
+
12MG
N 007638
N 007638
001
002
Mar CAHN
Mar CAHN
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

CHLOR-TRIMETON
+
BAYER HEALTHCARE LLC 8MG;120MG
N 018397
001
Mar CAHN
CLEMASTINE FUMARATE
TABLET;ORAL
CLEMASTINE FUMARATE
@ ANI PHARMS INC
A 073282
002 Dec 03, 1992
Jul CAHN
N 018052
002 Nov 30, 1990
Mar CAHN
N 020574
001 Nov 24, 1998
Mar CAHN
N 020289
002 Apr 26, 1993
Mar CAHN
N 017717
002 Nov 30, 1990
Mar CAHN
A 091070
A 091070
001 Aug 31, 2015

002 Aug 31, 2015
Aug NEWA
Aug NEWA
A 090397
001 Nov 22, 2010
Jan CAHN
10MG
20MG
A 090283
A 090283
001 Nov 17, 2009

002 Nov 17, 2009
Apr CAHN
Apr CAHN
10MG
N 020325
001 Apr 28, 1995
Jul CAHN
1.34MG
CLOTRIMAZOLE
CREAM;VAGINAL
GYNE-LOTRIMIN
+
BAYER HEALTHCARE LLC 1%
GYNE-LOTRIMIN 3
+
BAYER HEALTHCARE LLC 2%
CREAM, TABLET;TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK
+
BAYER HEALTHCARE LLC 1%,100MG
TABLET;VAGINAL
GYNE-LOTRIMIN
+
BAYER HEALTHCARE LLC 100MG
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
ACTAVIS LABS FL INC
30MG;600MG
60MG;1.2GM
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
CAPSULE;ORAL
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE
BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT
FAMOTIDINE
TABLET;ORAL
FAMOTIDINE
SUN PHARM INDS LTD
PEPCID AC
2 -2

October
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
+
10MG
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
JUBILANT GENERICS
5MG
10MG
CHILDREN'S ZYRTEC ALLERGY
5MG
@
10MG
CHILDREN'S ZYRTEC HIVES RELIEF
5MG
@
10MG
PAR PHARM INC
10MG
ZYRTEC ALLERGY
+
J AND J CONSUMER INC 10MG
10
2015
20MG
N 020325
002 Sep 23, 2003
Jul CAHN
10MG
N 020902
001 Aug 05, 1999
Aug CAHN
10MG
20MG
N 020801
N 020801
001 Sep 24, 1998

002 Dec 17, 2007
Aug CAHN
Aug CAHN
A 204507
A 204507
002 Sep 16, 2015

003 Sep 16, 2015
Aug NEWA
Aug NEWA
A 204507
A 204507
004 Sep 16, 2015

005 Sep 16, 2015
Aug NEWA
Aug NEWA
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARMA GLOBAL
60MG;120MG
A 090818
001 Jan 29, 2015
Jan NEWA
GUAIFENESIN
GUAIFENESIN
ACTAVIS LABS FL INC
1.2GM
A 091009
002 Sep 03, 2015
Aug NEWA
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
ACTAVIS LABS FL INC
600MG;60MG
1.2GM;120MG
A 091071
A 091071
001 May 27, 2015

002 May 27, 2015
May NEWA
May NEWA
IBUPROFEN
CAPSULE;ORAL
IBUPROFEN
EQ 200MG FREE ACID AND POTASSIUM

SALT
A 078682
001 Mar 24, 2009
Jan CAHN
200MG
N 021472
001 Oct 18, 2002
Jan CAHN
100MG/5ML
N 020516
001 Jun 16, 1995
Aug CAHN
40MG/ML
N 020603
001 Jun 10, 1996
Aug CAHN
200MG
200MG
200MG
200MG
A 071144
A 072901
A 072903
A 071144
001
001
001
001
Oct
Aug
Aug
Oct
100MG
N 020602
001 Jun 10, 1996
Aug CAHN
200MG
N 019012
003 Dec 17, 1990
Aug CAHN
200MG
N 019012
004 Feb 25, 2000
Aug CAHN
200MG
200MG
N 019012
N 019012
001 May 18, 1984

002 Jul 29, 1987
Aug CAHN
Aug CAHN
50MG
N 020601
001 Nov 15, 1996
Aug CAHN
100MG
N 020601
003 Nov 15, 1996
Aug CAHN
FEXOFENADINE HYDROCHLORIDE
TABLET;ORAL
FEXOFENADINE HYDROCHLORIDE ALLERGY
SCIEGEN PHARMS INC
60MG
180MG
FEXOFENADINE HYDROCHLORIDE HIVES
SCIEGEN PHARMS INC
60MG
180MG
>A>
>D>
MIDOL LIQUID GELS

+
SUSPENSION;ORAL
CHILDREN'S MOTRIN
+
SUSPENSION/DROPS;ORAL
CHILDREN'S MOTRIN
+
TABLET;ORAL
IBUPROFEN
@ ANI PHARMS INC
@
@
JUNIOR STRENGTH MOTRIN
MOTRIN IB
+
MOTRIN MIGRAINE PAIN
+
NUPRIN
@
CHILDREN'S MOTRIN
JUNIOR STRENGTH MOTRIN
+
2 -3
October
TABLET;ORAL
PEPCID AC
+
PEPCID AC
PEPCID AC
+
10
Jan
Dec
Dec
Jan
20,
19,
19,
20,
1987
1991
1991
1987
CAHN
CAHN
CAHN
CAHN
2015
A 206581
001 Aug 03, 2015
Jul NEWA
N 021128
001 Aug 01, 2000
Aug CAHN
N 019899
001 Dec 31, 1992
Aug CAHN
KETOTIFEN FUMARATE
ALAWAY
BAUSCH AND LOMB
EQ 0.035% BASE
N 021996
002 Feb 11, 2015
Feb NEWA
LEVONORGESTREL
TABLET;ORAL
LEVONORGESTREL
LOTUS PHARM CO LTD
OC PHARMA
1.5MG
1.5MG
A 202246
A 202380
001 Jun 05, 2015

001 May 29, 2015
May NEWA
May NEWA
1MG
2MG
N 021855
N 021855
001 Aug 04, 2005

002 Aug 04, 2005
Jan CAHN
Jan CAHN
1MG/5ML
N 019487
001 Mar 01, 1988
Aug CAHN
1MG/7.5ML
N 019487
002 Jul 08, 2004
Aug CAHN
2MG
N 019860
001 Nov 22, 1989
Aug CAHN
2MG
N 020448
001 Jul 24, 1997
Aug CAHN
N 021140
001 Nov 30, 2000
Aug CAHN
A 077500
001 Sep 06, 2006
Apr CAHN
N 020606
001 Jun 26, 1996
Aug CAHN
10MG
N 021952
001 Jun 16, 2008
Mar CAHN
1MG/ML
N 020641
002 Nov 27, 2002
Mar CAHN
1MG/ML
N 020641
003 Nov 19, 2003
Mar CAHN
1MG/ML
A 201865
001 Jul 31, 2015
Jul NEWA
10MG
A 076134
001 Aug 18, 2003
Apr CAHN
5MG
N 021891
001 Aug 23, 2006
Mar CAHN
EQ 200MG BASE
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL
CHILDREN'S MOTRIN COLD
+
J AND J CONSUMER INC 100MG/5ML;15MG/5ML
TABLET;ORAL
SINE-AID IB
CAPSULE;ORAL
+
SOLUTION;ORAL
IMODIUM A-D
+
SUSPENSION;ORAL
IMODIUM A-D
+
TABLET;ORAL
IMODIUM A-D
+
IMODIUM A-D EZ CHEWS
+
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
IMODIUM MULTI-SYMPTOM RELIEF
+
2MG;125MG
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
SUN PHARM INDS LTD
2MG;125MG
IMODIUM MULTI-SYMPTOM RELIEF
+
LORATADINE
CAPSULE;ORAL
CLARITIN
+
SYRUP;ORAL
CLARITIN
+
CLARITIN HIVES RELIEF
@ BAYER HEALTHCARE LLC
LORATADINE
TARO
TABLET;ORAL
LORATADINE
SUN PHARM INDS LTD
CHILDREN'S CLARITIN
+
2 -4

October
IBUPROFEN SODIUM
TABLET;ORAL
IBUPROFEN SODIUM
PERRIGO R AND D
10
2015
N 021993
001 Dec 12, 2006
Mar CAHN
A 077153
001 Apr 11, 2007
Apr CAHN
N 019670
002 Nov 27, 2002
Mar CAHN
N 020470
002 Nov 27, 2002
Mar CAHN
A 076557
001 Sep 22, 2004
Apr CAHN
EQ 200MG BASE
N 021920
001 Feb 17, 2006
Jan CAHN
EQ 200MG BASE
A 091183
001 May 20, 2011
Apr CAHN
EQ 2MG BASE
EQ 4MG BASE
A 076880
A 077850
001 Feb 18, 2009

001 Feb 18, 2009
Mar DISC
Mar DISC
A 204152
001 Jul 30, 2015
Jul NEWA
N 022281
001 Dec 01, 2009
Mar CAHN
N 022283
001 Jun 17, 2013
Mar CAHN
N 018471
001 May 30, 1986
Mar CAHN
N 022015
001 Oct 06, 2006
Mar CAHN
A 202071
001 Dec 28, 2012
Jan CAHN
A 077442
001 Sep 28, 2005
Apr CAHN
N 020021
002 Dec 15, 1992
Aug CAHN
A 075132
A 078884
001 Jan 14, 2000

001 Jul 31, 2008
Apr CAHN
Jan DISC
LORATADINE; PSEUDOEPHEDRINE SULFATE

CLARITIN-D
+
BAYER HEALTHCARE LLC 5MG;120MG
CLARITIN-D 24 HOUR
+
10MG;240MG
LORATADINE AND PSEUDOEPHEDRINE SULFATE
SUN PHARM INDS LTD
10MG;240MG
NAPROXEN SODIUM
CAPSULE;ORAL
NAPROXEN SODIUM
+
TABLET;ORAL
NAPROXEN SODIUM
SUN PHARM INDS LTD
NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
@
OMEPRAZOLE MAGNESIUM
OMEPRAZOLE MAGNESIUM
PERRIGO R AND D
EQ 20MG BASE
OMEPRAZOLE; SODIUM BICARBONATE
CAPSULE;ORAL
ZEGERID OTC
+
BAYER HEALTHCARE LLC 20MG;1.1GM
FOR SUSPENSION;ORAL
ZEGERID OTC
+
BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET
OXYMETAZOLINE HYDROCHLORIDE
OCUCLEAR
BAYER HEALTHCARE LLC 0.025%
POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
MIRALAX
+
17GM/SCOOPFUL
POLYETHYLENE GLYCOL 3350
RARITAN PHARMS INC
17GM/SCOOPFUL
PSEUDOEPHEDRINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD
120MG
SUDAFED 24 HOUR
+
J AND J CONSUMER INC 240MG
TABLET;ORAL
EQ 75MG BASE
@ WOCKHARDT
EQ 75MG BASE
2 -5

October

CLARITIN REDITABS
+
BAYER HEALTHCARE LLC 5MG
LORATADINE REDIDOSE
SUN PHARM INDS LTD
10MG
10
3-1
DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2015
NO OCTOBER 2015 APPROVALS
4-1
ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST
The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm
5-1
DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION
NO OCTOBER 2015 ADDITIONS
PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 35TH EDITION

A - 1

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2015
See List footnote for information regarding List content
APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

ABACAVIR SULFATE - ZIAGEN

N 020977 001
D-147
Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN

N 020978 001
D-147
Mar 23, 2018
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ

N 205551 001
6417191
Mar 28, 2016
DP U-1572
6417191*PED
Sep 28, 2016
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM
N 021652 001
6417191
Mar 28, 2016
6417191*PED
Sep 28, 2016
DP U-257
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR

N 204031 001
8980319
Dec 21, 2030
8992975
May 16, 2032
9050335
May 16, 2032
DP
DP
DP
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR

N 202450 001
9056100
Jul 07, 2020
DP U-1263
ACYCLOVIR; HYDROCORTISONE - XERESE

N 022436 001
7223387
7223387
Jul 24, 2021

Jul 24, 2021
DP U-1006
DP U-1484
ADAPALENE; BENZOYL PEROXIDE - EPIDUO

N 022320 001
8936800
Dec 23, 2022
DP U-1078
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE

N 207917 001
8445543
Jul 12, 2027
8703820
Mar 12, 2023
8729127
Mar 12, 2023
8785420
Dec 23, 2022
8909305
Dec 23, 2022
8936800
Dec 23, 2022
U-1078
U-1078
U-1078
U-1078
U-1078
DP U-1078
NP
Jul 15, 2018
ALBUTEROL SULFATE - PROAIR RESPICLICK

N 205636 001
6446627
Dec
6701917
Jun
6718972
Jun
6748947
Jun
6871646
Jun
7540282
May
8006690
Jun
8651103
Mar
DP
DP
DP
DP
DP
DP
DP
DP
NP
Mar 12, 2018
18,
23,
23,
23,
23,
06,
23,
26,
2017
2021
2021
2021
2021
2023
2021
2028
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT

N 021747 001
8733341
Dec 16, 2029
DP
9027967
Mar 31, 2027
DP
ALCAFTADINE - LASTACAFT
N 022134 001 >A> 8664215
Dec 23, 2027
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI

N 022426 001
8637079
Jun 04, 2029
DP
N 022426 002
8637079
Jun 04, 2029
DP
U-1493
A - 2

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 022426 003
8637079
Jun 04, 2029
DP
N 022426 004
8637079
Jun 04, 2029
DP
N 022426 005
8637079
Jun 04, 2029
DP
N 022426 006
8637079
Jun 04, 2029
DP
ALVIMOPAN - ENTEREG
N 021775 001
8946262
Feb 12, 2030
U-1655
AMBRISENTAN - LETAIRIS
N 022081 001 >A> 8377933
Dec 11, 2027
U-1754
>A> I-716
Oct 02, 2018
AMBRISENTAN - LETAIRIS
N 022081 002 >A> 8377933
Dec 11, 2027
U-1754
>A> I-716
Oct 02, 2018
AMOXICILLIN - MOXATAG
N 050813 001
8778924
Dec 08, 2026
AMPHETAMINE - DYANAVEL XR
N 208147 001 >A> 8062667
>A> 8597684
>A> 8747902
>A> 8883217
Mar
Mar
Mar
Mar
29,
15,
15,
15,
2029
2027
2027
2027
>A> NP
Oct 19, 2018
APIXABAN - ELIQUIS
N 202155 001
6967208
6967208
6967208
6967208
6967208
6967208
6967208
6967208
6967208
Feb
Feb
Feb
Feb
Feb
Feb
Feb
Feb
Feb
03,
03,
03,
03,
03,
03,
03,
03,
03,
2023
2023
2023
2023
2023
2023
2023
2023
2023
DS
DS
DS
DS
DS
DS
DS
DS
DS
DP
DP
DP
DP
DP
DP
DP
DP
DP
U-1167
U-1200
U-1301
U-1302
U-1323
U-1501
U-1502
U-1729
U-1730
APIXABAN - ELIQUIS
N 202155 002
6413980
6413980
6413980
6967208
6967208
6967208
6967208
Dec
Dec
Dec
Feb
Feb
Feb
Feb
22,
22,
22,
03,
03,
03,
03,
2019
2019
2019
2023
2023
2023
2023
DS
DS
DS
DS
DS
DS
DS
DP
DP
DP
DP
DP
DP
DP
U-1200
U-1301
U-1302
U-1200
U-1301
U-1302
U-1323
APREMILAST - OTEZLA
N 205437 001
9018243
9018243
Mar 19, 2023

Mar 19, 2023
U-1505
U-1595
APREMILAST - OTEZLA
N 205437 002
9018243
9018243
Mar 19, 2023

Mar 19, 2023
U-1505
U-1595
APREMILAST - OTEZLA
N 205437 003
9018243
9018243
Mar 19, 2023

Mar 19, 2023
U-1505
U-1595
DS DP U-897
DP
DP
DP
DP
A - 3

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

APREPITANT - EMEND

N 021549 001
6096742
6096742
6096742
8258132
8258132
Jul
Jul
Jul
Sep
Sep
01,
01,
01,
26,
26,
2018
2018
2018
2027
2027
DS DP U-745
DS DP U-1743

DS DP U-1744

DP U-901

DP U-1743

NPP
Aug 28, 2018
APREPITANT - EMEND

N 021549 002
6096742
6096742
6096742
8258132
8258132
Jul
Jul
Jul
Sep
Sep
01,
01,
01,
26,
26,
2018
2018
2018
2027
2027
DS DP U-745
DS DP U-1743

DS DP U-1744

DP U-901

DP U-1743

NPP
Aug 28, 2018
APREPITANT - EMEND

N 021549 003
6096742
6096742
6096742
8258132
8258132
Jul
Jul
Jul
Sep
Sep
01,
01,
01,
26,
26,
2018
2018
2018
2027
2027
DS DP U-745
DS DP U-1743

DS DP U-1744

DP U-901

DP U-1743

NPP
Aug 28, 2018
ARIPIPRAZOLE - ABILIFY

N 021436 001
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021436 002
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021436 003
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021436 004
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021436 005
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021436 006
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021713 001
5006528
5006528
5006528*PED
6977257
6977257*PED
Oct
Oct
Apr
Apr
Oct
ODE
Dec 12, 2021


N 021729 002
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021


N 021729 003
9089567
9125939
Jan 28, 2022

Jul 28, 2026
U-543
U-1749

ODE
Dec 12, 2021

20,
20,
20,
24,
24,
2014
2014
2015
2022
2022

DS DP U-543
DS DP U-761

DP

A - 4

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY
EXPIRATION
DATE
N 021729 004
ODE
Dec 12, 2021
N 021729 005
ODE
Dec 12, 2021
ODE
Dec 12, 2021
N 021866 001
5006528
5006528
5006528*PED
Oct 20, 2014

Oct 20, 2014
Apr 20, 2015
ARIPIPRAZOLE - ABILIFY MAINTENA KIT

N 202971 001
5006528
Oct 20, 2014
5006528
Oct 20, 2014
5006528*PED
Apr 20, 2015
8030313
Oct 19, 2024
8030313
Oct 19, 2024
8338427
Mar 15, 2025
8338427
Mar 15, 2025
8338428
Aug 06, 2023
8338428
Aug 06, 2023
8399469
Jun 29, 2025
8759351
Aug 06, 2023
8759351
Aug 06, 2023
8993761
Sep 25, 2022
9089567
Jan 28, 2022
N 202971 002
5006528
Oct 20, 2014
5006528
Oct 20, 2014
5006528*PED
Apr 20, 2015
8030313
Oct 19, 2024
8030313
Oct 19, 2024
8338427
Mar 15, 2025
8338427
Mar 15, 2025
8338428
Aug 06, 2023
8338428
Aug 06, 2023
8399469
Jun 29, 2025
8759351
Aug 06, 2023
8759351
Aug 06, 2023
8993761
Sep 25, 2022
9089567
Jan 28, 2022
N 202971 003
5006528
Oct 20, 2014
5006528
Oct 20, 2014
5006528*PED
Apr 20, 2015
8030313
Oct 19, 2024
8030313
Oct 19, 2024
8338427
Mar 15, 2025
8338427
Mar 15, 2025
8338428
Aug 06, 2023
8338428
Aug 06, 2023
8399469
Jun 29, 2025
8759351
Aug 06, 2023
8759351
Aug 06, 2023
8993761
Sep 25, 2022
9089567
Jan 28, 2022

N 202971 004
5006528
Oct 20, 2014
5006528
Oct 20, 2014
5006528*PED
Apr 20, 2015
8030313
Oct 19, 2024
8030313
Oct 19, 2024
DS DP U-543
DS DP U-763
DS DP U-543
DS DP U-1632
DP
DP
DP
DP
U-543
U-1632
U-543
U-1633
U-543
U-1633
DS
DP U-1530
DP U-1633
DS
U-543
DS DP U-543
DS DP U-1632
DP
DP
DP
DP
U-543
U-1632
U-543
U-1633
U-543
U-1633
DS
DP U-1530
DP U-1633
DS
U-543
DS DP U-543
DS DP U-1632
DP
DP
DP
DP
U-543
U-1632
U-543
U-1633
U-543
U-1633
DS
DP U-1530
DP U-1633
DS
U-543
DS DP U-543

DS DP U-1632

U-543

U-1632

A - 5

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 202971 004
8338427
Mar 15, 2025
8338427
Mar 15, 2025
8338428
Aug 06, 2023
8338428
Aug 06, 2023
8399469
Jun 29, 2025
8759351
Aug 06, 2023
8759351
Aug 06, 2023
8993761
Sep 25, 2022
9089567
Jan 28, 2022
PATENT
CODES
DP
DP
DP
DP
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-543

U-1633

U-543

U-1633

DS

DP U-1530

DP U-1633

DS

U-543

ARIPIPRAZOLE LAUROXIL - ARISTADA

N 207533 001 >A> 8431576
>A> 8796276
>A> 9034867
Oct 26, 2030

Jun 24, 2030
Nov 07, 2032
DS

N 207533 002 >A> 8431576
>A> 8796276
>A> 9034867
Oct 26, 2030

Jun 24, 2030
Nov 07, 2032
DS

N 207533 003 >A> 8431576
>A> 8796276
>A> 9034867
Oct 26, 2030

Jun 24, 2030
Nov 07, 2032
DS
ASENAPINE MALEATE - SAPHRIS

N 022117 001
5763476
5763476*PED
7741358
7741358*PED
8022228
8022228*PED
Jun
Dec
Apr
Oct
Apr
Oct
09,
09,
06,
06,
06,
06,
2020
2020
2026
2026
2026
2026

ASENAPINE MALEATE - SAPHRIS

N 022117 002
5763476
5763476*PED
7741358
7741358*PED
8022228
8022228*PED
Jun
Dec
Apr
Oct
Apr
Oct
09,
09,
06,
06,
06,
06,
2020
2020
2026
2026
2026
2026

ASPIRIN - ASPIRIN

N 203697 001
9101637
9101637
9101637
Mar 23, 2022

Mar 23, 2022
Mar 23, 2022
ATAZANAVIR SULFATE - REYATAZ

N 021567 001
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017

2018
2019

DS DP U-167


N 021567 002
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017

2018
2019

DS DP U-167


N 021567 003
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017

2018
2019

DS DP U-167

>A> NCE
Oct 05, 2020

>A> NCE
Oct 05, 2020

>A> NCE
Oct 05, 2020

U-543

DP U-543

U-543

DP U-543

U-543

DP U-543

DP U-326
DS DP U-1064
M-158
NPP
PED
PED
Mar
Mar
Sep
Sep
17,
17,
17,
17,
2018

2018

2018
2018
M-158
NPP
PED
PED
Mar
Mar
Sep
Sep
17,
17,
17,
17,
2018

2018

2018
2018
DS DP

DP U-326
DS DP U-1064
DS DP

U-1731

U-1732

U-1733

DS DP

DS DP

DS DP

A - 6

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 021567 003
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017
2018
2019
DS DP U-167

N 021567 004
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017
2018
2019
DS DP U-167

N 206352 001
5849911
5849911*PED
6087383
6087383*PED
Jun
Dec
Dec
Jun
20,
20,
21,
21,
2017
2017
2018
2019
DS DP U-167
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ

N 206353 001
5849911
Jun 20, 2017
5849911*PED
Dec 20, 2017
6087383
Dec 21, 2018
6087383*PED
Jun 21, 2019
8148374
Sep 03, 2029
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ
N 206494 001
7112592
Feb
7612087
Nov
8178554
Jul
8471025
Aug
8835455
Oct
8969566
Jun
24,
12,
24,
12,
08,
15,
2022
2026
2021
2031
2030
2032
AZELAIC ACID - FINACEA

N 207071 001
6730288
7700076
8435498
8722021
8900554
08,
18,
01,
24,
24,
2019
2027
2024
2023
2023
Sep
Sep
Mar
Oct
Oct
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY
EXPIRATION
DATE
DS DP
DS DP
DS DP
NP
NPP
PED
PED
Jun
Sep
Dec
Mar
02,
24,
02,
24,
2017
2018
2017
2019
NP
Jul 29, 2018
NPP
NPP
Feb 20, 2018

Feb 20, 2018
NPP
Feb 20, 2018
DS DP U-167
DS DP
DS DP U-1279
DS DP U-282
DP
DS DP U-282
DS
DP
DS
DP
DP
U-1727
DP
DP
AZELASTINE HYDROCHLORIDE - ASTEPRO

N 022203 001
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA

N 202236 001
8163723
Aug 29, 2023
U-77
8163723
Aug 29, 2023
U-81
8163723
Aug 29, 2023
U-644
8163723
Aug 29, 2023
U-707
8163723
Aug 29, 2023
U-1667
AZILSARTAN KAMEDOXOMIL - EDARBI
N 200796 001
9066936
Mar 26, 2028
DP
AZILSARTAN KAMEDOXOMIL - EDARBI

N 200796 002
9066936
Mar 26, 2028
DP
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR

N 202331 001
9066936
Mar 26, 2028
DP
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR

N 202331 002
9066936
Mar 26, 2028
DP
A - 7

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA

N 050819 001
8895070
Jun 03, 2029
9078870
Jun 03, 2029
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-124

DP

BESIFLOXACIN HYDROCHLORIDE - BESIVANCE

N 022308 001
8937062
Nov 13, 2029
U-80

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR

N 207589 001 >A> 6753013
Jun 10, 2031
>A> 9119781
Jun 10, 2031
DP U-1761
DP U-1761

>A> NP
BEXAROTENE - TARGRETIN

N 021055 001
BIMATOPROST - LUMIGAN

N 022184 001
8933120
8933127
Mar 16, 2025

Mar 16, 2025
BIMATOPROST - LATISSE

N 022369 001
7351404
7388029
8541466
8986715
May
Jan
Jan
Jan
25,
21,
31,
15,
2024
2022
2021
2023
BORTEZOMIB - VELCADE

N 021602 001
5780454
5780454*PED
6713446
6713446*PED
6958319
6958319*PED
May
Nov
Jan
Jul
Jan
Jul
03,
03,
25,
25,
25,
25,
2017
2017
2022
2022
2022
2022
BREXPIPRAZOLE - REXULTI

N 205422 001
7888362
8349840
8618109
Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
DS

N 205422 002
7888362
8349840
8618109
Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
DS

N 205422 003
7888362
8349840
8618109
Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
DS

N 205422 004
7888362
8349840
8618109
Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
DS

N 205422 005
7888362
8349840
8618109
Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
DS
Oct 16, 2018

M-164
Jul 29, 2018

D-141
D-142
I-695
M-139
M-165
ODE
PED
PED
PED
PED
PED
PED
Oct
Oct
Oct
Aug
Sep
Oct
Feb
Apr
Apr
Apr
Mar
Apr
NCE
Jul 10, 2020

NCE
Jul 10, 2020

NCE
Jul 10, 2020

NCE
Jul 10, 2020

NCE
Jul 10, 2020

DP

DP

U-939
U-938
U-1217

U-1217

DS DP
DS DP
DS DP
Y

Y

08,
08,
08,
08,
14,
08,
08,
08,
08,
08,
14,
08,
2017

2017

2017

2017
2018
2021

2018

2018
2018
2018
2019

2022

DP U-1529

U-543

DP U-1529

U-543

DP U-1529

U-543

DP U-1529

U-543

DP U-1529

U-543

A - 8

APPL/PROD
NO
PATENT

EXPIRATION
DATE
PATENT NO


N 205422 006
7888362

8349840

8618109

Feb 23, 2027

Apr 12, 2026
Apr 12, 2026
PATENT

CODES

DS

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
NCE
EXCLUSIVITY
EXPIRATION
DATE
Jul 10, 2020
DP U-1529

U-543

BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA

N 204251 001
9044484
Oct 30, 2030
DP

BROMFENAC SODIUM - PROLENSA

N 203168 001 >A> 9144609
Jan 16, 2024
DP

BROMOCRIPTINE MESYLATE - CYCLOSET

N 020866 001
8877708
Jun 07, 2030
DP U-1706

BUDESONIDE - UCERIS

N 203634 001
9132093
Sep 07, 2031
DP

BUDESONIDE - UCERIS

N 205613 001
5914122
Dec 19, 2015
DP

BUPRENORPHINE HYDROCHLORIDE - BELBUCA

N 207932 001

>A> NP
Oct 23, 2018

N 207932 002

>A> NP
Oct 23, 2018

N 207932 003

>A> NP
Oct 23, 2018

N 207932 004

>A> NP
Oct 23, 2018

N 207932 005

>A> NP
Oct 23, 2018

N 207932 006

>A> NP
Oct 23, 2018

N 207932 007

>A> NP
Oct 23, 2018
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV

N 204242 001
8470361
May 22, 2030
DP U-1425

8940330
Sep 18, 2032
DP

I-713
Aug 10, 2018

N 204242 002
8470361
May 22, 2030
DP U-1425

8940330
Sep 18, 2032
DP

I-713
Aug 10, 2018

N 204242 003
8470361
May 22, 2030
DP U-1425

8940330
Sep 18, 2032
DP

I-713
Aug 10, 2018

N 204242 004
8470361
May 22, 2030
DP U-1425

8940330
Sep 18, 2032
DP

I-713
Aug 10, 2018
I-713
Aug 10, 2018

N 204242 005
8454996
Sep 24, 2019
U-1421

8470361
May 22, 2030
DP U-1425

8658198
Dec 03, 2027
DP U-1494

A - 9

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 204242 005
8940330
Sep 18, 2032
DP

BUPROPION HYDROCHLORIDE; NALTREXONE
N 200063 001
8916195
9107837
>A> 9125868
HYDROCHLORIDE - CONTRAVE

Feb 02, 2030
U-1639

Jun 04, 2027
U-1639

Nov 08, 2027
U-1585

CALCIUM ACETATE - PHOSLO GELCAPS

N 021160 003
6875445
Jul 30, 2021
CALCIUM ACETATE - PHOSLYRA

N 022581 001
9089528
Jul 20, 2027
DP

U-1469

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
- PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
N 207026 001
ODE
Jan 13, 2022

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
- PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
N 207026 002
ODE
Jan 13, 2022

CANGRELOR - KENGREAL

N 204958 001
6114313
6130208
8680052
8759316
Dec
Jun
Mar
May
11,
29,
09,
13,
2017
2018
2033
2029
DP U-1715
DP U-1715

U-1715

U-1715

NCE
Jun 22, 2020

CARBIDOPA; LEVODOPA - RYTARY

N 203312 001
7094427
8377474
8377474
8454998
8454998
8454998
8454998
8454998
8557283
8557283
9089607
9089607
9089608
May
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
29,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
2022
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
DP U-1645
DP U-219

DP U-1645

DP U-219

DP U-1645

DP U-1646

DP U-1647

DP U-1649

DP U-219

DP U-1645

DP U-1645

DP U-1720

DP

NDF
Jan 07, 2018


N 203312 002
7094427
8377474
8377474
8454998
8454998
8454998
8454998
8454998
8557283
8557283
9089607
9089607
9089608
May
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
29,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
2022
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
DP U-1645
DP U-219

DP U-1645

DP U-219

DP U-1645

DP U-1646

DP U-1647

DP U-1649

DP U-219

DP U-1645

DP U-1645

DP U-1720

DP

NDF
Jan 07, 2018


N 203312 003
7094427
8377474
8377474
8454998
8454998
May
Dec
Dec
Dec
Dec
29,
26,
26,
26,
26,
2022
2028
2028
2028
2028
DP
DP
DP
DP
DP
NDF
Jan 07, 2018

U-1645
U-219

U-1645

U-219

U-1645

A - 10

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 203312 003
8454998
8454998
8454998
8557283
8557283
9089607
9089607
9089608
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
26,
26,
26,
26,
26,
26,
26,
26,
2028
2028
2028
2028
2028
2028
2028
2028
DP U-1646

DP U-1647

DP U-1649

DP U-219

DP U-1645

DP U-1645

DP U-1720

DP


N 203312 004
7094427
8377474
8377474
8454998
8454998
8454998
8454998
8454998
8557283
8557283
9089607
9089607
9089608
May
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
29,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
26,
2022
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
2028
DP U-1645
DP U-219

DP U-1645

DP U-219

DP U-1645

DP U-1646

DP U-1647

DP U-1649

DP U-219

DP U-1645

DP U-1645

DP U-1720

DP

CARBIDOPA; LEVODOPA - DUOPA

N 203952 001
CARFILZOMIB - KYPROLIS

N 202714 001
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

NDF
Jan 07, 2018

NP
ODE
Jan 09, 2018

Jan 09, 2022

I-712
Jul 24, 2018

CARIPRAZINE HYDROCHLORIDE - VRAYLAR

N 204370 001 >A> 7737142
Mar 27, 2027
>A> 7943621
Dec 16, 2028
DS DP U-1750
DS DP

NCE
Sep 17, 2020

N 204370 002 >A> 7737142
Mar 27, 2027
>A> 7943621
Dec 16, 2028
DS DP U-1750
DS DP

NCE
Sep 17, 2020

N 204370 003 >A> 7737142
Mar 27, 2027
>A> 7943621
Dec 16, 2028
DS DP U-1750
DS DP

NCE
Sep 17, 2020

N 204370 004 >A> 7737142
Mar 27, 2027
>A> 7943621
Dec 16, 2028
DS DP U-1750
DS DP

NCE
Sep 17, 2020
CEFTAROLINE FOSAMIL - TEFLARO

N 200327 001
6417175
Apr 11, 2022
DS DP U-1676

CEFTAROLINE FOSAMIL - TEFLARO

N 200327 002
6417175
Apr 11, 2022
DS DP U-1676

PC
Jun 02, 2015

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA

N 206829 001
8968753
Mar 14, 2034
8968753
Mar 14, 2034
CELECOXIB - CELECOXIB

A 076898 002
U-1672

U-1673

A - 11

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


A 076898 003
PC
Jun 02, 2015


A 076898 004
PC
Jun 02, 2015


A 078857 002
PC
Jun 02, 2015


A 078857 003
PC
Jun 02, 2015


A 078857 004
PC
Jun 02, 2015


A 200562 002
PC
Jun 02, 2015


A 200562 003
PC
Jun 02, 2015


A 200562 004
PC
Jun 02, 2015

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

N 206323 001
6248363
Nov 23, 2019
DP U-1716

6383471
Apr 06, 2019
DP U-1716

9066942
Jan 03, 2032
U-1716

>A> 9107921
Jan 03, 2032
DP

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR

N 207768 001
8062667
Mar 29, 2029
DP

8790700
Mar 15, 2027
DP

CHOLIC ACID - CHOLBAM

N 205750 001
ODE
Mar 17, 2022

CHOLIC ACID - CHOLBAM

N 205750 002
ODE
Mar 17, 2022

PC
Jul 01, 2015

CICLESONIDE - ALVESCO

N 021658 002
8371292
Feb 01, 2028
U-1355

CICLESONIDE - ALVESCO

N 021658 003
8371292
Feb 01, 2028
U-1355

CICLESONIDE - OMNARIS

N 022004 001
8371292
Feb 01, 2028
U-1356

CICLESONIDE - ZETONNA

N 202129 001
8371292
Feb 01, 2028
U-1357

CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX

N 021537 001 >A> 9149486
Sep 13, 2022
DP U-1578

CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE

A 090898 001
A - 12

APPL/PROD
NO
PATENT NO
CLOBETASOL PROPIONATE - OLUX E

N 022013 001
8962000
PATENT
EXPIRATION
DATE
PATENT
CODES
Aug 31, 2025
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX

N 205395 001
5843946
Dec 01, 2015
5843946*PED
Jun 01, 2016

7470506
Jun 23, 2019
7470506*PED
Dec 23, 2019

7700645
Dec 26, 2026
7700645*PED
Jun 26, 2027

8148374
Sep 03, 2029
8518987
Feb 16, 2024
8518987*PED
Aug 16, 2024
8597876
Jun 23, 2019
8597876*PED
Dec 23, 2019

RE42889
Oct 19, 2016
RE42889*PED
Apr 19, 2017
RE43596
May 09, 2017
RE43596*PED
Nov 09, 2017

RE43802
Oct 19, 2016
RE43802*PED
Apr 19, 2017

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP U-1410

DP U-1660

U-1660

DS DP

DS DP U-1660

DS DP

U-1660

DP

DS DP

U-1660

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD

N 203100 001
8981103
Oct 26, 2026
DS DP
I-704
Dec 17, 2017

COLCHICINE - MITIGARE

N 204820 001
8927607
Aug 22, 2033
CRIZOTINIB - XALKORI

N 202570 001
7230098
Aug 26, 2025
DS
M-163
Sep 14, 2018

CRIZOTINIB - XALKORI

N 202570 002
7230098
Aug 26, 2025
DS
M-163
Sep 14, 2018

CROFELEMER - FULYZAQ

N 202292 001
8962680
Oct 31, 2031
CYANOCOBALAMIN - NASCOBAL

N 021642 001
7229636
7879349
8003353
8940714
Aug
Aug
Aug
Feb
CYSTEAMINE BITARTRATE - PROCYSBI

N 203389 001 >A> 9173851
Jun 17, 2034
DP
NPP
Aug 14, 2018

CYSTEAMINE BITARTRATE - PROCYSBI

N 203389 002 >A> 9173851
Jun 17, 2034
DP
NPP
Aug 14, 2018

01,
01,
01,
26,
2024
2024
2024
2024
U-1020

U-1319

DP U-817

DP U-1152

U-817

U-1152

DABIGATRAN ETEXILATE MESYLATE - PRADAXA

N 022512 001 >A> 9034822
Jan 20, 2031
U-1759

DABIGATRAN ETEXILATE MESYLATE - PRADAXA

N 022512 002 >A> 9034822
Jan 20, 2031
U-1759

DABRAFENIB MESYLATE - TAFINLAR

N 202806 001
8703781
Oct 15, 2030
DS DP U-1713

DABRAFENIB MESYLATE - TAFINLAR

N 202806 002
8703781
Oct 15, 2030
DS DP U-1713

A - 13

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DACLATASVIR DIHYDROCHLORIDE - DAKLINZA

N 206843 001
8329159
Apr 13, 2028
8629171
Jun 13, 2031
8642025
Aug 11, 2027
8642025
Aug 11, 2027
8900566
Aug 08, 2027
8900566
Aug 08, 2027
DS
DS DP U-1724

DS DP U-1724

DS DP U-1725

U-1724

U-1725

NCE
Jul 24, 2020

DACLATASVIR DIHYDROCHLORIDE - DAKLINZA

N 206843 002
8329159
Apr 13, 2028
8629171
Jun 13, 2031
8642025
Aug 11, 2027
8642025
Aug 11, 2027
8900566
Aug 08, 2027
8900566
Aug 08, 2027
DS
DS DP U-1724

DS DP U-1724

DS DP U-1725

U-1724

U-1725

NCE
Jul 24, 2020

DANTROLENE SODIUM - RYANODEX

N 205579 001
ODE
Jul 22, 2021

DAPAGLIFLOZIN PROPANEDIOL - FARXIGA

N 202293 001
M-157
Mar 11, 2018

DAPAGLIFLOZIN PROPANEDIOL - FARXIGA

N 202293 002
M-157
Mar 11, 2018

DEFERASIROX - EXJADE

N 021882 001
ODE
Jan 23, 2020


N 021882 002
ODE
Jan 23, 2020


N 021882 003
ODE
Jan 23, 2020

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)
N 206619 001
6037157
Jun 26, 2016
U-1635

6703403
Jun 26, 2016
U-1635

7148359
Jul 19, 2019
DP

7364752
Nov 10, 2020
DP

8188104
May 17, 2029
DS DP U-1636

8268349
Aug 25, 2024
DP

8399015
Aug 25, 2024
DP

8420596
Apr 10, 2031
DS DP

8466159
Sep 04, 2032
U-1637

8492386
Sep 04, 2032
U-1637

8501238
Sep 17, 2028
DS DP U-1636

8642538
Sep 10, 2029
DS DP U-1638

8680106
Sep 04, 2032
U-1637

8685984
Sep 04, 2032
U-1637

8686026
Jun 09, 2031
DP

8691938
Apr 13, 2032
DS DP

9006387
Jun 10, 2030
U-1687

9044480
Apr 10, 2031
U-1638

>A> 9139536
Nov 09, 2028
U-1753

DEFERASIROX - JADENU

N 206910 001
6465504
6596750
Apr 05, 2019

Jun 24, 2017
DS DP

DS
U-735


N 206910 002
6465504
6596750
Apr 05, 2019

Jun 24, 2017
DS DP

DS
U-735

A - 14

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
N 206910 003
6465504
6596750
Apr 05, 2019

Jun 24, 2017
DS DP
DS
U-735
DEFERIPRONE - FERRIPROX
N 021825 001
7049328
Jun 28, 2021
U-735
DEFERIPRONE - FERRIPROX
N 208030 001
7049328
8703156
Jun 28, 2021

Oct 29, 2029
U-735
DP U-735
DEOXYCHOLIC ACID - KYBELLA

N 206333 001
7622130
7754230
8101593
8242294
8298556
8367649
8461140
8546367
8653058
8846066
8883770
Dec
Dec
Mar
May
Aug
Mar
Feb
Feb
Mar
Feb
Feb
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

NCE
ODE
Oct 14, 2016

Oct 14, 2016
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE

A 200653 001
PC
May 16, 2015
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE

A 200653 002
PC
May 16, 2015
10,
10,
02,
16,
03,
02,
21,
21,
02,
08,
21,
2027
2027
2030
2028
2025
2030
2028
2028
2030
2025
2028
DESONIDE - VERDESO
N 021978 001
8962000
Aug 31, 2025
DESVENLAFAXINE SUCCINATE - PRISTIQ

N 021992 003
6673838
6673838
8269040
Mar 01, 2022

Mar 01, 2022
Jul 05, 2027
DEXAMETHASONE - OZURDEX
N 022315 001
8043628
8088407
9012437
Oct 20, 2020

Oct 20, 2020
Oct 20, 2020
DEXLANSOPRAZOLE - DEXILANT
N 022287 001
9011926
>A> 9145389
Feb 24, 2026

Jun 15, 2020
DEXLANSOPRAZOLE - DEXILANT
N 022287 002
8784885
8784885
8784885
8784885*PED
9011926
>A> 9145389
Oct
Oct
Oct
Apr
Feb
Jun
15,
15,
15,
15,
24,
15,
2023
2023
2023
2024
2026
2020
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX

N 021038 004
6716867
Mar 31, 2019
6716867*PED
Oct 01, 2019
8242158
Jan 04, 2032
8242158*PED
Jul 04, 2032
8338470
Jan 04, 2032
8338470*PED
Jul 04, 2032
8455527
Jan 04, 2032
U-1690
U-1690
DP
DS
U-1690
DP
DP
DP U-1690
DP
U-1690
DP
DP U-1412
DS
DS
DS
U-860
U-1364
U-1205
U-1205
U-1205
DP
DS DP
DP U-1552
DP U-1553
DP U-1554
DP
DS DP
U-1472
DP
DP
U-421
A - 15

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX

N 021038 004
8455527*PED
Jul 04, 2032
8648106
Jan 04, 2032
8648106*PED
Jul 04, 2032
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE

A 078908 002
PC
Aug 01, 2015
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE

A 078908 003
PC
Dec 19, 2015
DICHLORPHENAMIDE - KEVEYIS
N 011366 002
ODE
Aug 07, 2022
M-166
Jul 30, 2018
DICLOFENAC - ZORVOLEX
N 204592 001
8999387
9017721
>A> 9173854
>A> 9180096
Apr
Apr
Apr
Apr
23,
23,
23,
23,
2030
2030
2030
2030
DP
DP
DP
DICLOFENAC - ZORVOLEX
N 204592 002
8999387
9017721
>A> 9173854
>A> 9180096
Apr
Apr
Apr
Apr
23,
23,
23,
23,
2030
2030
2030
2030
DP
DP
DP
DICLOFENAC POTASSIUM - CAMBIA

N 022165 001
8927604
Jun 16, 2026
DICLOFENAC SODIUM - DYLOJECT

N 022396 001
6407079
8946292
Jun 18, 2019

Mar 22, 2027
DP
DICLOFENAC SODIUM - PENNSAID

N 204623 001
9066913
9101591
9132110
>A> 9168304
>A> 9168305
Oct
Oct
Oct
Oct
Oct
DP U-1488
DP U-1488
U-1488
DP
U-1488
17,
17,
17,
16,
17,
2027
2027
2027
2027
2027
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM

N 021393 001 >A> 9155718
Jan 17, 2022
U-55
U-55
U-436
U-1659
DP
DOLUTEGRAVIR SODIUM - TIVICAY

N 204790 001
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC
N 206439 001
5061703
Apr 11, 2015
U-1641
5061703*PED
Oct 11, 2015
8058291
Dec 05, 2029
U-1641
8168209
Nov 22, 2025
DP
8168209*PED
May 22, 2026
8173708
Nov 22, 2025
U-1641
8173708*PED
May 22, 2026
8283379
Nov 22, 2025
U-1641
8283379*PED
May 22, 2026
8293794
Nov 22, 2025
DP
N 206439 002
5061703
Apr 11, 2015
U-1641
5061703*PED
Oct 11, 2015
8039009
Mar 24, 2029
U-1641
8039009*PED
Sep 24, 2029
A - 16

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 206439 002
8058291
Dec 05, 2029
U-1641
8168209
Nov 22, 2025
DP
8168209*PED
May 22, 2026
8173708
Nov 22, 2025
U-1641
8173708*PED
May 22, 2026
8283379
Nov 22, 2025
U-1641
8283379*PED
May 22, 2026
8293794
Nov 22, 2025
DP
8329752
Nov 22, 2025
DP
8329752*PED
May 22, 2026
8338485
Nov 22, 2025
DP
8338486
Nov 22, 2025
U-1641
8362085
Nov 22, 2025
U-1641
8362085*PED
May 22, 2026
8580858
Nov 22, 2025
U-1641
8598233
Nov 22, 2025
DP
8598233*PED
May 22, 2026
DOXEPIN HYDROCHLORIDE - SILENOR
N 022036 001
9107898
May 01, 2028
DP U-620
DOXEPIN HYDROCHLORIDE - SILENOR

N 022036 002
9107898
May 01, 2028
DP U-620
DOXYCYCLINE HYCLATE - DOXTERIC

N 050795 006
6958161
8715724
Dec 15, 2022

Feb 03, 2028
DP U-918
DP
DRONEDARONE HYDROCHLORIDE - MULTAQ

N 022425 001
9107900
9107900
Apr 16, 2029

Apr 16, 2029
U-1726
U-1728
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE

A 090694 003
PC
Jan 11, 2016
EDOXABAN TOSYLATE - SAVAYSA

N 206316 001
7365205
Jun 12, 2023
DS
NCE
Jan 08, 2020

N 206316 002
7365205
Jun 12, 2023
DS
NCE
Jan 08, 2020

N 206316 003
7365205
Jun 12, 2023
DS
NCE
Jan 08, 2020
D-149
I-711
ODE
PED
PED
PED
Jun
Jun
Aug
Dec
Dec
Feb
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA

N 021937 001
9018192
Jun 13, 2026
U-750
9018192
Jun 13, 2026
U-1170
ELTROMBOPAG OLAMINE - PROMACTA
N 022291 001
6280959
6280959
6280959
6280959
6280959*PED
7160870
7160870
7160870
7160870
7160870*PED
7332481
7332481
7332481
7332481
Oct
Oct
Oct
Oct
Apr
Nov
Nov
Nov
Nov
May
May
May
May
May
30,
30,
30,
30,
30,
20,
20,
20,
20,
20,
24,
24,
24,
24,
2018
2018
2018
2018
2019
2022
2022
2022
2022
2023
2021
2021
2021
2021
DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306
U-1575
U-1714
DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306
U-1575
U-1714
U-930
U-1306
U-1575
U-1714
11,
11,
26,
11,
11,
26,
2018
2018
2021
2018
2018
2022
A - 17

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 022291 001
7332481*PED

7452874

7452874*PED

7473686

7473686

7473686

7473686

7473686*PED

7547719

7547719

7547719

7547719

7547719*PED

7790704

7790704

7790704

7790704

7790704*PED

7795293

7795293

7795293

7795293

7795293*PED

8052993

8052993

8052993

8052993

8052993*PED

8052994

8052994*PED

8062665

8062665*PED

8071129

8071129*PED

8828430

8828430

8828430

8828430*PED

Nov
May
Nov
May
May
May
May
Nov
Jul
Jul
Jul
Jul
Jan
May
May
May
May
Nov
May
May
May
May
Nov
Aug
Aug
Aug
Aug
Feb
Aug
Feb
Aug
Feb
Aug
Feb
Aug
Aug
Aug
Feb
24,
24,
24,
24,
24,
24,
24,
24,
13,
13,
13,
13,
13,
24,
24,
24,
24,
24,
21,
21,
21,
21,
21,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
2021

2021
2021

2021
2021
2021
2021
2021

2025

2025

2025

2025

2026

2021
2021
2021
2021
2021

2023
2023
2023
2023
2023

2027
2027
2027
2027
2028

2027
2028

2027
2028

2027
2028

2027
2027
2027
2028


N 022291 002
6280959

6280959

6280959

6280959

6280959*PED

7160870

7160870

7160870

7160870

7160870*PED

7332481

7332481

7332481

7332481

7332481*PED

7452874

7452874*PED

7473686

7473686

7473686

7473686

7473686*PED

7547719

7547719

7547719

7547719

Oct
Oct
Oct
Oct
Apr
Nov
Nov
Nov
Nov
May
May
May
May
May
Nov
May
Nov
May
May
May
May
Nov
Jul
Jul
Jul
Jul
30,
30,
30,
30,
30,
20,
20,
20,
20,
20,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
13,
13,
13,
13,
2018

2018

2018

2018

2019
2022

2022

2022

2022

2023
2021
2021
2021
2021
2021

2021
2021

2021
2021
2021
2021
2021

2025

2025

2025

2025

PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DS DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DP U-1714

DP U-1714

DP U-1714

DP U-1306

DP U-1619

DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306
U-1575
U-1714
DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DS DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

D-149
I-711
ODE
PED
PED
PED
Jun
Jun
Aug
Dec
Dec
Feb
11,
11,
26,
11,
11,
26,
2018

2018

2021
2018

2018

2022

A - 18

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 022291 002
7547719*PED

7790704

7790704

7790704

7790704

7790704*PED

7795293

7795293

7795293

7795293

7795293*PED

8052993

8052993*PED

8052994

8052994

8052994

8052994

8052994*PED

8062665

8062665*PED

8071129

8071129*PED

8828430

8828430

8828430

8828430*PED

Jan
May
May
May
May
Nov
May
May
May
May
Nov
Aug
Feb
Aug
Aug
Aug
Aug
Feb
Aug
Feb
Aug
Feb
Aug
Aug
Aug
Feb
13,
24,
24,
24,
24,
24,
21,
21,
21,
21,
21,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
2026

2021
2021
2021
2021
2021

2023
2023
2023
2023
2023

2027
2028

2027
2027
2027
2027
2028

2027
2028

2027
2028

2027
2027
2027
2028


N 022291 003
6280959

6280959

6280959

6280959

6280959*PED

7160870

7160870

7160870

7160870

7160870*PED

7332481

7332481

7332481

7332481

7332481*PED

7452874

7452874*PED

7473686

7473686

7473686

7473686

7473686*PED

7547719

7547719

7547719

7547719

7547719*PED

7790704

7790704

7790704

7790704

7790704*PED

7795293

7795293

7795293

7795293

7795293*PED

8052993

Oct
Oct
Oct
Oct
Apr
Nov
Nov
Nov
Nov
May
May
May
May
May
Nov
May
Nov
May
May
May
May
Nov
Jul
Jul
Jul
Jul
Jan
May
May
May
May
Nov
May
May
May
May
Nov
Aug
30,
30,
30,
30,
30,
20,
20,
20,
20,
20,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
13,
13,
13,
13,
13,
24,
24,
24,
24,
24,
21,
21,
21,
21,
21,
01,
2018

2018

2018

2018

2019
2022

2022

2022

2022

2023
2021
2021
2021
2021
2021

2021
2021

2021
2021
2021
2021
2021

2025

2025

2025

2025

2026

2021
2021
2021
2021
2021

2023
2023
2023
2023
2023

2027

PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DP U-1714

DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DP U-1714

DP U-1714

DP U-1306

DP U-1619

DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306
U-1575
U-1714
DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DS DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DP U-1714

D-149
I-711
ODE
PED
PED
PED
Jun
Jun
Aug
Dec
Dec
Feb
11,
11,
26,
11,
11,
26,
2018

2018

2021
2018

2018

2022

A - 19

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 022291 003
8052993*PED

8052994

8052994*PED

8062665

8062665

8062665

8062665

8062665*PED

8071129

8071129*PED

8828430

8828430

8828430

8828430*PED

Feb
Aug
Feb
Aug
Aug
Aug
Aug
Feb
Aug
Feb
Aug
Aug
Aug
Feb
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
2028

2027
2028

2027
2027
2027
2027
2028

2027
2028

2027
2027
2027
2028


N 022291 004
6280959

6280959

6280959

6280959

6280959*PED

7160870

7160870

7160870

7160870

7160870*PED

7332481

7332481

7332481

7332481

7332481*PED

7452874

7452874*PED

7473686

7473686

7473686

7473686

7473686*PED

7547719

7547719

7547719

7547719

7547719*PED

7790704

7790704

7790704

7790704

7790704*PED

7795293

7795293

7795293

7795293

7795293*PED

8052993

8052993*PED

8052994

8052994*PED

8062665

8062665*PED

8071129

8071129

8071129

8071129

8071129*PED

8828430

8828430

Oct
Oct
Oct
Oct
Apr
Nov
Nov
Nov
Nov
May
May
May
May
May
Nov
May
Nov
May
May
May
May
Nov
Jul
Jul
Jul
Jul
Jan
May
May
May
May
Nov
May
May
May
May
Nov
Aug
Feb
Aug
Feb
Aug
Feb
Aug
Aug
Aug
Aug
Feb
Aug
Aug
30,
30,
30,
30,
30,
20,
20,
20,
20,
20,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
13,
13,
13,
13,
13,
24,
24,
24,
24,
24,
21,
21,
21,
21,
21,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
01,
2018

2018

2018

2018

2019
2022

2022

2022

2022

2023
2021
2021
2021
2021
2021

2021
2021

2021
2021
2021
2021
2021

2025

2025

2025

2025

2026

2021
2021
2021
2021
2021

2023
2023
2023
2023
2023

2027
2028

2027
2028

2027
2028

2027
2027
2027
2027
2028

2027
2027

PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP U-1714

DP
DP
DP
DP
U-714

U-930

U-1306

U-1575

DP U-1714

DP U-1306

DP U-1619

DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306
U-1575
U-1714
DS
DS
DS
DS
DP
DP
DP
DP
U-930
U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DS DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

U-930

U-1306

U-1575

U-1714

DP U-1714

DP U-1714

DP U-1714

DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DP U-1306

DP U-1619

D-149
I-711
ODE
PED
PED
PED
Jun
Jun
Aug
Dec
Dec
Feb
11,
11,
26,
11,
11,
26,
2018

2018

2021
2018

2018

2022

A - 20

APPL/PROD
NO
PATENT NO

PATENT

EXPIRATION

DATE

PATENT
CODES

N 022291 004
8828430

8828430*PED

Aug 01, 2027
Feb 01, 2028


N 022291 005
6280959

6280959

6280959

6280959

6280959*PED

7160870

7160870

7160870

7160870

7160870*PED

7332481

7332481

7332481

7332481

7332481*PED

7452874

7452874*PED

7473686

7473686

7473686

7473686

7473686*PED

7547719

7547719

7547719

7547719*PED

7790704

7790704

7790704

7790704*PED

7795293

7795293

7795293

7795293*PED

8052995

8052995

8052995*PED

Oct
Oct
Oct
Oct
Apr
Nov
Nov
Nov
Nov
May
May
May
May
May
Nov
May
Nov
May
May
May
May
Nov
Jul
Jul
Jul
Jan
May
May
May
Nov
May
May
May
Nov
Aug
Aug
Feb
30,
30,
30,
30,
30,
20,
20,
20,
20,
20,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
13,
13,
13,
13,
24,
24,
24,
24,
21,
21,
21,
21,
01,
01,
01,
2018

2018

2018

2018

2019
2022

2022

2022

2022

2023
2021
2021
2021
2021
2021

2021
2021

2021
2021
2021
2021
2021

2025

2025

2025

2026

2021
2021
2021
2021

2023
2023
2023
2023

2027
2027
2028

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714


N 207027 001
6280959

7160870

7332481

7452874

7473686

7547719

7790704

7795293

Oct
Nov
May
May
May
Jul
May
May
30,
20,
24,
24,
24,
13,
24,
24,
2018

2022

2021
2021
2021
2025

2021
2023

ELUXADOLINE - VIBERZI

N 206940 001
7741356

7786158

8344011

8609709

8691860

9115091

Mar
Mar
Mar
Mar
Jul
Jul
25,
14,
14,
14,
07,
07,
N 206940 002
7741356
7786158
8344011
8609709
Mar
Mar
Mar
Mar
25,
14,
14,
14,
PATENT

DELIST

REQUESTED

EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP U-1714

D-149
I-711
ODE
PED
PED
PED
Jun
Jun
Aug
Dec
Dec
Feb
11,
11,
26,
11,
11,
26,
2018

2018

2021
2018

2018

2022

DS DP U-1736

DS DP U-1736

U-1736

DS DP

DS DP U-1736

DS DP U-1736

U-1736

U-1736

D-149
I-711
ODE
PED
PED
Jun
Jun
Nov
Dec
Dec
11,
11,
20,
11,
11,
2018

2018

2015

2018

2018

2028

2025

2025

2025

2028

2028

DS DP

DS

NCE
May 27, 2020

2028
2025
2025
2025
DS DP
DS
NCE
May 27, 2020
U-930

U-1306

U-1575

U-1714

DS DP U-1714

DS
DS
DS
DS
DP
DP
DP
DP
U-930

U-1306

U-1575

U-1714

DS DP U-930

DS DP U-1306

DS DP U-1575

U-930

U-1306

U-1575

U-930

U-1306

U-1575

DP U-1306

DP U-1575

U-1709

DS

DS
U-1709

DS DP U-1738

U-1709
DS
A - 21

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 206940 002
8691860
9115091
Jul 07, 2028

Jul 07, 2028
DS
U-1709

DS DP U-1738

ELVITEGRAVIR - VITEKTA

N 203093 001
8981103
Oct 26, 2026
DS DP

ELVITEGRAVIR - VITEKTA

N 203093 002
8981103
Oct 26, 2026
DS DP

EMPAGLIFLOZIN - JARDIANCE

N 204629 001
EMPAGLIFLOZIN - JARDIANCE

N 204629 002
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI

N 206073 001
6303661
Apr
6890898
Feb
7078381
Feb
7407955
Aug
7459428
Feb
7579449
Nov
7713938
Apr
8119648
Aug
8178541
Aug
8178541
Aug
8551957
Oct
8673927
May
8846695
Jun
8883805
Nov
24,
02,
02,
12,
02,
05,
15,
12,
12,
12,
19,
04,
04,
26,
2017
2019
2019
2023
2019
2025
2027
2023
2023
2023
2029
2027
2030
2025
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI

N 206073 002
6303661
Apr
6890898
Feb
7078381
Feb
7407955
Aug
7459428
Feb
7579449
Nov
7713938
Apr
8119648
Aug
8178541
Aug
8178541
Aug
8551957
Oct
8673927
May
8846695
Jun
8883805
Nov
24,
02,
02,
12,
02,
05,
15,
12,
12,
12,
19,
04,
04,
26,
2017
2019
2019
2023
2019
2025
2027
2023
2023
2023
2029
2024
2030
2025
U-1651
U-1652
U-1651
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

M-160
M-161
Jun 26, 2018

Jun 26, 2018

M-160
M-161
Jun 26, 2018

Jun 26, 2018

NC
NCE
NCE
Jan 30, 2018

May 02, 2016
Aug 01, 2019
NC
NCE
NCE
Jan 30, 2018

May 02, 2016
Aug 01, 2019
DS DP

U-1651

DS

DS DP

DP
DP
DP
DP
U-1651

U-1653

U-1654

U-1651

U-1652

U-1652

DP

U-1651
U-1652
U-1651
DS DP

U-1651

DS

DS DP

DP
DP
DP
DP
U-1651

U-1653

U-1654

U-1651

U-1652

U-1652

DP

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY

N 206111 001
7579449
Nov 05, 2025
7713938
Apr 15, 2027
DS
DS DP
NCE
NP
Aug 01, 2019
Aug 26, 2018


N 206111 002
7579449
Nov 05, 2025
7713938
Apr 15, 2027
DS
DS DP
NCE
NP
Aug 01, 2019
Aug 26, 2018


N 206111 003
7579449
Nov 05, 2025
7713938
Apr 15, 2027
DS
DS DP
NCE
NP
Aug 01, 2019
Aug 26, 2018

A - 22

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 206111 004
7579449
Nov 05, 2025
7713938
Apr 15, 2027
PATENT
CODES
PATENT
DELIST
REQUESTED
DS
DS DP
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

NCE
NP
Aug 01, 2019

Aug 26, 2018
I-671
PED
May 14, 2016

Nov 14, 2016
I-671
PED
May 14, 2016

Nov 14, 2016
I-671
PED
May 14, 2016

Nov 14, 2016
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA

N 202123 001 >A> 7125879
Aug 09, 2022
DS DP U-257
ENZALUTAMIDE - XTANDI
N 203415 001
9126941
May 15, 2026
EPINEPHRINE - AUVI-Q
N 201739 001
8920377
8926594
9056170
>A> 9149579
Nov
Mar
Nov
Jul
23,
31,
23,
19,
2024
2026
2024
2025
DP
DP
DP
EPINEPHRINE - AUVI-Q
N 201739 002
8920377
8926594
9056170
>A> 9149579
Nov
Mar
Nov
Jul
23,
31,
23,
19,
2024
2026
2024
2025
DP
DP
DP
EPINEPHRINE - ADRENALIN
N 204640 001
9119876
Mar 13, 2035
DP
ERIBULIN MESYLATE - HALAVEN

N 201532 001
6214865
Jul 20, 2023
DS
ERLOTINIB HYDROCHLORIDE - TARCEVA

N 021743 001
5747498
5747498*PED
6900221
6900221
6900221
6900221
6900221*PED
7087613
7087613
7087613
7087613*PED
RE41065
RE41065*PED
Nov
May
Nov
Nov
Nov
Nov
May
Nov
Nov
Nov
May
Nov
May
08,
08,
09,
09,
09,
09,
09,
09,
09,
09,
09,
08,
08,
2018
2019
2020
2020
2020
2020
2021
2020
2020
2020
2021
2018
2019
DS DP U-659

N 021743 002
5747498
5747498*PED
6900221
6900221
6900221
6900221
6900221*PED
7087613
7087613
7087613
7087613*PED
RE41065
RE41065*PED
Nov
May
Nov
Nov
Nov
Nov
May
Nov
Nov
Nov
May
Nov
May
08,
08,
09,
09,
09,
09,
09,
09,
09,
09,
09,
08,
08,
2018
2019
2020
2020
2020
2020
2021
2020
2020
2020
2021
2018
2019
DS DP U-659

N 021743 003
5747498
5747498*PED
6900221
6900221
6900221
Nov
May
Nov
Nov
Nov
08,
08,
09,
09,
09,
2018
2019
2020
2020
2020
DS DP U-659
U-1588
U-1758
U-1758
DS
DS
DS
DS
DP
DP
DP
DP
U-659
U-875
U-1046
U-1403
U-659
U-1045
U-1403
DS DP
DS
DS
DS
DS
DP
DP
DP
DP
U-659
U-875
U-1046
U-1403
U-659
U-1045
U-1403
DS DP
DS DP U-659
DS DP U-875
DS DP U-1046
A - 23

APPL/PROD
NO
PATENT NO
PATENT

EXPIRATION

DATE

PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 021743 003
6900221
6900221*PED
7087613
7087613
7087613
7087613*PED
RE41065
RE41065*PED
Nov
May
Nov
Nov
Nov
May
Nov
May
ESLICARBAZEPINE ACETATE - APTIOM

N 022416 001
5753646
5753646
Jun 27, 2016

Jun 27, 2016

DS DP U-1451
DS DP U-1746
D-150
I-715
Aug 27, 2018
Aug 27, 2018


N 022416 002
5753646
5753646
Jun 27, 2016

Jun 27, 2016

DS DP U-1451
DS DP U-1746
D-150
I-715
Aug 27, 2018
Aug 27, 2018


N 022416 003
5753646
5753646
Jun 27, 2016

Jun 27, 2016

DS DP U-1451
DS DP U-1746
D-150
I-715
Aug 27, 2018
Aug 27, 2018


N 022416 004
5753646
5753646
Jun 27, 2016

Jun 27, 2016

DS DP U-1451
DS DP U-1746
D-150
I-715
Aug 27, 2018
Aug 27, 2018

ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR

N 204655 001
5690960
Nov
5690960*PED
May
5714504
Feb
5714504*PED
Aug
5877192*PED
Nov
5900424
May
5900424*PED
Nov
6369085
May
6369085*PED
Nov
6428810
Nov
6428810*PED
May
6875872*PED
Nov
7411070
May
7411070*PED
Nov
09,
09,
09,
09,
09,
09,
08,
08,
25,
25,
03,
03,
27,
04,
04,
25,
25,
03,
03,
27,
25,
25,
2020

2021
2020

2020

2020

2021
2018

2019

2014

2015
2015

2015
2014

2016
2016

2018
2018

2019

2020
2014

2018
2018

DS DP U-1403

U-659

U-1045

U-1403

DS DP

DP U-1509

DP U-1509

DS
U-1509

DS DP U-1509

DP U-1509

DS

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO

N 022511 001
8945621
Oct 17, 2031

>A> 9161920
May 31, 2022

U-1661

U-1760

ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO

N 022511 002
8945621
Oct 17, 2031

>A> 9161920
May 31, 2022

U-1661

U-1760

ESTRADIOL - MINIVELLE

N 203752 005
6841716
8231906
Apr 27, 2020
Jul 04, 2030

DP

DS DP

EVEROLIMUS - AFINITOR

N 022334 001
8410131
8410131*PED
9006224
Nov 01, 2025

May 01, 2026
Jul 01, 2028

DS DP U-1368


N 022334 002
8410131
8410131*PED
9006224
Nov 01, 2025

May 01, 2026
Jul 01, 2028

DS DP U-1368

U-1681

U-1681

A - 24

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 022334 002
8410131
8410131*PED
9006224
Nov 01, 2025

May 01, 2026
Jul 01, 2028
DS DP U-1368


N 022334 003
8410131
8410131*PED
9006224
Nov 01, 2025

May 01, 2026
Jul 01, 2028
DS DP U-1368


N 022334 004
8410131
8410131*PED
9006224
Nov 01, 2025

May 01, 2026
Jul 01, 2028
DS DP U-1368

EXCLUSIVITY
CODE(S)
U-1681

U-1681

M-162
FEBUXOSTAT - ULORIC

N 021856 001
9107912
Sep 08, 2031
U-1346

FEBUXOSTAT - ULORIC

N 021856 002
9107912
Sep 08, 2031
U-1346

FENTANYL CITRATE - LAZANDA

N 022569 001
9078814
Jan 08, 2024
DP

FENTANYL CITRATE - LAZANDA

N 022569 002
9078814
Jan 08, 2024
DP

FENTANYL HYDROCHLORIDE - IONSYS

N 021338 001
6169920
6181963
8301238
8428708
8428709
8781571
9095706
Jan
Nov
Sep
May
Jun
Mar
Jan
DP U-736

DP

DP

U-736

DP U-736

DP U-736

DP

FERRIC CITRATE - AURYXIA

N 205874 001
8901349
9050316
Feb 18, 2024

Feb 18, 2024
U-1577

U-1577

FERRIC PYROPHOSPHATE CITRATE - TRIFERIC

N 206317 001
6689275
Dec 31, 2016
6779468
Dec 31, 2016
7816404
Apr 17, 2029
U-1656

U-1656

DP U-1656

02,
02,
30,
21,
11,
31,
17,
2018
2019
2031
2032
2032
2032
2033
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY

N 201373 001
8933097
Aug 16, 2032
DP

FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES

N 201373 002
8933097
Aug 16, 2032
Apr
Apr
Aug
Jul
12,
12,
08,
02,
2017
2017
2031
2030
EXCLUSIVITY

EXPIRATION

DATE

U-1681

EXENATIDE SYNTHETIC - BYDUREON

N 022200 001
FINAFLOXACIN - XTORO

N 206307 001
6133260
6432948
8536167
9119859
PATENT
DELIST
REQUESTED
DP

DS DP

DS DP

U-1679

U-1679

Sep 24, 2018

A - 25

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
FLIBANSERIN - ADDYI

N 022526 001
7151103
7420057
8227471
May 09, 2023

Aug 01, 2022
May 09, 2023
FLUOROURACIL - TOLAK

N 022259 001 >A> 7169401
Jul 18, 2023
DP
FLUTEMETAMOL F-18 - VIZAMYL

N 203137 001
8916131
Sep 16, 2028
DP

FLUTEMETAMOL F-18 - VIZAMYL

N 203137 002
8916131
Sep 16, 2028
DP

U-1734
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

NCE
Aug 18, 2020
NP
Sep 18, 2018

I-708
Apr 30, 2018
NP
Apr 30, 2018
FLUTICASONE PROPIONATE - CUTIVATE

N 021152 001
NPP
Jan 16, 2018

GADOXETATE DISODIUM - EOVIST

N 022090 001
M-155
Mar 27, 2018

GADOXETATE DISODIUM - EOVIST

N 022090 002
M-155
Mar 27, 2018

NP
ODE
Jul 13, 2018

Jul 13, 2022

DS DP

U-1734

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA

N 204275 001
6537983
Aug 03, 2021
DP U-1401
6537983
Aug 03, 2021
DP U-1691

6759398
Aug 03, 2021
DP U-1401

6759398
Aug 03, 2021
DP U-1691

7101866
Aug 03, 2021
DS DP U-1401

7101866
Aug 03, 2021
DS DP U-1691

7439393
Sep 11, 2022
DS DP U-1401

7439393
Sep 11, 2022
DS DP U-1691

8511304
Jun 14, 2027
DP U-1424

8511304
Jun 14, 2027
DP U-1691

RE44874
Mar 23, 2023
DS DP U-1548

RE44874
Mar 23, 2023
DS DP U-1691

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA

N 204275 002
5873360
Feb 23, 2016
DP
6537983
Aug 03, 2021
DP U-1691

6759398
Aug 03, 2021
DP U-1691

7101866
Aug 03, 2021
DS DP U-1691

7439393
Sep 11, 2022
DS DP U-1691

7629335
Aug 03, 2021
DP

7776895
Sep 11, 2022
DP

8113199
Oct 23, 2027
DP

8161968
Feb 05, 2028
DP

8511304
Jun 14, 2027
DP U-1691

8534281
Aug 10, 2029
DP

8746242
Oct 11, 2030
DP

RE44874
Mar 23, 2023
DS DP U-1691

GEFITINIB - IRESSA

N 206995 001 >A> 5770599
May 05, 2017
DS DP U-1755
GLATIRAMER ACETATE - COPAXONE

N 020622 003
8969302
9155776
Aug 19, 2030

Aug 19, 2030
U-441

U-441

GLYCEROL PHENYLBUTYRATE - RAVICTI

N 203284 001
9095559
Mar 09, 2032
U-1383

A - 26

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY
EXPIRATION
DATE
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE

A 200881 001
PC
May 30, 2015

A 200881 002
PC
May 30, 2015

A 200881 003
PC
May 30, 2015

A 200881 004
PC
May 30, 2015
GUANFACINE HYDROCHLORIDE - INTUNIV

N 022037 001
M-154
Mar 18, 2018

N 022037 002
M-154
Mar 18, 2018

N 022037 003
M-154
Mar 18, 2018

N 022037 004
M-154
Mar 18, 2018
HYDROCODONE BITARTRATE - ZOHYDRO ER

N 202880 001
9132096
Sep 12, 2034
DP

N 202880 002
9132096
Sep 12, 2034
DP

N 202880 003
9132096
Sep 12, 2034
DP

N 202880 004
9132096
Sep 12, 2034
DP

N 202880 005
9132096
Sep 12, 2034
DP

N 202880 006
9132096
Sep 12, 2034
DP
HYDROCODONE BITARTRATE - HYSINGLA

N 206627 001
9023401
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Oct
Aug
Aug
Aug
30,
30,
30,
24,
24,
24,
2021
2021
2021
2027
2027
2027
DP
DP

N 206627 002
9023401
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Oct
Aug
Aug
Aug
30,
30,
30,
24,
24,
24,
2021
2021
2021
2027
2027
2027
DP
DP

N 206627 003
9023401
9056052
Oct 30, 2021

Oct 30, 2021
DP
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
A - 27

APPL/PROD
NO
PATENT NO
PATENT

EXPIRATION
DATE
PATENT

CODES


N 206627 003
9060940
9084816
9095614
9095615
Oct
Aug
Aug
Aug
30,
24,
24,
24,
2021
2027
2027
2027

N 206627 004
9023401
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Oct
Aug
Aug
Aug
30,
30,
30,
24,
24,
24,
2021
2021
2021
2027
2027
2027
DP
DP

N 206627 005
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Aug
Aug
Aug
30,
30,
24,
24,
24,
2021
2021
2027
2027
2027
DP

N 206627 006
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Aug
Aug
Aug
30,
30,
24,
24,
24,
2021
2021
2027
2027
2027
DP

N 206627 007
9056052
9060940
9084816
9095614
9095615
Oct
Oct
Aug
Aug
Aug
30,
30,
24,
24,
24,
2021
2021
2027
2027
2027
DP
IBRUTINIB - IMBRUVICA
N 205552 001
8497277
8497277
8497277
8957079
8999999
8999999
9125889
Dec
Dec
Dec
Dec
Jun
Jun
Jun
28,
28,
28,
28,
03,
03,
03,
2026
2026
2026
2026
2031
2031
2031
IBUPROFEN - CALDOLOR
N 022348 002
8871810
9012508
9114068
>A> 9138404
Sep
Sep
Sep
Sep
30,
14,
30,
30,
2029
2030
2029
2029
U-1599
U-981
U-1735
U-1756
ICATIBANT ACETATE - FIRAZYR

N 022150 001
5648333
Jul 15, 2019
DS DP U-1187
IDELALISIB - ZYDELIG
N 205858 001
8138195
8865730
8980901
>A> 9149477
RE44599
RE44599
Apr
Mar
May
May
Jul
Jul
2021
2033
2025
2025
2025
2025
DS DP U-1549
DS DP U-1615
U-1678
U-1757
U-1558
U-1615
N 205858 002
8138195
8865730
Apr 24, 2021

Mar 05, 2033
DS DP U-1549
DS DP U-1615
24,
05,
12,
12,
21,
21,
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1556
DP
U-1456
U-1491
U-1650
DS DP
U-1683
U-1684
U-1745
I-702
ODE
Jan 29, 2018

Jan 29, 2022

A - 28

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 205858 002
8980901
>A> 9149477
RE44599
RE44599
May
May
Jul
Jul
12,
12,
21,
21,
2025
2025
2025
2025
U-1678

U-1757

U-1558

U-1615

ILOPERIDONE - FANAPT

N 022192 001
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 002
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 003
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 004
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 005
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 006
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

A - 29

APPL/PROD
NO
PATENT NO
PATENT

EXPIRATION
DATE
PATENT

CODES


N 022192 006
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674


N 022192 007
8652776
8999638
9072742
9074254
9074255
9074256
9138432
9157121
Aug
Oct
Jan
Dec
Dec
Feb
Sep
Apr
31,
28,
16,
28,
17,
10,
30,
05,
2030
2030
2031
2031
2030
2031
2025
2030
U-1685

U-1674

U-1674

U-1674

U-1674

U-1674

U-1737

U-1674

INDACATEROL MALEATE - ARCAPTA NEOHALER

N 022383 001
8658673
Jun 02, 2020
DS DP U-1168

INDOMETHACIN - TIVORBEX

N 204768 001
8992982
9089471
Apr 23, 2030

Apr 23, 2030
DP

INDOMETHACIN - TIVORBEX

N 204768 002
8992982
9089471
Apr 23, 2030

Apr 23, 2030
DP

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-55

U-55

INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH

N 020986 005
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DP

INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30
N 203313 001
5866538
Jun 20, 2017
6899699
Jan 02, 2022
7615532
May 25, 2025
7686786
Aug 03, 2026
8672898
Jan 02, 2022
8684969
Oct 20, 2025
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DS DP

DP

DP

DP

DP

DP

DP

NCE
Sep 25, 2020

INSULIN DEGLUDEC - TRESIBA

N 203314 001
6899699
7615532
7686786
8672898
8684969
8920383
9108002
9132239
Jan
May
Aug
Jan
Oct
Jul
Jan
Feb
02,
25,
03,
02,
20,
17,
20,
01,
2022
2025
2026
2022
2025
2026
2026
2032
DP

DS DP

DP

DP

DP

DP

DP

DP

NCE
Sep 25, 2020


N 203314 002
6899699
7615532
7686786
8672898
8684969
8920383
Jan
May
Aug
Jan
Oct
Jul
02,
25,
03,
02,
20,
17,
2022
2025
2026
2022
2025
2026
DP
DS DP

DP

DP

DP

DP

NCE
Sep 25, 2020
A - 30

APPL/PROD
NO
PATENT NO

N 203314 002
9108002
9132239
PATENT

EXPIRATION
DATE
PATENT

CODES

Jan 20, 2026

Feb 01, 2032
DP

DP

INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH

N 021536 005
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DP

INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR

N 021081 002
8992486
Jun 05, 2024
9011391
Mar 26, 2024
DP

DP

INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR

N 206538 001
7918833
Sep 23, 2027
7918833*PED
Mar 23, 2028

8512297
Sep 15, 2024
8556864
Mar 03, 2024
8603044
Mar 02, 2024
8679069
Apr 12, 2025
8992486
Jun 05, 2024
9011391
Mar 26, 2024
DP

DP

DP

INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN

N 205747 001
6034054
Jun 11, 2018
6034054
Jun 11, 2018
6551992
Jun 11, 2018
6551992
Jun 11, 2018
7291132
Aug 09, 2024
DP U-1707

DP U-1708

DP U-1707

DP U-1708

DP

INSULIN RECOMBINANT HUMAN - AFREZZA

N 022472 001 >A> 8729019
Dec 26, 2028
8912193
Jun 12, 2029
DP

DP U-1538


N 022472 003
6444226
Jun 29, 2020
6652885
Jun 29, 2020
7305986
Jan 16, 2023
7464706
Mar 02, 2023
7648960
Jun 29, 2020
7943178
Jun 29, 2020
7943572
Aug 10, 2026
8119593
Aug 11, 2029
8146588
Apr 24, 2023
8156936
Jan 16, 2023
8215300
Nov 24, 2022
8258095
Aug 11, 2029
8389470
Jun 29, 2020
8394414
May 15, 2015
8424518
Oct 17, 2031
8485180
Mar 25, 2030
8499757
Feb 19, 2032
8551528
Jun 11, 2030
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

NP
Feb 25, 2018

NP
Jun 27, 2017

DP

DP

DP

DP

DP

DP

INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR

N 021629 003
8992486
Jun 05, 2024
9011391
Mar 26, 2024

N 022472 002
7943572
Aug 10, 2026
8424518
Oct 17, 2031
8623817
Sep 18, 2029
>A> 8729019
Dec 26, 2028
8912193
Jun 12, 2029
PATENT
DELIST
REQUESTED
U-1539

DP

U-1537

DP

DP U-1538

DP U-1534

U-1535

DP

DP

U-1535

DP U-1535

U-1539

U-1537

DP

DP

DP

U-1537

DP U-1697

DP U-1533

DP

DP

DP

DP

A - 31

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 022472 003
8623817
Sep 18, 2029
8636001
Jul 12, 2032
>A> 8729019
Dec 26, 2028
8734845
Jun 11, 2030
8778403
Jun 11, 2030
8889099
Jun 29, 2020
8912193
Jun 12, 2029
U-1537
DP
DP
DP
DP U-1538
DP U-1621
DP U-1538
IPRATROPIUM BROMIDE - ATROVENT HFA

N 021527 001
8474447
DP
Jan 17, 2030
IRINOTECAN HYDROCHLORIDE - ONIVYDE

N 207793 001
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
>A> NP
EXCLUSIVITY

EXPIRATION

DATE

Oct 22, 2018
ISAVUCONAZONIUM SULFATE - CRESEMBA

N 207500 001
6812238
7459561
Oct 31, 2020

Oct 31, 2020
DS
DS
NCE
ODE
GAIN
GAIN
Mar
Mar
Mar
Mar
06,
06,
06,
06,
2020
2022
2025
2027
ISAVUCONAZONIUM SULFATE - CRESEMBA

N 207501 001
6812238
7459561
Oct 31, 2020

Oct 31, 2020
DS
DS
NCE
ODE
GAIN
GAIN
Mar
Mar
Mar
Mar
06,
06,
06,
06,
2020
2022
2025
2027
ISOTRETINOIN - ABSORICA
N 021951 001
8952064
9078925
9089534
Sep 21, 2021

Sep 21, 2021
Sep 21, 2021
DP
DP
DP
N 021951 002
8952064
9078925
9089534
Sep 21, 2021

Sep 21, 2021
Sep 21, 2021
DP
DP
DP
N 021951 003
8952064
9078925
9089534
Sep 21, 2021

Sep 21, 2021
Sep 21, 2021
DP
DP
DP
N 021951 004
8952064
9078925
9089534
Sep 21, 2021

Sep 21, 2021
Sep 21, 2021
DP
DP
DP
N 021951 005
7435427
8367102
8952064
9078925
9089534
Sep
Sep
Sep
Sep
Sep
21,
21,
21,
21,
21,
2021
2021
2021
2021
2021
DP
N 021951 006
7435427
8367102
8952064
9078925
9089534
Sep
Sep
Sep
Sep
Sep
21,
21,
21,
21,
21,
2021
2021
2021
2021
2021
DP
U-1347
DP
DP
DP
U-1347
DP
DP
DP
A - 32

APPL/PROD
NO
PATENT NO

PATENT

EXPIRATION

DATE

PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY
EXPIRATION
DATE
IVABRADINE HYDROCHLORIDE - CORLANOR

N 206143 001
7361649

Apr
7361650

Apr
7867996

Feb
7879842

Feb
17,
14,
22,
22,
2026
2026
2026

2026

DS
DS
DS
DS
DP
DP
DP
DP
U-1694
U-1694

U-1694

U-1694

NCE
Apr 15, 2020
IVABRADINE HYDROCHLORIDE - CORLANOR

N 206143 002
7361649

Apr
7361650

Apr
7867996

Feb
7879842

Feb
17,
14,
22,
22,
2026
2026
2026

2026

DS
DS
DS
DS
DP
DP
DP
DP
U-1694
U-1694

U-1694

U-1694

NCE
Apr 15, 2020
U-1311
I-705
Dec 30, 2017

NCE
ODE
Jul 02, 2020

Jul 02, 2022

IVACAFTOR - KALYDECO

N 203188 001
8354427

Jul 06, 2026


N 207925 001
7495103

8324242

8354427

8410274

8754224

8883206

May
Apr
Jul
Dec
Dec
Feb
20,
18,
06,
28,
28,
27,
2027
2027
2026

2026

2026

2033

DS DP


N 207925 002
7495103

8324242

8354427

8410274

8754224

8883206

May
Apr
Jul
Dec
Dec
Feb
20,
18,
06,
28,
28,
27,
2027
2027
2026

2026

2026

2033

DS DP

IVACAFTOR; LUMACAFTOR - ORKAMBI

N 206038 001
7495103

8324242

8410274

8507534

8653103

8716338

8741933

8754224

8846718

8993600

May
Apr
Dec
Sep
Dec
Nov
Nov
Dec
Dec
Dec
20,
18,
28,
20,
04,
08,
08,
28,
04,
11,
2027
2027
2026

2030
2028

2026

2026

2026

2028

2030

DS DP
IVERMECTIN - SOOLANTRA

N 206255 001
5952372

6133310

7550440

8080530

8093219

8415311

8470788

8815816

9089587

Sep
Apr
Apr
Apr
Apr
Apr
Apr
Apr
Mar
18,
26,
22,
22,
22,
22,
22,
22,
13,
2018
2019
2024
2024
2024
2024
2024
2024
2034

U-1311

U-1311

DP

DS DP

DP

U-1311

U-1311

DP

DS DP

DP

U-1311
DP

DS DP

DP

DP U-1718

U-1717

DS DP

U-1717

DP

DP
DP
DP
DP
DP
DP
KETOROLAC TROMETHAMINE - ACULAR LS

N 021528 001
8946281

May 28, 2024

KETOROLAC TROMETHAMINE - ACUVAIL

N 022427 001
8992952

Aug 05, 2024

U-1631

U-1631

U-1631

U-1631

U-1631

U-1631

U-1631

U-1631

U-1631

U-1662

DP

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA

N 205388 001
9066856
Oct 23, 2033
DP

A - 33

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
LAMIVUDINE - LAMIVUDINE

A 203564 001
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

PC
Sep 01, 2015
LAMIVUDINE - EPIVIR
N 020564 001
5905082
5905082*PED
May 18, 2016

Nov 18, 2016
DS DP
D-147
Mar 23, 2018
LAMIVUDINE - EPIVIR
N 020564 003
5905082
5905082*PED
May 18, 2016

Nov 18, 2016
DS DP
D-147
Mar 23, 2018
LAMIVUDINE - EPIVIR
N 020596 001
5905082
6004968
6004968*PED
May 18, 2016

Mar 20, 2018
Sep 20, 2018
DS DP
DP U-248
D-147
Mar 23, 2018
LAMOTRIGINE - LAMOTRIGINE
A 200828 001
PC
Sep 28, 2015
A 200828 002
PC
Sep 28, 2015
A 200828 003
PC
Sep 28, 2015
A 200828 004
PC
Sep 28, 2015
LAMOTRIGINE - LAMICTAL
N 020241 001
M-159
May 18, 2018
N 020241 002
M-159
May 18, 2018
N 020241 003
M-159
May 18, 2018
N 020241 004
M-159
May 18, 2018
N 020241 005
M-159
May 18, 2018
N 020241 006
M-159
May 18, 2018
LAMOTRIGINE - LAMICTAL CD
N 020764 001
M-159
May 18, 2018
N 020764 002
M-159
May 18, 2018
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS

N 206510 001
7169780
Oct 03, 2023
7217713
Oct 21, 2022
7435734
Oct 21, 2022
7754731
Mar 11, 2029
7820660
Apr 25, 2023
DS DP
U-1663
U-1663
DS DP U-1663
DS
A - 34

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY
EXPIRATION
DATE
N 020764 003
M-159
May 18, 2018
N 020764 004
M-159
May 18, 2018
LAMOTRIGINE - LAMICTAL ODT

N 022251 001
M-159
May 18, 2018

N 022251 002
M-159
May 18, 2018

N 022251 003
M-159
May 18, 2018

N 022251 004
M-159
May 18, 2018
LAMOTRIGINE - LAMICTAL XR
N 022115 001 >A> 9144547
Sep 22, 2023
DP
N 022115 002 >A> 9144547
Sep 22, 2023
DP
N 022115 003 >A> 9144547
Sep 22, 2023
DP
N 022115 004 >A> 9144547
Sep 22, 2023
DP
N 022115 005 >A> 9144547
Sep 22, 2023
DP
N 022115 006 >A> 9144547
Sep 22, 2023
DP
LANTHANUM CARBONATE - FOSRENOL

N 204734 001
8980327
Dec 01, 2030
DP
LANTHANUM CARBONATE - FOSRENOL

N 204734 002
8980327
Dec 01, 2030
DP
LAPATINIB DITOSYLATE - TYKERB

N 022059 001
8821927
Sep 18, 2029
DS DP
LEDIPASVIR; SOFOSBUVIR - HARVONI

N 205834 001
9085573
Mar 21, 2028
DS DP U-1470
LENALIDOMIDE - REVLIMID
N 021880 001
9056120
9101621
9101622
Apr 11, 2023

May 15, 2023
May 15, 2023
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
N 021880 002
9056120
9101621
9101622
Apr 11, 2023

May 15, 2023
May 15, 2023
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
A - 35

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

N 021880 003
9056120
9101621
9101622
Apr 11, 2023

May 15, 2023
May 15, 2023
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
N 021880 004
9056120
9101621
9101622
Apr 11, 2023

May 15, 2023
May 15, 2023
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
N 021880 005
9056120
9101621
9101622
Apr 11, 2023

May 15, 2023
May 15, 2023
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
N 021880 006
5635517
9056120
9101621
9101622
Oct
Apr
May
May
U-1211
U-1215
U-1216
U-1216
I-706
ODE
Feb 17, 2018

Feb 17, 2022
LENVATINIB MESYLATE - LENVIMA

N 206947 001
7253286
7612208
9006256
Oct 19, 2021

Sep 19, 2026
Jul 27, 2027
DS DP
DS DP
NCE
ODE
Feb 13, 2020

Feb 13, 2022
LENVATINIB MESYLATE - LENVIMA

N 206947 002
7253286
7612208
9006256
Oct 19, 2021

Sep 19, 2026
Jul 27, 2027
DS DP
DS DP
NCE
ODE
Feb 13, 2020

Feb 13, 2022
LEUPROLIDE ACETATE - LUPRON DEPOT

N 020517 003
7429559
8815801
8921326
Jan 13, 2019

Jun 28, 2022
Feb 05, 2031
LEVALBUTEROL HYDROCHLORIDE - XOPENEX

N 020837 001
M-151
Jan 22, 2018

N 020837 002
M-151
Jan 22, 2018

N 020837 003
M-151
Jan 22, 2018

N 020837 004
M-151
Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA

N 021730 001
M-156
Mar 12, 2018
04,
11,
15,
15,
2019
2023
2023
2023
DS
U-1695
U-1695
DP
DP
DP U-1666
LEVETIRACETAM - SPRITAM
N 207958 001
6471992
Feb 20, 2018
DP
N 207958 002
6471992
Feb 20, 2018
DP
N 207958 003
6471992
Feb 20, 2018
DP
A - 36

APPL/PROD
NO
PATENT NO
N 207958 004
6471992
PATENT
EXPIRATION
DATE
PATENT
CODES
Feb 20, 2018
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM

A 203563 001
PC
Oct 20, 2015
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM

A 203563 002
PC
Oct 20, 2015
LEVONORGESTREL - LILETTA
N 206229 001
NP
Feb 26, 2018
LINEZOLID - LINEZOLID
A 078061 001
PC
Dec 19, 2015
LINEZOLID - LINEZOLID
A 200222 001
PC
Jul 04, 2015
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM

N 202231 001
9006289
Oct 03, 2032
>A> 9168238
Aug 29, 2032
>A> 9168239
Aug 29, 2032
DP
DP
DP

N 202231 002
9006289
Oct 03, 2032
>A> 9168238
Aug 29, 2032
>A> 9168239
Aug 29, 2032
DP
DP
DP

N 202231 003
9006289
Oct 03, 2032
>A> 9168238
Aug 29, 2032
>A> 9168239
Aug 29, 2032
DP
DP
DP
LINACLOTIDE - LINZESS
N 202811 001
8933030
Feb 17, 2031
DP
LINACLOTIDE - LINZESS
N 202811 002
8933030
Feb 17, 2031
DP
LINAGLIPTIN - TRADJENTA
N 201280 001
8673927
8853156
May 04, 2027

Mar 05, 2031
U-1503
U-1642
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO

N 201281 001
8673927
May 04, 2027
>A> 9155705
May 21, 2030
DP

N 201281 002
8673927
May 04, 2027
>A> 9155705
May 21, 2030
DP

N 201281 003
8673927
May 04, 2027
>A> 9155705
May 21, 2030
DP
LINEZOLID - ZYVOX
N 021131 002
6559305
6559305*PED
Jan 29, 2021

Jul 29, 2021
U-1503
U-1503
U-1503
DS
A - 37

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
LINEZOLID - ZYVOX

N 021131 003
6559305

6559305*PED

Jan 29, 2021

Jul 29, 2021

LIRAGLUTIDE RECOMBINANT - VICTOZA

N 022341 001
8846618

Jun 27, 2022
LIRAGLUTIDE RECOMBINANT - SAXENDA

N 206321 001
6268343

6458924

6899699

7235627

7686786

8114833

8672898

8684969

8846618

8920383

9108002

9132239

Aug
Aug
Jan
Aug
Aug
Aug
Jan
Oct
Jun
Jul
Jan
Feb
22,
22,
01,
22,
03,
13,
02,
20,
27,
17,
26,
01,
2022
2017
2022
2017
2026
2025
2022
2025
2022
2026
2026
2032
LISDEXAMFETAMINE DIMESYLATE - VYVANSE

N 021977 001
7105486
Feb
7223735
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023

N 021977 002
7105486
Feb
7223735
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023

N 021977 003
7105486
Feb
7223735
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023

N 021977 004
7105486
Feb
7105486
Feb
7223735
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023
2023
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DS

DP

DS DP U-1255

DS DP U-1255

DP

DS DP

DP

DP

DP

DP

DP

DP

DP

DP

U-727
I-703
Jan 30, 2018

I-703
Jan 30, 2018

I-703
Jan 30, 2018

I-703
Jan 30, 2018

DP

U-727

DP U-842

U-842

DP U-842

DP U-842

DP

U-727
DP

U-727

DP U-842

U-842

DP U-842

DP U-842

DP

U-727
DP

U-727

DP U-842

U-842

DP U-842

DP U-842

DP

U-727
U-842

DP

U-727

DP U-842

U-842

DP U-842

DP U-842

DP

A - 38

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 021977 005
7105486
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
U-842
U-727

DP U-842

U-842

DP U-842

DP U-842

DP

I-703
Jan 30, 2018


N 021977 006
7105486
Feb
7105486
Feb
7223735
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687467
Feb
7700561
Feb
24,
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023
2023
U-727
U-842

I-703
Jan 30, 2018


N 021977 007
7223735
Feb
7655630
Feb
7659253
Feb
7659254
Feb
7662787
Feb
7662788
Feb
7671030
Feb
7671031
Feb
7674774
Feb
7678770
Feb
7678771
Feb
7687466
Feb
7687467
Feb
7700561
Feb
7713936
Feb
7718619
Feb
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
24,
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
I-703
Jan 30, 2018

DP

U-727

DP U-842

U-842

DP U-842

DP U-842

DP

DP
DS

DS DP U-727

U-1034

DS

U-727

DP U-727

U-727

DP U-842

U-842

DP

DP

DP U-842

DP

U-727

DP U-842

LOMITAPIDE MESYLATE - JUXTAPID

N 203858 001
5712279
Feb 21, 2016
DS
U-1317


N 203858 002
5712279
Feb 21, 2016
DS
U-1317


N 203858 003
5712279
Feb 21, 2016
DS
U-1317


N 203858 004
5712279
6492365
7932268
8618135
Feb
Dec
Aug
Mar
21,
10,
19,
07,
2016
2019
2027
2025
DS
U-1317
U-1318
U-1316

U-1316

NCE
ODE
Dec 21, 2017

Dec 21, 2019


N 203858 005
5712279
6492365
7932268
8618135
Feb
Dec
Aug
Mar
21,
10,
19,
07,
2016
2019
2027
2025
DS
U-1317
U-1318
U-1316

U-1316

NCE
ODE
Dec 21, 2017

Dec 21, 2019


N 203858 006
5712279
6492365
7932268
8618135
Feb
Dec
Aug
Mar
21,
10,
19,
07,
2016
2019
2027
2025
DS
U-1317
U-1318
U-1316
U-1316
NCE
ODE
Dec 21, 2017

Dec 21, 2019
A - 39

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 203858 006
5712279
6492365
7932268
8618135
Feb
Dec
Aug
Mar
LORATADINE - CLARITIN
N 020641 002
6132758
Jun 01, 2018
DP
LORCASERIN HYDROCHLORIDE - BELVIQ

N 022529 001
8946207
8980881
8980881
8980881
8980881
8999970
8999970
8999970
Jun
Dec
Dec
Dec
Dec
Feb
Feb
Feb
2024
2025
2025
2025
2025
2033
2033
2033
DP
LOXAPINE - ADASUVE
N 022549 001
8955512
8991387
Oct 26, 2021

May 21, 2024
DP
DP
LULICONAZOLE - LUZU
N 204153 001
8980931
9012484
Apr 28, 2034

Sep 06, 2033
DP
DS DP U-540
LURASIDONE HYDROCHLORIDE - LATUDA

N 200603 001
RE45573
Jun 23, 2025
DS

N 200603 002
RE45573
Jun 23, 2025
DS

N 200603 003
RE45573
Jun 23, 2025
DS

N 200603 004
RE45573
Jun 23, 2025
DS

N 200603 005
RE45573
Jun 23, 2025
DS
MEGESTROL ACETATE - MEGACE ES

N 021778 001
9040088
9101540
9101549
9107827
Apr
Apr
Apr
Apr
21,
10,
19,
07,
16,
20,
20,
20,
20,
07,
07,
07,
22,
22,
22,
22,
2016
2019
2027
2025
2024
2024
2024
2024
DS
U-1317
U-1318
U-1316
U-1316
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
NCE
ODE
EXCLUSIVITY

EXPIRATION

DATE

Dec 21, 2017

Dec 21, 2019
U-1252
U-1253
U-1254
U-1255
U-1688
U-1689
U-1692
U-755
DP U-755
U-755
U-755
MELOXICAM - VIVLODEX
N 207233 001
>A> NP
Oct 22, 2018
MELOXICAM - VIVLODEX
N 207233 002
>A> NP
Oct 22, 2018
MESALAMINE - ASACOL HD
N 021830 001
9089492
Nov 15, 2021
DP
MESALAMINE - APRISO
N 022301 001
8940328
8956647
Apr 20, 2018

Apr 20, 2018
DP
DP
A - 40

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET

N 021842 001
9101660
Jan 22, 2027
DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET

N 021842 002
9101660
Jan 22, 2027
DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR

N 022024 001
9060941
Sep 19, 2023
DP

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR

N 022024 002
9060941
Sep 19, 2023
DP

METHOTREXATE - OTREXUP

N 204824 001
8945063
Mar 19, 2030
DP U-1442


N 204824 002
8945063
Mar 19, 2030
DP U-1442


N 204824 003
8945063
Mar 19, 2030
DP U-1442


N 204824 004
8945063
Mar 19, 2030
DP U-1442


N 204824 005
8945063
Mar 19, 2030
DP U-1442

METHYLPHENIDATE - DAYTRANA

N 021514 001
9034370
Oct 07, 2025
DP


N 021514 002
9034370
Oct 07, 2025
DP


N 021514 003
9034370
Oct 07, 2025
DP


N 021514 004
9034370
Oct 07, 2025
DP

METHYLPHENIDATE HYDROCHLORIDE - CONCERTA

N 021121 001
9000038
Jul 31,
9000038
Jul 31,
9000038*PED
Jan 31,
9029416
Jul 31,
9144549
Jul 31,
9144549
Jul 31,
2017
2017
2018

2017
2017
2017

N 021121 002
9000038
Jul 31,
9000038
Jul 31,
9000038*PED
Jan 31,
9029416
Jul 31,
9144549
Jul 31,
9144549
Jul 31,
2017
2017
2018

2017
2017
2017

N 021121 003
9000038
Jul 31,
9000038
Jul 31,
9000038*PED
Jan 31,
9029416
Jul 31,
9144549
Jul 31,
9144549
Jul 31,
2017
2017
2018

2017
2017
2017
U-666

U-1693

DP U-666

U-1747

U-1748

U-666

U-1693

DP U-666

U-1747

U-1748

U-666

U-1693

DP U-666

U-1747

U-1748

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

A - 41

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE

N 021121 003
9000038
Jul 31, 2017
9000038
Jul 31, 2017
9000038*PED
Jan 31, 2018
9029416
Jul 31, 2017
9144549
Jul 31, 2017
9144549
Jul 31, 2017
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-666
U-1693
DP U-666
U-1747
U-1748

N 021121 004
9000038
Jul 31, 2017
9000038
Jul 31, 2017
9000038*PED
Jan 31, 2018
9029416
Jul 31, 2017
9144549
Jul 31, 2017
9144549
Jul 31, 2017
DP U-666
U-1747
U-1748
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR

N 202100 001
8956649
Feb 15, 2031
9040083
Feb 15, 2031
DP U-1665
DP
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR

N 205831 001
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
NP
Apr 17, 2018

N 205831 002
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
NP
Apr 17, 2018

N 205831 003
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
NP
Apr 17, 2018

N 205831 004
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
NP
Apr 17, 2018

N 205831 005
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
NP
Apr 17, 2018

N 205831 006
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
DP
DP
DP
NP
Apr 17, 2018
U-666
U-1693
A - 42

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 205831 006
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP

N 205831 007
6419960
Dec 16, 2019
7083808
Dec 16, 2019
7247318
Dec 16, 2019
7438930
Dec 16, 2019
8580310
Dec 16, 2019
9066869
Dec 16, 2019
DP
DP
DP
DP
DP
DP
METRONIDAZOLE - NUVESSA
N 205223 001
7893097
8658678
8877792
8946276
Feb
Jun
Feb
Jun
MIFEPRISTONE - KORLYM
N 202107 001
8921348
Aug 27, 2028
19,
27,
02,
28,
2028
2028
2028
2032
U-1682
DP
U-1664
U-1643
U-282
MINOCYCLINE HYDROCHLORIDE - ARESTIN

N 050781 001
7699609
Mar 29, 2022
DP
MINOXIDIL - WOMEN'S ROGAINE

N 021812 002
6946120
DP U-702
Apr 20, 2019
MORPHINE SULFATE - MORPHINE SULFATE

N 204223 001
9072781
Mar 12, 2034
DP

N 204223 002
9072781
Mar 12, 2034
DP

N 204223 003
9072781
Mar 12, 2034
DP

N 204223 004
9072781
Mar 12, 2034
DP

N 204223 005
9072781
Mar 12, 2034
DP
EXCLUSIVITY
CODE(S)
NP
DP
MINOCYCLINE HYDROCHLORIDE - MINOCIN

N 050444 001
9084802
May 12, 2031
PATENT
DELIST
REQUESTED
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA

N 022321 001
8623418
Nov 07, 2029
U-1640

N 022321 002
8623418
Nov 07, 2029
U-1640

N 022321 003
8623418
Nov 07, 2029
U-1640

N 022321 004
8623418
Nov 07, 2029
U-1640

N 022321 005
8623418
Nov 07, 2029
U-1640
EXCLUSIVITY
EXPIRATION
DATE
Apr 17, 2018
A - 43

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 022321 006
8623418
Nov 07, 2029
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA

N 022428 001
9114168
May 29, 2029
EXCLUSIVITY

EXPIRATION

DATE

DP

Jan 31, 2033
NALOXEGOL OXALATE - MOVANTIK

N 204760 001
7056500
9012469
Jun 29, 2024

Apr 02, 2032
DP U-1185

DS DP

NALOXEGOL OXALATE - MOVANTIK

N 204760 002
7056500
9012469
Jun 29, 2024

Apr 02, 2032
DP U-1185

DS DP

NALOXONE HYDROCHLORIDE - EVZIO

N 205787 001
8926594
8939943
9022022
9056170
Mar
Feb
Feb
Nov
2026
2031
2031
2024
EXCLUSIVITY
CODE(S)
U-1640

NAFTIFINE HYDROCHLORIDE - NAFTIN

N 204286 001 >A> 9161914
31,
28,
28,
23,
PATENT
DELIST
REQUESTED
U-540

DP

DP

DP

DP

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ

N 205777 001
8969369
May 10, 2022
DP U-1556

9056051
May 10, 2022
DP U-1556

9073933
Mar 30, 2025
DS

9084729
May 10, 2022
DP U-1556

>A> 9161937
May 10, 2022
DP U-1556

>A> 9168252
May 10, 2022
DP U-1556


N 205777 002
8969369
May 10, 2022
DP U-1556

9056051
May 10, 2022
DP U-1556

9073933
Mar 30, 2025
DS

9084729
May 10, 2022
DP U-1556

>A> 9161937
May 10, 2022
DP U-1556

>A> 9168252
May 10, 2022
DP U-1556


N 205777 003
8969369
May 10, 2022
DP U-1556

9056051
May 10, 2022
DP U-1556

9073933
Mar 30, 2025
DS

9084729
May 10, 2022
DP U-1556

>A> 9161937
May 10, 2022
DP U-1556

>A> 9168252
May 10, 2022
DP U-1556

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET

N 021926 001
6060499
Aug 14, 2017
6060499*PED
Feb 14, 2018

6586458
Aug 14, 2017
6586458*PED
Feb 14, 2018

7332183
Oct 02, 2025
7332183*PED
Apr 02, 2026
8022095
Aug 14, 2017
8022095*PED
Feb 14, 2018


N 021926 002
5872145
Aug 14, 2017
5872145*PED
Feb 14, 2018

6060499
Aug 14, 2017
6060499*PED
Feb 14, 2018

6586458
Aug 14, 2017
6586458*PED
Feb 14, 2018

DP U-867

DP U-867

DP U-867

DP U-867

DP U-1719

DP U-1719

DP U-1719

NP
PED
May 14, 2018
Nov 14, 2018

A - 44

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES

N 021926 002
7332183
Oct 02, 2025
7332183*PED
Apr 02, 2026
NEPAFENAC - ILEVRO
N 203491 001
8921337
EXCLUSIVITY
CODE(S)
DP
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO

N 205718 001
8951969
Nov 18, 2030
DP
NICOTINE - NICODERM CQ
N 020165 004
8999379
Feb 13, 2020
U-1686
N 020165 005
8999379
Feb 13, 2020
U-1686
N 020165 006
8999379
Feb 13, 2020
U-1686
NICOTINE POLACRILEX - NICORETTE

N 022360 001
8940772
Apr 30, 2029
DP
NICOTINE POLACRILEX - NICORETTE

N 022360 002
8940772
Apr 30, 2029
DP
NINTEDANIB ESYLATE - OFEV

N 205832 001
7989474
Apr 06, 2024
U-1677
NINTEDANIB ESYLATE - OFEV

N 205832 002
7989474
Apr 06, 2024
U-1677
NITRIC OXIDE - INOMAX

N 020845 003
>A> M-167
Apr
Oct
Oct
Aug
Sep
Aug
Mar
29,
11,
11,
12,
24,
04,
12,
2022
2024
2024
2027
2028
2031
2024
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT

N 203108 001
8733341
Dec 16, 2029
9027967
Mar 31, 2027
EXCLUSIVITY
EXPIRATION
DATE
DP U-1719
Mar 31, 2032
OLAPARIB - LYNPARZA
N 206162 001
7151102
7449464
7981889
8143241
8247416
8859562
8912187
PATENT
DELIST
REQUESTED
DS DP
DS DP
DS DP
Oct 09, 2018
ODE
Dec 19, 2021
NC
NCE
May 21, 2018

Jul 31, 2019
U-1634
DS
U-1634
U-1634
DP
DP
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT

N 206756 001
5964416
Oct 04, 2016
DP
6149054
Dec 19, 2016
DP
6176442
Oct 04, 2016
DP
6453795
Dec 05, 2016
DP
6726124
Oct 04, 2016
DP
6846413
Aug 28, 2018
DP
6977042
Aug 28, 2018
DP
6988496
Feb 23, 2020
DP
7056916
Dec 07, 2023
DS DP
7104470
Oct 04, 2016
DP
7220742
May 12, 2025
DS DP U-1703
7246615
May 31, 2016
DP
7284474
Aug 26, 2024
DP
7396341
Oct 10, 2026
DP
A - 45

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT

N 206756 001
7491719
Nov 10, 2023
DS DP
7727984
Nov 10, 2023
DS
7786111
Nov 10, 2023
DP
7802568
Feb 26, 2019
DP
7837235
Mar 13, 2028
DP
7896264
May 26, 2025
DP
7988001
Aug 04, 2021
DP
8034809
May 12, 2025
U-1702
8044046
Nov 10, 2023
U-1702
8733341
Dec 16, 2029
DP
9027967
Mar 31, 2027
DP
RE39820
Jan 30, 2018
DS DP U-1702
OLOPATADINE HYDROCHLORIDE - PAZEO
N 206276 001
8791154
May 19, 2032
OMBITASVIR; PARITAPREVIR; RITONAVIR

N 207931 001
6037157
6037157*PED
6703403
6703403*PED
7148359
7148359*PED
7364752
7364752*PED
8268349
8268349*PED
8399015
8399015*PED
8420596
8420596*PED
8642538
8686026
8691938
9006387
9044480
- TECHNIVIE
Jun 26, 2016
Dec 26, 2016
Jun 26, 2016
Dec 26, 2016
Jul 19, 2019
Jan 19, 2020
Nov 10, 2020
May 10, 2021
Aug 25, 2024
Feb 25, 2025
Aug 25, 2024
Feb 25, 2025
Apr 10, 2031
Oct 10, 2031
Sep 10, 2029
Jun 09, 2031
Apr 13, 2032
Jun 10, 2030
Apr 10, 2031
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA

N 205060 001
9012501
9050308
9050309
9132112
Feb
Jan
Jan
Feb
OMEPRAZOLE - OMEPRAZOLE
N 022032 001
9023391
Aug 16, 2025
DP
ONDANSETRON - ZUPLENZ
N 022524 001
9095577
Jul 13, 2030
DP
ONDANSETRON - ZUPLENZ
N 022524 002
9095577
Jul 13, 2030
DP
OSELTAMIVIR PHOSPHATE - TAMIFLU

N 021246 002 >A> 5763483
>A> 5763483*PED
Aug 23, 2016

Feb 23, 2017
OSPEMIFENE - OSPHENA
N 203505 001
8642079
Jul 09, 2028
OXCARBAZEPINE - OXTELLAR XR
N 202810 001
9119791
Apr 13, 2027
07,
04,
04,
07,
2025
2033
2033
2025
DP U-1680
NP
PED
Jan 30, 2018

Jul 30, 2018
U-1635
NCE
NP
Dec 19, 2019

Jul 24, 2018
U-1635
DP
DP
DP
DP
DS DP
DS DP U-1638
DP
DS DP
U-1687
U-1638
DP U-1511
U-1511
DS
DP U-1511
DS DP U-1113
DP
U-1298
A - 46

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
N 202810 002
9119791
Apr 13, 2027
U-1298
N 202810 003
9119791
Apr 13, 2027
U-1298
OXYBUTYNIN CHLORIDE - GELNIQUE

N 022204 001
8920392
Mar 26, 2031
U-1644
OXYCODONE HYDROCHLORIDE - OXYCONTIN

N 022272 001
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 002
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 003
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 004
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 005
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 006
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS

N 022272 007
9060976
Aug 06, 2022
9073933
Mar 30, 2025
DS
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
DP
M-153
NPP
Apr 16, 2016

Aug 13, 2018
NCE
Feb 03, 2020
NCE
Feb 03, 2020
NCE
Feb 03, 2020
NP
May 18, 2018
PACLITAXEL - ABRAXANE
N 021660 001
9101543
Feb 21, 2026
PALBOCICLIB - IBRANCE
N 207103 001
6936612
7208489
7456168
Jan 22, 2023

Jan 16, 2023
Jan 16, 2023
DS DP
DS DP
N 207103 002
6936612
7208489
7456168
Jan 22, 2023

Jan 16, 2023
Jan 16, 2023
DS DP
DS DP
N 207103 003
6936612
7208489
7456168
Jan 22, 2023

Jan 16, 2023
Jan 16, 2023
DS DP
DS DP
PALIPERIDONE PALMITATE - INVEGA TRINZA

N 207946 001
6077843
May 12, 2017
6077843*PED
Nov 12, 2017
PATENT
DELIST
REQUESTED
U-1434
U-1658
U-1658
U-1658
DP U-543
A - 47

APPL/PROD
NO
PATENT
EXPIRATION
DATE
PATENT NO
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 207946 002
6077843
May 12, 2017
6077843*PED
Nov 12, 2017
DP U-543
NP
May 18, 2018

N 207946 003
6077843
May 12, 2017
6077843*PED
Nov 12, 2017
DP U-543
NP
May 18, 2018

N 207946 004
6077843
May 12, 2017
6077843*PED
Nov 12, 2017
DP U-543
NP
May 18, 2018
PALONOSETRON HYDROCHLORIDE - ALOXI

N 021372 001
9066980
9125905
>A> 9173942
Jan 30, 2024

Jan 30, 2024
Jan 30, 2024
DP U-528
DP
DP
PALONOSETRON HYDROCHLORIDE - ALOXI

N 021372 002
9125905
>A> 9173942
Jan 30, 2024

Jan 30, 2024
DP
DP
PANOBINOSTAT LACTATE - FARYDAK

N 205353 001
6552065
6833384
7067551
7989494
8883842
Aug
Sep
Aug
Jan
Jun
31,
30,
31,
17,
13,
2021
2021
2021
2028
2028
DS DP
DS DP U-1669
U-1669
DS DP
U-1669
NCE
ODE
Feb 23, 2020

Feb 23, 2022

N 205353 002
6552065
6833384
7067551
7989494
8883842
Aug
Sep
Aug
Jan
Jun
31,
30,
31,
17,
13,
2021
2021
2021
2028
2028
DS DP
DS DP U-1669
U-1669
DS DP
U-1669
NCE
ODE
Feb 23, 2020

Feb 23, 2022

N 205353 003
6552065
6833384
7067551
7989494
8883842
Aug
Sep
Aug
Jan
Jun
31,
30,
31,
17,
13,
2021
2021
2021
2028
2028
DS DP
DS DP U-1669
U-1669
DS DP
U-1669
NCE
ODE
Feb 23, 2020

Feb 23, 2022
PAROXETINE MESYLATE - BRISDELLE

N 204516 001
8946251
Aug 04, 2026
PATIROMER SORBITEX CALCIUM - VELTASSA

N 205739 001
>A> NCE
Oct 21, 2020

N 205739 002
>A> NCE
Oct 21, 2020

N 205739 003
>A> NCE
Oct 21, 2020
DS DP U-904
PERAMPANEL - FYCOMPA
N 202834 001
I-710
Jun 19, 2018
N 202834 002
I-710
Jun 19, 2018
A - 48

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

N 202834 003
I-710
Jun 19, 2018
N 202834 004
I-710
Jun 19, 2018
N 202834 005
I-710
Jun 19, 2018
N 202834 006
I-710
Jun 19, 2018
POMALIDOMIDE - POMALYST
N 204026 001
I-707
Apr 23, 2018
N 204026 002
I-707
Apr 23, 2018
N 204026 003
I-707
Apr 23, 2018
N 204026 004
I-707
Apr 23, 2018
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA

N 022580 001
9011905
Jun 09, 2028
9011906
Jun 09, 2028
DP

N 022580 002
9011905
Jun 09, 2028
9011906
Jun 09, 2028
DP

N 022580 003
9011905
Jun 09, 2028
9011906
Jun 09, 2028
DP

N 022580 004
9011905
Jun 09, 2028
9011906
Jun 09, 2028
DP
U-1262
U-1262
U-1262
U-1262
PIRFENIDONE - ESBRIET
N 022535 001
7696236
Dec 18, 2027
U-1601
POLIDOCANOL - VARITHENA
N 205098 001
RE40640
Oct 14, 2016
DS DP U-1462
PONATINIB HYDROCHLORIDE - ICLUSIG

N 203469 001
9029533
9029533
9029533
9029533
9029533
Dec
Dec
Dec
Dec
Dec
22,
22,
22,
22,
22,
2026
2026
2026
2026
2026
U-836
U-1283
U-1699
U-1700
U-1701

N 203469 002
9029533
9029533
9029533
9029533
9029533
Dec
Dec
Dec
Dec
Dec
22,
22,
22,
22,
22,
2026
2026
2026
2026
2026
U-836
U-1283
U-1699
U-1700
U-1701
A - 49

APPL/PROD
NO
PATENT NO
PATENT

EXPIRATION
DATE
PATENT

CODES

PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 203469 003
9029533
9029533
9029533
9029533
9029533
Dec
Dec
Dec
Dec
Dec
2026
2026
2026
2026
2026
U-836

U-1283

U-1699

U-1700

U-1701

POSACONAZOLE - NOXAFIL

N 205596 001
9023790
Jul 04, 2031
DP U-1698

PREDNISONE - RAYOS

N 202020 001
9040085
Apr 23, 2024
U-1362

PREDNISONE - RAYOS

N 202020 002
9040085
Apr 23, 2024
U-1362

PREDNISONE - RAYOS

N 202020 003
9040085
Apr 23, 2024
U-1362

REGADENOSON - LEXISCAN

N 022161 001
9045519
9085601
Jun 22, 2019

Feb 02, 2027
DP

DP

REGORAFENIB - STIVARGA

N 203085 001
8637553
8680124
Feb 16, 2031

Jun 02, 2030
DS DP

RIFAXIMIN - XIFAXAN

N 022554 001
6861053
6861053
7452857
7452857
7605240
7605240
7718608
7718608
7915275
7915275
7935799
7935799
8193196
8193196
8309569
8309569
8741904
8741904
8741904
8946252
8969398
Aug
Aug
Aug
Aug
Aug
Aug
Aug
Aug
Feb
Feb
Aug
Aug
Sep
Sep
Jul
Jul
Feb
Feb
Feb
Jul
Oct
2019
2019
2019
2019
2019
2019
2019
2019
2025
2025
2019
2019
2027
2027
2029
2029
2026
2026
2026
2029
2029
U-1707

U-1708

U-1707

U-1708

U-1707

U-1708

U-1707

U-1708

U-1707

U-1708

U-1707

U-1708

DS DP U-1707

DS DP U-1708

U-1707

U-1708

DS
U-1526

DS
U-1707

DS
U-1708

U-1481

U-1481

I-709
May 27, 2018

RILPIVIRINE HYDROCHLORIDE - EDURANT

N 202022 001 >A> 7125879
Aug 09, 2022
>A> 7125879
Aug 09, 2022
>A> 7125879
Aug 09, 2022
DS DP U-1153

DS DP U-1307

DS DP U-1740

NPP
Aug 26, 2018

RISEDRONATE SODIUM - RISEDRONATE SODIUM

A 077132 001
PC
Nov 28, 2015

A 077132 002
PC
Nov 28, 2015
22,
22,
22,
22,
22,
11,
11,
11,
11,
11,
11,
11,
11,
23,
23,
11,
11,
02,
02,
18,
18,
27,
27,
27,
24,
02,
U-1506

A - 50

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


A 077132 003
PC
Nov 28, 2015
RIVASTIGMINE - RIVASTIGMINE
A 204403 003
PC
Feb 29, 2016
NCE
Sep 01, 2020
NCE
Jul 07, 2020
NCE
Jul 07, 2020
NCE
Jul 07, 2020
ROFLUMILAST - DALIRESP
N 022522 001
5712298
Jan 27, 2020
DS DP U-1115
ROLAPITANT HYDROCHLORIDE - VARUBI

N 206500 001
7049230
7563801
7981905
7981905
8178550
8361500
8404702
8470842
8796299
Dec
Apr
Apr
Apr
Apr
Oct
Oct
Jan
Dec
2023
2027
2027
2027
2027
2029
2029
2029
2022
DS DP U-1741
DP
U-1741
U-1742
DS DP
DP
U-1741
U-1741
U-1741
RUXOLITINIB PHOSPHATE - JAKAFI

N 202192 001
9079912
9079912
Dec 12, 2026

Dec 12, 2026
U-1573
U-1721

N 202192 002
9079912
9079912
Dec 12, 2026

Dec 12, 2026
U-1573
U-1721

N 202192 003
9079912
9079912
Dec 12, 2026

Dec 12, 2026
U-1573
U-1721

N 202192 004
9079912
9079912
Dec 12, 2026

Dec 12, 2026
U-1573
U-1721

N 202192 005
9079912
9079912
Dec 12, 2026

Dec 12, 2026
U-1573
U-1721
SACUBITRIL; VALSARTAN - ENTRESTO

N 207620 001
7468390
8101659
8404744
8796331
8877938
Nov
Jan
Jan
Jan
May
27,
14,
14,
14,
27,
2023
2023
2023
2023
2027

N 207620 002
7468390
8101659
8404744
8796331
8877938
Nov
Jan
Jan
Jan
May
27,
14,
14,
14,
27,
2023
2023
2023
2023
2027

N 207620 003
7468390
8101659
8404744
8796331
8877938
Nov
Jan
Jan
Jan
May
27,
14,
14,
14,
27,
2023
2023
2023
2023
2027
08,
04,
04,
04,
04,
09,
09,
18,
17,
DP
DP
DP
U-1723
DS DP
DP
DP
DP
U-1723
DS DP
DP
DP
DP
U-1723
DS DP
A - 51

APPL/PROD
NO
PATENT NO
SIMEPREVIR SODIUM - OLYSIO

N 205123 001
9040562
PATENT
EXPIRATION
DATE
Jul 28, 2026
PATENT
CODES
DS DP U-1467
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
>A> D-151
>A> I-717
EXCLUSIVITY

EXPIRATION

DATE

Oct 05, 2018

Oct 05, 2018

SIROLIMUS - RAPAMUNE

N 021083 001
ODE
May 28, 2022


N 021110 001
ODE
May 28, 2022


N 021110 002
ODE
May 28, 2022


N 021110 003
ODE
May 28, 2022


N 021110 004
ODE
May 28, 2022

NCE
Jul 24, 2020

SODIUM OXYBATE - XYREM

N 021196 001
8952062
8952062
9050302
Dec 22, 2019

Dec 22, 2019
Mar 15, 2033
U-1101

U-1102

U-1532

SOFOSBUVIR - SOVALDI

N 204671 001
9085573
Mar 21, 2028
DS DP U-1470

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO

N 021148 008
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DP


N 021148 009
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DP


N 021148 010
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
DP

DP

DP


N 021148 011
5849700
Dec 15, 2015
5849704
Dec 15, 2015
6899699
Jan 02, 2022
7686786
Aug 03, 2026
8672898
Jan 02, 2022
8684969
Oct 20, 2025
8841252
Dec 26, 2017
8920383
Jul 17, 2026
9108002
Jan 20, 2026
9132239
Feb 01, 2032
U-1041

DS DP U-1041

DP

DP

DP

DP

DP

DP

DP

DP

SONIDEGIB PHOSPHATE - ODOMZO

N 205266 001
8063043
8178563
Sep 15, 2029

Feb 06, 2029
DS DP
DS
U-1722

SORAFENIB TOSYLATE - NEXAVAR

N 021923 001
8124630
8841330
Jan 12, 2020

Jan 12, 2020
U-1459

U-1696

A - 52

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
SPINOSAD - NATROBA

N 022408 001
6063771
Jul 25, 2023
DP U-1670
SUMATRIPTAN SUCCINATE - ZECUITY

N 202278 001
8983594
Nov 19, 2030
DP U-1328

TACROLIMUS - ENVARSUS XR

N 206406 001
7994214
>A> 8486993
>A> 8586084
>A> 8591946
>A> 8617599
>A> 8623410
>A> 8623411
>A> 8664239
>A> 8685998
>A> 8889185
>A> 8889186
Aug
Aug
Aug
Aug
Aug
Aug
Aug
May
May
Aug
Aug
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
2024
2024
2024
2024
2024
2024
2024
2028
2028
2024
2024

N 206406 002
7994214
>A> 8486993
>A> 8586084
>A> 8591946
>A> 8617599
>A> 8623410
>A> 8623411
>A> 8664239
>A> 8685998
>A> 8889185
>A> 8889186
Aug
Aug
Aug
Aug
Aug
Aug
Aug
May
May
Aug
Aug
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,

N 206406 003
7994214
>A> 8486993
>A> 8586084
>A> 8591946
>A> 8617599
>A> 8623410
>A> 8623411
>A> 8664239
>A> 8685998
>A> 8889185
>A> 8889186
Aug
Aug
Aug
Aug
Aug
Aug
Aug
May
May
Aug
Aug
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
30,
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

M-152
Nov 30, 2017

DP
DP U-1752

U-1752

DP

DP

DP

U-1752

U-1752

DP U-1752

U-1752

U-1752

ODE
Jul 10, 2022

2024
2024
2024
2024
2024
2024
2024
2028
2028
2024
2024
DP
DP U-1752

U-1752

DP

DP

DP

U-1752

U-1752

DP U-1752

U-1752

U-1752

ODE
Jul 10, 2022

2024
2024
2024
2024
2024
2024
2024
2028
2028
2024
2024
DP
DP U-1752

U-1752

DP

DP

DP

U-1752

U-1752

DP U-1752

U-1752

U-1752

ODE
Jul 10, 2022

TAPENTADOL HYDROCHLORIDE - NUCYNTA ER

N 200533 001
8536130
Sep 22, 2028
U-1739


N 200533 002
8536130
Sep 22, 2028
U-1739


N 200533 003
8536130
Sep 22, 2028
U-1739


N 200533 004
8536130
Sep 22, 2028
U-1739


N 200533 005
8536130
Sep 22, 2028
U-1739

TASIMELTEON - HETLIOZ

N 205677 001
9060995
U-1710

Jan 25, 2033
A - 53

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
TEDUGLUTIDE RECOMBINANT - GATTEX KIT

N 203441 001
5789379
Apr 14, 2016
9060992
Nov 01, 2025
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
DS DP U-1320
U-1320
TESTOSTERONE - ANDROGEL
N 021015 001
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-490
U-490
N 021015 002
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-490
U-490
N 021015 003
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-490
U-490
N 022309 001
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-1103
U-1103
N 022309 002
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-1103
U-1103
N 022309 003
9125816
9132089
Aug 30, 2020

Aug 30, 2020
U-1103
U-1103
TESTOSTERONE - AXIRON
N 022504 001
8435944
8993520
Sep 27, 2027

Jun 02, 2026
U-1390
U-1390
TICAGRELOR - BRILINTA
N 022433 001
I-714
TICAGRELOR - BRILINTA
N 022433 002
6251910
6525060
7250419
7265124
>A> 8425934
Jul
Dec
Dec
Jul
Apr
TIGECYCLINE - TYGACIL
N 021821 001
8975242
Oct 24, 2028
DP
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT

N 021936 001
8733341
Dec 16, 2029
9027967
Mar 31, 2027
DP
DP

N 021936 002
5964416
Oct
6149054
Dec
6176442
May
6453795
Dec
6726124
Oct
6846413
Aug
6977042
Aug
6988496
Feb
7104470
Oct
7246615
May
7284474
Aug
7396341
Oct
7802568
Feb
DP
DP
DP
DP
DP
DP
DP
DP
DP
DP
DP
DP
DP
15,
02,
02,
09,
17,
04,
16,
31,
05,
04,
28,
28,
23,
04,
31,
26,
10,
26,
2018
2019
2019
2021
2030
2016
2016
2016
2016
2016
2018
2018
2020
2016
2016
2024
2026
2019
EXCLUSIVITY

EXPIRATION

DATE

DS
DS DP U-1171
DS DP U-1171
DS DP U-1171
DP
>A> NCE
NS
NP
Sep 03, 2018
Jul 20, 2016

Sep 03, 2018
Sep 15, 2018
A - 54

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 021936 002
7837235
Mar
7896264
May
7988001
Aug
8733341
Dec
9027967
Mar
RE39820
Jan
13,
26,
04,
16,
31,
30,
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE N 207981 001 >A> 5744475

Mar
>A> 6479500
Mar
>A> 7799783
Dec
LONSURF
28, 2016
16, 2020
16, 2026
DS DP U-1751
U-1751
U-1751
NCE
Sep 22, 2020
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE N 207981 002 >A> 5744475

Mar
>A> 6479500
Mar
>A> 7799783
Dec
LONSURF
28, 2016
16, 2020
16, 2026
DS DP U-1751
U-1751
U-1751
NCE
Sep 22, 2020
TOPIRAMATE - TROKENDI XR
N 201635 001
8298576
8992989
Apr 04, 2028

Nov 16, 2027
DP U-106
DP U-1675
N 201635 002
8298576
8992989
Apr 04, 2028

Nov 16, 2027
DP U-106
DP U-1675
N 201635 003
8298576
8992989
Apr 04, 2028

Nov 16, 2027
DP U-106
DP U-1675
N 201635 004
8298576
8992989
Apr 04, 2028

Nov 16, 2027
DP U-106
DP U-1675
TOPIRAMATE - QUDEXY XR
N 205122 001
9101545
Mar 19, 2033
DP
N 205122 002
9101545
Mar 19, 2033
DP
N 205122 003
9101545
Mar 19, 2033
DP
N 205122 004
9101545
Mar 19, 2033
DP
N 205122 005
9101545
Mar 19, 2033
DP
>A> NCE
Oct 23, 2020
2028
2025
2021
2029
2027
2018
DP
DP
DP
DP
DP
DS DP
TRABECTEDIN - YONDELIS
N 207953 001
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST
N 204114 001
8703781
Oct 15, 2030
DS DP U-1712

N 204114 002
8703781
Oct 15, 2030
DS DP U-1712

N 204114 003
8703781
Oct 15, 2030
DS DP U-1712
A - 55

APPL/PROD
NO
PATENT
EXPIRATION
DATE
PATENT NO
TRANEXAMIC ACID - LYSTEDA

N 022430 001
8957113
9060939
PATENT
CODES
Mar 04, 2025

Mar 04, 2025
DP U-1182
DP
Oct 10, 2029

Mar 13, 2029
DP
DP
TRAZODONE HYDROCHLORIDE - DESYREL

N 018207 001
8133893
Mar 13, 2029
DS DP

N 018207 002
8133893
Mar 13, 2029
DS DP

N 018207 003
8133893
Mar 13, 2029
DS DP

N 018207 004
8133893
Mar 13, 2029
DS DP
TREPROSTINIL DIOLAMINE - ORENITRAM

N 203496 001
7417070
9050311
Jul 30, 2026

May 24, 2024
DS
DS DP

N 203496 002
7417070
9050311
Jul 30, 2026

May 24, 2024
DS
DS DP

N 203496 003
7417070
9050311
Jul 30, 2026

May 24, 2024
DS
DS DP

N 203496 004
7417070
9050311
Jul 30, 2026

May 24, 2024
DS
DS DP
TRETINOIN - RETIN-A-MICRO
N 020475 003
5955109
Sep 21, 2016
DP U-134
ULIPRISTAL ACETATE - ELLA

N 022474 001 >A> 8512745
8962603
Jun 02, 2030

Jun 12, 2030
DP
TRAVOPROST - IZBA
N 204822 001
8178582
9144561
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE

U-1657
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA

N 203975 001
8511304
Jun 14, 2027
DP U-1476
URIDINE TRIACETATE - XURIDEN
N 208169 001 >A> 6258795
Jul 10, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE

N 021304 001
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE

N 022257 001
VILAZODONE HYDROCHLORIDE - VIIBRYD

N 022567 001
DP
NCE
ODE
Sep 04, 2020

Sep 04, 2022
D-148
NPP
Apr 23, 2018

Apr 23, 2018
D-148
NPP
Apr 23, 2018

Apr 23, 2018
D-146
Mar 16, 2018
A - 56

APPL/PROD
NO
PATENT NO
PATENT
EXPIRATION
DATE
PATENT
CODES
PATENT
DELIST
REQUESTED
EXCLUSIVITY
CODE(S)
EXCLUSIVITY

EXPIRATION

DATE


N 022567 002
D-146
Mar 16, 2018

N 022567 003
D-146
Mar 16, 2018
ZOLMITRIPTAN - ZOMIG
N 021450 003
NPP
Jun 12, 2018
ZOLMITRIPTAN - ZOMIG
N 021450 004
NPP
Jun 12, 2018
VORTIOXETINE HYDROBROMIDE - BRINTELLIX

N 204447 001
8722684
Jun 30, 2031
8969355
Jun 15, 2027
DS DP

N 204447 002
8722684
Jun 30, 2031
8969355
Jun 15, 2027
DS DP

N 204447 003
8722684
Jun 30, 2031
8969355
Jun 15, 2027
DS DP

N 204447 004
8722684
Jun 30, 2031
8969355
Jun 15, 2027
DS DP
U-1668
U-1668
U-1668
U-1668
Footnote:
1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as
described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and
submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
B-1
PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns,
abbreviations and references have been developed. Refer to the APPROVED DRUG
PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35h Edition for a full listing of
patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications,
and Patent Use Codes).
The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm
The current complete list of exclusivity terms is available at

http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm

Approved Drugs

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Approved Drugs

Încărcat de

Drepturi de autor:

Formate disponibile

CUMULATIVE

THERAPEUTIC EQUIVALENCE EVALUATIONS

Department of Health and Human Services

Office of Medical Products and Tobacco

Center for Drug Evaluation and Research

Office of Generic Drugs

Office of Generic Drugs

Office of Medical Products and Tobacco

Center for Drug Evaluation and Research

Food and Drug Administration

APPROVED DRUG PRODUCTS

THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION Cumulative

1.1 How to use the Cumulative Supplement ........................................................................................... iii

1.2 Cumulative Supplement Content ...................................................................................................... iv

1.3 Applicant Name Changes .................................................................................................................. v

1.4 Levothyroxine Sodium ....................................................................................................................... .v

1.5 Availability of the Edition.................................................................................................................... vi

1.7 Cumulative Supplement Legend ...................................................................................................... viii

DRUG PRODUCT LISTS

Prescription Drug Product List ...................................................................................................... 1-1

OTC Drug Product List .................................................................................................................. 2-1

Drug Products with Approval under Section 505 of the Act

Orphan Product Designations and Approvals List ........................................................................ 4-1

Drug Products W hich Must Demonstrate in vivo Bioavailability

Only if Product Fails to Achieve Adequate Dissolution ............................................................. 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

B. Patent and Exclusivity Terms ................................................................................................ B-1

APPROVED DRUG PRODUCTS

THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION CUMULATIVE

HOW TO USE THE CUMULATIVE SUPPLEMENT

CUMULATIVE SUPPLEMENT CONTENT

Generic product ANDA (Abbreviated New Drug Approval) approvals as of

All product changes received and processed as of the date of

Patent information, also updated daily in the EOB, is current to

Exclusivity information is updated monthly and current to the date of

Every effort is made to ensure the Cumulative Supplement is current and

FDA/CDER Orange Book Staff

Office of Generic Drugs

7620 Standish Place

APPLICANT NAME CHANGES

NEW APPLICANT NAME

AGILA SPECIALTIES PRIVATE LTD

MYLAN LABORORATORIES LTD

EXCELLIUM PHARMACEUTICAL INC

LEADING PHARMA LLC

MYLAN PHARMACEUTICALS INC

MYLAN LABORATORIES LTD

ONCO THERAPIES LTD

MYLAN LABORATORIES LTD

to establish their drugs' therapeutic equivalence to other reference

KING PHARMS 0.025MG AB1

ALARA PHARM 0.025MG AB2

1.5 AVAILABILITY OF THE EDITION

number. Product search categories are: prescription, over-the-counter,

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

New Molecular Entity

DRUG PRODUCTS LISTED

NEW MOLECULAR ENTITIES

Amino acid-containing products of varying composition (see Introduction, page xx of the

1.7 CUMULATIVE SUPPLEMENT LEGEND

New drug product approval usually in the supplement

Change. There has been a change in the Ingredient(s) name.